



Digitally signed by Bolea Petru
Date: 2024.04.05 07:04:19 EEST
Reason: MoldSign Signature
Location: Moldova



Form	Catalog No.	Form	Catalog No.
FITC	345801	PerCP-Cy5.5	347222
PE	345802	PE-Cy7	348811
PerCP	345803	APC	345804

23-5085(07)
2021-09
English



1. INTENDED USE

CD34 (8G12) is intended for in vitro diagnostic use in the identification of cells expressing the CD34 antigen in peripheral blood, using a BD FACSLytic™ flow cytometer.

Clinical Applications

Expression of the CD34 antigen in the characterization of subjects having, or suspected of having, hematological neoplasia.^{1,2,3,4,5,6}

CD34 (8G12) is a qualitative reagent intended for laboratory professional use only.

2. SUMMARY OF THE TEST

The CD34 antigen is a single-chain transmembrane glycoprotein with molecular weight ranging from 105 to 120 kilodaltons (kDa). It is expressed on immature hematopoietic precursor cells and all hematopoietic colony-forming cells in bone marrow and blood. The CD34 antigen is also found on capillary endothelial cells and approximately 1% of human thymocytes. Normal peripheral blood lymphocytes, monocytes, granulocytes, and platelets do not express the CD34 antigen.⁷

Approximately 60% of B-cell acute lymphoid leukemias and acute myeloid leukemias (AML) and 1% to 5% of T-cell acute lymphoid leukemias express the CD34 antigen.⁷ The antigen is not expressed on chronic lymphoid leukemias or lymphomas.⁷

Principle of Operation

The CD34 (8G12) reagent is a monoclonal antibody conjugated to a specific fluorochrome. The reagent is added to the specimen and incubated, allowing the antibodies to bind to the CD34 antigen on the surface of the leucocytes. After incubation, BD FACS™ Lysing Solution is used to lyse the red blood cells in the sample. Cells are acquired on the BD FACSLytic™ flow cytometer using the BD FACSuite™ application. During acquisition, the cells travel past the laser beam and scatter the laser light. The stained cells fluoresce. These scatter and fluorescence signals, detected by the instrument, provide information about the cell's size, internal complexity, and relative fluorescence intensity. The CD34 (8G12) reagents employ fluorescence triggering, allowing direct fluorescence gating of the leucocyte population to reduce contamination of unlysed or nucleated red blood cells in the gate. The user performs manual gating to analyze the data and identify the CD34⁺ population.

3. REAGENT

Reagent Composition

CD34 (8G12)⁸ is derived from hybridization of mouse Sp2/0-Ag14 myeloma cells with spleen cells from BALB/c mice immunized with human cell line KG-1a. CD34 (8G12) is composed of mouse IgG₁ heavy chains and kappa light chains.

Each of the following reagents is supplied in buffer containing a stabilizer and preservative. The purity presented is the free fluorochrome at bottling, as measured by size-exclusion chromatography.

Table 1 Bottling concentrations

Form	Number of tests	Concentration (µg/mL)	Stabilizer	Preservative	Purity
FITC	100	25	Gelatin	0.1% Sodium azide	≤5%
PE	100	25	Gelatin	0.1% Sodium azide	≤20%
PerCP	50	50	Gelatin	0.1% Sodium azide	≤20%
PerCP-Cy5.5	50	12.5	Gelatin	0.1% Sodium azide	≤20%
PE-Cy7	100	50	Gelatin	0.1% Sodium azide	≤20%
APC	100	100	Gelatin	0.1% Sodium azide	≤20%

Precautions

- The reagent should be clear. Do not use the reagent if you observe any change in appearance. Precipitation, cloudiness, or change in color indicates instability or deterioration.
- Go to regdocs.bd.com/regdocs/sdsSearch to download the Safety Data Sheet.

Storage and Handling

- Store the reagent at 2°C–8°C.
- Reagent in unopened vials is stable until the expiration date shown on the label when stored as directed. Do not use after the expiration date.
- Use reagent within 12 months of opening the vial when stored as directed.
- Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the reagent vial dry.

4. INSTRUMENT

Table 2 BD FACSLytic™ system

Flow cytometer	Setup beads	Setup software	Analysis software
BD FACSLytic™	BD [®] CS&T Beads BD [®] FC Beads 7-Color Kit	BD FACSuite™ application v1.3 or later	BD FACSuite™ application v1.3 or later

The BD FACS™ Universal Loader can be used with this product.

5. SPECIMEN COLLECTION AND PREPARATION

Collect peripheral blood specimens aseptically by venipuncture into a BD Vacutainer[®] EDTA blood collection tube, or equivalent.⁹ We recommend that you follow guidelines described in consensus protocols for flow cytometric immunophenotyping of hematopoietic malignancies.^{10,11}

Samples with large numbers of nonviable cells can give erroneous results due to selective loss of populations and to increased nonspecific binding of antibodies to nonviable cells. Viability of specimens should be assessed. A minimum viability of 75% is recommended.¹²

WARNING All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection^{13,14} and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves.

Interference

- Lipemic specimens can interfere with the assay.^{15,16}
- Monoclonal antibodies in patient treatment can interfere with the assay.

6. PROCEDURE

Reagents and Materials

Reagent provided

The reagent is provided in an amber vial as described in Table 1.

Reagents and materials required but not provided

- Disposable 12 × 75-mm capped polystyrene test tubes
- Micropipettor with tips
- Vortex mixer
- Centrifuge
- BD FACS™ Lysing Solution (Catalog No. 349202)
See the instructions for use (IFU) for warnings and precautions.
- Wash buffer (1X phosphate buffered saline [PBS] with 0.1% sodium azide)
- Stain buffer (1X PBS plus 0.2% bovine serum albumin [BSA] with 0.1% sodium azide)
- Fixative solution (1% paraformaldehyde [PFA] solution in 1X PBS with 0.1% sodium azide)

Store at 2°C–8°C in amber glass for up to 1 week.

- (Optional) BD FACS™ Universal Loader

Diluting BD FACS™ Lysing Solution

Dilute the 10X concentrate 1:10 with room temperature (20°C–25°C) deionized water. The prepared solution is stable for 1 month when stored in a glass or high density polyethylene (HDPE) container at room temperature.

Staining the Cells

1. Add the appropriate volume of CD34 (8G12) fluorochrome-conjugated monoclonal antibody to 100 µL of whole blood in a 12 × 75-mm capped polystyrene test tube.

Table 3 Reagent test volumes

Fluorochrome	Volume per test (µL)
FITC	20
PE	20
PerCP	20
PerCP-Cy5.5	20

Table 3 Reagent test volumes (continued)

Fluorochrome	Volume per test (μL)
PE-Cy7	5
APC	5

2. Vortex gently and incubate for 15–30 minutes at room temperature (20°C–25°C), protected from light.
3. Add 2 mL of 1X BD FACS™ Lysing Solution to each tube.
4. Vortex the tube 3-5 seconds at low speed and incubate for 10 minutes at room temperature, protected from light.
5. Centrifuge at 300g for 5 minutes.
6. Aspirate the supernatant without disturbing the cell pellet.
7. Add 2 to 3 mL of wash buffer to each tube.
8. Vortex gently.
9. Centrifuge at 200g for 5 minutes.
10. Aspirate the supernatant without disturbing the cell pellet.
11. Add 0.5 mL of wash buffer to each tube and acquire the samples immediately.

Optional: Instead of adding wash buffer, fix the stained sample as described in the following section.

Fixing the Stained Sample (optional)

1. Add 0.5 mL of fixative solution.
2. Vortex gently.
3. Incubate for 60 minutes at 2°C–8°C, protected from light.
4. Centrifuge at 300g for 5 minutes.
5. Aspirate the supernatant without disturbing the cell pellet.
6. Add 0.5 mL of wash buffer to each tube.
7. Vortex gently.

Store at 2°C–8°C, protected from light, until acquisition. We recommend acquiring the samples within 24 hours of staining.

CAUTION Some PE-Cy7 conjugates show changes in their emission spectra with prolonged exposure to paraformaldehyde or light. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.

Creating an Experiment

Before you begin:

1. Ensure that Characterization QC (CQC) and lyse/wash reference settings have not expired.
2. Add reagent lots to library, if needed.

See the *BD FACSLyric™ Reference System* for information.

3. Perform daily Performance QC (PQC) using BD® CS&T Beads.

See the *BD® CS&T Beads IFU* and the *BD FACSLyric™ Reference System* for information.

To create an experiment:

1. Create an experiment and a user-defined assay as described in the *BD FACSLyric™ Reference System*.

Acquiring the Sample

1. Create a worklist.
2. Add the user-defined assay to the worklist as a task, as needed.

See the *BD FACSLyric™ Reference System* for information.

3. To acquire a specific tube, set the run pointer to the sample you want to run and select **Run from Pointer** from the **Run** menu in the **Worklist Controls** bar.

Alternatively, select **Run All** from the **Run** menu to run the entire worklist from the beginning.

4. Vortex each stained tube 3–5 seconds at low speed immediately prior to acquisition.¹⁷
5. Follow the prompts in the software to load or unload tubes.

NOTE If you are using the BD FACS™ Universal Loader, vortex tubes immediately before placing them into the Loader racks.

Before acquiring samples, adjust the threshold and voltage to minimize debris and ensure populations of interest are included.

Analyzing the Sample

1. Review the plots created in the assay.
2. Create and review a report, as needed.

See the *BD FACSLyric™ Reference System* for information.

7. RESULTS


Analytical Results


Abnormal numbers of cells expressing this antigen or aberrant expression levels of the antigen can be expected in some disease states. It is important to understand the normal expression pattern for this antigen and its relationship to expression of other relevant antigens in order to perform appropriate analysis.

Representative Data

A hematologically normal adult peripheral blood sample with KG1a cells added (black population) was stained with each of the CD34 (8G12) conjugates and acquired on a BD FACSLyric™ flow cytometer. Conjugates with brighter fluorochromes (PE and APC) will give greater separation than those with other fluorochromes (FITC and PerCP). When populations overlap, calculation of the percentage of cells positive for the marker can be affected by the choice of fluorochrome. See Figure 1.

Figure 1 Representative data





8. LIMITATIONS

- Use of monoclonal antibodies in patient treatment can interfere with recognition of target antigens by this reagent. This should be considered when analyzing samples from patients treated in this fashion. BD Biosciences has not characterized the effect of the presence of therapeutic antibodies on the performance of this reagent.
- Single reagents can provide only limited information in the analysis of leukemias and lymphomas. Using combinations of reagents can provide more information than using the reagents individually. Multicolor analysis using relevant combinations of reagents is highly recommended.¹¹
- Since reagents can be used in different combinations, laboratories need to become familiar with the properties of each antibody in conjunction with other markers in normal and abnormal samples.
- Reagent performance data typically was collected using EDTA-treated blood. Reagent performance can be affected by the use of other anticoagulants.

9. PERFORMANCE CHARACTERISTICS

Precision

A 5-day study was performed at one site to assess repeatability and within-site precision using control material. Estimates of precision were determined across two BD FACSLyric™ flow cytometers and two operators by acquiring BD® Stem Cell Control, stained in triplicate using two lots of each CD34 (8G12) reagent. Two separate runs were analyzed during each of the 5 tested days.

The following table presents the means, coefficients of variation (%CV), and the 97.5% one-sided confidence interval (Upper %CV) for repeatability and within-site precision of CD34 (8G12) MFI of the leucocyte population.

Table 4 CD34 (8G12) Repeatability and within-site precision, control material, CD34 MFI

Marker	Mean MFI	Repeatability		Within-site Precision	
		%CV	Upper %CV	%CV	Upper %CV
CD34 FITC	5,537.33	4.62	5.31	9.00	10.31
CD34 PE	13,400.32	4.59	5.28	5.41	6.19
CD34 PerCP	3,841.49	4.04	4.65	5.33	6.10
CD34 PerCP-Cy5.5	6,679.04	4.53	5.21	11.51	13.18
CD34 PE-Cy7	13,104.83	7.91	9.11	9.44	10.82
CD34 APC	21,371.88	5.86	6.75	12.36	14.15

The following table presents the means, standard deviation (SD), and the 97.5% one-sided confidence interval (Upper SD) for repeatability and within-site precision of CD34 (8G12) % positive of the leucocyte population.

Table 5 CD34 (8G12) Repeatability and within-site precision, control material, CD34 % Positive

Marker	Mean % Positive	Repeatability		Within-site Precision	
		SD	Upper SD	SD	Upper SD
CD34 FITC	0.57	0.05	0.05	0.05	0.06
CD34 PE	0.54	0.05	0.05	0.05	0.05
CD34 PerCP	0.60	0.04	0.04	0.04	0.04
CD34 PerCP-Cy5.5	0.55	0.05	0.06	0.06	0.06
CD34 PE-Cy7	0.58	0.05	0.06	0.05	0.06
CD34 APC	0.55	0.05	0.06	0.05	0.06

Reproducibility was estimated for the following components: instrument/operator-to-instrument/operator, run-to-run, lot-to-lot, and day-to-day. The following table presents the means and %CV for reproducibility of CD34 (8G12) MFI of the leucocyte population.

Table 6 CD34 (8G12) Reproducibility, control material, CD34 MFI

Marker	Mean MFI	%CV
CD34 FITC	5,537.33	7.73
CD34 PE	13,400.32	2.85
CD34 PerCP	3,841.49	3.47
CD34 PerCP-Cy5.5	6,679.04	10.58
CD34 PE-Cy7	13,104.83	5.15
CD34 APC	21,371.88	10.88

Reproducibility was estimated for the following components: instrument/operator-to-instrument/operator, run-to-run, lot-to-lot, and day-to-day. The following table presents the means and SD for reproducibility of CD34 (8G12) % positive of the leucocyte population.

Table 7 CD34 (8G12) Reproducibility, control material, CD34 % Positive

Marker	Mean % Positive	SD
CD34 FITC	0.57	0.02
CD34 PE	0.54	0.01
CD34 PerCP	0.60	0.01
CD34 PerCP-Cy5.5	0.55	0.02
CD34 PE-Cy7	0.58	0.01
CD34 APC	0.55	0.01

10. TROUBLESHOOTING

Problem	Possible Cause	Solution
Poor resolution between debris and leucocytes population.	Cell interaction with other cells and platelets.	Prepare and stain another sample.
	Rough handling during cell preparation.	Check cell viability. Centrifuge cells at lower speed.
	Inappropriate instrument settings.	Follow proper instrument setup procedures. Optimize instrument settings as required.
	Incomplete lysis.	Complete mixing of BD FACS™ Lysing Solution before and after addition to samples.
Staining dim or fading.	Cell concentration too high at staining step.	Check and adjust cell concentration or sample volume. Stain with fresh sample.
	Insufficient reagent.	Repeat staining with increased amount of antibody.
	Cells not analyzed within 24 hours of staining.	Repeat staining with fresh sample. Analyze promptly.
	Improper buffer preparation (sodium azide omitted).	Use sodium azide in stain buffer, wash buffer, and fixative solution.
Few or no cells.	Cell concentration too low.	Resuspend fresh sample at a higher concentration. Repeat staining and analysis.
	Cytometer malfunctioning.	Troubleshoot instrument.

NOTICE

EU Only: Users should report any serious incident related to the device to the Manufacturer and National Competent Authority.

Outside EU: Contact your local BD representative for any incident or inquiry related to this device.

Refer to the Eudamed website: <https://ec.europa.eu/tools/eudamed> for Summary of Safety and Performance.

WARRANTY

Unless otherwise indicated in any applicable BD general conditions of sale for non-US customers, the following warranty applies to the purchase of these products.

THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NONINFRINGEMENT. BD'S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT.

REFERENCES

1. Waller EK, Barlett N, Chen C-H, et al. Variations in the content of CD34+ cells in the peripheral blood of cancer patients receiving out-patient chemotherapy. *Cytotherapy*. 1999;1:21-29.
2. Aires A, Teixeira MDA, Lau C, et al. A pilot study on the usefulness of peripheral blood flow cytometry for the diagnosis of lower risk myelodysplastic syndromes: the "MDS thermometer". *BMC Hematol*. 2018;18:6.
3. Churchill HR, Fuda FS, Xu J, et al. Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation. *Cytometry B Clin Cytom*. 2020; Online ahead of print.
4. Dunphy CH, Tang W. The value of CD64 expression in distinguishing acute myeloid leukemia with monocytic differentiation from other subtypes of acute myeloid leukemia: a flow cytometric analysis of 64 cases. *Arch Pathol Lab Med*. 2007;131(5):748-754.
5. Ehninger A, Kramer M, Rolig C, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. *Blood Cancer J*. 2014;4:e218.
6. Cesana C, Klersy C, Brando B, et al. Prognostic value of circulating CD34+ cells in myelodysplastic syndromes. *Leuk Res*. 2008;32(11):1715-1723.
7. Civin CI, Trischmann TM, Fackler MJ, et al. Report on the CD34 cluster workshop. In: Knapp W, Dörken B, Gilks WR, et al, eds. *Leucocyte Typing IV: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1989:818-825.
8. Greaves MF, Tittley I, Colman SM, et al. CD34 cluster workshop report. In: Schlossman SF, Boumsell L, Gilks W, et al, eds. *Leucocyte Typing V: White Cell Differentiation Antigens*. Vol 1. New York, NY: Oxford University Press; 1995;1:840-846.
9. CLSI. *Collection of Diagnostic Venous Blood Specimens, 7th ed. CLSI standard GP41*. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
10. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. *Leukemia*. 1996;10:877-895.
11. Stelzer GT, Marti G, Hurley A, McCoy P, Jr, Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. *Cytometry*. 1997;30:214-230.
12. *Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells; Approved Guideline—Second Edition*. Wayne, PA: Clinical and Laboratory Standards Institute; 2007. CLSI document H43-A2.
13. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline—Fourth Edition*. Wayne, PA: Clinical and Laboratory Standards Institute; 2014. CLSI document M29-A4.
14. Centers for Disease Control and Prevention. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. <https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html>. Accessed March 12, 2019.
15. Kroll MH. Evaluating interference caused by lipemia. *Clin Chemistry*. 2004;50.
16. Nikolac N. Lipemia: causes, interference mechanisms, detection and management. *Biochem Med (Zagreb)*. 2014;24(1):57-67.
17. Jackson AL, Warner NL. Preparation, staining, and analysis by flow cytometry of peripheral blood leukocytes. In: Rose NR, Friedman H, Fahey JL, eds. *Manual of Clinical Laboratory Immunology*. 3rd ed. Washington, DC: American Society for Microbiology; 1986:226-235.

PATENTS AND TRADEMARKS

BD, the BD Logo, FACS, FACSLyric, FACSuite and Vacutainer are trademarks of Becton, Dickinson and Company or its affiliates. All other trademarks are the property of their respective owners.

© 2021 BD. All rights reserved.

Cy™ is a trademark of GE Healthcare. This product is subject to proprietary rights of GE Healthcare and Carnegie Mellon University, and is made and sold under license from GE Healthcare. This product is licensed

for sale only for in vitro diagnostics. It is not licensed for any other use. If you require any additional license to use this product and do not have one, return this material, unopened, to BD Biosciences, 2350 Qume Drive, San Jose, CA 95131, and any money paid for the material will be refunded.

HISTORY

Revision	Date	Changes made
23-5085(07)	2021-09	Updated to meet requirements of Regulation (EU) 2017/746.

SYMBOLS GLOSSARY [L006715(06) 2021-08]

Some symbols listed below may not apply to this product.

US Customers only: For symbol glossary, refer to [bd.com/symbols-glossary](https://www.bd.com/symbols-glossary)

Symbol	Meaning
	Manufacturer
	Authorized representative in the European Community
	Authorized representative in Switzerland
	Date of manufacture
	Use-by date
	Batch code
	Catalogue number
	Serial number
	Sterile
	Sterilized using aseptic processing techniques
	Sterilized using ethylene oxide
	Sterilized using irradiation
	Sterilized using steam or dry heat
	Do not resterilize
	Non-sterile
	Do not use if package is damaged and consult <i>instructions for use</i>
	Sterile fluid path
	Sterile fluid path (ethylene oxide)
	Sterile fluid path (irradiation)
	Fragile, handle with care
	Keep away from sunlight
	Keep dry
	Lower limit of temperature
	Upper limit of temperature
	Temperature limit
	Humidity limitation
	Biological risks
	Do not re-use
	Consult <i>instructions for use</i> or consult electronic <i>instructions for use</i>
	Caution
	Contains or presence of natural rubber latex
	In vitro diagnostic medical device
	Negative control
	Positive control
	Contains sufficient for <n> tests
	For IVD performance evaluation only
	Non-pyrogenic

Symbol	Meaning
	Patient number
	This way up
	Do not stack
	Single sterile barrier system
	Contains or presence of phthalate: combination of bis(2-ethylhexyl) phthalate (DEHP) and benzyl butyl phthalate (BBP)
	Collect separately Indicates separate collection for waste of electrical and electronic equipment required.
	CE marking; Signifies European technical conformity
	Device for near-patient testing
	Device for self-testing
	This only applies to US: "Caution: Federal Law restricts this device to sale by or on the order of a licensed practitioner."
	Country of manufacture "CC" shall be replaced by either the two letter or the three letter country code.
	Collection time
	Cut
	Peel here
	Collection date
	Keep away from light
	Hydrogen gas is generated
	Perforation
	Start panel sequence number
	End panel sequence number
	Internal sequence number
	Medical device
	Contains hazardous substances
	Ukrainian conformity mark
	Meets FCC requirements per 21 CFR Part 15
	UL product certification for US and Canada
	Unique device identifier

CONTACT INFORMATION



Becton, Dickinson and Company
BD Biosciences
2350 Qume Drive
San Jose, California 95131 USA



Becton Dickinson Ireland Ltd.
Donore Road, Drogheda
Co. Louth, A92 YW26
Ireland



BD Switzerland Sàrl
Terre Bonne Park – A4
Route de Crassier 17
1262 Eysins, Switzerland

BD Biosciences
European Customer Support
Tel +32.53.720.600
help.biosciences@bd.com

Australian and New Zealand Distributors:

Becton Dickinson Pty Ltd.
66 Waterloo Road
Macquarie Park NSW 2113
Australia

Becton Dickinson Limited
14B George Bourke Drive
Mt. Wellington Auckland 1060
New Zealand

Technical Service and Support: Contact
your local BD representative or
bdbiosciences.com.

ClinicalApplications@bd.com



eifu.bd.com

Technical Data Sheet


PE Mouse Anti-Human LAIR-1 (CD305)

Product Information

Material Number:	550811
Alternate Name:	CD305; LAIR1; hLAIR1; Leukocyte-associated Ig-like receptor 1
Size:	100 Tests
Vol. per Test:	20 µl
Clone:	DX26
Immunogen:	Human NK Cell Clone
Isotype:	Mouse (BALB/c) IgG1, κ
Reactivity:	QC Testing: Human
Storage Buffer:	Aqueous buffered solution containing BSA and ≤0.09% sodium azide.

Description

The DX26 monoclonal antibody specifically binds to Leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1/hLAIR1/Leukocyte-associated Ig-like receptor 1) that is encoded by *LAIR1*, and also known as, CD305. LAIR-1 is a ~32 kDa type I transmembrane glycoprotein with a single immunoglobulin-like domain and a cytoplasmic tail containing two immune receptor tyrosine-based inhibitory (ITIM) motifs. LAIR-1 is expressed on T cells, B cells, NK cells, monocytes, and dendritic cells. LAIR-1 recruits SHP-1 and SHP-2 tyrosine phosphatases upon activation. Crosslinking of the LAIR-1 expressed on T cells or NK cells can result in strong inhibition of cell-mediated cytotoxicity. Although it is structurally related to human killer cell inhibitory receptors, LAIR-1 does not appear to recognize MHC class I molecules and thus represents a novel MHC class I-independent mechanism of NK cell regulation.



Flow cytometric analysis of LAIR-1 (CD305) expression on human peripheral lymphocytes. Whole blood was stained with either PE Mouse Anti-Human LAIR-1 (CD305) (Cat. No. 550811; solid line histogram) or PE Mouse IgG1, κ Isotype Control (Cat. No. 555749; dashed line histogram). Erythrocytes were lysed with Pharm Lyse™ Lysing Buffer (Cat. No. 555899). Fluorescent histograms were derived from gated events with the side and forward light-scattering characteristics of viable lymphocytes.

Preparation and Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

The antibody was conjugated with R-PE under optimum conditions, and unconjugated antibody and free PE were removed.

Application Notes

Application

Flow cytometry	Routinely Tested
----------------	------------------

Suggested Companion Products

Catalog Number	Name	Size	Clone
555749	PE Mouse IgG1, κ Isotype Control	100 Tests	MOPC-21
554656	Stain Buffer (FBS)	500 mL	(none)
554657	Stain Buffer (BSA)	500 mL	(none)
349202	BD FACS™ Lysing Solution	100 mL	(none)
555899	Lysing Buffer	100 mL	(none)

BD Biosciences

bdbiosciences.com

United States Canada Europe Japan Asia Pacific Latin America/Caribbean
877.232.8995 866.979.9408 32.2.400.98.95 0120.8555.90 65.6861.0633 55.11.5185.9995

For country contact information, visit bdbiosciences.com/contact

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

© 2017 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company.

550811 Rev. 6



Product Notices

1. This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1×10^6 cells in a 100- μ l experimental sample (a test).
2. An isotype control should be used at the same concentration as the antibody of interest.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Please refer to <http://regdocs.bd.com> to access safety data sheets (SDS).
7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.

References

Meyaard L, Adema GJ, Chang C, et al. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. *Immunity*. 1997; 7(2):283-290. (Biology)

Poggi A, Tomasello E, Ferrero E, Zocchi MR, Moretta L. p40/LAIR-1 regulates the differentiation of peripheral blood precursors to dendritic cells induced by granulocyte-monocyte colony-stimulating factor. *Eur J Immunol*. 1998; 28(7):2086-2091. (Biology)

van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. *Leukemia*. 2012; 26(9):1908-1975. (Biology)

Xu M, Zhao R, Zhao ZJ. Identification and characterization of leukocyte-associated Ig-like receptor-1 as a major anchor protein of tyrosine phosphatase SHP-1 in hematopoietic cells. *J Biol Chem*. 2000; 275(23):17440-17446. (Biology)

Technical Data Sheet


APC Mouse Anti-Human IgM

Product Information

Material Number:	551062
Size:	100 tests
Vol. per Test:	20 µl
Clone:	G20-127
Isotype:	Mouse IgG1, κ
Reactivity:	QC Testing: Human
Storage Buffer:	Aqueous buffered solution containing BSA and ≤0.09% sodium azide.

Description

The G20-127 monoclonal antibody specifically binds to the heavy chain of human IgM. It does not react with other immunoglobulin heavy chain isotypes.



Preparation and Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

The antibody was conjugated to APC under optimum conditions, and unconjugated antibody and free APC were removed.

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.

Application Notes

Application

Flow cytometry	Routinely Tested
----------------	------------------

Suggested Companion Products

Catalog Number	Name	Size	Clone
555751	APC Mouse IgG1, κ Isotype Control	100 tests	MOPC-21

Product Notices

1. This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1×10^6 cells in a 100-µl experimental sample (a test).
2. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
3. Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.
4. For fluorochrome spectra and suitable instrument settings, please refer to our Fluorochrome Web Page at www.bdbiosciences.com/colors.
5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
6. Source of all serum proteins is from USDA inspected abattoirs located in the United States.

References

Zola H, Macardle PJ, Flego L, Webster J. The expression of sub-population markers on B cells: a re-evaluation using high-sensitivity fluorescence flow cytometry. *Dis Markers*. 1991; 9(2):103-118. (Biology)

BD Biosciences

bdbiosciences.com

United States	Canada	Europe	Japan	Asia Pacific	Latin America/Caribbean
877.232.8995	888.268.5430	32.53.720.550	0120.8555.90	65.6861.0633	0800.771.7157

For country-specific contact information, visit bdbiosciences.com/how_to_order/

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton Dickinson and Company is strictly prohibited.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. ©2011 BD



Technical Data Sheet


FITC Mouse Anti-Human CD2

Product Information

Material Number:	555326
Alternate Name:	LFA-2; Lymphocyte function antigen-2; T11/Leu-5; Rosette receptor
Size:	100 Tests
Vol. per Test:	20 µl
Clone:	RPA-2.10
Immunogen:	Human Phytohemagglutinin-treated Lymphoblasts
Isotype:	Mouse (BALB/c) IgG1, κ
Reactivity:	QC Testing: Human
	Tested in Development: Rhesus, Cynomolgus, Baboon
Workshop:	IV T085
Storage Buffer:	Aqueous buffered solution containing BSA and ≤0.09% sodium azide.

Description

The RPA-2.10 monoclonal antibody specifically binds to CD2. CD2 is a 50 kDa single-chain transmembrane glycoprotein, also known as LFA-2 or the receptor for sheep erythrocytes. CD2 belongs to the immunoglobulin superfamily of proteins along with its ligand LFA-3, CD58. It is present on about 80-90% of human peripheral blood lymphocytes, greater than 95% of thymocytes, all T lymphocytes that form E-rosettes and a subset of NK cells. CD2 plays a role in T-cell signaling and in lymphocyte adhesion.



Flow cytometric analysis of CD2 expression on human peripheral blood lymphocytes. Whole blood was stained with either FITC Mouse IgG1, κ Isotype Control (Cat. No. 555748; dashed line histogram) or FITC Mouse Anti-Human CD2 antibody (Cat. No. 555326/561759/556608; solid line histogram). Erythrocytes were lysed with BD FACS™ Lysing Solution (Cat. No. 349202). The fluorescence histograms showing CD2 expression (or Ig Isotype control staining) were derived from gated events with the forward and side light-scatter characteristics of intact lymphocytes. Flow cytometry was performed on a BD FACScan™ system.

Preparation and Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

The antibody was conjugated with FITC under optimum conditions, and unreacted FITC was removed.

Application Notes

Application

Flow cytometry	Routinely Tested
----------------	------------------

Suggested Companion Products

Catalog Number	Name	Size	Clone
555748	FITC Mouse IgG1, κ Isotype Control	100 Tests	MOPC-21
554656	Stain Buffer (FBS)	500 mL	(none)
554657	Stain Buffer (BSA)	500 mL	(none)
561759	FITC Mouse Anti-Human CD2	25 Tests	RPA-2.10
556608	FITC Mouse Anti-Human CD2	50 Tests	RPA-2.10
555899	Lysing Buffer	100 mL	(none)
349202	BD FACS™ Lysing Solution	100 mL	(none)

BD Biosciences

bdbiosciences.com

United States Canada Europe Japan Asia Pacific Latin America/Caribbean
877.232.8995 866.979.9408 32.2.400.98.95 0120.8555.90 65.6861.0633 55.11.5185.9995

For country contact information, visit bdbiosciences.com/contact

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

© 2017 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company.

555326 Rev. 2



Product Notices

1. This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1×10^6 cells in a 100- μ l experimental sample (a test).
2. An isotype control should be used at the same concentration as the antibody of interest.
3. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Species testing during development may have been performed with a different format of the same clone. Selected applications have been tested for cross-reactivity.
7. Please refer to www.bdbiosciences.com/pharming/protocols for technical protocols.

References

Aversa GG, Bishop GA, Suranyi MG, Hall BM. RPA-2.10: an anti-CD2 monoclonal antibody that inhibits alloimmune responses and monitors T cell activation. *Transplant Proc.* 1987; 19(1):277-278. (Biology)

Kato K. CD2 Workshop Panel report. In: Kishimoto T, Tadamitsu Kishimoto .. et al., ed. *Leucocyte typing VI : white cell differentiation antigens : proceedings of the sixth international workshop and conference held in Kobe, Japan, 10-14 November 1996*. New York: Garland Pub.; 1997:39-43. (Biology)

Hahn WC, Burakoff SJ, Bierer BE. Signal transduction pathways involved in T cell receptor-induced regulation of CD2 avidity for CD58. *J Immunol.* 1993; 150(7):2607-2619. (Biology)

Knapp W. W. Knapp .. et al., ed. *Leucocyte typing IV : white cell differentiation antigens*. Oxford New York: Oxford University Press; 1989:1-1182. (Clone-specific)

Jonker M, Slingerland W. Reactivity of mAb specific for human CD markers with Rhesus monkey leucocytes. In: Knapp W. W. Knapp .. et al., ed. *Leucocyte typing IV : white cell differentiation antigens*. Oxford New York: Oxford University Press; 1989:1058-1063. (Biology)

Suranyi MG, Bishop GA, Clayberger C, et al. Lymphocyte adhesion molecules in T cell-mediated lysis of human kidney cells. *Kidney Int.* 1991; 39(2):312-319. (Biology)

Technical Data Sheet


FITC Mouse Anti-Human CD35

Product Information

Material Number:	555452
Alternate Name:	CR1; Complement receptor type 1; C3b/C4b receptor; C3BR; C4BR; KN
Size:	100 Tests
Vol. per Test:	20 µl
Clone:	E11
Immunogen:	Human Cells of the Monocyte Lineage
Isotype:	Mouse IgG1, κ
Reactivity:	QC Testing: Human
Workshop:	III 204
Storage Buffer:	Aqueous buffered solution containing BSA and ≤0.09% sodium azide.

Description

The E11 monoclonal antibody specifically binds to CD35. CD35 is also known as Complement receptor type 1 (CR1), C3b/C4b receptor, C3BR, C4BR, Immune adherence receptor, or KN. CD35 is a type I transmembrane glycoprotein that exists in four allelic forms of 160, 190, 220 and 250 kDa. CD35 serves as a receptor for complement fragments C3b, iC3b, C3dg, C4b, iC3, and iC4. It enhances phagocytosis by neutrophils and monocytes and regulates complement activation. It is expressed on erythrocytes, granulocytes, monocytes, B cells, and some dendritic cells, T cells, and NK cells. It binds complement components C3b and C4b, mediating. This antibody cannot inhibit the phagocytic capacity of granulocytes. The CD35 antibody is useful in studies of cells that express complement receptors.



Flow cytometric analysis of CD35 expression on human peripheral blood granulocytes (left panel) and lymphocytes (right panel). Whole blood was stained with either FITC Mouse Anti-Human CD35 (Cat. No. 555452, solid line histogram), or FITC Mouse IgG1, κ Isotype Control (Cat. No. 555748, dashed line histogram). Erythrocytes were lysed with BD FACS™ Lysing Solution (Cat. No. 349202). Fluorescence histograms were derived from gated events with the side and forward light-scatter characteristics of viable granulocytes or lymphocytes. Flow cytometry was carried out on a BD FACScan™ System.

Preparation and Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

The antibody was conjugated with FITC under optimum conditions, and unreacted FITC was removed.

Application Notes

Application

Flow cytometry	Routinely Tested
----------------	------------------

BD Biosciences

bdbiosciences.com

United States Canada Europe Japan Asia Pacific Latin America/Caribbean
877.232.8995 866.979.9408 32.2.400.98.95 0120.8555.90 65.6861.0633 55.11.5185.9995

For country contact information, visit bdbiosciences.com/contact

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

© 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company.

555452 Rev. 9



Suggested Companion Products

Catalog Number	Name	Size	Clone
555748	FITC Mouse IgG1, κ Isotype Control	100 Tests	MOPC-21
554656	Stain Buffer (FBS)	500 mL	(none)
554657	Stain Buffer (BSA)	500 mL	(none)
349202	BD FACS™ Lysing Solution	100 mL	(none)
555899	Lysing Buffer	100 mL	(none)

Product Notices

1. This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1×10^6 cells in a 100- μ l experimental sample (a test).
2. An isotype control should be used at the same concentration as the antibody of interest.
3. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Please refer to www.bdbiosciences.com/pharming/protocols for technical protocols.

References

Barclay NA, Brown MH, Birkeland ML, et al, ed. *The Leukocyte Antigen FactsBook*. San Diego, CA: Academic Press; 1997(Biology)

Dougherty GJ, Selvendran Y, Murdoch S, Palmer DG, Hogg N. The human mononuclear phagocyte high-affinity Fc receptor, FcRI, defined by a monoclonal antibody, 10.1. *Eur J Immunol*. 1987; 17(10):1453-1459. (Biology)

Schlossman SF, Stuart F, Schlossman .. et al., ed. *Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993*. Oxford: Oxford University Press; 1995(Biology)

Technical Data Sheet


PE Mouse Anti-Human CD99

Product Information

Material Number:	555689
Alternate Name:	E2; MIC2
Size:	100 Tests
Vol. per Test:	20 µl
Clone:	TÜ12
Isotype:	Mouse IgG2a, κ
Reactivity:	QC Testing: Human
RRID:	AB_396040
Workshop:	IV N92
Storage Buffer:	Aqueous buffered solution containing BSA and ≤0.09% sodium azide.

Description

The TÜ12 monoclonal antibody specifically recognizes CD99, also referred to as E2 antigen, a 32 kDa sialoglycoprotein expressed on all leucocyte lineages. The E2 antigen is the MIC2 gene product and is differentially expressed during T- and B-lymphoid and granulocytic development, with higher densities being expressed during early hematopoietic stages. Mature granulocytes express very little or no CD99. E2 has been shown to be involved in T-cell adhesion processes and is suggested to have a functional role in hematopoietic adhesion pathways.



Multiparameter flow cytometric analysis of CD99 expression on human peripheral blood leucocytes populations. Whole blood was stained with either PE Mouse IgG2a, κ Isotype Control (Cat. No. 555574; Left Plot) or PE Mouse Anti-Human CD99 antibody (Cat. No. 555689; Right Plot). Erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). Bivariate pseudocolor density plots showing CD99 expression (or Ig Isotype control staining) versus side light-scatter (SSC-A) signals were derived from gated events with the forward and side light-scattering characteristics of intact leucocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa™ Cell Analyzer System and FlowJo™ software.

Preparation and Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.

The antibody was conjugated to the dye under optimum conditions and unconjugated antibody and free dye were removed.

Application Notes

Application

Flow cytometry	Routinely Tested
----------------	------------------

Recommended Assay Procedure:

BD® CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

BD Biosciences

bdbiosciences.com
 United States Canada Europe Japan Asia Pacific Latin America/Caribbean
 877.232.8995 866.979.9408 32.2.400.98.95 0120.8555.90 65.6861.0633 55.11.5185.9995
 For country contact information, visit bdbiosciences.com/contact

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.
 © 2017 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company.



Suggested Companion Products

Catalog Number	Name	Size	Clone
555574	PE Mouse IgG2a, κ Isotype Control	100 Tests	G155-178
554656	Stain Buffer (FBS)	500 mL	(none)
554657	Stain Buffer (BSA)	500 mL	(none)
349202	Lysing Solution 10X Concentrate	100 mL	(none)
555899	Lysing Buffer	100 mL	(none)

Product Notices

1. This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1×10^6 cells in a 100- μ l experimental sample (a test).
2. An isotype control should be used at the same concentration as the antibody of interest.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
5. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
7. Please refer to <http://regdocs.bd.com> to access safety data sheets (SDS).

References

Aussel C, Bernard G, Breittmayer JP, Pelassy C, Zoccola D, Bernard A. Monoclonal antibodies directed against the E2 protein (MIC2 gene product) induce exposure of phosphatidylserine at the thymocyte cell surface. *Biochemistry*. 1993; 32(38):10096-10101. (Biology)

Chang A, Benda PM, Wood BL, Kussick SJ. Lineage-specific identification of nonhematopoietic neoplasms by flow cytometry. *Am J Clin Pathol*. 2003; 119(5):643-55. (Clone-specific: Flow cytometry)

Dworzak MN, Fritsch G, Buchinger P, et al. Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood. *Blood*. 1994; 83(2):415-425. (Biology)

Gelin C, Aubrit F, Phalipon A, et al. The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product. *EMBO J*. 1989; 8(11):3253-3259. (Biology)

Knapp W. W. Knapp .. et al., ed. *Leucocyte typing IV : white cell differentiation antigens*. Oxford New York: Oxford University Press; 1989:1-1182. (Clone-specific)

Uchańska-Ziegler B, Wernet P, Ziegler A. Differentiation of a human myeloid cell line (HL-60) toward granulocyte- and macrophage-like cells: comparison of cell surface antigen expression. *Haematol Blood Transfus*. 1983; 28:386-8. (Clone-specific: Immunofluorescence)

Technical Data Sheet

FITC Mouse Anti-Human CD58


Product Information

Material Number:	555920
Alternate Name:	LFA-3
Size:	100 tests
Vol. per Test:	20 µl
Clone:	1C3 (AICD58.6)
Isotype:	Mouse IgG2a κ
Reactivity:	QC Testing: Human Tested in Development: Dog
Workshop:	V S029
Storage Buffer:	Aqueous buffered solution containing BSA and ≤0.09% sodium azide.

Description

Reacts with a 60-70 kDa membrane glycoprotein member of the immunoglobulin superfamily. CD58, also referred to as the lymphocyte function-associated antigen-3 (LFA-3), has a wide tissue distribution, being expressed on both hematopoietic and non-hematopoietic cells, including endothelial cells and fibroblasts. There are two isoforms of CD58: a glycosylphosphatidylinositol (GPI)-linked formed and a transmembrane form. Both isoforms may be expressed in the same cell type. Erythrocytes, however, only have the GPI-linked isoform. CD58 interacts with CD2 during cell adhesion. This binding can enhance antigen-specific T-cell activation.

This antibody is routinely tested by flow cytometric analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.



Preparation and Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with FITC under optimum conditions, and unreacted FITC was removed. Store undiluted at 4° C and protected from prolonged exposure to light. Do not freeze.

Application Notes

Application

Flow cytometry	Routinely Tested
----------------	------------------

BD Biosciences

bdbiosciences.com

United States	Canada	Europe	Japan	Asia Pacific	Latin America/Caribbean
877.232.8995	888.259.0187	32.53.720.550	0120.8555.90	65.6861.0633	55.11.5185.9995

For country-specific contact information, visit bdbiosciences.com/how_to_order/

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton Dickinson and Company is strictly prohibited.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. ©2006 BD



Suggested Companion Products

Catalog Number	Name	Size	Clone
555573	FITC Mouse IgG2a Kappa Isotype Control	100 tests	G155-178

Product Notices

1. This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 X 10⁶ cells in a 100- μ l experimental sample (a test).
2. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
3. Please refer to www.bdbiosciences.com/pharming/en/protocols for technical protocols.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. Source of all serum proteins is from USDA inspected abattoirs located in the United States.

References

Schlossman SF, Boumsell L, Gilks W, et al, ed. *Leukocyte Typing V: White Cell Differentiation Antigens*. New York: Oxford University Press; 1995.(Clone-specific)
Barclay NA, Brown MH, Birkeland ML, et al, ed. *The Leukocyte Antigen FactsBook*. San Diego, CA: Academic Press; 1997.(Biology)
Schlossman S, Boumsell L, et al, ed. *Leukocyte Typing IV*. New York: Oxford University Press; 1995.(Biology)
Dengler TJ, Hoffmann JC, Knolle P, et al. Structural and functional epitopes of the human adhesion receptor CD58 (LFA-3). *Eur J Immunol*. 1992; 22(11):2809-2817.(Biology)


Technical Data Sheet

Pacific Blue™ Mouse Anti-Human CD3**Product Information**

Material Number:	558117
Alternate Name:	CD3ε; CD3E; T3E; TCRE; T-cell surface antigen T3/Leu-4 epsilon
Size:	0.1 mg
Concentration:	0.2 mg/ml
Clone:	UCHT1
Immunogen:	Human infant thymocytes and peripheral blood lymphocytes from a Sézary Syndrome donor
Isotype:	Mouse (BALB/c) IgG1, κ
Reactivity:	QC Testing: Human
Workshop:	III 471
Storage Buffer:	Aqueous buffered solution containing protein stabilizer and ≤0.09% sodium azide.

Description

The UCHT1 monoclonal antibody specifically binds to the human CD3ε-chain, a 20-kDa subunit of the CD3/T cell antigen receptor complex. CD3ε is expressed on 70-80% of normal human peripheral blood lymphocytes and 60-85% of thymocytes. Studies from the HLDA Workshop show that this antibody is mitogenic for CD3ε-positive cells when used in conjunction with costimulatory agents such as pokeweed mitogen or anti-CD28 antibody. CD3 plays a central role in signal transduction during antigen recognition. The UCHT1 antibody stains both surface and intracellular CD3ε unlike the other CD3 clone, HIT3a, that stains only extracellular CD3ε.



Flow cytometric analysis of CD3 expression on human peripheral blood lymphocytes. Whole blood was stained with either Pacific Blue™ Mouse IgG1, κ Isotype Control (Cat. No. 558120; dashed line histogram) or Pacific Blue™ Mouse Anti-Human CD3 (Cat. No. 558117; solid line histogram). Erythrocytes were lysed with Lysing Buffer (Cat. No. 555899). Fluorescence histograms were derived from events with the forward and side light-scattering characteristics of viable lymphocytes.

Preparation and Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

The antibody is conjugated to Pacific Blue™ under optimum conditions, and unreacted Pacific Blue™ was removed.

Application Notes**Application**

Flow cytometry	Routinely Tested
----------------	------------------

Suggested Companion Products

Catalog Number	Name	Size	Clone
558120	Pacific Blue™ Mouse IgG1, κ Isotype Control	0.1 mg	MOPC-21
554656	Stain Buffer (FBS)	500 mL	(none)
554657	Stain Buffer (BSA)	500 mL	(none)
349202	BD FACS™ Lysing Solution	100 mL	(none)
555899	Lysing Buffer	100 mL	(none)

BD Biosciences

bdbiosciences.com

United States Canada Europe Japan Asia Pacific Latin America/Caribbean
877.232.8995 866.979.9408 32.2.400.98.95 0120.8555.90 65.6861.0633 55.11.5185.9995

For country contact information, visit bdbiosciences.com/contact

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

© 2017 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company.

558117 Rev. 7



Product Notices

1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. An isotype control should be used at the same concentration as the antibody of interest.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
5. The Alexa Fluor®, Pacific Blue™, and Cascade Blue® dye antibody conjugates in this product are sold under license from Molecular Probes, Inc. for research use only, excluding use in combination with microarrays, or as analyte specific reagents. The Alexa Fluor® dyes (except for Alexa Fluor® 430), Pacific Blue™ dye, and Cascade Blue® dye are covered by pending and issued patents.
6. Pacific Blue™ has a maximum absorption of 416 nm and maximum emission of 451 nm. Before staining with this reagent, please confirm that your flow cytometer is capable of exciting the fluorochrome and discriminating the resulting fluorescence.
7. Pacific Blue™ is a trademark of Molecular Probes, Inc., Eugene, OR.
8. Please refer to www.bdbiosciences.com/pharming/protocols for technical protocols.

References

- Barclay NA, Brown MH, Birkeland ML, et al, ed. *The Leukocyte Antigen FactsBook*. San Diego, CA: Academic Press; 1997(Biology)
- Beverley PC, Callard RE. Distinctive functional characteristics of human "T" lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody. *Eur J Immunol*. 1981; 11(4):329-334. (Biology)
- Knapp W. W. Knapp .. et al., ed. *Leucocyte typing IV : white cell differentiation antigens*. Oxford New York: Oxford University Press; 1989:1-1182. (Clone-specific)
- Lanier LL, Allison JP, Phillips JH. Correlation of cell surface antigen expression on human thymocytes by multi-color flow cytometric analysis: implications for differentiation. *J Immunol*. 1986; 137(8):2501-2507. (Biology)
- McMichael AJ. A.J. McMichael .. et al., ed. *Leucocyte typing III : white cell differentiation antigens*. Oxford New York: Oxford University Press; 1987:1-1050. (Clone-specific)
- Schlossman SF, Stuart F. Schlossman .. et al., ed. *Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993*. Oxford: Oxford University Press; 1995(Biology)
- Schlossman SF, Stuart F. Schlossman .. et al., ed. *Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993*. Oxford: Oxford University Press; 1995(Clone-specific)

Technical Data Sheet


APC Mouse Anti-Human CD1a

Product Information

Material Number:	559775
Size:	100 tests
Vol. per Test:	20 µl
Clone:	HI149
Isotype:	Mouse IgG1, κ
Reactivity:	QC Testing: Human
Workshop:	V 5T CD01.01
Storage Buffer:	Aqueous buffered solution containing BSA and ≤0.09% sodium azide.

Description

Reacts with a 49 kDa polypeptide associated with β2-microglobulin. CD1a is expressed on cortical thymocytes, dendritic cells and Langerhans cells. CD1a has structural similarities to the MHC class I antigen, and plays a role in antigen presentation.



Profile of MOLT-4 cell line analyzed by flow cytometry

Preparation and Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.

The antibody was conjugated to APC under optimum conditions, and unconjugated antibody and free APC were removed.

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Application Notes

Application

Flow cytometry	Routinely Tested
----------------	------------------

Suggested Companion Products

Catalog Number	Name	Size	Clone
555751	APC Mouse IgG1, κ Isotype Control	100 tests	MOPC-21
554656	Stain Buffer (FBS)	500 ml	(none)

Product Notices

1. This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1×10^6 cells in a 100-µl experimental sample (a test).
2. Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.
3. For fluorochrome spectra and suitable instrument settings, please refer to our Fluorochrome Web Page at www.bdbiosciences.com/colors.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
6. This APC-conjugated reagent can be used in any flow cytometer equipped with a dye, HeNe, or red diode laser.
7. An isotype control should be used at the same concentration as the antibody of interest.

BD Biosciences

bdbiosciences.com

United States	Canada	Europe	Japan	Asia Pacific	Latin America/Caribbean
877.232.8995	888.268.5430	32.53.720.550	0120.8555.90	65.6861.0633	0800.771.7157

For country-specific contact information, visit bdbiosciences.com/how_to_order/

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton Dickinson and Company is strictly prohibited.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. ©2011 BD



References

- Calabi F, Bradbury A. The CD1 system. *Tissue Antigens*. 1991; 37(1):1-9. (Biology)
- Hanau D, Schmitt DA, Bieber T, Schmitt D, Cazenave JP. Possible mechanism of action of CD1a antigens. *J Invest Dermatol*. 1990; 95(5):503-505. (Biology)
- Knapp W, Dorken B, Rieber EP, et al, ed. *Leucocyte Typing IV*. New York: Oxford University Press; 1989:1-1208. (Biology)
- Schlossman SF, Boumsell L, Gilks W, et al, ed. *Leukocyte Typing V: White Cell Differentiation Antigens*. New York: Oxford University Press; 1995. (Clone-specific)

Technical Data Sheet

V450 Mouse Anti-Human CD4


Product Information

Material Number:	560345
Size:	120 tests
Vol. per Test:	5 µl
Clone:	RPA-T4
Isotype:	Mouse IgG1, κ
Reactivity:	QC Testing: Human
Workshop:	IV T114
Storage Buffer:	Aqueous buffered solution containing protein stabilizer and ≤0.09% sodium azide.

Description

The RPA-T4 clone reacts with CD4, a 59 kDa single-chain transmembrane glycoprotein [receptor for human immunodeficiency virus (HIV)] present on T-helper/inducer cell populations. This antibody binds to the D1 domain (CDR1 and CDR3 epitopes) of the CD4 antigen and reacts with approximately 80% of thymocytes and 45% of peripheral blood lymphocytes. CD4 is also present in low density on peripheral blood monocytes. RPA-T4 is capable of blocking HIV-1, gp120, and inhibits syncytium formation.

The antibody is conjugated to BD Horizon™ V450, which has been developed for use in multicolor flow cytometry experiments and is available exclusively from BD Biosciences. It is excited by the Violet laser Ex max of 406 nm and has an Em Max at 450 nm. Conjugates with BD Horizon™ V450 can be used in place of Pacific Blue™ conjugates.



Analysis of CD4 on human lymphocytes. Whole blood was stained with BD Horizon™ V450 Mouse Anti-Human CD4 and compared to whole blood stained with BD Horizon™ V450 Mouse IgG1, κ Isotype Control (clone MOPC-21, Cat. No. 560373). The isotype control is represented by a dashed line and the V450 Mouse Anti-Human CD4 by the solid line. Lymphocytes were selected by light scatter profile. Flow cytometry was performed on a BD LSR™ II flow cytometry system.

Preparation and Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

The antibody was conjugated with BD Horizon™ V450 under optimum conditions, and unreacted BD Horizon™ V450 was removed.

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.

Application Notes

Application

Flow cytometry	Routinely Tested
----------------	------------------

Suggested Companion Products

Catalog Number	Name	Size	Clone
560373	V450 Mouse IgG1, κ Isotype Control	0.1 mg	MOPC-21

BD Biosciences

bdbiosciences.com

United States	Canada	Europe	Japan	Asia Pacific	Latin America/Caribbean
877.232.8995	888.259.0187	32.53.720.550	0120.8555.90	65.6861.0633	55.11.5185.9995

For country-specific contact information, visit bdbiosciences.com/how_to_order/

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton Dickinson and Company is strictly prohibited.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. ©2008 BD



Product Notices

1. This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1×10^6 cells in a 100- μ l experimental sample (a test).
2. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
3. Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.
4. For fluorochrome spectra and suitable instrument settings, please refer to our Fluorochrome Web Page at www.bdbiosciences.com/colors.
5. BD Horizon™ V450 has a maximum absorption of 406 nm and maximum emission of 450 nm. Before staining with this reagent, please confirm that your flow cytometer is capable of exciting the fluorochrome and discriminating the resulting fluorescence.
6. Pacific Blue™ is a trademark of Molecular Probes, Inc., Eugene, OR.
7. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

References

- Schlossman SF, Boumsell L, Gilks W, et al, ed. *Leukocyte Typing V: White Cell Differentiation Antigens*. New York: Oxford University Press; 1995.(Clone-specific)
- Schlossman S, Boumsell L, et al, ed. *Leucocyte Typing V*. New York: Oxford University Press; 1995.(Biology)
- Knapp W, Dorken B, Rieber EP, et al, ed. *Leucocyte Typing IV*. New York: Oxford University Press; 1989.(Clone-specific)

Technical Data Sheet


PE Mouse anti-Human CD105

Product Information

Material Number:	560839
Alternate Name:	END; Endoglin; HHT1; MSC; ORW; ORW1
Size:	100 Tests
Vol. per Test:	5 µl
Clone:	266
Immunogen:	Human Umbilical Vein Endothelial Cells
Isotype:	Mouse (BALB/c) IgG1, κ
Reactivity:	QC Testing: Human
Storage Buffer:	Aqueous buffered solution containing BSA and ≤0.09% sodium azide.

Description

The 266 monoclonal antibody specifically binds to CD105. CD105 is a type I transmembrane glycoprotein that is encoded by *END* (Endoglin) and belongs to the transforming growth factor-β (TGF-β) type III receptor family. CD105 is expressed on cells as a homodimer comprised of ~95 kDa subunits. CD105 is expressed on vascular endothelial cells and placental syncytiotrophoblasts and at lower levels on stromal fibroblasts. It is also expressed on mesenchymal stem cells, erythroid precursors, activated macrophages, pre-B cells, and some tumor cells and cell lines including U937 cells. CD105 serves as a regulatory component of the TGF-β receptor system. In association with TGF-βRI or TGF-βRII, CD105 binds TGF-β1 and TGF-β3 with high affinity but does not bind to TGF-β2. Expression of CD105 is increased on activated endothelium in tissues undergoing angiogenesis, such as in tumors, or in cases of wound healing or dermal inflammation.



Flow cytometric analysis of CD105 expression on human U937 cells. U937 cells (ATCC, Cat No. CRL-1593.2) were stained with PE Mouse anti-Human CD105 antibody (Cat. No. 560839; solid line histogram) or a PE mIgG1, κ isotype control (Cat. No. 554680; dashed line histogram). Flow cytometric fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable cells. Flow cytometry was performed using a BD LSR™ II flow cytometry system.

Preparation and Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

The antibody was conjugated with R-PE under optimum conditions, and unconjugated antibody and free PE were removed.

Application Notes

Application

Flow cytometry	Routinely Tested
----------------	------------------

Suggested Companion Products

Catalog Number	Name	Size	Clone
554680	PE Mouse IgG1, κ Isotype Control	0.1 mg	MOPC-21
554656	Stain Buffer (FBS)	500 mL	(none)
554657	Stain Buffer (BSA)	500 mL	(none)

BD Biosciences

bdbiosciences.com

United States Canada Europe Japan Asia Pacific Latin America/Caribbean
877.232.8995 866.979.9408 32.2.400.98.95 0120.8555.90 65.6861.0633 55.11.5185.9995

For country contact information, visit bdbiosciences.com/contact

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

© 2017 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company.

560839 Rev. 2



Product Notices

1. This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1×10^6 cells in a 100- μ l experimental sample (a test).
2. An isotype control should be used at the same concentration as the antibody of interest.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Please refer to <http://regdocs.bd.com> to access safety data sheets (SDS).
7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.

References

Gougos A, Letarte M. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. *J Immunol.* 1988; 141(6):1925-1933. (Biology)

Lastres P, Bellon T, Cabañas C, et al. Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. *Eur J Immunol.* 1992; 22(2):393-397. (Biology)

Tomchuck SL, Zvezdaryk KJ, Coffelt SB, Waterman RS, Danko ES, Scandurro AB. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. *Stem Cells.* 2008; 26(1):99-109. (Clone-specific: Flow cytometry)

Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. *Int J Cancer.* 1993; 54(3):363-370. (Biology)

Westphal JR, Willems HW, Schalkwijk CJ, Ruiter DJ, de Waal RM. A new 180-kDa dermal endothelial cell activation antigen: in vitro and in situ characteristics. *J Invest Dermatol.* 1993; 100(1):27-34. (Biology)

Monoclonal Antibodies Detecting Human Antigens

CD14 (MφP9)

Form	Catalog number	Form	Catalog number
Pure	347490	APC	340436
FITC	347493	APC-Cy7	333945
PE	347497	APC-H7	641394
PerCP	340585	V500-C	647459

Product availability varies by region. Contact BD Biosciences Customer Support or your local sales representative for information.

RESEARCH APPLICATIONS

Research applications include:

- Identification and enumeration of mature monocytes in peripheral blood
- Study of monocyte-derived dendritic cells¹⁻³
- Study of inflammatory disease⁴

DESCRIPTION

Specificity

The CD14 antibody recognizes a human monocyte/macrophage antigen with a molecular weight of 55 kilodaltons (kDa).⁵

Antigen distribution

The CD14 antigen is present on the majority of normal peripheral blood monocytes.⁶ CD14 has weak reactivity with peripheral blood granulocytes.⁷

Clone

The CD14 antibody, clone MφP9,^{8,9} is derived from hybridization of Sp2/0 mouse myeloma cells with spleen cells from BALB/c mice immunized with peripheral blood monocytes from a patient with rheumatoid arthritis.

Composition

The CD14 antibody is composed of mouse IgG_{2b} heavy chains and kappa light chains.

Product configuration

The following are supplied in phosphate buffered saline (PBS) containing a stabilizer and a preservative.

Form	Number of tests	Volume per test (μL) ^a	Amount provided (μg)	Total volume (mL)	Concentration (μg/mL)	Stabilizer	Preservative
Pure	100	20	50.0	2.0	25	Gelatin	0.1% Sodium azide
FITC	100	20	50.0	2.0	25	Gelatin	0.1% Sodium azide
PE	100	20	100.0	2.0	50	Gelatin	0.1% Sodium azide
PerCP	50	20	25.0	1.0	25	Gelatin	0.1% Sodium azide
APC	100	5	25.0	0.5	50	Gelatin	0.1% Sodium azide
APC-Cy TM 7	100	5	25.0	0.5	50	Gelatin	0.1% Sodium azide
APC-H7	100	5	12.5	0.5	25	BSA	ProClin TM 300
V500-C ^b	100	5	50.0	0.5	100	BSA	ProClin TM 950

a. Volume required to stain 10⁶ cells.

b. BD HorizonTM V500-C.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Becton, Dickinson and Company
BD Biosciences
 2350 Qume Drive
 San Jose, CA 95131 USA



CAUTION Some APC-Cy7 conjugates, and to a lesser extent APC-H7 conjugates, show changes in their emission spectra with prolonged exposure to paraformaldehyde or light. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.


CAUTION Prolonged exposure of cells to paraformaldehyde can lead to increased autofluorescence in the violet channels. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.

PROCEDURE

Visit our website (bdbiosciences.com) or contact your local BD representative for the lyse/wash protocol for direct immunofluorescence.

REPRESENTATIVE DATA

Flow cytometric analysis was performed on whole blood stained with the indicated conjugated antibody. Laser excitation was at 405 nm, 488 nm, or 635 nm. Representative data analyzed with a BD FACS™ brand flow cytometer is shown in the following plots.



HANDLING AND STORAGE

Store vials at 2°C – 8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

WARNING

All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection^{10,11} and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves.

Some reagents are bottled with ProClin 300, and contain 0.003% of a mixture of CMIT/MIT (3:1), CAS number 55965-84-9.



Warning

H317 May cause an allergic skin reaction.

Wear protective gloves/eye protection. Wear protective clothing. Avoid breathing mist/vapours/spray. If skin irritation or rash occurs: Get medical advice/attention. IF ON SKIN: Wash with plenty of water. Dispose of contents/container in accordance with local/regional/national/international regulations.

CHARACTERIZATION

To ensure consistently high-quality reagents, each lot of antibody is tested for conformance with characteristics of a standard reagent. Representative flow cytometric data is included in this data sheet.

WARRANTY

Unless otherwise indicated in any applicable BD general conditions of sale for non-US customers, the following warranty applies to the purchase of these products.

THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NONINFRINGEMENT. BD'S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT.

REFERENCES

1. Li G, Kim YJ, Mantel C, Broxmeyer HE. P-selectin enhances generation of CD14⁺CD16⁺ dendritic-like cells and inhibits macrophage maturation from human peripheral blood monocytes. *J Immunol.* 2003;171:669–677.
2. Chomarat P, Dantin C, Bennett L, Banchereau J, Palucka AK. TNF skews monocyte differentiation from macrophages to dendritic cells. *J Immunol.* 2003;171:2262–2269.
3. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. *Annu Rev Immunol.* 2000;18:767–811.
4. Scherberich JE, Nockher WA. CD14⁺⁺ monocytes, CD14⁺/CD16⁺ subset and soluble CD14 as biological markers of inflammatory systemic diseases and monitoring immunosuppressive therapy. *Clin Chem Lab Med.* 1999;37:209–213.
5. Goyert SM, Ferrero E. Biochemical analysis of myeloid antigens and cDNA expression of gp55 (CD14). In: McMichael AJ, ed. *Leukocyte Typing III: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1987:613–619.
6. Bernstein ID, Self S. Joint report of the myeloid section of the Second International Workshop on Human Leukocyte Differentiation Antigens. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, eds. *Leukocyte Typing II: Human Myeloid and Hematopoietic Cells*. Vol 3. New York, NY: Springer-Verlag; 1986:1–25.
7. Jayaram Y, Hogg N. Surface expression of CD14 molecules on human neutrophils. In: Knapp W, Dörken B, Gilks WR, et al., eds. *Leukocyte Typing IV: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1989:796–797.
8. Dimitriu-Bona A, Burmester GR, Waters SJ, Winchester RJ. Human mononuclear phagocyte differentiation antigens. I. Patterns of antigenic expression on the surface of human monocytes and macrophages defined by monoclonal antibodies. *J Immunol.* 1983;130:145–152.
9. Herrmann F, Komischke B, Odenwald E, Ludwig WD. Use of monoclonal antibodies as a diagnostic tool in human leukemia. I. Acute myeloid leukemia and acute phase of chronic myeloid leukemia. *Blut.* 1983;47:157–163.

PATENTS AND TRADEMARKS

10. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline — Third Edition*. Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI document M29-A3.
11. Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. *MMWR*. 1988;37:377-388.

Cy™ is a trademark of GE Healthcare. This product is subject to proprietary rights of GE Healthcare and Carnegie Mellon University, and is made and sold under license from GE Healthcare. This product is licensed for sale only for research. It is not licensed for any other use. If you require a commercial license to use this product and do not have one, return this material, unopened, to BD Biosciences, 2350 Qume Drive, San Jose, CA 95131, and any money paid for the material will be refunded.

ProClin is a trademark of the Dow Chemical Company or an affiliated company of Dow.

© 2018 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company.

Monoclonal Antibodies Detecting Human Antigens

CD19 (SJ25C1)

Form	Catalog number	Form	Catalog number
FITC	340409	APC-R700	659121
PE	340364	APC-Cy7	348794
PerCP	340421	APC-H7	641395
PerCP-Cy5.5	340951	AmCyan	339190
PE-Cy7	341093	V450	644491
APC	340437		

Product availability varies by region. Contact BD Biosciences Customer Support or your local sales representative for information.

RESEARCH APPLICATIONS

Research applications include:

- Studies of B-lymphocyte proliferation and activation^{1,2}
- Enumeration of B-lymphocytes in peripheral blood³
- Research on B-lymphocyte neoplasms⁴
- Investigation into B-cell differentiation in bone marrow⁵
- Examination of B-lymphocyte apoptosis⁶

DESCRIPTION

Specificity

The CD19 antibody recognizes a 90-kilodalton (kDa) antigen that is present on human B lymphocytes.^{7,8}

Antigen distribution

The CD19 antigen is present on approximately 7% to 23% of human peripheral blood lymphocytes⁹ and on splenocytes.¹⁰ CD19 is reactive with the B-lymphocyte areas of normal tonsil and lymph nodes.³ The CD19 antigen is present on human B lymphocytes at all stages of maturation.³ CD19 does not react with resting or activated T lymphocytes, granulocytes, or monocytes.⁵

Clone

The CD19 antibody, clone SJ25C1,⁸ is derived from the hybridization of Sp2/0 mouse myeloma cells with spleen cells isolated from BALB/c mice immunized with NALM1 and NALM16 cells.

Composition

The CD19 antibody is composed of mouse IgG₁ heavy chains and kappa light chains.

Product configuration

The following are supplied in phosphate buffered saline (PBS) containing a stabilizer and a preservative.

Form	Number of tests	Volume per test (μL) ^a	Amount provided (μg)	Total volume (mL)	Concentration (μg/mL)	Stabilizer	Preservative
FITC	50	20	6	1	6	Gelatin	0.1% Sodium azide
PE	50	20	12.5	1	12.5	Gelatin	0.1% Sodium azide
PerCP	50	20	12.5	1	12.5	Gelatin	0.1% Sodium azide
PerCP-Cy TM 5.5	50	20	5	1	5	Gelatin	0.1% Sodium azide
PE-Cy TM 7	100	5	12.5	0.5	25	Gelatin	0.1% Sodium azide
APC	100	5	25	0.5	50	Gelatin	0.1% Sodium azide
APC-R700 ^b	100	5	6.25	0.5	12.5	BSA	ProClin TM 300

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Becton, Dickinson and Company
BD Biosciences
 2350 Qume Drive
 San Jose, CA 95131 USA



Form	Number of tests	Volume per test (μL) ^a	Amount provided (μg)	Total volume (mL)	Concentration (μg/mL)	Stabilizer	Preservative
APC-Cy7	100	5	25	0.5	50	Gelatin	0.1% Sodium azide
APC-H7	100	5	25	0.5	50	Gelatin	0.1% Sodium azide
AmCyan	100	5	12.5	0.5	25	BSA	0.1% Sodium azide
V450 ^b	100	5	12.5	0.5	25	Gelatin	0.1% Sodium azide

a. Volume required to stain 10⁶ cells.

b. BD Horizon™ APC-R700, BD Horizon™ V450.

CAUTION Some APC-Cy7 conjugates, and to a lesser extent PE-Cy7, APC-H7, and APC-R700 conjugates, show changes in their emission spectra with prolonged exposure to paraformaldehyde or light. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.

CAUTION Prolonged exposure of cells to paraformaldehyde can lead to increased autofluorescence in the violet channels. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.


PROCEDURE


Visit our website (bdbiosciences.com) or contact your local BD representative for the lyse/wash protocol for direct immunofluorescence.

REPRESENTATIVE DATA

Flow cytometric analysis was performed on whole blood stained with the indicated conjugated antibody. Laser excitation was at 405 nm, 488 nm, 635 nm, or 640 nm.

The APC-R700 conjugate is read off the red laser (640 nm) using a 685 longpass mirror with a 712/21 bandpass filter. Representative data analyzed with a BD FACST[™] brand flow cytometer is shown in the following plots.





HANDLING AND STORAGE

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

WARNING

All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection^{11,12} and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves.

Some reagents are bottled with ProClin 300, and contain 0.003% of a mixture of CMIT/MIT (3:1), CAS number 55965-84-9.



Warning

H317 May cause an allergic skin reaction.

Wear protective gloves/eye protection. Wear protective clothing. Avoid breathing mist/vapours/spray. If skin irritation or rash occurs: Get medical advice/attention. IF ON SKIN: Wash with plenty of water. Dispose of contents/container in accordance with local/regional/national/international regulations.

CHARACTERIZATION

To ensure consistently high-quality reagents, each lot of antibody is tested for conformance with characteristics of a standard reagent. Representative flow cytometric data is included in this data sheet.

WARRANTY

Unless otherwise indicated in any applicable BD general conditions of sale for non-US customers, the following warranty applies to the purchase of these products.

THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NONINFRINGEMENT. BD'S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT.

REFERENCES

1. Lewis DE, Cook RG, Dittmore RD, et al. Effects of monoclonal antibodies against CD19, CD20, and a new B-cell antigen, 37.1, on B-cell proliferation and differentiation. In: McMichael AJ, Beverley PC, Cobbold S, et al, eds. *Leucocyte Typing III: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1987:452-453.
2. Pezzutto A, Dörken B, Rabinovitch PS, Ledbetter JA, Moldenhauer G, Clark EA. CD19 monoclonal antibodies inhibit B-cell activation and proliferation. In: McMichael AJ, Beverley PC, Cobbold S, et al, eds. *Leucocyte Typing III: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1987:358-360.
3. Dörken B, Möller P, Pezzutto A, Schwartz-Albiez R, Moldenhauer G. B-cell antigens: CD19. In: Knapp W, Dörken B, Gilks WR, et al, eds. *Leucocyte Typing IV: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1989:34-36.
4. Ling NR, MacLennan ICM, Mason DY. B-cell and plasma cell antigens: new and previously defined clusters. In: McMichael AJ, Beverley PC, Cobbold S, et al, eds. *Leucocyte Typing III: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1987:302-335.
5. Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. II. Normal B-lymphocyte development. *Blood*. 1987;70:1316-1324.

6. Mongini PK, Jackson AE, Tolani S, Fattah RJ, Inman JK. Role of complement-binding CD21/CD19/CD81 in enhancing human B cell protection from Fas-mediated apoptosis. *J Immunol.* 2003;171:5244-5254.
7. Moldenhauer G, Dörken B, Schwartz R, Pezzutto A, Knops J, Hammerling GJ. Analysis of ten B lymphocyte-specific workshop monoclonal antibodies. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, eds. *Leukocyte Typing II: Human B Lymphocytes*. Vol 2. New York, NY: Springer-Verlag; 1986:61-67.
8. Nadler LM. B Cell/Leukemia Panel Workshop: Summary and Comments. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, eds. *Leukocyte Typing II: Human B Lymphocytes*. Vol 2. New York, NY: Springer-Verlag; 1986:3-43.
9. Reichert T, DeBruyère M, Deney V, et al. Lymphocyte subset reference ranges in adult Caucasians. *Clin Immunol Immunopathol.* 1991;60:190-208.
10. Tedder TF, Zhou LJ, Engel P. The CD19/CD21 signal transduction complex of B lymphocytes. *Immunol Today.* 1994;15:437-442.
11. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline — Third Edition.* Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI document M29-A3.
12. Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. *MMWR.* 1988;37:377-388.

PATENTS AND TRADEMARKS

Cy™ is a trademark of GE Healthcare. This product is subject to proprietary rights of GE Healthcare and Carnegie Mellon University, and is made and sold under license from GE Healthcare. This product is licensed for sale only for research. It is not licensed for any other use. If you require a commercial license to use this product and do not have one, return this material, unopened, to BD Biosciences, 2350 Qume Drive, San Jose, CA 95131, and any money paid for the material will be refunded.

ProClin is a trademark of the Dow Chemical Company or an affiliated company of Dow.

BD and the BD Logo are trademarks of Becton, Dickinson and Company or its affiliates. © 2019 BD. All rights reserved.



CD64 (10.1)

Form **Catalog number**
PE 644385

Product availability varies by region. Contact BD Biosciences Customer Support or your local sales representative for information.

RESEARCH APPLICATIONS

Research applications include studies of:

- Inflammatory response¹
- Neutrophil and monocyte function^{1, 2}
- Dendritic cell function³
- Sepsis⁴
- Vaccine development⁵
- Cancer therapy⁶

DESCRIPTION

Specificity

The CD64 antibody recognizes the 72-kilodalton (kDa) human FcγRI that can bind monomeric IgG.^{1,2}

Antigen distribution

The CD64 antigen is one of three Fc receptors for immunoglobulins, including human FcγRII (CD32 antigen) and human FcγRIII (CD16 antigen), present on the surface of leucocytes.^{1,2} While FcγRII and FcγRIII are low-affinity receptors for immunoglobulin, FcγRI bind with high affinity.^{1,2} Structurally, the CD64 antigen possesses an extracellular region of 292 amino acids with three C2 set Ig-like domains, a 21-amino acid transmembrane region, and a charged cytoplasmic tail of 61 amino acids.^{1,2} Stable expression of FcγRI requires coexpression of the IgG-binding α-chain as an oligomeric complex with the FcR γ-chain homodimer.⁷

CD64, a key receptor in the development of immune responses, has a dual role as a low-affinity receptor for IgG₃ and a high-affinity receptor for IgG_{2a} linking innate and adaptive immunities.

The CD64 antigen is expressed on monocytes, macrophages, at low levels on polymorphonuclear neutrophils (PMNs),^{1,2} and on a subpopulation of circulating dendritic cells.³ CD64 is an early granulomonocytic lineage marker on CD34⁺ hematopoietic progenitors.⁸ Soluble human FcγRI molecules have been found in human serum.⁹ Three genes have been characterized for FcγRI, each gene consisting of six exons, spanning 9.5 kilobases, and localized to chromosome 1.^{9,10}

Clone

The CD64 antibody, clone 10.1, is derived from a fusion of Sp2/0-Ag14 cells with spleen cells from a BALB/c mouse that was immunized first with 2×10^7 rheumatoid synovial fluid cells and on subsequent occasions with 1.5×10^7 fibronectin-purified human monocytes obtained from pools of blood group-matched donors.¹¹

Composition

The CD64 antibody is composed of mouse IgG₁ heavy chains and kappa light chains.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Product configuration

The following is supplied in phosphate buffered saline (PBS) containing bovine serum albumin (BSA) and a preservative.

Form	Number of tests	Volume per test (μL) ^a	Amount provided (μg)	Total volume (mL)	Concentration (μg/mL)	Stabilizer	Preservative
PE	50	20	25	1.0	25	BSA	0.1% Sodium azide

a. Volume required to stain 10^6 cells.


PROCEDURE

Visit our website (bdbiosciences.com) or contact your local BD representative for the lyse/wash protocol for direct immunofluorescence.

REPRESENTATIVE DATA

Flow cytometric analysis was performed on whole blood. Laser excitation was at 488 nm.

Figure 1 Representative data analyzed with a BD FACSTM brand flow cytometer



HANDLING AND STORAGE

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

WARNING

All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection^{12,13} and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves.

CHARACTERIZATION

To ensure consistently high-quality reagents, each lot of antibody is tested for conformance with characteristics of a standard reagent. Representative flow cytometric data is included in this data sheet.

WARRANTY

Unless otherwise indicated in any applicable BD general conditions of sale for non-US customers, the following warranty applies to the purchase of these products.

THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NONINFRINGEMENT. BD'S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT.

REFERENCES

1. van de Winkel JG, Capel PJ. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. *Immunol Today*. 1993;14:215-221.
2. van de Winkel JG, Anderson CL. Biology of human immunoglobulin G Fc receptors. *J Leukoc Biol*. 1991;49:511-524.
3. Fanger NA, Wardwell K, Shen L, Tedder TF, Guyre PM. Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. *J Immunol*. 1996;157:541-548.

4. Davis BH, Bigelow NC, Curnutte JT, Ornvald K. Neutrophil CD64 expression: potential diagnostic indicator of acute inflammation and therapeutic monitor of interferon- γ therapy. *Lab Hematol.* 1995;1:3-12.
5. Gosselin EJ, Wardwell K, Gosselin DR, Alter N, Fisher JL, Guyre PM. Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens. *J Immunol.* 1992;149:3477-3481.
6. Valerius T, Repp R, de Wit TP, et al. Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. *Blood.* 1993;82:931-939.
7. van Vugt MJ, Heijnen IAFM, Capel PJ, et al. FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo. *Blood.* 1996;87:3593-3599.
8. Olweus J, Terstappen LWMM, Thompson PA, Lund-Johansen F. Expression and function of receptors for stem cell factor and erythropoietin during lineage commitment of human hematopoietic progenitor cells. *Blood.* 1996;88:1594-1607.
9. Ernst LK, van de Winkel JG, Chiu IM, Anderson CL. Three genes for the human high affinity Fc receptor for IgG (Fc gamma RI) encode four distinct transcription products. *J Biol Chem.* 1992;267:15692-15700.
10. van de Winkel JG, Ernst LK, Anderson CL, Chiu IM. Gene organization of the human high affinity receptor for IgG, Fc gamma RI (CD64). Characterization and evidence for a second gene. *J Biol Chem.* 1991;266:13449-13455.
11. Dougherty GJ, Selvendran Y, Murdoch S, Palmer DG, Hogg N. The human mononuclear phagocyte high-affinity Fc receptor, FcRI, defined by a monoclonal antibody, 10.1. *Eur J Immunol.* 1987;17:1453-1459.
12. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline — Third Edition.* Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI document M29-A3.
13. Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. *MMWR.* 1988;37:377-388.

PATENTS AND TRADEMARKS

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2014 BD

Monoclonal Antibodies Detecting Human Antigens

CD10 (HI10a)

Form	Catalog number
FITC	340925
PE	340921
PE-Cy7	341092
APC	340923
APC-H7	655404
APC-R700	659120

Product availability varies by region. Contact BD Biosciences Customer Support or your local sales representative for information.

RESEARCH APPLICATIONS

Research applications include:

- Characterization of non-T (common) acute lymphoblastic leukemias^{1,2}
- Analysis of early stages of hematopoietic differentiation³⁻⁵
- Analysis of neutrophil chemotaxis⁶⁻⁸

DESCRIPTION

Specificity

The CD10 antibody recognizes a 100-kilodalton (kDa) type II transmembrane, glycosylated, zinc-containing metalloprotease.^{9,10} The CD10 antigen is also known as common acute lymphoblastic leukemia antigen (CALLA), neutral endopeptidase (NEP), gp100, and enkephalinase.¹¹

Antigen distribution

The CD10 antigen is found on lymphocytes from samples with acute B-lymphoid leukemia.¹² The CD10 antigen is also present on a wide variety of normal and neoplastic cell types including renal epithelium, fibroblasts, granulocytes, germinal center B lymphocytes,¹³ neutrophils,^{6,7,14} some T-cell leukemias,¹⁵ and some lymphoma, melanoma, and glioma cell lines.¹¹

The CD10 antigen cleaves a number of biologically active peptides,¹⁶ including fMLP, and may modulate the chemotactic activity of fMLP towards neutrophils.⁸ Inhibition of the CD10 antigen promotes B-cell maturation,¹⁷ suggesting that it plays a role in B-cell development.

Clone

The CD10 antibody, clone HI10a,¹⁰ is derived from the hybridization of P3-63-Ag8.653 mouse myeloma cells with spleen cells isolated from BALB/c mice immunized with blasts from a patient with acute CALLA leukemia.

Composition

The CD10 antibody is composed of mouse IgG₁ heavy chains and kappa light chains.

Product configuration

The following are supplied in phosphate buffered saline (PBS) containing a stabilizer and a preservative.

Form	Number of tests	Volume per test (μL) ^a	Amount provided (μg)	Total volume (mL)	Concentration (μg/mL)	Stabilizer	Preservative
FITC	50	20	12.5	1	12.5	Gelatin	0.1% Sodium azide
PE	50	20	6	1	6	Gelatin	0.1% Sodium azide
PE-Cy TM 7	100	5	12.5	0.5	25	Gelatin	0.1% Sodium azide
APC	100	5	12.5	0.5	25	Gelatin	0.1% Sodium azide

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Becton, Dickinson and Company
BD Biosciences
 2350 Qume Drive
 San Jose, CA 95131 USA



Form	Number of tests	Volume per test (μL) ^a	Amount provided (μg)	Total volume (mL)	Concentration (μg/mL)	Stabilizer	Preservative
APC-H7	100	5	2.5	0.5	50	BSA	ProClin® 300
APC-R700 ^b	100	5	6.25	0.5	12.5	BSA	ProClin 300

a. Volume required to stain 10⁶ cells.

b. BD Horizon™ APC-R700

CAUTION Some PE-Cy7, APC-H7, and APC-R700 conjugates show changes in their emission spectra with prolonged exposure to paraformaldehyde or light. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.


PROCEDURE

Visit our website (bdbiosciences.com) or contact your local BD representative for the lyse/wash protocol for direct immunofluorescence.

REPRESENTATIVE DATA

Flow cytometric analysis was performed on 10⁶ REH cells added per mL of whole blood stained with the indicated conjugated antibody and gated on lymphocytes, monocytes, and REH cells. Laser excitation was at 488 nm, 635 nm, or 640 nm.

The APC-R700 conjugate is read off the red laser (640 nm) using a 685 longpass mirror with a 712/21 bandpass filter. Representative data analyzed with a BD FACST™ brand flow cytometer is shown in the following plots.



HANDLING AND STORAGE

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

WARNING

All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection^{18,19} and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing and gloves.

Some reagents are bottled with ProClin 300, and contain 0.003% of a mixture of CMIT/MIT (3:1), CAS number 55965-84-9.



Warning

H317 May cause an allergic skin reaction.

Wear protective gloves/eye protection. Wear protective clothing. Avoid breathing mist/vapours/spray. If skin irritation or rash occurs: Get medical advice/attention. IF ON SKIN: Wash with plenty of water. Dispose of contents/container in accordance with local/regional/national/international regulations.

CHARACTERIZATION

To ensure consistently high-quality reagents, each lot of antibody is tested for conformance with characteristics of a standard reagent. Representative flow cytometric data is included in this data sheet.

WARRANTY

Unless otherwise indicated in any applicable BD general conditions of sale for non-US customers, the following warranty applies to the purchase of these products.

THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NON-INFRINGEMENT. BD'S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT.

REFERENCES

1. Hann IM, Richards SM, Eden OB, Hill FGH. Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI). *Leukemia*. 1998;12:1249-1255.
2. Nadler LM, Korsmeyer SJ, Anderson KC, et al. B cell origin of non-T cell acute lymphoblastic leukemia: a model for discrete stages of neoplastic and normal pre-B cell differentiation. *J Clin Invest*. 1984;74:332-340.
3. Dworzak MN, Fritsch G, Fleischer C, et al. Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow. *Leukemia*. 1997;11:1266-1273.
4. Dworzak MN, Fritsch G, Fröschl G, Printz D, Gadner H. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny. *Blood*. 1998;92:3203-3209.
5. Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. II. Normal B-lymphocyte development. *Blood*. 1987;70:1316-1324.
6. Connelly JC, Skidgel RA, Schulz WW, Johnson AR, Erdos EG. Neutral endopeptidase 24.11 in human neutrophils: cleavage of chemotactic peptide. *Proc Natl Acad Sci USA*. 1985;82:8737-8741.
7. Erdös EG, Wagner B, Harbury CB, Painter RG, Skidgel RA, Fa XG. Down-regulation and inactivation of neutral endopeptidase 24.11 (enkephalinase) in human neutrophils. *J Biol Chem*. 1989;264:14519-14523.
8. Hofman P, Selva E, Le Negrate G, et al. CD10 inhibitors increase f-Met-Leu-Phe-induced neutrophil transmigration. *J Leukoc Biol*. 1998;63:312-320.
9. Greaves MF. Monoclonal antibodies as probes for leukemic heterogeneity and hematopoietic differentiation. In: Knapp W, ed. *Leukemia Markers*. New York, NY: Academic Press; 1981:19.
10. Zola H. CD10 Workshop Panel report. In: Schlossman SF, Boumsell L, Gilks W, et al, eds. *Leucocyte Typing V: White Cell Differentiation Antigens*. Vol 1. New York, NY: Oxford University Press; 1995:505-507.
11. Letarte M, Vera S, Tran R, et al. Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase. *J Exp Med*. 1988;168:1247-1253.

12. LeBien TW, McCormack RT. The common acute lymphoblastic leukemia antigen (CD10)—emancipation from a functional enigma. *Blood*. 1989;73:625-635.
13. Caligaris-Cappio F, Riva M, Tesio L, Schena M, Gaidano G, Bergui L. Human normal CD5⁺ B lymphocytes can be induced to differentiate to CD5⁻ B lymphocytes with germinal center cell features. *Blood*. 1989;73:1259-1263.
14. Connelly JC, Chambless R, Holiday D, Chittenden K, Johnson AR. Up-regulation of neutral endopeptidase (CALLA) in human neutrophils by granulocyte-macrophage colony-stimulating factor. *J Leukoc Biol*. 1993;53:685-690.
15. Consolini R, Legitimo A, Rondelli R, et al. Clinical relevance of CD10 expression in childhood ALL. *Haematologica*. 1998;83:967-973.
16. Erdös EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. *FASEB J*. 1989;3:145-151.
17. Salles G, Rodewald HR, Chin BS, Reinherz EL, Shipp MA. Inhibition of CD10/neutral endopeptidase 24.11 promotes B-cell reconstitution and maturation in vivo. *Proc Natl Acad Sci USA*. 1993;90:7618-7622.
18. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline — Third Edition*. Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI document M29-A3.
19. Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. *MMWR*. 1988;37:377-388.

PATENTS AND TRADEMARKS

Cy™ is a trademark of GE Healthcare. This product is subject to proprietary rights of GE Healthcare and Carnegie Mellon University, and is made and sold under license from GE Healthcare. This product is licensed for sale only for research. It is not licensed for any other use. If you require a commercial license to use this product and do not have one, return this material, unopened, to BD Biosciences, 2350 Qume Drive, San Jose, CA 95131, and any money paid for the material will be refunded.

ProClin is a registered trademark of Rohm and Haas Company.

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2015 BD

Monoclonal Antibodies Detecting Human Antigens

CD43 (1G10)

Form APC-H7 Catalog number 655407

Product availability varies by region. Contact BD Biosciences Customer Support or your local sales representative for information.

RESEARCH APPLICATIONS

Research applications include:

- Research on T cell-macrophage interactions¹
- Research on neutrophil spreading and movement^{2,3}
- Study of *Streptococcus gordonii* DL1 binding to myeloid cells⁴

DESCRIPTION

Specificity

The CD43 antibody reacts specifically with the major 95–135-kilodalton (kDa) sialoglycoprotein found on most human leucocytes.⁵ The CD43 antigen is also known as leukosialin or sialophorin.

Antigen distribution

The CD43 antigen is expressed on T cells, natural killer (NK) cells, pre-B and activated B cells,⁵ granulocytes,⁶ and neutrophils.³ The CD43 antigen is differentially expressed on subpopulations of mononuclear phagocytic cells.⁷ It is not present on most peripheral blood resting B cells, erythrocytes, and non-hematopoietic cells.⁵ Additionally, expression of the CD43 antigen by committed myeloid, erythroid, and lymphoid progenitors has been reported.

The CD43 antigen may be involved in the regulation of B, T, and NK cell function.^{5,8–10} The CD43 antigen plays a role in cell adhesion, which can be positive or negative, depending on the context.^{2,11} The CD43 antigen serves as a counter-receptor for CD169, the prototypical member of the sialic acid binding Ig-like lectins (Siglec) family expressed on macrophages.¹

Clone

The CD43 antibody, clone 1G10,⁵ is derived from the hybridization of X63 mouse myeloma cells with spleen cells isolated from mice immunized with a lymph node suspension from a patient with Hodgkin lymphoma.

Composition

The CD43 antibody is composed of mouse IgG₁ heavy chains and kappa light chains.

Product configuration

The following is supplied in phosphate buffered saline (PBS) containing a stabilizer and a preservative.

Form	Number of tests	Volume per test (μL) ^a	Amount provided (μg)	Total volume (mL)	Concentration (μg/mL)	Stabilizer	Preservative
APC-H7	100	5	25	0.5	50	BSA	ProClin® 300

a. Volume required to stain 10⁶ cells.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Becton, Dickinson and Company
BD Biosciences
2350 Qume Drive
San Jose, CA 95131 USA




CAUTION Some APC-H7 conjugates show changes in their emission spectra with prolonged exposure to paraformaldehyde or light. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.

PROCEDURE

Visit our website (bdbiosciences.com) or contact your local BD representative for the lyse/wash protocol for direct immunofluorescence.

REPRESENTATIVE DATA

Flow cytometric analysis was performed on whole blood stained with the indicated conjugated antibody. Laser excitation was at 635 nm. Representative data analyzed with a BD FACS™ brand flow cytometer is shown in the following plot.



HANDLING AND STORAGE

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

WARNING

All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection^{12,13} and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves.

Some reagents are bottled with ProClin 300, and contain 0.003% of a mixture of CMIT/MIT (3:1), CAS number 55965-84-9.



Warning

H317 May cause an allergic skin reaction.

Wear protective gloves/eye protection. Wear protective clothing. Avoid breathing mist/vapours/spray. If skin irritation or rash occurs: Get medical advice/attention. IF ON SKIN: Wash with plenty of water. Dispose of contents/container in accordance with local/regional/national/international regulations.

CHARACTERIZATION

To ensure consistently high-quality reagents, each lot of antibody is tested for conformance with characteristics of a standard reagent. Representative flow cytometric data is included in this data sheet.

WARRANTY

Unless otherwise indicated in any applicable BD general conditions of sale for non-US customers, the following warranty applies to the purchase of these products.

THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NONINFRINGEMENT. BD'S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT.

REFERENCES

1. van den Berg TK, Nath D, Ziltener HJ, et al. Cutting edge: CD43 functions as a T cell counterreceptor for the macrophage adhesion receptor sialoadhesin (Siglec-1). *J Immunol.* 2001;166:3637-3640.
2. Matsumoto M, Shigeta A, Miyasaka M, Hirata T. CD43 plays both antiadhesive and proadhesive roles in neutrophil rolling in a context-dependent manner. *J Immunol.* 2008;181:3628-3635.

3. Nathan C, Xie QW, Halbwachs-Mecarelli L, Jin WW. Albumin inhibits neutrophil spreading and hydrogen peroxide release by blocking the shedding of CD43 (sialophorin, leukosialin). *J Cell Biol.* 1993;122:243-256.
4. Urano-Tashiro Y, Yajima A, Takashima E, Takahashi Y, Konishi K. Binding of the Streptococcus gordonii DL1 surface protein Hsa to the host cell membrane glycoproteins CD11b, CD43, and CD50. *Infect Immun.* 2008;76:4686-4691.
5. Horejsi V, Stockinger H. CD43 Workshop Panel report. In: Kishimoto H, Kikutani H, von dem Borne AEGK, et al, eds. *Leucocyte Typing VI: White Cell Differentiation Antigens*. New York: Garland Publishing, Inc.; 1998:494-497.
6. Bazil V, Strominger JL. CD43, the major sialoglycoprotein of human leukocytes, is proteolytically cleaved from the surface of stimulated lymphocytes and granulocytes. *Proc Natl Acad Sci U S A.* 1993;90:3792-3796.
7. Howell DN, Ahuja V, Jones L, Blow O, Sanfilippo FP. Differential expression of CD43 (leukosialin, sialophorin) by mononuclear phagocyte populations. *J Leukoc Biol.* 1994;55:536-544.
8. Bettaieb A, Farace F, Mitjavila MT, et al. Use of a monoclonal antibody (GA3) to demonstrate lineage restricted O-glycosylation on leukosialin during terminal erythroid differentiation. *Blood.* 1988;71:1226-1233.
9. Borche L, Lozano F, Vilella R, Vives J. CD43 monoclonal antibodies recognize the large sialoglycoprotein of human leukocytes. *Eur J Immunol.* 1987;17:1523-1526.
10. Zola H, Swart B, Nicholson I, Voss E. *Leukocyte and Stromal Cell Molecules: The CD Markers*. Hoboken, NJ: John Wiley & Sons, Inc.; 2007.
11. Ardman B, Sikorski MA, Staunton DE. CD43 interferes with T-lymphocyte adhesion. *Proc Natl Acad Sci U S A.* 1992;89:5001-5005.
12. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline — Third Edition*. Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI document M29-A3.
13. Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. *MMWR.* 1988;37:377-388.

PATENTS AND TRADEMARKS

ProClin is a registered trademark of Rohm and Haas Company.

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2015 BD

CD16 (CLB/FcGran1)

Form Catalog number
FITC 656146

Product availability varies by region. Contact BD Biosciences Customer Support or your local sales representative for information.

RESEARCH APPLICATIONS

Research applications include:

- Enumeration of natural killer (NK) cells¹
- Delineation of NK cell activation and signal transduction²
- Investigation of antibody-dependent cellular cytotoxicity (ADCC)³
- Characterization of leukemias and lymphomas⁴

DESCRIPTION

Specificity

The CD16 antibody recognizes a 50–65 kilodalton (kDa) transmembrane glycoprotein which is a member of the Fcγ receptor subfamily of the immunoglobulin (Ig) superfamily. The antigen is also known as FcγRIIIa.⁵

Antigen distribution

The CD16 antigen is expressed on approximately 15% of peripheral blood lymphocytes and is present on virtually all resting NK lymphocytes.⁶ The CD16 antigen can be expressed on CD3⁺ T lymphocytes from certain individuals.⁷ The CD16 antigen is also expressed on macrophages, granulocytes, and neutrophils.^{5,8} A variable number of CD16⁺ lymphocytes co-express either the CD57 antigen or low-density CD8 antigen, or both.⁸⁻¹⁰ CD16⁺CD56⁺ NK cells and dendritic cells demonstrate a reciprocal activation of one another.¹¹

Clone

The CD16 antibody, clone CLB/FcGran1,¹² is derived from the hybridization of Sp2/0 mouse myeloma cells with spleen cells isolated from BALB/c mice immunized with human granulocytes.

Composition

The CD16 antibody is composed of mouse IgG_{2a} heavy chains and kappa light chains.

Product configuration

The following is supplied in phosphate buffered saline (PBS) containing a stabilizer and a preservative.

Form	Number of tests	Volume per test (μL) ^a	Amount provided (μg)	Total volume (mL)	Concentration (μg/mL)	Stabilizer	Preservative
FITC	50	20	50	1	50	Gelatin	0.1% Sodium azide

a. Volume required to stain 10⁶ cells.


PROCEDURE

Visit our website (bdbiosciences.com) or contact your local BD representative for the lyse/wash protocol for direct immunofluorescence.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

REPRESENTATIVE DATA

Flow cytometric analysis was performed on whole blood stained with the indicated conjugated antibody. Laser excitation was at 488 nm. Representative data analyzed with a BD FACS™ brand flow cytometer is shown in the following plot.



HANDLING AND STORAGE

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

WARNING

All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection^{13,14} and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves.

CHARACTERIZATION

To ensure consistently high-quality reagents, each lot of antibody is tested for conformance with characteristics of a standard reagent. Representative flow cytometric data is included in this data sheet.

WARRANTY

Unless otherwise indicated in any applicable BD general conditions of sale for non-US customers, the following warranty applies to the purchase of these products.

THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NONINFRINGEMENT. BD'S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT.

REFERENCES

1. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. *Trends Immunol.* 2001;22:633-640.
2. Galandrini R, Tassi I, Mattia G, et al. SH2-containing inositol phosphatase (SHIP-1) transiently translocates to raft domains and modulates CD16-mediated cytotoxicity in human NK cells. *Blood.* 2002;100:4581-4589.
3. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. *Nat Rev Immunol.* 2008;8:34-47.
4. van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. *Leukemia.* 2012;26:1908-1975.
5. Zola H, Swart B, Nicholson I, Voss E. *Leukocyte and Stromal Cell Molecules: The CD Markers.* Hoboken, NJ: John Wiley & Sons, Inc.; 2007.
6. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. *J Immunol.* 1986;136:4480-4486.
7. Lanier LL, Kipps T, Phillips JH. Functional properties of a unique subset of cytotoxic CD3⁺ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen). *J Exp Med.* 1985;162:2089-2106.
8. Lanier LL, Le AM, Phillips JH, Warner NL, Babcock GF. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. *J Immunol.* 1983;131:1789-1796.

9. Perussia B, Starr S, Abraham S, Fanning V, Trinchieri G. Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. *J Immunol.* 1983;130:2133-2141.
10. Perussia B, Trinchieri G, Jackson A, et al. The Fc receptor for IgG on human natural killer cells: phenotypic, functional, and comparative studies with monoclonal antibodies. *J Immunol.* 1984;133:180-189.
11. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. *J Exp Med.* 2002;195:327-333.
12. Schmidt RE, Perussia B. Cluster report: CD16. In: Knapp W, Dörken B, Gilks WR, et al., eds. *Leucocyte Typing IV: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1989:574-578.
13. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline — Third Edition*. Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI document M29-A3.
14. Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. *MMWR.* 1988;37:377-388.

**PATENTS AND
TRADEMARKS**

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2015 BD

Monoclonal Antibodies Detecting Human Antigens

CD23 (EBVCS-5)

Form	Catalog number
FITC	656148
PE	341007
APC	340935
APC-R700	659125

Product availability varies by region. Contact BD Biosciences Customer Support or your local sales representative for information.

RESEARCH APPLICATIONS

Research applications include:

- Investigation into the regulation of IgE synthesis¹
- Examination of B-lymphocyte differentiation²
- Analysis of aminoacyl-tRNA-synthetase-interacting multifunctional protein 1 (AIMP1)-induced inflammation³
- Characterization of leukemias and lymphomas⁴

DESCRIPTION

Specificity

The CD23 antibody recognizes a 45-kilodalton (kDa) type II membrane glycoprotein, which is a human B-lymphocyte differentiation antigen. The CD23 antigen is also known as the low affinity IgE receptor, Fc epsilon RII, and FcεRII.^{2,5-7}

Antigen distribution

The CD23 antigen is present at low density on most normal B lymphocytes⁸ and at higher levels on activated B lymphocytes, Epstein-Barr virus (EBV)-transformed lymphoblasts, chronic lymphocytic leukemia (CLL) cells of B-lymphocyte origin, and tonsillar B lymphocytes.⁶ The human B-lymphoblastoid cell line, RPMI-8866, releases a 25-kDa species into the culture supernatant.⁹

The CD23 antigen density increases on the surface of B lymphocytes shortly after activation.¹⁰ Expression is induced by interleukin-4 (IL-4) and down-regulated by B-cell growth factor (BCGF).^{5,9} The antigen is lost after isotype switching to IgA, IgG, or IgE.^{2,9} The CD23 antigen is not present on immature bone marrow B lymphocytes or on T lymphocytes,² but it has been reported on monocytes, hypodense eosinophils, and a subpopulation of platelets.¹¹

Clone

The CD23 antibody, clone EBVCS-5 (Leu 20),^{7,12} is derived from the hybridization of Sp2/0 mouse myeloma cells with spleen cells isolated from BALB/c mice immunized with an in vitro transformed EBV cell line.¹³

Composition

The CD23 antibody is composed of mouse IgG₁ heavy chains and kappa light chains.

Product configuration

The following are supplied in phosphate buffered saline (PBS) containing a stabilizer and a preservative.

Form	Number of tests	Volume per test (μL) ^a	Amount provided (μg)	Total volume (mL)	Concentration (μg/mL)	Stabilizer	Preservative
FITC	50	20	12.5	1	12.5	Gelatin	0.1% Sodium azide
PE	50	20	12.5	1	12.5	Gelatin	0.1% Sodium azide

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Becton, Dickinson and Company
BD Biosciences
2350 Qume Drive
San Jose, CA 95131 USA



Form	Number of tests	Volume per test (µL) ^a	Amount provided (µg)	Total volume (mL)	Concentration (µg/mL)	Stabilizer	Preservative
APC	100	5	12.5	0.5	25	Gelatin	0.1% Sodium azide
APC-R700 ^b	100	5	6.25	0.5	12.5	BSA	ProClin® 300

a. Volume required to stain 10⁶ cells.

b. BD Horizon™ APC-R700

CAUTION Some APC-R700 conjugates show changes in their emission spectra with prolonged exposure to paraformaldehyde or light. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.


PROCEDURE

Visit our website (bdbiosciences.com) or contact your local BD representative for the lyse/wash protocol for direct immunofluorescence.

REPRESENTATIVE DATA

Flow cytometric analysis was performed on whole blood stained with the indicated conjugated antibody. Laser excitation was at 488 nm, 635 nm, or 640 nm.

The APC-R700 conjugate is read off the red laser (640 nm) using a 685 longpass mirror with a 712/21 bandpass filter. Representative data analyzed with a BD FACS™ brand flow cytometer is shown in the following plots.



HANDLING AND STORAGE

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

WARNING

All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection^{14,15} and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves.

Some reagents are bottled with ProClin 300, and contain 0.003% of a mixture of CMIT/MIT (3:1), CAS number 55965-84-9.



Warning

H317 May cause an allergic skin reaction.

Wear protective gloves/eye protection. Wear protective clothing. Avoid breathing mist/vapours/spray. If skin irritation or rash occurs: Get medical advice/attention. IF ON SKIN: Wash with plenty of water. Dispose of contents/container in accordance with local/regional/national/international regulations.

CHARACTERIZATION

To ensure consistently high-quality reagents, each lot of antibody is tested for conformance with characteristics of a standard reagent. Representative flow cytometric data is included in this data sheet.

WARRANTY

Unless otherwise indicated in any applicable BD general conditions of sale for non-US customers, the following warranty applies to the purchase of these products.

THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NONINFRINGEMENT. BD'S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT.

REFERENCES

1. Sherr E, Macy E, Kimata H, Gilly M, Saxon A. Binding the low affinity Fc epsilon R on B cells suppresses ongoing human IgE synthesis. *J Immunol.* 1989;142:481-489.
2. Yukawa K, Kikutani H, Owaki H, et al. A B cell-specific differentiation antigen, CD23, is a receptor for IgE (FcεR) on lymphocytes. *J Immunol.* 1987;138:2576-2580.
3. Kwon HS, Park MC, Kim DG, et al. Identification of CD23 as a functional receptor for the proinflammatory cytokine AIMP1/p43. *J Cell Sci.* 2012;125:4620-4629.
4. van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. *Leukemia.* 2012;26:1908-1975.
5. Gordon J, Webb AJ, Walker L, Guy GR, Rowe M. Evidence of an association between CD23 and the receptor for a low molecular weight B cell growth factor. *Eur J Immunol.* 1986;16:1627-1630.
6. Thorley-Lawson DA, Nadler LM, Bhan AK, Schooley RT. BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus. *J Immunol.* 1985;134:3007-3012.
7. Nadler LM. B Cell/Leukemia Panel Workshop: Summary and Comments. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, eds. *Leukocyte Typing II: Human B Lymphocytes*. Vol 2. New York, NY: Springer-Verlag; 1986:3-43.
8. Kikutani H, Suemura M, Owaki H, et al. Fcε receptor, a specific differentiation marker transiently expressed on mature B cells before isotype switching. *J Exp Med.* 1986;164:1455-1469.
9. Kikutani H, Inui S, Sato R, et al. Molecular structure of human lymphocyte receptor for immunoglobulin E. *Cell.* 1986;47:657-665.
10. Gordon J, Rowe M, Walker L, Guy G. Ligation of the CD23,p45 (BLAST-2,EBVCS) antigen triggers the cell-cycle progression of activated B lymphocytes. *Eur J Immunol.* 1986;16:1075-1080.
11. Capron M, Jouault T, Prin L, et al. Functional study of a monoclonal antibody to IgE Fc receptor (Fc epsilon R2) of eosinophils, platelets, and macrophages. *J Exp Med.* 1986;164:72-89.
12. Sarfati M, Ishihara H, Delespesse G. CD23 Workshop Panel report. In: Schlossman SF, Boumsell L, Gilks W, et al, eds. *Leucocyte Typing V: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1995:530-533.
13. Kintner C, Sugden B. Identification of antigenic determinants unique to the surfaces of cells transformed by Epstein-Barr virus. *Nature.* 1981;294:458-460.
14. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline — Third Edition*. Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI document M29-A3.
15. Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. *MMWR.* 1988;37:377-388.

PATENTS AND TRADEMARKS

ProClin is a registered trademark of Rohm and Haas Company.

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2015 BD

Monoclonal Antibodies Detecting Human Antigens

RESEARCH APPLICATIONS

DESCRIPTION

Specificity

The CD36 antibody specifically binds to the 88-kilodalton (kDa) glycoprotein IV of platelets.⁶ The antigen is also known as GPIV, GP4, GP3B, thrombospondin receptor, PASIV, FAT, and SCARB3.

Antigen distribution

The CD36 antigen is expressed on platelets, megakaryocytes, monocytes, macrophages, dendritic cells, erythroid precursors, adipocytes, and some endothelial and epithelial cells.^{7,8}

The CD36 antigen is the receptor for extracellular matrix proteins such as collagen and thrombospondin.^{8,9} The CD36 antigen can mediate the adhesion of erythrocytes infected with the human malaria parasite, *Plasmodium falciparum*.¹⁰⁻¹² The CD36 antigen functions as a scavenger receptor in macrophages.⁷

Clone

The CD36 antibody, clone CLB-IVC7,¹³ is derived from the hybridization of Sp2/0 mouse myeloma cells with spleen cells isolated from BALB/c mice immunized with human monocytes.

Composition

The CD36 antibody is composed of mouse IgG₁ heavy chains and kappa light chains.

Product configuration

The following is supplied in phosphate buffered saline (PBS) containing a stabilizer and a preservative.

Form	Number of tests	Volume per test (μL) ^a	Amount provided (μg)	Total volume (mL)	Concentration (μg/mL)	Stabilizer	Preservative
FITC	50	20	12.5	1	12.5	Gelatin	0.1% Sodium azide

a. Volume required to stain 10⁶ cells.

PROCEDURE

Visit our website (bdbiosciences.com) or contact your local BD representative for the lyse/wash protocol for direct immunofluorescence.

REPRESENTATIVE DATA


Flow cytometric analysis was performed on whole blood stained with the indicated conjugated antibody. Laser excitation was at 488 nm. Representative data analyzed with a BD FACST[™] brand flow cytometer is shown in the following plot.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Becton, Dickinson and Company
BD Biosciences
2350 Qume Drive
San Jose, CA 95131 USA

bdbiosciences.com
ResearchApplications@bd.com





HANDLING AND STORAGE

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

WARNING

All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection^{14,15} and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves.

CHARACTERIZATION

To ensure consistently high-quality reagents, each lot of antibody is tested for conformance with characteristics of a standard reagent. Representative flow cytometric data is included in this data sheet.

WARRANTY

Unless otherwise indicated in any applicable BD general conditions of sale for non-US customers, the following warranty applies to the purchase of these products.

THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NONINFRINGEMENT. BD'S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT.

REFERENCES

- Scicchitano MS, McFarland DC, Tierney LA, Narayanan PK, Schwartz LW. In vitro expansion of human cord blood CD36+ erythroid progenitors: temporal changes in gene and protein expression. *Exp Hematol.* 2003;31:760-769.
- Garçon L, Lacout C, Svinartchouk F, et al. Gfi-1B plays a critical role in terminal differentiation of normal and transformed erythroid progenitor cells. *Blood.* 2005;105:1448-1455.
- de Wolf JT, Muller EW, Hendriks DH, Halie RM, Vellenga E. Mast cell growth factor modulates CD36 antigen expression on erythroid progenitors from human bone marrow and peripheral blood associated with ongoing differentiation. *Blood.* 1994;84:59-64.
- Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA. CD36 is a receptor for oxidized low density lipoprotein. *J Biol Chem.* 1993;268:11811-11816.
- van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. *Leukemia.* 2012;26:1908-1975.
- Zola H, Swart B, Nicholson I, Voss E. *Leukocyte and Stromal Cell Molecules: The CD Markers.* Hoboken, NJ: John Wiley & Sons, Inc.; 2007.
- Barclay AN, Brown MH, Law SKA, McKnight AJ, Tomlinson MG, van der Merwe PA. *The Leukocyte Antigen FactsBook.* 2nd ed. San Diego: Academic Press; 1997.
- Greenwalt DE, Lipsky RH, Ockenhouse CF, Ikeda H, Tandon NN, Jamieson GA. Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. *Blood.* 1992;80:1105-1115.
- Tandon NN, Kralisz U, Jamieson GA. Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion. *J Biol Chem.* 1989;264:7576-7583.

10. Handunnetti SM, van Schravendijk MR, Hasler T, Barnwell JW, Greenwalt DE, Howard RJ. Involvement of CD36 on erythrocytes as a rosetting receptor for Plasmodium falciparum-infected erythrocytes. *Blood*. 1992;80:2097-2104.
11. Ockenhouse CF, Magowan C, Chulay JD. Activation of monocytes and platelets by monoclonal antibodies or malaria-infected erythrocytes binding to the CD36 surface receptor in vitro. *J Clin Invest*. 1989;84:468-475.
12. Ockenhouse CF, Tandon NN, Magowan C, Jamieson GA, Chulay JD. Identification of a platelet membrane glycoprotein as a falciparum malaria sequestration receptor. *Science*. 1989;243:1469-1471.
13. de Haas M, von dem Borne AEG. CD36 Workshop Panel report. In: Kishimoto T, Kikutani H, von dem Borne AEG, et al., eds. *Leucocyte Typing VI: White Cell Differentiation Antigens*. New York, NY: Garland Publishing, Inc.; 1997:636-637.
14. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline — Third Edition*. Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI document M29-A3.
15. Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. *MMWR*. 1988;37:377-388.

**PATENTS AND
TRADEMARKS**

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2015 BD

Monoclonal Antibodies Detecting Human Antigens

CD79b (SN8)

Form	Catalog number
FITC	335798
PE	335799
PerCP-Cy5.5	656644
APC	335800
APC-R700	657702

Product availability varies by region. Contact BD Biosciences Customer Support or your local sales representative for information.

RESEARCH APPLICATIONS

Research applications include:

- Characterization of leukemias and lymphomas¹⁻³
- Analysis of lymphocyte development⁴

DESCRIPTION

Specificity

The CD79b antibody recognizes an epitope on the extracellular domain of a 36–40 kilodalton (kDa) type I membrane glycoprotein.⁵ Immunoglobulin (Ig) antigen receptors are composed of a non-covalently associated complex of Ig and two other proteins, Igα and Igβ, which have been designated as CD79a and CD79b, respectively.⁵

Antigen distribution

The CD79b antigen is expressed on surface-Ig (sIg)–positive lymphocytes and B-cell lines. It can also be found in the cytoplasm of sIg-negative cells, including most terminal deoxynucleotidyl transferase (TdT)–positive early pre-B and all cytoplasmic μ-positive pre-B–cell lines.⁵ The vast majority of chronic lymphocytic leukemia cells are CD79b[–] while cells from other B-cell disorders usually express high levels of the CD79b antigen.⁶

Clone

The CD79b antibody, clone SN8 (3A2-2E7-1F5),⁵ is derived from the hybridization of NS-1 mouse myeloma cells with spleen cells isolated from BALB/c mice immunized with cell membrane preparations from B-prolymphocytic leukemia (B-PLL) cells.⁷

Composition

The CD79b antibody is composed of mouse IgG₁ heavy chains and kappa light chains.

Product configuration

The following are supplied in phosphate buffered saline (PBS) containing a stabilizer and a preservative.

Form	Number of tests	Volume per test (μL) ^a	Amount provided (μg)	Total volume (mL)	Concentration (μg/mL)	Stabilizer	Preservative
FITC	50	20	25	1.0	25	Gelatin	0.1% Sodium azide
PE	50	20	25	1.0	25	Gelatin	0.1% Sodium azide
PerCP-Cy TM 5.5	50	20	13	1.0	13	Gelatin	0.1% Sodium azide
APC	100	5	50	0.5	100	Gelatin	0.1% Sodium azide
APC-R700 ^b	100	5	25	0.5	50	BSA	ProClin® 300

a. Volume required to stain 10⁶ cells.

b. BD HorizonTM APC-R700.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Becton, Dickinson and Company
BD Biosciences
 2350 Qume Drive
 San Jose, CA 95131 USA



CAUTION Some APC-R700 conjugates show changes in their emission spectra with prolonged exposure to paraformaldehyde or light. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.


PROCEDURE

Visit our website (bdbiosciences.com) or contact your local BD representative for the lyse/wash protocol for direct immunofluorescence.

REPRESENTATIVE DATA

Flow cytometric analysis was performed on whole blood stained with the indicated conjugated antibody and gated on lymphocytes. Laser excitation was at 488 nm, 635 nm, or 640 nm.

The APC-R700 conjugate is read off the red laser (640 nm) using a 685 longpass mirror with a 712/21 bandpass filter. Representative data analyzed with a BD FACS™ brand flow cytometer is shown in the following plots.



HANDLING AND STORAGE

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

WARNING

All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection^{8,9} and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves.

Some reagents are bottled with ProClin 300, and contain 0.003% of a mixture of CMIT/MIT (3:1), CAS number 55965-84-9.



Warning

H317 May cause an allergic skin reaction.

Wear protective gloves/eye protection. Wear protective clothing. Avoid breathing mist/vapours/spray. If skin irritation or rash occurs: Get medical advice/attention. IF ON SKIN: Wash with plenty of water. Dispose of contents/container in accordance with local/regional/national/international regulations.

CHARACTERIZATION

To ensure consistently high-quality reagents, each lot of antibody is tested for conformance with characteristics of a standard reagent. Representative flow cytometric data is included in this data sheet.

WARRANTY

Unless otherwise indicated in any applicable BD general conditions of sale for non-US customers, the following warranty applies to the purchase of these products.

THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NONINFRINGEMENT. BD'S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT.

REFERENCES

1. Garcia Vela J, Delgado I, Benito L, et al. CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection. *Leukemia*. 1999;13:1501-1505.
2. Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. *Blood*. 2001;98:29-35.
3. van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. *Leukemia*. 2012;26:1908-1975.
4. Nakamura T, Kubagawa H, Cooper MD. Heterogeneity of immunoglobulin-associated molecules on human B cells identified by monoclonal antibodies. *Proc Natl Acad Sci USA*. 1992;89:8522-8526.
5. Engel P, Wagner N, Tedder TF. CD79 Workshop report. In: Schlossman SF, Boumsell L, Gilks W, et al, eds. *Leucocyte Typing V: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1995:667-670.
6. Zomas AP, Matutes E, Morilla R, Owusu-Ankomah K, Seon BK, Catovsky D. Expression of the immunoglobulin-associated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b). *Leukemia*. 1996;10:1966-1970.
7. Okazaki M, Luo Y, Han T, Yoshida M, Seon BK. Three new monoclonal antibodies that define a unique antigen associated with prolymphocytic leukemia/non-Hodgkin's lymphoma and are effectively internalized after binding to the cell surface antigen. *Blood*. 1993;81:84-94.
8. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline — Third Edition*. Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI document M29-A3.
9. Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. *MMWR*. 1988;37:377-388.

PATENTS AND TRADEMARKS

Cy™ is a trademark of GE Healthcare. This product is subject to proprietary rights of GE Healthcare and Carnegie Mellon University, and is made and sold under license from GE Healthcare. This product is licensed for sale only for research. It is not licensed for any other use. If you require a commercial license to use this product and do not have one, return this material, unopened, to BD Biosciences, 2350 Qume Drive, San Jose, CA 95131, and any money paid for the material will be refunded.

ProClin is a registered trademark of Rohm and Haas Company.

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2015 BD

CD81 (JS-81)

Form **Catalog number**
APC-H7 656647

Product availability varies by region. Contact BD Biosciences Customer Support or your local sales representative for information.

RESEARCH APPLICATIONS

Research applications include:

- Studies of B-cell proliferation¹
- Research on antibody deficiency²
- Research on the hepatitis C virus receptor^{3,4}

DESCRIPTION

Specificity

The CD81 antibody recognizes a 26-kilodalton (kDa) member of the tetraspanin family (TM4SF).¹ The CD81 antigen is also known as TAPA-1.

Antigen distribution

The CD81 antigen has a very broad cellular distribution, being expressed on cells of hematopoietic, neuroectodermal, and mesenchymal origin. In hematopoietic cells, the CD81 antigen is expressed on B and T lymphocytes, natural killer (NK) cells, thymocytes, eosinophils, germinal center follicular dendritic cells, and to a variable extent on monocytes.⁵ The CD81 antigen is not expressed on neutrophils, platelets, or erythrocytes.⁵

The CD81 antibody has been shown to have anti-proliferative effects on different lymphoid cell lines, particularly those derived from large cell lymphomas.¹ The CD81 antigen is involved in cell growth and signal transduction.⁶ Immunoprecipitation studies reveal that the CD81 antigen is a component of a multimolecular complex that can include the Leu13 molecule,⁷ and the CD19 and CD21 molecules in B cells.^{8,9}

Clone

The CD81 antibody, clone JS-81,⁵ is derived from the hybridization of P3/NS1/1-Ag4-1 mouse myeloma cells with spleen cells isolated from mice immunized with the Burkitt lymphoma cell line, Ramos.¹⁰

Composition

The CD81 antibody is composed of mouse IgG₁ heavy chains and kappa light chains.

Product configuration

The following is supplied in phosphate buffered saline (PBS) containing a stabilizer and a preservative.

Form	Number of tests	Volume per test (μL) ^a	Amount provided (μg)	Total volume (mL)	Concentration (μg/mL)	Stabilizer	Preservative
APC-H7	100	5	50	0.5	100	BSA	ProClin® 300

a. Volume required to stain 10⁶ cells.

CAUTION Some APC-H7 conjugates show changes in their emission spectra with prolonged exposure to paraformaldehyde or light. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.


For Research Use Only. Not for use in diagnostic or therapeutic procedures.

PROCEDURE

Visit our website (bdbiosciences.com) or contact your local BD representative for the lyse/wash protocol for direct immunofluorescence.

REPRESENTATIVE DATA

Flow cytometric analysis was performed on whole blood stained with the indicated conjugated antibody. Laser excitation was at 635 nm. Representative data analyzed with a BD FACS™ brand flow cytometer is shown in the following plot.



HANDLING AND STORAGE

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

WARNING

All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection^{11,12} and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves.

Some reagents are bottled with ProClin 300, and contain 0.003% of a mixture of CMIT/MIT (3:1), CAS number 55965-84-9.



Warning

H317 May cause an allergic skin reaction.

Wear protective gloves/eye protection. Wear protective clothing. Avoid breathing mist/vapours/spray. If skin irritation or rash occurs: Get medical advice/attention. IF ON SKIN: Wash with plenty of water. Dispose of contents/container in accordance with local/regional/national/international regulations.

CHARACTERIZATION

To ensure consistently high-quality reagents, each lot of antibody is tested for conformance with characteristics of a standard reagent. Representative flow cytometric data is included in this data sheet.

WARRANTY

Unless otherwise indicated in any applicable BD general conditions of sale for non-US customers, the following warranty applies to the purchase of these products.

THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NONINFRINGEMENT. BD'S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT.

REFERENCES

1. Oren R, Takahashi S, Doss C, Levy R, Levy S. TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. *Mol Cell Biol.* 1990;10:4007-4015.
2. van Zelm MC, Smet J, Adams B, et al. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. *J Clin Invest.* 2010;120:1265-1274.
3. Flint M, Maidens C, Loomis-Price LD, et al. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. *J Virol.* 1999;73:6235-6244.
4. Petracca R, Falugi F, Galli G, et al. Structure-function analysis of hepatitis C virus envelope-CD81 binding. *J Virol.* 2000;74:4824-4830.

5. Tedder TF, Wagner N, Engel P. CD81 Workshop report. In: Schlossman SF, Boumsell L, Gilks W, et al, eds. *Leukocyte Typing V: White Cell Differentiation Antigens*. Vol 1. New York, NY: Oxford University Press; 1995:684-688.
6. Levy S, Todd SC, Maecker HT. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. *Ann Rev Immunol*. 1998;16:89-109.
7. Takahashi S, Doss C, Levy S, Levy R. TAPA-1, the target of an antiproliferative antibody, is associated on the cell surface with the Leu-13 antigen. *J Immunol*. 1990;145:2207-2213.
8. Bradbury LE, Kansas GS, Levy S, Evans RL, Tedder TF. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. *J Immunol*. 1992;149:2841-2850.
9. Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. *Annu Rev Immunol*. 2000;18:393-422.
10. Pesando JM, Hoffman P, Conrad T. Malignant human B cells express two populations of p24 surface antigens. *J Immunol*. 1986;136:2709-2714.
11. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline — Third Edition*. Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI document M29-A3.
12. Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. *MMWR*. 1988;37:377-388.

PATENTS AND TRADEMARKS

ProClin is a registered trademark of Rohm and Haas Company.

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2015 BD

Monoclonal Antibodies Detecting Human Antigens

CD9 (M-L13)

Form	Catalog number	Form	Catalog number
FITC	341646	APC	341648
PE	341647	APC-H7	655409
PerCP-Cy5.5	341649	V450	658167

Product availability varies by region. Contact BD Biosciences Customer Support or your local sales representative for information.

RESEARCH APPLICATIONS

Research applications include:

- Characterization of leukemias and lymphomas¹⁻³
- Analysis of hematopoiesis⁴
- Investigation of T-cell activation and apoptosis⁵
- Detection of platelet activation and aggregation^{1,6-8}

DESCRIPTION

Specificity

The CD9 antibody recognizes a 24-kilodalton (kDa) cell surface glycoprotein⁹⁻¹³ belonging to the tetraspanin family.¹ The CD9 antigen is also known as p24, tetraspanin-29 (Tspan-29), motility-related protein-1 (MRP-1), and leucocyte antigen MIC3.¹⁴

Antigen distribution

The CD9 antigen has a very broad tissue distribution. It is present on basophils, eosinophils, monocytes, pre-B cells, B cells, and various leukemic cell lines (erythroid, myeloid, some T lymphoid, and pre-B lymphoid). It is also found on follicular center cells, sinus histiocytes, macrophages, Kupffer cells, osteoclasts, hepatocytes, bile duct endothelia, renal glomeruli, proximal and distal tubuli, epithelia (intercellular spinous spaces) of skin and mucosa, fibroblasts, connective tissues, endothelia, smooth muscle, cardiac muscle, synovial lining cells, brain white matter, and peripheral nerves.⁹⁻¹³

The CD9 antibody provides a co-stimulatory signal to T cells, resulting in a transient activation followed by apoptosis.⁵ The CD9 antibody activates platelets, inducing mitogenesis, aggregation,^{1,6-8} and p72syk kinase activity.¹⁵ The CD9 antigen associates with integrins and can modulate integrin signaling, cell migration, and cell adhesion.^{1,5,9-13,16}

Clone

The CD9 antibody, clone M-L13,^{6,7} is derived from the hybridization of mouse myeloma cells with spleen cells isolated from mice immunized with common acute lymphoblastic leukemia (cALL) cells.

Composition

The CD9 antibody is composed of mouse IgG₁ heavy chains and kappa light chains.

Product configuration

The following are supplied in phosphate buffered saline (PBS) containing a stabilizer and a preservative.

Form	Number of tests	Volume per test (μL) ^a	Amount provided (μg)	Total volume (mL)	Concentration (μg/mL)	Stabilizer	Preservative
FITC	50	20	25	1.0	25	Gelatin	0.1% Sodium azide

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Becton, Dickinson and Company
BD Biosciences
 2350 Qume Drive
 San Jose, CA 95131 USA



Form	Number of tests	Volume per test (µL) ^a	Amount provided (µg)	Total volume (mL)	Concentration (µg/mL)	Stabilizer	Preservative
PE	50	20	25	1.0	25	Gelatin	0.1% Sodium azide
PerCP-Cy TM 5.5	50	20	25	1.0	25	Gelatin	0.1% Sodium azide
APC	100	5	50	0.5	100	Gelatin	0.1% Sodium azide
APC-H7	100	5	50	0.5	100	BSA	ProClin® 300
V450 ^b	100	5	50	0.5	100	Gelatin	0.1% Sodium azide

a. Volume required to stain 10⁶ cells.

b. BD HorizonTM V450.

CAUTION Some APC-H7 conjugates show changes in their emission spectra with prolonged exposure to paraformaldehyde or light. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.


CAUTION Prolonged exposure of cells to paraformaldehyde can lead to increased autofluorescence in the violet channels. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.

PROCEDURE

Visit our website (bdbiosciences.com) or contact your local BD representative for the lyse/wash protocol for direct immunofluorescence.

REPRESENTATIVE DATA

Flow cytometric analysis was performed on whole blood stained with the indicated conjugated antibody and gated on lymphocytes. Laser excitation was at 405 nm, 488 nm, or 635 nm. Representative data analyzed with a BD FACSTTM brand flow cytometer is shown in the following plots.



HANDLING AND STORAGE

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

WARNING

All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection^{17,18} and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves.

Some reagents are bottled with ProClin 300, and contain 0.003% of a mixture of CMIT/MIT (3:1), CAS number 55965-84-9.



Warning

H317 May cause an allergic skin reaction.

Wear protective gloves/eye protection. Wear protective clothing. Avoid breathing mist/vapours/spray. If skin irritation or rash occurs: Get medical advice/attention. IF ON SKIN: Wash with plenty of water. Dispose of contents/container in accordance with local/regional/national/international regulations.

CHARACTERIZATION

To ensure consistently high-quality reagents, each lot of antibody is tested for conformance with characteristics of a standard reagent. Representative flow cytometric data is included in this data sheet.

WARRANTY

Unless otherwise indicated in any applicable BD general conditions of sale for non-US customers, the following warranty applies to the purchase of these products.

THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NONINFRINGEMENT. BD'S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT.

REFERENCES

1. Maecker HT, Todd SC, Levy S. The tetraspanin superfamily: molecular facilitators. *FASEB J*. 1997;11:428-442.
2. van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. *Leukemia*. 2012;26:1908-1975.
3. Weir EG, Cowan K, LeBeau P, Borowitz MJ. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. *Leukemia*. 1999;13:558-567.
4. Aoyama K, Oritani K, Yokota T, et al. Stromal cell CD9 regulates differentiation of hematopoietic stem/progenitor cells. *Blood*. 1999;93:2586-2594.
5. Tai XG, Toyooka K, Yashiro Y, et al. CD9-mediated costimulation of TCR-triggered naive T cells leads to activation followed by apoptosis. *J Immunol*. 1997;159:3799-3807.
6. Boucheix C, Benoit P, Krief P, et al. Platelet aggregation induced by CD9 mAbs. Mechanisms and comparison with platelet aggregating properties of mAbs directed against other membrane antigens. In: McMichael AJ, Beverley PCL, Cobbold S, et al, eds. *Leucocyte Typing III: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1987:780-782.
7. Slaper-Cortenbach ICM, Admiraal LG, von dem Borne AEG, van Leeuwen EF, Tetteroo PAT. Epitope specificity and complement-binding studies with monoclonal antibodies (CD9, 10, 24) useful for purging autologous bone-marrow grafts of cALL patients. In: McMichael AJ, Beverley PCL, Cobbold S, et al, eds. *Leucocyte Typing III: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1987:480-484.
8. Zeleznik NJ, Hollingsworth MA, Metzgar RS. Studies of the CD9 antigen defined by monoclonal antibody DU-ALL-1. In: McMichael AJ, Beverley PCL, Cobbold S, et al, eds. *Leucocyte Typing III: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1987:389-392.
9. Johnson GD, MacLennan ICM. Reactivity of the B panel mAb with non-lymphoid constituents of normal tissues. In: Knapp W, Dörken B, Gilks WR, et al, eds. *Leucocyte Typing IV: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1989:187-189.
10. Powling MJ, Cox AD, Higgins J, Hardisty RM, Goodall AH. Phenotypic and functional characterization of pro-aggregatory platelet mAb: subsets of CD9, CD41, and CD36. In: Knapp W, Dörken B, Gilks WR, et al, eds. *Leucocyte Typing IV: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1989:1012-1014.

11. von dem Borne AEG, Admiraal LG, Daams M, Hogervorst F, Modderman PW. Immunocytological evaluation of the mAb of the platelet panel. In: Knapp W, Dörken B, Gilks WR, et al, eds. *Leucocyte Typing IV: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1989:967-970.
12. von dem Borne AEG, Modderman PW. Cluster report: CD9. In: Knapp W, Dörken B, Gilks WR, et al, eds. *Leucocyte Typing IV: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1989:989-990.
13. von dem Borne AEG, Modderman PW, Admiraal LG, Nieuwenhuis HK. Platelet antibodies, the overall results. In: Knapp W, Dörken B, Gilks WR, et al, eds. *Leucocyte Typing IV: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1989:951-966.
14. Zola H, Swart B, Nicholson I, Voss E. *Leukocyte and Stromal Cell Molecules: The CD Markers*. Hoboken, NJ: John Wiley & Sons, Inc.; 2007.
15. Ozaki Y, Satoh K, Kuroda K, et al. Anti-CD9 monoclonal antibody activates p72syk in human platelets. *J Biol Chem*. 1995;270:15119-15124.
16. Berditchevski F, Odintsova E. Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling. *J Cell Biol*. 1999;146:477-492.
17. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline — Third Edition*. Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI document M29-A3.
18. Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. *MMWR*. 1988;37:377-388.

PATENTS AND TRADEMARKS

Cy™ is a trademark of GE Healthcare. This product is subject to proprietary rights of GE Healthcare and Carnegie Mellon University, and is made and sold under license from GE Healthcare. This product is licensed for sale only for research. It is not licensed for any other use. If you require a commercial license to use this product and do not have one, return this material, unopened, to BD Biosciences, 2350 Qume Drive, San Jose, CA 95131, and any money paid for the material will be refunded.

ProClin is a registered trademark of Rohm and Haas Company.

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2015 BD

CD21 (B-ly4)

Form
V450

Catalog number
658169

Product availability varies by region. Contact BD Biosciences Customer Support or your local sales representative for information.

RESEARCH APPLICATIONS

Research applications include:

- Investigation of lymphocyte transformation by Epstein-Barr virus (EBV)¹
- Analysis of the complement system²
- Examination of B-cell activation and survival³⁻⁵
- Characterization of leukemias and lymphomas⁶

DESCRIPTION

Specificity

The CD21 antibody specifically binds to a 145-kilodalton (kDa) glycosylated type I integral membrane protein.⁷ The CD21 antigen is also known as complement receptor type 2 (CR2), C3d receptor, and Epstein-Barr virus receptor (EBV-R).

Antigen distribution

The CD21 antigen is expressed on mature B cells,⁸ marginal zone B cells,⁹ follicular dendritic cells,¹⁰ and some epithelial cells.⁷ The CD21 antigen is expressed at low levels on some subsets of thymocytes and T cells.⁷

The CD21 antigen is a receptor for the C3d fragment of complement² and for EBV.¹¹ The CD21 antigen forms a complex with CD19 and CD81, which provides a co-stimulatory signal for the B-cell receptor.³⁻⁵

Clone

The CD21 antibody, clone B-ly4,⁸ is derived from the hybridization of mouse myeloma cells with spleen cells isolated from immunized mice.

Composition

The CD21 antibody is composed of mouse IgG₁ heavy chains and kappa light chains.

Product configuration

The following is supplied in phosphate buffered saline (PBS) containing a stabilizer and a preservative.

Form	Number of tests	Volume per test (μL) ^a	Amount provided (μg)	Total volume (mL)	Concentration (μg/mL)	Stabilizer	Preservative
V450 ^b	100	5	6.5	0.5	13	Gelatin	0.1% Sodium azide

a. Volume required to stain 10⁶ cells.

b. BD Horizon™ V450.

CAUTION Prolonged exposure of cells to paraformaldehyde can lead to increased autofluorescence in the violet channels. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.


PROCEDURE

Visit our website (bdbiosciences.com) or contact your local BD representative for the lyse/wash protocol for direct immunofluorescence.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

REPRESENTATIVE DATA

Flow cytometric analysis was performed on whole blood stained with the indicated conjugated antibody. Laser excitation was at 405 nm. Representative data analyzed with a BD FACS™ brand flow cytometer is shown in the following plot.



HANDLING AND STORAGE

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

WARNING

All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection^{12,13} and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves.

CHARACTERIZATION

To ensure consistently high-quality reagents, each lot of antibody is tested for conformance with characteristics of a standard reagent. Representative flow cytometric data is included in this data sheet.

WARRANTY

Unless otherwise indicated in any applicable BD general conditions of sale for non-US customers, the following warranty applies to the purchase of these products.

THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NONINFRINGEMENT. BD'S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT.

REFERENCES

1. Boyd AW, Fecondo J. Role of the CD21 antigen in lymphocyte transformation by Epstein-Barr virus. *Immunol Cell Biol.* 1988;66:159-165.
2. Weis JJ, Tedder TF, Fearon DT. Identification of a 145,000 M_r membrane protein as the C3d receptor (CR2) of human B lymphocytes. *Proc Natl Acad Sci USA.* 1984;81:881-885.
3. Cherukuri A, Shoham T, Sohn HW, et al. The tetraspanin CD81 is necessary for partitioning of coligated CD19/CD21-B cell antigen receptor complexes into signaling-active lipid rafts. *J Immunol.* 2004;172:370-380.
4. Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. *Annu Rev Immunol.* 2000;18:393-422.
5. Mongini PK, Jackson AE, Tolani S, Fattah RJ, Inman JK. Role of complement-binding CD21/CD19/CD81 in enhancing human B cell protection from Fas-mediated apoptosis. *J Immunol.* 2003;171:5244-5254.
6. van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. *Leukemia.* 2012;26:1908-1975.
7. Zola H, Swart B, Nicholson I, Voss E. *Leukocyte and Stromal Cell Molecules: The CD Markers.* Hoboken, NJ: John Wiley & Sons, Inc.; 2007.
8. Dörken B, Möller P, Pezzutto A, Schwartz-Albiez R, Moldenhauer G. B-cell antigens: CD21. In: Knapp W, Dörken B, Gilks WR, et al, eds. *Leucocyte Typing IV: White Cell Differentiation Antigens.* New York, NY: Oxford University Press; 1989:58-60.

9. Timens W, Boes A, Poppema S. Human marginal zone B cells are not an activated B cell subset: strong expression of CD21 as a putative mediator for rapid B cell activation. *Eur J Immunol.* 1989;19:2163-2166.
10. Petrasch S, Schmitz J, Perez-Alvarez C, Brittinger G. Reactivity of mAb of the B-cell panel with isolated follicular dendritic cells. In: Knapp W, Dörken B, Gilks WR, et al, eds. *Leucocyte Typing IV: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1989:185-187.
11. Fingerroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. *Proc Natl Acad Sci USA.* 1984;81:4510-4514.
12. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline — Third Edition.* Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI document M29-A3.
13. Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. *MMWR.* 1988;37:377-388.

**PATENTS AND
TRADEMARKS**

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2015 BD

CD123 (9F5)

Form	Catalog number
PE	340545
APC	658171

Product availability varies by region. Contact BD Biosciences Customer Support or your local sales representative for information.

RESEARCH APPLICATIONS

Research applications include:

- Analysis of interleukin-3 (IL-3)–dependent differentiation and proliferation¹
- Immunophenotyping of leukemias and lymphomas²
- Characterization of precursor stem cell populations³
- Investigation of dendritic cell subpopulations³⁻⁷
- Enumeration of basophils⁸⁻¹¹

DESCRIPTION

Specificity

The CD123 antibody recognizes a 70-kilodalton (kDa) type I integral membrane glycoprotein, also known as the interleukin-3 receptor α -chain (IL-3R α).¹²

Antigen distribution

The CD123 antigen is expressed on a subset of peripheral blood dendritic cells,^{3,5-7} on a subset of progenitor cells,³ monocytes,¹³ eosinophils,¹³ mast cells,¹⁴ and basophils.⁸⁻¹¹ The expression of CD123 is induced when isolated neutrophils are cultured overnight with granulocyte-macrophage colony-stimulating factor (GM-CSF).¹⁵ Since IL-3 stimulates the production of hematopoietic cells, such as megakaryocytes, erythroid cells, and B cells, it is assumed that these lineages can also express the CD123 antigen.¹³

The CD123 antigen binds IL-3 with low affinity and associates with the 120–140 kDa β chain (CD131) to form the high affinity IL-3 receptor. The β chain is common to the receptors for IL-5 and GM-CSF.¹⁶

Clone

The CD123 antibody, clone 9F5,¹⁶ is derived from the hybridization of NS-1 mouse myeloma cells with spleen cells isolated from BALB/c mice immunized with IL-3R α –transfected COS cells.¹³

Composition

The CD123 antibody is composed of mouse IgG₁ heavy chains and kappa light chains.

Product configuration

The following are supplied in phosphate buffered saline (PBS) containing a stabilizer and a preservative.

Form	Number of tests	Volume per test (μ L) ^a	Amount provided (μ g)	Total volume (mL)	Concentration (μ g/mL)	Stabilizer	Preservative
PE	50	20	12.5	1.0	12.5	Gelatin	0.1% Sodium azide
APC	100	5	12.5	0.5	25	Gelatin	0.1% Sodium azide

a. Volume required to stain 10⁶ cells.


For Research Use Only. Not for use in diagnostic or therapeutic procedures.

PROCEDURE

Visit our website (bdbiosciences.com) or contact your local BD representative for the lyse/wash protocol for direct immunofluorescence.

REPRESENTATIVE DATA

Flow cytometric analysis was performed on normal whole blood stained with the indicated conjugated antibody. Laser excitation was at 488 nm or 635 nm. Representative data analyzed with a BD FACS™ brand flow cytometer is shown in the following plots.



HANDLING AND STORAGE

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

WARNING

All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection^{17,18} and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves.

CHARACTERIZATION

To ensure consistently high-quality reagents, each lot of antibody is tested for conformance with characteristics of a standard reagent. Representative flow cytometric data is included in this data sheet.

WARRANTY

Unless otherwise indicated in any applicable BD general conditions of sale for non-US customers, the following warranty applies to the purchase of these products.

THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NONINFRINGEMENT. BD'S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT.

REFERENCES

1. Baumeister T, Rössner S, Pech G, et al. Interleukin-3Rα⁺ myeloid dendritic cells and mast cells develop simultaneously from different bone marrow precursors in cultures with interleukin-3. *J Invest Dermatol*. 2003;121:280-288.
2. van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. *Leukemia*. 2012;26:1908-1975.
3. Olweus J, BitMansour A, Warnke R, et al. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. *Proc Natl Acad Sci USA*. 1997;94:12551-12556.
4. Bauer M, Redecke V, Ellwart JW, et al. Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. *J Immunol*. 2001;166:5000-5007.
5. Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. *J Exp Med*. 1997;185:1101-1111.
6. Hart DN, McKenzie JL. Isolation and characterization of human tonsil dendritic cells. *J Exp Med*. 1988;168:157-170.
7. O'Doherty U, Peng M, Gezelter S, et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. *Immunology*. 1994;82:487-493.

8. Agis H, Beil WJ, Bankl HC, et al. Mast cell-lineage versus basophil lineage involvement in myeloproliferative and myelodysplastic syndromes: diagnostic role of cell-immunophenotyping. *Leuk Lymphoma*. 1996;22:187-204.
9. Agis H, Füreder W, Bankl HC, et al. Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes. *Immunology*. 1996;87:535-543.
10. Valent P. Immunophenotypic characterization of human basophils and mast cells. *Chem Immunol*. 1995;61:34-48.
11. Valent P, Besemer J, Muhm M, Majdic O, Lechner K, Bettelheim P. Interleukin 3 activates human blood basophils via high-affinity binding sites. *Proc Natl Acad Sci USA*. 1989;86:5542-5546.
12. Zola H, Swart B, Nicholson I, Voss E. *Leukocyte and Stromal Cell Molecules: The CD Markers*. Hoboken, NJ: John Wiley & Sons, Inc.; 2007.
13. Sun Q, Woodcock JM, Rapoport A, et al. Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific IL-3 receptor antagonist. *Blood*. 1996;87:83-92.
14. Dahl C, Hoffmann HJ, Saito H, Schiotz PO. Human mast cells express receptors for IL-3, IL-5 and GM-CSF; a partial map of receptors on human mast cells cultured in vitro. *Allergy*. 2004;59:1087-1096.
15. Smith WB, Guida L, Sun Q, et al. Neutrophils activated by granulocyte-macrophage colony-stimulating factor express receptors for interleukin-3 which mediate class II expression. *Blood*. 1995;86:3938-3944.
16. Miyajima A. CDw123 (interleukin 3 receptor α chain) Workshop Panel report. In: Kishimoto T, Kikutani H, von dem Borne AEG, et al, eds. *Leucocyte Typing VI: White Cell Differentiation Antigens*. New York, NY: Garland Publishing, Inc; 1998:854-855.
17. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline — Third Edition*. Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI document M29-A3.
18. Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. *MMWR*. 1988;37:377-388.

**PATENTS AND
TRADEMARKS**

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2015 BD

CD11c (B-Ly6)

Form	Catalog number
PerCP-Cy™5.5	658330
PE-Cy™7	652358
BV605	663807

Product availability varies by region. Contact BD Biosciences Customer Support or your local sales representative for information.

RESEARCH APPLICATIONS

Research applications include:

- Enumeration of monocytes and macrophages¹
- Studies of complement receptors²
- Investigation into dendritic cell subsets in peripheral blood and lymphoid tissues³⁻⁶
- Immunophenotyping of leukemias and lymphomas⁷

DESCRIPTION

Specificity

The CD11c antibody specifically binds to a 150-kilodalton (kDa) type I integral membrane glycoprotein. The CD11c antigen is also known as p150, integrin alpha X (integrin α X), and CR4.⁸

Antigen distribution

The CD11c antigen is expressed on monocytes, macrophages, dendritic cells, granulocytes, neutrophils, NK cells, and certain subsets of T and B lymphocytes.² It is also expressed on hairy cell leukemias and on some acute myeloid leukemias.^{9,10}

The CD11c antigen associates with CD18 (p95) to form the CD11c/CD18 heterodimer that binds to fibrinogen¹¹ and has been reported to be a receptor for iC3b, ICAM-1, and VCAM-1.^{2,12,13} Reports indicate that CD11c/CD18 plays a role as an adhesion molecule that mediates cellular binding to ligands expressed on stimulated endothelium.¹⁴

Clone

The CD11c antibody, clone B-Ly6,¹⁵ is derived from the hybridization of X63 mouse myeloma cells with spleen cells isolated from BALB/c mice immunized with a cell suspension isolated from the spleen of a patient with hairy cell leukemia.¹⁰

Composition

The CD11c antibody is composed of mouse IgG₁ heavy chains and kappa light chains.

Product configuration

The following are supplied in buffer containing a stabilizer and a preservative.

Form	Number of tests	Volume per test (μL) ^a	Amount provided (μg)	Total volume (mL)	Concentration (μg/mL)	Stabilizer	Preservative
PerCP-Cy5.5	50	20	13	1	13	Gelatin	0.1% Sodium azide
PE-Cy7	100	5	25	0.5	50	BSA	0.1% Sodium azide
BV605 ^b	100	5	100	0.5	200	BSA	0.09% Sodium azide

a. Volume required to stain 10⁶ cells.

b. BD Horizon Brilliant™ Violet 605

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

PROCEDURE

Visit our website (bdbiosciences.com) or contact your local BD representative for the lyse/wash protocol for direct immunofluorescence.

CAUTION Some PE-Cy7 conjugates show changes in their emission spectra with prolonged exposure to paraformaldehyde or light. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.


CAUTION Prolonged exposure of cells to paraformaldehyde can lead to increased autofluorescence in the violet channels. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.

CAUTION For optimal results, use BD Horizon™ Brilliant Stain Buffer any time two or more BD Horizon Brilliant™ reagents are used in the same multicolor staining cocktail.

REPRESENTATIVE DATA

Flow cytometric analysis was performed on whole blood stained with the indicated conjugated antibody. Laser excitation was at 405 nm or 488 nm.

The BV605 conjugates are read off the violet laser using a 606/36 filter. Representative data analyzed with a BD FACST™ brand flow cytometer is shown in the following plots. The BV605 conjugate in the new formulation is shown in the second CD11c BV605-A vs SSC-A dot plot.



HANDLING AND STORAGE

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

WARNING

All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection^{16,17} and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves.

Visit regdocs.bd.com to download the Safety Data Sheet.

CHARACTERIZATION

To ensure consistently high-quality reagents, each lot of antibody is tested for conformance with characteristics of a standard reagent. Representative flow cytometric data is included in this data sheet.

WARRANTY

Unless otherwise indicated in any applicable BD general conditions of sale for non-US customers, the following warranty applies to the purchase of these products.

THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NONINFRINGEMENT. BD'S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT.

REFERENCES

1. Barclay AN, Brown MH, Law SKA, McKnight AJ, Tomlinson MG, van der Merwe PA. *The Leucocyte Antigen FactsBook*. 2nd ed. San Diego, CA: Academic Press; 1997.

2. Myones BL, Dalzell JG, Hogg N, Ross GD. Neutrophil and monocyte cell surface p150,95 has iC3b-receptor (CR₃) activity resembling CR₃. *J Clin Invest.* 1988;82:640-651.
3. Grouard G, Durand I, Filgueira L, Banchereau J, Liu YJ. Dendritic cells capable of stimulating T cells in germinal centres. *Nature.* 1996;384:364-367.
4. O'Doherty U, Peng M, Gezelter S, et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. *Immunology.* 1994;82:487-493.
5. Olweus J, BitMansour A, Warnke R, et al. Dendritic cell ontogeny: A human dendritic cell lineage of myeloid origin. *Proc Natl Acad Sci USA.* 1997;94:12551-12556.
6. Thomas R, Lipsky PE. Human peripheral blood dendritic cell subsets. Isolation and characterization of precursor and mature antigen-presenting cells. *J Immunol.* 1994;153:4016-4028.
7. van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. *Leukemia.* 2012;26:1908-1975.
8. Zola H, Swart B, Nicholson I, Voss E. *Leukocyte and Stromal Cell Molecules: The CD Markers.* Hoboken, NJ: John Wiley & Sons, Inc.; 2007.
9. Schwarting R, Stein H, Wang CY. The monoclonal antibodies αS-HCL 1 (αLeu-14) and αS-HCL 3 (αLeu-M5) allow the diagnosis of hairy cell leukemia. *Blood.* 1985;65:974-983.
10. Visser L, Shaw A, Slupsky J, Vos H, Poppema S. Monoclonal antibodies reactive with hairy cell leukemia. *Blood.* 1989;74:320-325.
11. Lishko VK, Yakubenko VP, Hertzberg KM, Grieninger G, Ugarova TP. The alternatively spliced α_EC domain of human fibrinogen-420 is a novel ligand for leukocyte integrins α_Mβ₂ and α_Xβ₂. *Blood.* 2001;98:2448-2455.
12. Frick C, Odermatt A, Zen K, et al. Interaction of ICAM-1 with β2-integrin CD11c/CD18: Characterization of a peptide ligand that mimics a putative binding site on domain D4 of ICAM-1. *Eur J Immunol.* 2005;35:3610-3621.
13. Gower RM, Wu H, Foster GA, et al. CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. *Arterioscler Thromb Vasc Biol.* 2011;31:160-166.
14. Stacker SA, Springer TA. Leukocyte integrin P150,95 (CD11c/CD18) functions as an adhesion molecule binding to a counter-receptor on stimulated endothelium. *J Immunol.* 1991;146:648-655.
15. Schmidt RE. Non-lineage/natural killer Section report: new and previously defined clusters. In: Knapp W, Dörken B, Gilks WR, et al, eds. *Leucocyte Typing IV: White Cell Differentiation Antigens.* New York, NY: Oxford University Press; 1989:517-542.
16. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline — Fourth Edition.* Wayne, PA: Clinical and Laboratory Standards Institute; 2014. CLSI document M29-A4.
17. Centers for Disease Control and Prevention. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. <https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html>. Accessed March 12, 2019.

PATENTS AND TRADEMARKS

BV605 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; or 8,354,239.

Cy™ is a trademark of GE Healthcare. This product is subject to proprietary rights of GE Healthcare and Carnegie Mellon University, and is made and sold under license from GE Healthcare. This product is licensed for sale only for research. It is not licensed for any other use. If you require a commercial license to use this product and do not have one, return this material, unopened, to BD Biosciences, 2350 Qume Drive, San Jose, CA 95131, and any money paid for the material will be refunded.

BD, the BD Logo, FACS, Horizon and Horizon Brilliant are trademarks of Becton, Dickinson and Company or its affiliates. All other trademarks are the property of their respective owners. © 2020 BD. All rights reserved.

Technical Data Sheet

BUV615 Mouse Anti-Human CD56

Product Information

Material Number:	751387
Size:	50 µg
Clone:	MY31
Alternative Name:	N-CAM; NCAM1; NCAM-1; Neural cell adhesion molecule 1; NKH1; MSK39
Reactivity:	Tested in Development:Human
Isotype:	Mouse BALB/c X C57BL/6 IgG1, κ
Immunogen:	KG1a Cell Line
Application:	Flow cytometry(Qualified)
Concentration:	0.2 mg/ml
Workshop No.:	V NK19
Entrez Gene ID:	4684,916
Storage Buffer:	Aqueous buffered solution containing ≤0.09% sodium azide.
Regulatory Status:	RUO

Description

Clone MY31 specifically recognizes the human form of the 220/135 kDa heavily glycosylated antigen, CD56, found on a subpopulation of peripheral blood large granular lymphocytes which demonstrate natural killer cell activity, but not on myeloid cells, erythrocytes or B cells. This clone also cross-reacts with a subset of peripheral blood lymphocytes of baboon, and both rhesus and cynomolgus macaque monkeys. The distribution on lymphocytes is similar to that observed with peripheral blood lymphocytes from normal human donors, with a subset of CD16+ cells co-expressing CD56. In contrast to what is observed with human peripheral blood cells, however, clone MY31 also reacts with a major subset of non-human primate CD14+ monocytes. Studies in rhesus macaque monkeys suggest that CD56 reacts with monocytes and not natural killer cells.

The antibody was conjugated to BD Horizon BUV615 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome with an Ex Max near 350 nm and an Em Max near 615 nm. BD Horizon Brilliant BUV615 can be excited by the ultraviolet laser (355 nm) and detected with a 610/20 filter and a 595 nm LP. Due to the excitation of the acceptor dye by the blue/yellow-green laser line, there may be significant spillover into channels detecting PE-CF594 like emissions (eg, 610/20-nm filter).

Preparation and Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedure

BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to BD CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD CompBead to ensure that BD CompBeads are appropriate for your specific cellular application.

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).

Note: When using high concentrations of antibody, background binding of this dye to erythroid cell subsets (mature erythrocytes and precursors) has been observed. For researchers studying these cell populations, or in cases where light scatter gating does not adequately exclude these cells from the analysis, this background may be an important factor to consider when selecting reagents for panel(s).

Suggested Companion Products

Catalog Number	Name	Size	Clone
564219	Human BD Fc Block™	50 µg	Fc1
554656	Stain Buffer (FBS)	500 mL	
554657	Stain Buffer (BSA)	500 mL	
563794	Brilliant Stain Buffer	100 Tests	
566385	Brilliant Stain Buffer Plus	1000 Tests	
566349	Brilliant Stain Buffer	100 Tests	
555899	Lysing Buffer	100 mL	
349202	Lysing Solution 10X Concentrate	100 mL	
612986	BUV615 Mouse IgG1, κ Isotype Control	50 µg	X40

Product Notices

1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
2. Researchers should determine the optimal concentration of this reagent for their individual applications.
3. An isotype control should be used at the same concentration as the antibody of interest.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
8. Please refer to <http://regdocs.bd.com> to access safety data sheets (SDS).
9. CF™ is a trademark of Biotium, Inc.
10. BD Horizon Brilliant Ultraviolet 615 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,575,303; 8,354,239.

References

Hercend T, Griffin JD, Bensussan A, et al. Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest. 1985; 75(3):932-43. (Biology).

Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon: relative contribution of peripheral blood natural killer cells and T lymphocytes to cytotoxicity. J Exp Med. 1986; 164(3):814-825. (Clone-specific: Flow cytometry).

Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol. 1986; 136(12):4480-4486. (Immunogen: Flow cytometry).

Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med. 1989; 169(6):2233-2238. (Clone-specific: Immunoprecipitation).

Lanier LL, Chang C, Azuma M, Ruitenberg JJ, Hemperly JJ, Phillips JH. Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAM/CD56). J Immunol. 1991; 146(12):4421-4426. (Clone-specific: Flow cytometry, Fluorescence activated cell sorting, Immunoprecipitation).

Schubert J, Lanier LL, Schmidt RE. Cluster report: CD56. In: Knapp W, W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:699-702.

Edelman GM. Cell adhesion molecules. Science. 1983; 219(4584):450-7. (Biology).

BD Biosciences

bdbiosciences.com

United States 877.232.8995	Canada 888.268.5430	Europe 32.53.720.550	Japan 0120.8555.90	Asia Pacific 65.6861.0633	Latin America/Caribbean 0800.771.7157
-------------------------------	------------------------	-------------------------	-----------------------	------------------------------	--

For country contact information, visit bdbiosciences.com/contact

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for a patent infringement or other

©2020 BD. All rights reserved. Unless otherwise noted, BD, the BD Logo and all other trademarks are the property of Becton, Dickinson and Company or its affiliates.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

FICHE DE DONNÉES DE SÉCURITÉ

Conformément au règlement (CE) n° 1907/2006 (REACH) Article 31, Annexe II et ses modifications

RUBRIQUE 1 — Identification de la substance/du mélange et de la société/de l'entreprise

Identificateur de produit

N° de produit:	Nom du produit:	Nom(s) commun(s) et synonyme(s)
332771	BD® CD3 (SK7) PerCP-Cy5.5	Aucune donnée disponible
332772	BD® CD4 (SK3) PerCP-Cy5.5	Aucune donnée disponible
332780	BD® CD19 (SJ25C1) PerCP-Cy5.5	Aucune donnée disponible
332781	BD® CD20 (L27) PerCP-Cy5.5	Aucune donnée disponible
333146	BD® CD33 (P67.6) PerCP-Cy5.5	Aucune donnée disponible
333148	BD® CD41a (HIP8) PerCP-Cy5.5	Aucune donnée disponible
333153	BD® CD79a (HM47) PerCP-Cy5.5	Aucune donnée disponible
333950	BD® CD117 (104D2) PerCP-Cy5.5	Aucune donnée disponible
338440	BD® CD16 (3G8) PerCP-Cy5.5	Aucune donnée disponible
339216	BD® Anti-HLA-DR (L243) PerCP-Cy5.5	Aucune donnée disponible
341050	BD® CD8 (SK1) PerCP-Cy5.5	Aucune donnée disponible
341107	BD® CD138 (MI15) PerCP-Cy5.5	Aucune donnée disponible
341109	BD® CD5 (L17F12) PerCP-Cy5.5	Aucune donnée disponible
345766	BD® CD3 (SK7) PerCP-Cy5.5	Aucune donnée disponible
345770	BD® CD4 (SK3) PerCP	Aucune donnée disponible
345774	BD® CD8 (SK1) PerCP	Aucune donnée disponible
345778	BD® CD19 (4G7) PerCP	Aucune donnée disponible
345786	BD® CD14 (MφP9) PerCP	Aucune donnée disponible
345790	BD® CD19 (SJ25C1) PerCP	Aucune donnée disponible
345794	BD® CD20 (L27) PerCP	Aucune donnée disponible
345803	BD® CD34 (8G12) PerCP	Aucune donnée disponible



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

347222	BD® CD34 (8G12) PerCP-Cy5.5	Aucune donnée disponible
347402	BD® Anti-HLA-DR (L243) PerCP	Aucune donnée disponible
347408	BD® CD61 (RUU-PL7F12) PerCP	Aucune donnée disponible

1.2 Utilisations identifiées pertinentes de la substance ou du mélange et utilisations déconseillées

Utilisations identifiées: Utilisation en laboratoire scientifique et industriel. À usage diagnostique in vitro.

Usages déconseillés: Aucuns connus.

1.3 Renseignements concernant le fournisseur de la fiche de données de sécurité

Fabricant

Becton Dickinson France S.A.S. Belgian Branch
Erembodegem-Dorp 86
9320 Erembodegem
Belgium

Téléphone: 32 2 400 98 95

Télécopie :: 32 2 401 70 94

Personne à contacter: BD Biosciences - Centralized European Office
Regulatory Compliance Department

E-mail: help.biosciences@europe.bd.com

1.4 Numéro d'appel d'urgence: 32 2 400 98 95

RUBRIQUE 2 — Identification des dangers

2.1 Classification de la substance ou du mélange

Le produit n'a pas été classé comme dangereux selon la législation en vigueur.

Classification selon le règlement (CE) n° 1272/2008 et ses amendements.

Non classé

2.2 Éléments d'étiquetage Non applicable

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

2.3 Autres dangers

Propriétés perturbant le système endocrinien-Toxicité

La substance/Le mélange ne contient pas de composants considérés comme ayant des propriétés perturbatrices du système endocrinien selon l'article 57(f) de REACH ou le règlement délégué de la Commission (UE) 2017/2100 ou le règlement de la Commission (EU) 2018/605 à des niveaux de 0,1 % ou plus.

Propriétés perturbant le système endocrinien-Écotoxicité

La substance/Le mélange ne contient pas de composants considérés comme ayant des propriétés perturbatrices du système endocrinien selon l'article 57(f) de REACH ou le règlement délégué de la Commission (UE) 2017/2100 ou le règlement de la Commission (EU) 2018/605 à des niveaux de 0,1 % ou plus.

RUBRIQUE 3 — Composition/informations sur les composants

3.2 Mélanges

Informations générales: Pas d'ingrédient dangereux.

RUBRIQUE 4 — Premiers secours

4.1 Description des mesures de premiers secours

Informations générales:	Consulter un médecin en cas de symptômes.
Inhalation:	Garder à l'air frais, au chaud et au repos, de préférence en position assise, confortable, le dos droit.
Contact avec la Peau:	Laver les zones de contact à l'eau et au savon. Enlever les vêtements contaminés. Laver les vêtements contaminés avant réutilisation.
Contact oculaire:	Rincer immédiatement à grande eau pendant au moins 15 minutes. Enlever les lentilles de contact si cela est facile à faire.
Ingestion:	Contactez immédiatement un médecin ou un centre antipoison. Faire vomir uniquement à la demande du personnel médical. Ne jamais faire ingérer quoi que ce soit à une personne inconsciente.
Protection individuelle des secouristes:	Aucune information disponible.

4.2 Principaux symptômes et effets, aigus et différés

Symptômes: Aucune information disponible.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Dangers: Aucune information disponible.

4.3 Indication d'un besoin médical immédiat et traitement spécial requis

Traitement: Aucune information disponible.

RUBRIQUE 5 — Mesures de lutte contre l'incendie

Dangers d'Incendie Généraux: Éteindre toutes les sources d'ignition. Éviter les étincelles, les flammes et la chaleur. Ne pas fumer. Aérer. Garder au frais les récipients exposés à l'incendie à l'aide d'un jet d'eau.

5.1 Moyens d'extinction

Moyens d'extinction appropriés: Choisir le moyen d'extinction de l'incendie en tenant compte d'autres produits chimiques éventuels.

Moyens d'extinction inappropriés: Non applicable

5.2 Dangers particuliers résultant de la substance ou du mélange: En cas d'incendie ou de chaleur excessive, des produits de décomposition dangereux peuvent se former.

5.3 Conseils aux pompiers

Procédures spéciales de lutte contre l'incendie: Aucun risque exceptionnel d'incendie et d'explosion.

Équipement de protection spécial pour le personnel préposé à la lutte contre le feu: Les pompiers doivent porter un équipement de protection standard, notamment vêtement ignifuge, casque à masque facial, gants, bottes en caoutchouc et, dans les espaces clos, un appareil respiratoire autonome.

RUBRIQUE 6 — Mesures à prendre en cas de dispersion accidentelle

6.1 Précautions individuelles, équipement de protection et procédures d'urgence: Contacter les autorités locales en cas de déversement dans les égouts/le milieu aquatique. Assurer une protection individuelle appropriée (y compris une protection respiratoire) durant l'enlèvement du produit répandu dans une atmosphère confinée.

6.1.1 Pour les non-secouristes: Aucune information disponible.

6.1.2 Pour les secouristes: Aucune information disponible.

6.2 Précautions pour la protection de l'environnement: Éviter le rejet dans l'environnement.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

- 6.3 Méthodes et matériel de confinement et de nettoyage:** Absorber les déversements avec une matière absorbante adéquate. Éviter que les écoulements ne pénètrent les canalisations, les égouts ou les rivières. Voir l'équipement de protection individuelle à la Section 8. Pour l'élimination des déchets, voir la section 13 de la FDS.
- 6.4 Référence à d'autres rubriques:** Aucune information disponible.

RUBRIQUE 7 — Manipulation et stockage

7.1 Précautions à prendre pour une manipulation sans danger

- Mesures techniques (par exemple ventilation localisée et générale):** Aucune exigence particulière dans les conditions normales d'utilisation avec une ventilation suffisante.
- Conseil de manipulation en toute sécurité:** Ne pas manger, ne pas boire et ne pas fumer pendant l'utilisation. Lire et suivre les recommandations du fabricant. Utiliser l'équipement de protection individuel requis.
- Mesures à prendre pour éviter le contact:** Aucune information disponible.

7.2 Conditions d'un stockage sûr, y compris les éventuelles incompatibilités

- Conditions d'un stockage sûr:** Conserver dans un endroit frais et sec. Conserver le récipient bien fermé.
- Matériaux d'emballage sûrs:** Aucune information disponible.

- 7.3 Utilisation(s) finale(s) particulière(s):** Réservé aux utilisateurs industriels et professionnels. Lire l'étiquette avant utilisation.

RUBRIQUE 8 — Contrôles de l'exposition/protection individuelle

8.1 Paramètres de contrôle

Valeurs Limites d'Exposition Professionnelle

Aucun des composants ne fait l'objet d'une limite d'exposition.

Valeurs Limites Biologiques

Aucune limite d'exposition biologique n'est indiquée pour ce ou ces composants.

Valeurs de DNEL

Remarques: Valeurs de DNEL

Composant critique	Type	Voie d'exposition	Avertissements sanitaires	Remarques



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Sodium Chloride (NaCl)	Population en général	Inhalation	Systémique, long terme; 443,28 mg/m3	Toxicité à des doses répétées
	Travailleurs	Inhalation	Systémique, long terme; 2068,62 mg/m3	Toxicité à des doses répétées
	Travailleurs	Inhalation	Systémique, court terme; 2068,62 mg/m3	Toxicité à des doses répétées
	Population en général	Inhalation	Systémique, court terme; 443,28 mg/m3	Toxicité à des doses répétées
	Population en général	Oral	Systémique, long terme; 126,65 mg/kg	Toxicité à des doses répétées
	Travailleurs	Cutané	Systémique, long terme; 295,52 mg/kg	Toxicité à des doses répétées
	Travailleurs	Cutané	Systémique, court terme; 295,52 mg/kg	Toxicité à des doses répétées
	Population en général	Oral	Systémique, court terme; 126,65 mg/kg	Toxicité à des doses répétées
	Population en général	Cutané	Systémique, court terme; 126,65 mg/kg	Toxicité à des doses répétées
	Population en général	Cutané	Systémique, long terme; 126,65 mg/kg	Toxicité à des doses répétées

Phosphoric acid, sodium salt (1:2)	Travailleurs	Yeux	Effet local;	Aucun danger identifié
	Travailleurs	Inhalation	Systémique, long terme; 4,07 mg/m3	Toxicité à des doses répétées
	Population en général	Inhalation	Systémique, long terme; 3,04 mg/m3	Toxicité à des doses répétées
	Population en général	Inhalation	Systémique, long terme; 6,63 mg/m3	Toxicité à des doses répétées
	Travailleurs	Inhalation	Systémique, long terme; 15,47 mg/m3	Toxicité à des doses répétées

Sodium azide (Na(N3))	Travailleurs	Inhalation	Systémique, long terme; 0,164 mg/m3	Toxicité à des doses répétées
	Population en général	Yeux	Effet local;	Aucun danger identifié
	Population en général	Inhalation	Systémique, long terme; 29 µg/m3	Toxicité à des doses répétées
	Travailleurs	Yeux	Effet local;	Aucun danger identifié
	Travailleurs	Cutané	Systémique, long terme; 0,0467 mg/kg	Toxicité à des doses répétées
	Population en général	Oral	Systémique, long terme; 0,0167 mg/kg	Toxicité à des doses répétées
	Population en général	Cutané	Systémique, long terme; 0,0167 mg/kg	Toxicité à des doses répétées

Phosphoric acid, potassium salt (1:1)	Travailleurs	Yeux	Effet local;	Aucun danger identifié
	Population en général	Yeux	Effet local;	Aucun danger identifié
	Travailleurs	Inhalation	Systémique, long terme; 14,82 mg/m3	Toxicité à des doses répétées
	Population en général	Inhalation	Systémique, long terme; 6,35 mg/m3	Toxicité à des doses répétées

Potassium chloride (KCl)	Travailleurs	Inhalation	Systémique, long terme; 1064 mg/m3	Toxicité à des doses répétées
	Population en général	Inhalation	Systémique, long terme; 273 mg/m3	Toxicité à des doses répétées
	Population en général	Inhalation	Systémique, court terme; 1365 mg/m3	Toxicité à des doses répétées
	Travailleurs	Inhalation	Systémique, court terme; 5320 mg/m3	Toxicité à des doses répétées

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Population en général	Oral	Systémique, court terme; 455 mg/kg	Toxicité à des doses répétées
	Population en général	Cutané	Systémique, long terme; 182 mg/kg	Toxicité à des doses répétées
	Population en général	Oral	Systémique, long terme; 91 mg/kg	Toxicité à des doses répétées
	Travailleurs	Cutané	Systémique, long terme; 303 mg/kg	Toxicité à des doses répétées
	Travailleurs	Cutané	Systémique, court terme; 910 mg/kg	Toxicité à des doses répétées
	Population en général	Cutané	Systémique, court terme; 910 mg/kg	Toxicité à des doses répétées

Valeurs de PNEC

Remarques: Valeurs de PNEC

Composant critique	Milieu environnemental	Valeurs de PNEC	Remarques
Sodium Chloride (NaCl)	Terre	4,86 mg/kg	
	Aquatique (eau douce)	5 mg/l	
	Station d'épuration des eaux usées	500 mg/l	

Phosphoric acid, sodium salt (1:2)	Station d'épuration des eaux usées	50 mg/l	
	Aquatique (eau douce)	0,05 mg/l	
	Aquatique (eau de mer)	0,005 mg/l	

Sodium azide (Na(N3))	Aquatique (eau de mer)	15 ng/l	
	Station d'épuration des eaux usées	30 µg/l	
	Sédiment (eau douce)	0,0167 mg/kg	
	Aquatique (eau douce)	0,35 µg/l	
	Sédiments (eau de mer)	0,00072 mg/kg	

Potassium chloride (KCl)	Aquatique (eau de mer)	0,1 mg/l	
	Station d'épuration des eaux usées	10 mg/l	
	Aquatique (eau douce)	0,1 mg/l	

8.2 Contrôles de l'exposition

Contrôles Techniques Appropriés:

Aucune exigence particulière dans les conditions normales d'utilisation avec une ventilation suffisante.

Mesures de protection individuelle, telles que les équipements de protection individuelle

Protection des yeux/du visage:

Porter des lunettes de sécurité à écrans latéraux ou des lunettes étanches.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Protection des Mains:	Matière: Gants de protection chimique Informations supplémentaires: Se laver les mains après tout contact. Matière: Suivre les recommandations du fournisseur pour le choix des gants adéquats.
Protection de la peau et du corps:	Porter une blouse de laboratoire ou un vêtement de protection semblable.
Protection respiratoire:	Si les mesures techniques de contrôle de l'exposition ne permettent pas de maintenir les concentrations émises dans l'air en-dessous des limites d'exposition recommandées ou à un niveau acceptable (dans les pays où des limites d'exposition n'ont pas été établies), un appareil respiratoire homologué doit être porté.
Mesures d'hygiène:	Se conformer aux bonnes pratiques d'hygiène industrielle.
Contrôles environnementaux:	Aucune information disponible.

RUBRIQUE 9 — Propriétés physiques et chimiques

9.1 Informations sur les propriétés physiques et chimiques essentielles

Aspect	
État:	liquide
Forme:	liquide
Couleur:	Incolore à marron
Odeur:	Inodore
Seuil olfactif:	Aucune information disponible.
Point de congélation:	Aucune information disponible.
Point d'ébullition:	Aucune information disponible.
Inflammabilité:	Aucune information disponible.
Limites supérieures/inférieures d'inflammabilité ou d'explosivité	
Limites d'explosivité - supérieure (%) :	Aucune information disponible.
Limites d'explosivité - inférieure (%):	Aucune information disponible.
Point d'éclair:	Aucune information disponible.
Température d'auto-inflammation:	Aucune information disponible.
Température de décomposition:	Aucune information disponible.
pH:	7,20 - 7,60
Viscosité	

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Viscosité, dynamique: Aucune information disponible.

Viscosité, cinématique: Aucune information disponible.

Durée d'écoulement: Aucune information disponible.

Solubilités

Solubilité dans l'eau: Soluble

Solubilité (autre): Aucune information disponible.

Taux de dissolution: Aucune information disponible.

Coefficient de partition (n-octanol/eau): Aucune information disponible.

Stabilité de la dispersion: Aucune information disponible.

Pression de vapeur: Aucune information disponible.

Densité relative: Aucune information disponible.

Densité: Aucune information disponible.

Densité apparente: Aucune information disponible.

Densité de vapeur relative: Aucune information disponible.

9.2 Autres informations

Donnée non disponible

RUBRIQUE 10 — Stabilité et réactivité

10.1 Réactivité: Ce produit est stable dans des conditions normales.

10.2 Stabilité chimique: Ce produit est stable dans des conditions normales.

10.3 Possibilité de réactions dangereuses: Stable

10.4 Conditions à éviter: Éviter l'exposition aux températures élevées ou à la lumière du jour.

10.5 Matières incompatibles: Métaux. Matières réactives avec l'eau.

10.6 Produits de décomposition dangereux: Stable ; cependant, peut se décomposer en cas d'élévation de température.

RUBRIQUE 11 — Informations toxicologiques

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

11.1 Informations sur les classes de danger telles que définies dans le règlement (CE) no 1272/2008

Inhalation: Aucune information disponible.

Contact avec la Peau: Aucune information disponible.

Contact oculaire: Aucune information disponible.

Ingestion: Aucune information disponible.

Informations sur les voies d'exposition probables

Toxicité aiguë (répertoirer toutes les voies d'exposition possibles)

Ingestion

Produit: Non classé comme présentant une toxicité aiguë d'après les données disponibles.

Contact avec la peau

Produit: Non classé comme présentant une toxicité aiguë d'après les données disponibles.

Inhalation

Produit: Non classé comme présentant une toxicité aiguë d'après les données disponibles.

Toxicité à dose répétée

Produit: Aucune information disponible.

Corrosion ou Irritation de la Peau

Produit: Aucune information disponible.

Blessure ou Irritation Grave des Yeux

Produit: Aucune information disponible.

Sensibilisation Respiratoire ou Cutanée

Produit: Aucune information disponible.

Cancérogénicité

Produit: Aucune information disponible.

Mutagénicité des Cellules Germinales

In vitro

Produit: Aucune information disponible.

In vivo

Produit: Aucune information disponible.

Toxicité pour la reproduction

Produit: Aucune information disponible.

Toxicité Spécifique au Niveau de l'Organe Cible- Exposition Unique



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Produit: Aucune information disponible.

Toxicité Spécifique au Niveau de l'Organe Cible- Expositions répétées

Produit: Aucune information disponible.

Risque d'Aspiration

Produit: Aucune information disponible.

11.2 Informations sur les autres dangers

Propriétés perturbant le système endocrinien

Produit: La substance/Le mélange ne contient pas de composants considérés comme ayant des propriétés perturbatrices du système endocrinien selon l'article 57(f) de REACH ou le règlement délégué de la Commission (UE) 2017/2100 ou le règlement de la Commission (EU) 2018/605 à des niveaux de 0,1 % ou plus.;

Autres informations

Produit: Aucune information disponible.

RUBRIQUE 12 — Informations écologiques

12.1 Toxicité:

Risques aigus pour l'environnement aquatique:

Poisson

Produit: Aucune information disponible.

Invertébrés Aquatiques

Produit: Aucune information disponible.

Toxicité pour les plantes aquatiques

Produit: Aucune information disponible.

Toxicité pour les microorganismes

Produit: Aucune information disponible.

Risques chroniques pour l'environnement aquatique:

Poisson

Produit: Aucune information disponible.

Invertébrés Aquatiques

Produit: Aucune information disponible.

Toxicité pour les plantes aquatiques

Produit: Aucune information disponible.

Toxicité pour les microorganismes

Produit: Aucune information disponible.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

12.2 Persistance et dégradabilité

Biodégradation

Produit: Aucune information disponible.

Rapport DBO/DCO

Produit: Aucune information disponible.

12.3 Potentiel de bioaccumulation

Facteur de Bioconcentration (BCF)

Produit: Aucune information disponible.

Coefficient de Partage n-octanol/eau (log K_{ow})

Produit: Aucune information disponible.

12.4 Mobilité dans le sol:

Produit Aucune information disponible.

12.5 Résultats des évaluations PBT et vPvB:

Produit Aucune information disponible.

12.6 Propriétés perturbant le système endocrinien:

Produit: La substance/Le mélange ne contient pas de composants considérés comme ayant des propriétés perturbatrices du système endocrinien selon l'article 57(f) de REACH ou le règlement délégué de la Commission (UE) 2017/2100 ou le règlement de la Commission (EU) 2018/605 à des niveaux de 0,1 % ou plus.

12.7 Autres effets néfastes:

Autres dangers

Produit: Aucune information disponible.

RUBRIQUE 13 — Considérations relatives à l'élimination

13.1 Méthodes de traitement des déchets

Informations générales:

Éliminer les rejets et les déchets conformément aux règlements municipaux.

Méthodes d'élimination:

Éliminer les déchets dans une installation de traitement et d'élimination des déchets appropriée conformément aux lois et aux réglementations en vigueur et en fonction des caractéristiques du produit au moment de l'élimination.

**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Emballages Contaminés:

Éliminer le contenu/récipient dans une installation de traitement et d'élimination appropriée, conformément aux lois et aux réglementations en vigueur et en fonction des caractéristiques du produit au moment de l'élimination.

RUBRIQUE 14 — Informations relatives au transport
--

ADR

14.1 Numéro ONU ou numéro d'identification:	Non réglementé.
14.2 Désignation officielle de transport de l'ONU:	Non réglementé.
14.3 Classe(s) de danger pour le transport	
Classe:	Non réglementé.
Étiquettes:	Non réglementé.
N° de danger (ADR):	Non réglementé.
Code de restriction en tunnel:	Non réglementé.
14.4 Groupe d'emballage:	Non réglementé.
Quantité limitée	Non réglementé.
Quantité exemptée	Non réglementé.
14.5 Dangers pour l'environnement	Non réglementé.
14.6 Précautions particulières à prendre par l'utilisateur:	Non réglementé.

ADN

14.1 Numéro ONU ou numéro d'identification:	Non réglementé.
14.2 Désignation officielle de transport de l'ONU:	Non réglementé.
14.3 Classe(s) de danger pour le transport	
Classe:	Non réglementé.
Étiquettes:	Non réglementé.
N° de danger (ADR):	Non réglementé.
Code de restriction en tunnel:	Non réglementé.
14.4 Groupe d'emballage:	Non réglementé.
Quantité limitée	Non réglementé.
Quantité exemptée	Non réglementé.
14.5 Précautions particulières à prendre par l'utilisateur:	Non réglementé.

RID

14.1 Numéro ONU ou numéro d'identification:	Non réglementé.
14.2 Désignation officielle de transport de l'ONU:	Non réglementé.
14.3 Classe(s) de danger pour le transport	
Classe:	Non réglementé.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Étiquettes:	Non réglementé.
14.4 Groupe d'emballage:	Non réglementé.
Quantité limitée	Non réglementé.
Quantité exemptée	Non réglementé.
14.5 Dangers pour l'environnement	Non réglementé.
14.6 Précautions particulières à prendre par l'utilisateur:	Non réglementé.

IMDG

14.1 Numéro ONU ou numéro d'identification:	Non réglementé.
14.2 Désignation officielle de transport de l'ONU:	Non réglementé.
14.3 Classe(s) de danger pour le transport	
Classe:	Non réglementé.
Étiquettes:	Non réglementé.
N° d'urgence:	Non réglementé.
14.4 Groupe d'emballage:	Non réglementé.
Quantité limitée	Non réglementé.
Quantité exemptée	Non réglementé.
14.5 Dangers pour l'environnement	Non réglementé.
14.6 Précautions particulières à prendre par l'utilisateur:	Non réglementé.

IATA

14.1 Numéro ONU ou numéro d'identification:	Non réglementé.
14.2 Désignation officielle de transport de l'ONU:	Non réglementé.
14.3 Classe(s) de danger pour le transport	
Classe:	Non réglementé.
Étiquettes:	Non réglementé.
14.4 Groupe d'emballage:	Non réglementé.
Aéronefs de transport de passagers et de marchandises :	Non réglementé.
Quantité limitée	Non réglementé.
Quantité exemptée	Non réglementé.
14.5 Dangers pour l'environnement	Non réglementé.
14.6 Précautions particulières à prendre par l'utilisateur:	Non réglementé.

14.7 Transport maritime en vrac conformément aux instruments de l'OMI

Non applicable pour le produit tel qu'il est fourni.

RUBRIQUE 15 — Informations relatives à la réglementation

15.1 Réglementations/législation particulières à la substance ou au mélange en matière de sécurité, de santé et d'environnement:

Règlements UE

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Règlement 1005/2009/CE relatif à des substances qui appauvrissent la couche d'ozone, Annexe I, Substances réglementées: Aucun présent ou aucun présent dans des quantités réglementées.

RÈGLEMENT (CE) No 1907/2006 (REACH), ANNEXE XIV LISTE DES SUBSTANCES SOUMISES À AUTORISATION: Aucun présent ou aucun présent dans des quantités réglementées.

Règlement (CE) 2019/1021 concernant les polluants organiques persistants (refonte), et ses modifications: Aucun présent ou aucun présent dans des quantités réglementées.

UE. Directive 2010/75/UE elative aux émissions industrielles (prévention et réduction intégrées de la pollution), Annexe II, L 334/17: Aucun présent ou aucun présent dans des quantités réglementées.

Règlement (UE) n° 649/2012 concernant les exportations et importations de produits chimiques dangereux, Annexe I, partie 1 et ses modifications: Aucun présent ou aucun présent dans des quantités réglementées.

Règlement (UE) n° 649/2012 concernant les exportations et importations de produits chimiques dangereux, Annexe I, partie 2 et ses modifications: Aucun présent ou aucun présent dans des quantités réglementées.

Règlement (UE) n° 649/2012 concernant les exportations et importations de produits chimiques dangereux, Annexe I, partie 3 et ses modifications: Aucun présent ou aucun présent dans des quantités réglementées.

Règlement (UE) n° 649/2012 concernant les exportations et importations de produits chimiques dangereux, Annexe V et ses modifications: Aucun présent ou aucun présent dans des quantités réglementées.

UE. Liste des substances extrêmement préoccupantes candidates en vue d'une autorisation (SVHC), REACH: Aucun présent ou aucun présent dans des quantités réglementées.

Règlement (CE) n° 1907/2006, Annexe XVII, Substances soumises à restrictions de mise sur le marché et d'utilisation:

Directive 2004/37/CE concernant la protection des travailleurs contre les risques liés à l'exposition à des agents cancérigènes ou mutagènes au travail.: Aucun présent ou aucun présent dans des quantités réglementées.

Directive 92/85/CEE concernant la mise en oeuvre de mesures visant à promouvoir l'amélioration de la sécurité et de la santé des travailleuses enceintes, accouchées ou allaitantes au travail.: Aucun présent ou aucun présent dans des quantités réglementées.

DIRECTIVE 2012/18/UE concernant la maîtrise des dangers liés aux accidents majeurs impliquant des substances dangereuses, ANNEXE I: Aucun présent ou aucun présent dans des quantités réglementées.

RÈGLEMENT (CE) No 166/2006 concernant la création d'un registre européen des rejets et des transferts de polluants, ANNEXE II: Polluants: Aucun présent ou aucun présent dans des quantités réglementées.

Directive 98/24/CEE concernant la protection de la santé et de la sécurité des travailleurs contre les

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

risques liés à des agents chimiques sur le lieu de travail:

Désignation chimique	N° CAS	Concentration
azoture de sodium	26628-22-8	0 - <0,1%

15.2 Évaluation de la sécurité chimique: Aucune évaluation de la sécurité chimique n'a été mise en œuvre.

Règlements internationaux

Protocole de Montréal
Non applicable

Convention de Stockholm
Non applicable

Convention de Rotterdam
Non applicable

Protocole de Kyoto
Non applicable

RUBRIQUE 16 — Autres informations

Abréviations et acronymes:
Aucune information disponible.

Principales références de la littérature et sources de données: Agence européenne des produits chimiques (ECHA) : Informations sur les substances chimiques.

Texte des mentions dans les sections 2 et 3
: aucune

Informations de formation: Aucune information disponible.

FDS n°: UN0000000000000332771-4012-1-01



**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Avis de non-responsabilité:

Disclaimer:

Les renseignements contenus dans le présent document ont été obtenus de diverses sources et l'on croit être justes à la date d'émission. Toutefois, ni BD ni aucune de ses succursales ne peut assumer toute responsabilité quant à l'exactitude ou l'exhaustivité des informations contenues dans ce document. La décision finale d'aptitude à une utilisation particulière de tout matériel est la responsabilité exclusive de l'utilisateur. Tous les matériaux peuvent présenter des dangers inconnus et doivent être utilisés avec prudence. Bien que certains dangers soient décrits aux présentes, nous ne pouvons pas garantir que ce sont les seuls risques qui existent. BD fournit FS sous forme électronique si l'information peut être plus facilement accessible. En raison de la possibilité d'erreurs lors de la transmission, BD ne fait aucune déclaration quant à l'exhaustivité ou l'exactitude de l'information.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

FICHA DE DATOS DE SEGURIDAD

Conforme al Reglamento (CE) nº 1907/2006 (REACH) Artículo 31, Anexo II con las enmiendas correspondientes

SECCIÓN 1. Identificación de la sustancia o la mezcla y de la sociedad o la empresa

Identificador de producto

Núm. de producto:	Nombre del producto:	Nombre(s) común(es) y sinónimo(s)
332777	BD® CD10 (HI10a) APC	No hay datos disponibles.
332791	BD® Anti-TdT (E17-1519) APC	No hay datos disponibles.
333143	BD® CD11b (D12) APC	No hay datos disponibles.
333144	BD® CD11c (S-HCL-3) APC	No hay datos disponibles.
333145	BD® CD22 (S-HCL-1) APC	No hay datos disponibles.
333154	BD® CD79a (HM47) APC	No hay datos disponibles.
333233	BD® CD117 (104D2) APC	No hay datos disponibles.
333951	BD® CD14 (MφP9) APC-Cy7	No hay datos disponibles.
335036	BD® CD23 (EBVCS-5) APC	No hay datos disponibles.
335829	BD® CD20 (L27) APC-Cy7	No hay datos disponibles.
335831	BD® Anti-HLA-DR (L243) APC-Cy7	No hay datos disponibles.
335834	BD® CD79b (SN8) APC	No hay datos disponibles.
337447	BD® CD71 (L01.1) APC	No hay datos disponibles.
340907	BD® CD25 (2A3) APC	No hay datos disponibles.
340908	BD® CD20 (L27) APC	No hay datos disponibles.
341024	BD® CD2 (L303.1) APC	No hay datos disponibles.
341027	BD® CD56 (NCAM16.2) APC	No hay datos disponibles.
341108	BD® Anti-Kappa (TB 28-2) APC	No hay datos disponibles.
341110	BD® CD3 (SK7) APC-Cy7	No hay datos disponibles.
341115	BD® CD4 (SK3) APC-Cy7	No hay datos disponibles.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

345767	BD® CD3 (SK7) APC	No hay datos disponibles.
345771	BD® CD4 (SK3) APC	No hay datos disponibles.
345775	BD® CD8 (SK1) APC	No hay datos disponibles.
345783	BD® CD5 (L17F12) APC	No hay datos disponibles.
345787	BD® CD14 APC	No hay datos disponibles.
345791	BD® CD19 (SJ25C1) APC	No hay datos disponibles.
345800	BD® CD33 (P67.6) APC	No hay datos disponibles.
345804	BD® CD34 (8G12) APC	No hay datos disponibles.
345807	BD® CD38 (HB7) APC	No hay datos disponibles.
345818	BD® Mouse IgG1 (X40) APC	No hay datos disponibles.
347216	BD® CD138 (MI15) APC	No hay datos disponibles.
347403	BD® Anti-HLA-DR (L243) APC-H7	No hay datos disponibles.
348812	BD® Mouse IgG1 (X40) APC-Cy7	No hay datos disponibles.
348813	BD® CD8 (SK1) APC-Cy7	No hay datos disponibles.
348814	BD® CD19 (SJ25C1) APC-Cy7	No hay datos disponibles.
641411	BD® Anti-HLA-DR (L243) APC-H7	No hay datos disponibles.
641414	BD® CD20 (L27) APC-H7	No hay datos disponibles.

1.2 Usos pertinentes identificados de la sustancia o de la mezcla y usos desaconsejados

Uso identificado: Para uso científico y en laboratorios industriales. Para uso en diagnósticos in vitro.

Usos no recomendados: Ningunos conocidos/Ninguna conocida.

1.3 Datos del proveedor de la ficha de datos de seguridad

Fabricante

Becton Dickinson France S.A.S. Belgian Branch
Erembodegem-Dorp 86
9320 Erembodegem
Belgium

teléfono: 32 2 400 98 95
fax: 32 2 401 70 94

Persona de contacto: BD Biosciences - Centralized European Office
Regulatory Compliance Department

Correo electrónico: help.biosciences@europe.bd.com

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

1.4 Teléfono de emergencia: 32 2 400 98 95

SECCIÓN 2. Identificación de los peligros

2.1 Clasificación de la sustancia o de la mezcla

El producto no ha sido clasificado como peligroso de acuerdo con la legislación vigentes.

Clasificación de acuerdo con el reglamento (CE) No. 1272/2008 con sus modificaciones posteriores.

No clasificado

2.2 Elementos de la etiqueta No aplicable

2.3 Otros peligros

Propiedades de alteración endocrina-Toxicidad

La sustancia/la mezcla no contienen componentes que tengan propiedades alteradoras endocrinas de acuerdo con el artículo 57(f) de REACH o el Reglamento delegado de la Comisión (UE) 2017/2100 o el Reglamento de la Comisión (UE) 2018/605 en niveles del 0,1 % o superiores.

Propiedades de alteración endocrina-Ecotoxicidad

La sustancia/la mezcla no contienen componentes que tengan propiedades alteradoras endocrinas de acuerdo con el artículo 57(f) de REACH o el Reglamento delegado de la Comisión (UE) 2017/2100 o el Reglamento de la Comisión (UE) 2018/605 en niveles del 0,1 % o superiores.

SECCIÓN 3. Composición/información sobre los componentes

3.2 Mezclas

Información general: No contiene ingredientes peligrosos.

SECCIÓN 4. Primeros auxilios

4.1 Descripción de los primeros auxilios

Información general: Obtenga atención médica en caso de síntomas.

Inhalación: Proporcionar aire fresco, calor moderado y reposo. Poner la persona en posición vertical, cómoda, y sentada.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Contacto con la Piel:	Lave las áreas de contacto con agua y jabón. Quítese la ropa contaminada. Lave la ropa contaminada antes de volver a usarla.
Contacto con los ojos:	Enjuagar inmediatamente los ojos con agua abundante durante por los menos 15 minutos. Si resulta fácil, quitar las lentes de contacto.
Ingestión:	Llamar inmediatamente al médico o al centro toxicológico. Solamente debe provocar el vómito siguiendo las instrucciones del personal médico. No darle nunca nada por la boca a una persona inconsciente.
Equipo de protección personal para el personal de primeros auxilios:	No hay datos disponibles.
4.2 Principales síntomas y efectos, agudos y retardados	
Síntomas:	No hay datos disponibles.
Riesgos:	No hay datos disponibles.
4.3 Indicación de asistencia médica inmediata y tratamiento especial necesario	
Tratamiento:	No hay datos disponibles.

SECCIÓN 5. Medidas de lucha contra incendios

Riesgos Generales de Incendio:	Extinguir todas las fuentes de ignición. Evitar chispas, llamas, calor y humo. Ventilar. Use agua nebulizada para mantener refrigerados los contenedores expuestos al fuego.
---------------------------------------	--

5.1 Medios de extinción

Medios de extinción apropiados:	Seleccione el medio de extinción más apropiado, teniendo en cuenta la posible presencia de otros productos químicos.
Medios de extinción no apropiados:	No aplicable

5.2 Peligros específicos derivados de la sustancia o la mezcla:	En caso de incendio o calor excesivo se pueden generar productos de descomposición peligrosos.
--	--

5.3 Recomendaciones para el personal de lucha contra incendios

Medidas especiales de lucha contra incendios:	Ningún riesgo excepcional de incendio o explosión señalado.
Equipos de protección especial que debe llevar el personal de lucha contra incendios:	Los bomberos deben utilizar un equipo de protección estándar incluyendo chaqueta ignífuga, casco con careta, guantes, botas de goma, y, en espacios cerrados, equipo de respiración autónomo (SCBA, según sus siglas en inglés).



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SECCIÓN 6. Medidas en caso de vertido accidental

- | | |
|--|--|
| 6.1 Precauciones personales, equipo de protección y procedimientos de emergencia: | Contacte las autoridades locales en caso de escape al desagüe o el ambiente acuático. Asegúrese una protección personal adecuada (protección respiratoria inclusive) durante la eliminación de derrames en cámaras pequeñas. |
| 6.1.1 Para el personal que no forma parte de los servicios de emergencia: | No hay datos disponibles. |
| 6.1.2 Para el personal de emergencia: | No hay datos disponibles. |
| 6.2 Precauciones relativas al medio ambiente: | Evitar su liberación al medio ambiente. |
| 6.3 Métodos y material de contención y de limpieza: | Absorber el producto derramado con material absorbente. Evite que las aguas residuales entren en las cunetas, alcantarillados o vías fluviales. Consulte la sección 8 de la FDS sobre equipo de protección personal. Para información sobre la eliminación, véase la sección 13. |
| 6.4 Referencia a otras secciones: | No hay datos disponibles. |

SECCIÓN 7. Manipulación y almacenamiento

7.1 Precauciones para una manipulación segura

- | | |
|---|--|
| Medidas de carácter técnico (p.ej. Ventilación local y general): | Ningún requisito especial en condiciones normales de uso y con ventilación adecuada. |
| Manipulación: | No comer, ni beber, ni fumar durante su utilización. Leer y seguir las recomendaciones del proveedor. Utilizar los equipos de protección individual según las necesidades. |
| Medidas para evitar el contacto: | No hay datos disponibles. |

7.2 Condiciones de almacenamiento seguro, incluidas posibles incompatibilidades

- | | |
|--|--|
| Condiciones de almacenamiento seguro: | Almacene en un lugar fresco y seco. Manténgase el recipiente bien cerrado. |
| Materiales de embalaje seguros: | No hay datos disponibles. |

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

7.3 Usos específicos finales: Reservado a usos industriales y profesionales. Leer la etiqueta antes del uso.

SECCIÓN 8. Controles de exposición/protección individual

8.1 Parámetros de control

Valores Límite de Exposición Profesional

No se asignaron límites de exposición a ninguno de los componentes.

Valor Límite Biológico

No se han indicado límites de exposición biológica para el/los componente(s).

Valores DNEL

Observaciones: Valores DNEL

Componente crítico	Tipo	Ruta de exposición	Advertencias para la salud	Observaciones
Sodium Chloride (NaCl)	Población general	Inhalation	Sistémicos, largo plazo; 443,28 mg/m3	Toxicidad por dosis repetidas
	Trabajadores	Inhalation	Sistémicos, largo plazo; 2068,62 mg/m3	Toxicidad por dosis repetidas
	Trabajadores	Inhalation	Sistémicos, corto plazo; 2068,62 mg/m3	Toxicidad por dosis repetidas
	Población general	Inhalation	Sistémicos, corto plazo; 443,28 mg/m3	Toxicidad por dosis repetidas
	Población general	Oral	Sistémicos, largo plazo; 126,65 mg/kg	Toxicidad por dosis repetidas
	Trabajadores	Dérmico	Sistémicos, largo plazo; 295,52 mg/kg	Toxicidad por dosis repetidas
	Trabajadores	Dérmico	Sistémicos, corto plazo; 295,52 mg/kg	Toxicidad por dosis repetidas
	Población general	Oral	Sistémicos, corto plazo; 126,65 mg/kg	Toxicidad por dosis repetidas
	Población general	Dérmico	Sistémicos, corto plazo; 126,65 mg/kg	Toxicidad por dosis repetidas
	Población general	Dérmico	Sistémicos, largo plazo; 126,65 mg/kg	Toxicidad por dosis repetidas
Phosphoric acid, sodium salt (1:2)	Trabajadores	Ojos	Efecto local;	Sin peligro identificado
	Trabajadores	Inhalation	Sistémicos, largo plazo; 4,07 mg/m3	Toxicidad por dosis repetidas
	Población general	Inhalation	Sistémicos, largo plazo; 3,04 mg/m3	Toxicidad por dosis repetidas
	Población general	Inhalation	Sistémicos, largo plazo; 6,63 mg/m3	Toxicidad por dosis repetidas
	Trabajadores	Inhalation	Sistémicos, largo plazo; 15,47 mg/m3	Toxicidad por dosis repetidas
Sodium azide (Na(N3))	Trabajadores	Inhalation	Sistémicos, largo plazo; 0,164 mg/m3	Toxicidad por dosis repetidas
	Población general	Ojos	Efecto local;	Sin peligro identificado
	Población general	Inhalation	Sistémicos, largo plazo; 29 µg/m3	Toxicidad por dosis repetidas
	Trabajadores	Ojos	Efecto local;	Sin peligro identificado

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Trabajadores	Dérmico	Sistémicos, largo plazo; 0,0467 mg/kg	Toxicidad por dosis repetidas
	Población general	Oral	Sistémicos, largo plazo; 0,0167 mg/kg	Toxicidad por dosis repetidas
	Población general	Dérmico	Sistémicos, largo plazo; 0,0167 mg/kg	Toxicidad por dosis repetidas

Potassium chloride (KCl)	Trabajadores	Inhalation	Sistémicos, largo plazo; 1064 mg/m3	Toxicidad por dosis repetidas
	Población general	Inhalation	Sistémicos, largo plazo; 273 mg/m3	Toxicidad por dosis repetidas
	Población general	Inhalation	Sistémicos, corto plazo; 1365 mg/m3	Toxicidad por dosis repetidas
	Trabajadores	Inhalation	Sistémicos, corto plazo; 5320 mg/m3	Toxicidad por dosis repetidas
	Población general	Oral	Sistémicos, corto plazo; 455 mg/kg	Toxicidad por dosis repetidas
	Población general	Dérmico	Sistémicos, largo plazo; 182 mg/kg	Toxicidad por dosis repetidas
	Población general	Oral	Sistémicos, largo plazo; 91 mg/kg	Toxicidad por dosis repetidas
	Trabajadores	Dérmico	Sistémicos, largo plazo; 303 mg/kg	Toxicidad por dosis repetidas
	Trabajadores	Dérmico	Sistémicos, corto plazo; 910 mg/kg	Toxicidad por dosis repetidas
	Población general	Dérmico	Sistémicos, corto plazo; 910 mg/kg	Toxicidad por dosis repetidas

Phosphoric acid, potassium salt (1:1)	Trabajadores	Ojos	Efecto local;	Sin peligro identificado
	Población general	Ojos	Efecto local;	Sin peligro identificado
	Trabajadores	Inhalation	Sistémicos, largo plazo; 14,82 mg/m3	Toxicidad por dosis repetidas
	Población general	Inhalation	Sistémicos, largo plazo; 6,35 mg/m3	Toxicidad por dosis repetidas

Valores PNEC

Observaciones: Valores PNEC

Componente crítico	Compartimento medioambiental	Valores PNEC	Observaciones
Sodium Chloride (NaCl)	Tierra	4,86 mg/kg	
	Acuático (agua dulce)	5 mg/l	
	Planta de tratamiento de aguas residuales	500 mg/l	

Phosphoric acid, sodium salt (1:2)	Planta de tratamiento de aguas residuales	50 mg/l	
	Acuático (agua dulce)	0,05 mg/l	
	Acuático (agua marina)	0,005 mg/l	

Sodium azide (Na(N3))	Acuático (agua marina)	15 ng/l	
	Planta de tratamiento de aguas residuales	30 µg/l	
	Sedimento (agua dulce)	0,0167 mg/kg	
	Acuático (agua dulce)	0,35 µg/l	



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Sedimentos (agua marina)	0,00072 mg/kg	
Potassium chloride (KCl)	Acuático (agua marina)	0,1 mg/l	
	Planta de tratamiento de aguas residuales	10 mg/l	
	Acuático (agua dulce)	0,1 mg/l	

8.2 Controles de la exposición

Controles Técnicos Apropiados:

Ningún requisito especial en condiciones normales de uso y con ventilación adecuada.

Medidas de protección individual, tales como equipos de protección personal

Protección de los ojos/la cara:

Use gafas de seguridad con protectores laterales (o gafas estancas).

Protección de las Manos:

Material: Guantes resistente a productos químicos
Información adicional: Lávese las manos después de la exposición.
Material: El proveedor puede recomendar los guantes adecuados.

Protección de la Piel y del Cuerpo:

Utilice una bata de laboratorio o ropa protectora similar.

Protección respiratoria:

Si los controles de ingeniería no mantienen las concentraciones en el aire por debajo de los límites de exposición recomendados (cuando proceda) o a un nivel aceptable (en países donde no se hayan establecido límites de exposición), ha de utilizarse un respirador aprobado.

Medidas de higiene:

Respete las normas para una manipulación correcta de productos químicos.

Controles medioambientales:

No hay datos disponibles.

SECCIÓN 9. Propiedades físicas y químicas

9.1 Información sobre propiedades físicas y químicas básicas

Aspecto

Forma/estado: líquido

Forma/Figura: líquido

Color: De incoloro a azul

Olor: Inodoro

Olor, umbral: No hay datos disponibles.

Punto de congelamiento: No hay datos disponibles.

Punto ebullición: No hay datos disponibles.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Inflamabilidad:	No hay datos disponibles.
Límites superior/inferior de inflamabilidad o de explosividad	
Límite superior de explosividad (%) :	No hay datos disponibles.
Límite inferior de explosividad (%) :	No hay datos disponibles.
Punto de inflamación:	No hay datos disponibles.
Temperatura de autoignición:	No hay datos disponibles.
descomposición, temperatura de:	No hay datos disponibles.
pH:	7,20 - 7,60
Viscosidad	
Viscosidad dinámica:	No hay datos disponibles.
Viscosidad cinemática:	No hay datos disponibles.
flujo, tiempo de:	No hay datos disponibles.
Solubilidad(es)	
Solubilidad en agua:	Soluble
Solubilidad (otra):	No hay datos disponibles.
Velocidad de disolución:	No hay datos disponibles.
Coefficiente de reparto (n-octanol/agua):	No hay datos disponibles.
Estabilidad de la dispersión:	No hay datos disponibles.
Presión de vapor:	No hay datos disponibles.
Densidad relativa:	No hay datos disponibles.
Densidad:	No hay datos disponibles.
Densidad aparente:	No hay datos disponibles.
Densidad relativa del vapor:	No hay datos disponibles.

9.2 Otros datos

Sin datos disponibles

SECCIÓN 10. Estabilidad y reactividad

10.1 Reactividad:	El material es estable bajo condiciones normales.
10.2 Estabilidad química:	El material es estable bajo condiciones normales.
10.3 Posibilidad de reacciones peligrosas:	estable

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

- | | | |
|------|--|---|
| 10.4 | Condiciones que deben evitarse: | Evítese la exposición a altas temperaturas o a los rayos del sol. |
| 10.5 | Materiales incompatibles: | metales Reacciona con el agua. |
| 10.6 | Productos de descomposición peligrosos: | Estable; sin embargo, puede descomponerse en caso de calentamiento. |

SECCIÓN 11. Información toxicológica

11.1 Información sobre las clases de peligro definidas en el Reglamento (CE) n.o 1272/2008

Inhalación: No hay datos disponibles.

Contacto con la Piel: No hay datos disponibles.

Contacto con los ojos: No hay datos disponibles.

Ingestión: No hay datos disponibles.

Información sobre posibles vías de exposición

Toxicidad aguda (listar todas las vías de exposición posibles)

Ingestión

Producto: No clasificado en cuanto a toxicidad aguda con los datos disponibles.

Contacto dermal

Producto: No clasificado en cuanto a toxicidad aguda con los datos disponibles.

Inhalación

Producto: No clasificado en cuanto a toxicidad aguda con los datos disponibles.

Toxicidad por dosis repetidas

Producto: No hay datos disponibles.

Corrosión/Irritación Cutáneas

Producto: No hay datos disponibles.

Lesiones Oculares Graves/Irritación Ocular

Producto: No hay datos disponibles.

Sensibilización de la Piel o Respiratoria

Producto: No hay datos disponibles.

Carcinogenicidad

Producto: No hay datos disponibles.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Mutagenicidad en Células Germinales

En vitro

Producto: No hay datos disponibles.

En vivo

Producto: No hay datos disponibles.

Toxicidad para la reproducción

Producto: No hay datos disponibles.

Toxicidad Sistémica Específica de Órganos Diana- Exposición Única

Producto: No hay datos disponibles.

Toxicidad Sistémica Específica de Órganos Diana- Exposiciones Repetidas

Producto: No hay datos disponibles.

Peligro por Aspiración

Producto: No hay datos disponibles.

11.2 Información relativa a otros peligros

Propiedades de alteración endocrina

Producto: La sustancia/la mezcla no contienen componentes que tengan propiedades alteradoras endocrinas de acuerdo con el artículo 57(f) de REACH o el Reglamento delegado de la Comisión (UE) 2017/2100 o el Reglamento de la Comisión (UE) 2018/605 en niveles del 0,1 % o superiores.;

Otros datos

Producto: No hay datos disponibles.

SECCIÓN 12. Información ecológica

12.1 Toxicidad:

Peligros agudos para el medio ambiente acuático:

Pez

Producto: No hay datos disponibles.

Invertebrados Acuáticos

Producto: No hay datos disponibles.

Toxicidad para plantas acuáticas

Producto: No hay datos disponibles.

Toxicidad para los microorganismos

Producto: No hay datos disponibles.

Peligros crónicos para el medio ambiente acuático:



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Pez

Producto: No hay datos disponibles.

Invertebrados Acuáticos

Producto: No hay datos disponibles.

Toxicidad para plantas acuáticas

Producto: No hay datos disponibles.

Toxicidad para los microorganismos

Producto: No hay datos disponibles.

12.2 Persistencia y degradabilidad

Biodegradable

Producto: No hay datos disponibles.

Relación DBO/DQO

Producto: No hay datos disponibles.

12.3 Potencial de bioacumulación

Factor de Bioconcentración (BCF)

Producto: No hay datos disponibles.

Coefficiente de Partición n-octanol/agua (log Kow)

Producto: No hay datos disponibles.

12.4 Movilidad en el suelo:

Producto No hay datos disponibles.

12.5 Resultados de la valoración PBT y mPmB:

Producto No hay datos disponibles.

12.6 Propiedades de alteración endocrina:

Producto: La sustancia/la mezcla no contienen componentes que tengan propiedades alteradoras endocrinas de acuerdo con el artículo 57(f) de REACH o el Reglamento delegado de la Comisión (UE) 2017/2100 o el Reglamento de la Comisión (UE) 2018/605 en niveles del 0,1 % o superiores.

12.7 Otros efectos adversos:

Otros peligros

Producto: No hay datos disponibles.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SECCIÓN 13. Consideraciones relativas a la eliminación

13.1 Métodos para el tratamiento de residuos

Información general:	Eliminar los desperdicios y residuos de conformidad con la normativa promulgada por las autoridades locales.
Métodos de eliminación:	Elimine el residuo en una instalación adecuada de tratamiento y eliminación de acuerdo con las leyes y reglamentos correspondientes y características del producto en el momento de la eliminación.
Envases Contaminados:	Eliminar el contenido/el recipiente en una instalación de tratamiento y eliminación de desechos apropiada de conformidad con las leyes y reglamentos aplicables y con las características del producto en el momento de la eliminación.

SECCIÓN 14. Información relativa al transporte

ADR

14.1 Número ONU o número ID:	No reglamentado.
14.2 Designación oficial de transporte de las Naciones Unidas:	No reglamentado.
14.3 Clase(s) de peligro para el transporte	
Clase:	No reglamentado.
Etiqueta(s):	No reglamentado.
No. de riesgo (ADR):	No reglamentado.
Código de restricciones en túneles:	No reglamentado.
14.4 Grupo de embalaje:	No reglamentado.
Cantidad limitada	No reglamentado.
Cantidad exceptuada	No reglamentado.
14.5 Peligros para el medio ambiente	No reglamentado.
14.6 Precauciones particulares para los usuarios:	No reglamentado.

ADN

14.1 Número ONU o número ID:	No reglamentado.
14.2 Designación oficial de transporte de las Naciones Unidas:	No reglamentado.
14.3 Clase(s) de peligro para el transporte	
Clase:	No reglamentado.
Etiqueta(s):	No reglamentado.
No. de riesgo (ADR):	No reglamentado.
Código de restricciones en túneles:	No reglamentado.
14.4 Grupo de embalaje:	No reglamentado.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Cantidad limitada	No reglamentado.
Cantidad exceptuada	No reglamentado.
14.5 Precauciones particulares para los usuarios:	No reglamentado.

RID

14.1 Número ONU o número ID:	No reglamentado.
14.2 Designación oficial de transporte de las Naciones Unidas:	No reglamentado.
14.3 Clase(s) de peligro para el transporte	
Clase:	No reglamentado.
Etiqueta(s):	No reglamentado.
14.4 Grupo de embalaje:	No reglamentado.
Cantidad limitada	No reglamentado.
Cantidad exceptuada	No reglamentado.
14.5 Peligros para el medio ambiente	No reglamentado.
14.6 Precauciones particulares para los usuarios:	No reglamentado.

IMDG

14.1 Número ONU o número ID:	No reglamentado.
14.2 Designación oficial de transporte de las Naciones Unidas:	No reglamentado.
14.3 Clase(s) de peligro para el transporte	
Clase:	No reglamentado.
Etiqueta(s):	No reglamentado.
EmS No.:	No reglamentado.
14.4 Grupo de embalaje:	No reglamentado.
Cantidad limitada	No reglamentado.
Cantidad exceptuada	No reglamentado.
14.5 Peligros para el medio ambiente	No reglamentado.
14.6 Precauciones particulares para los usuarios:	No reglamentado.

IATA

14.1 Número ONU o número ID:	No reglamentado.
14.2 Designación oficial de transporte de las Naciones Unidas:	No reglamentado.
14.3 Clase(s) de peligro para el transporte	
Clase:	No reglamentado.
Etiqueta(s):	No reglamentado.
14.4 Grupo de embalaje:	No reglamentado.
Transporte aéreo de pasajeros y mercancías :	No reglamentado.
Cantidad limitada	No reglamentado.
Cantidad exceptuada	No reglamentado.
14.5 Peligros para el medio ambiente	No reglamentado.
14.6 Precauciones particulares para los usuarios:	No reglamentado.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

14.7 Transporte marítimo a granel con arreglo a los instrumentos de la OMI

No aplicable al producto suministrado.

SECCIÓN 15. Información reglamentaria

15.1 Reglamentación y legislación en materia de seguridad, salud y medio ambiente específicas para la sustancia o la mezcla:

Legislación de la UE

Reglamento 1005/2009/EC sobre las sustancias que agotan la capa de ozono. Anexo I, Sustancias controladas: No están presentes, o no están presentes en las cantidades reguladas.

REGLAMENTO (CE) No 1907/2006 (REACH), ANEXO XIV LISTA DE SUSTANCIAS SUJETAS A AUTORIZACIÓN: No están presentes, o no están presentes en las cantidades reguladas.

Reglamento nº. 2019/1021/UE de la UE que prohíbe y restringe contaminantes orgánicos persistentes (COP), con sus modificaciones ulteriores: No están presentes, o no están presentes en las cantidades reguladas.

UE. Directiva 2010/75/UE sobre las emisiones industriales (prevención y control integrados de la contaminación), Anexo II, L 334/17: No están presentes, o no están presentes en las cantidades reguladas.

Reglamento (UE) nº 649/2012 relativo a la exportación e importación de productos químicos peligrosos, Anexo I, parte 1, con las enmiendas correspondientes: No están presentes, o no están presentes en las cantidades reguladas.

Reglamento (UE) nº 649/2012 relativo a la exportación e importación de productos químicos peligrosos, Anexo I, parte 2, con las enmiendas correspondientes: No están presentes, o no están presentes en las cantidades reguladas.

Reglamento (UE) nº 649/2012 relativo a la exportación e importación de productos químicos peligrosos, Anexo I, parte 3, con las enmiendas correspondientes: No están presentes, o no están presentes en las cantidades reguladas.

Reglamento (UE) nº 649/2012 relativo a la exportación e importación de productos químicos peligrosos, Anexo V, con las enmiendas correspondientes: No están presentes, o no están presentes en las cantidades reguladas.

UE. Lista provisional (lista de candidatas) de sustancias extremadamente preocupantes (SEP) que pueden estar sujetas a autorización en el marco de REACH: No están presentes, o no están presentes en las cantidades reguladas.

Reglamento (CE) No. 1907/2006, Anexo XVII, Sustancias sujetas a restricciones aplicables a la comercialización y uso:

Directiva 2004/37/CE relativa a la protección de los trabajadores contra los riesgos relacionados con la exposición a agentes carcinógenos o mutágenos durante el trabajo.: No están presentes, o no están presentes en las cantidades reguladas.

Directiva 92/85/CEE relativa a la aplicación de medidas para promover la mejora de la seguridad y de

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

la salud en el trabajo de la trabajadora embarazada, que haya dado a luz o en período de lactancia:
No están presentes, o no están presentes en las cantidades reguladas.

DIRECTIVA 2012/18/UE relativa al control de los riesgos inherentes a los accidentes graves en los que intervengan sustancias peligrosas, ANEXO I: No están presentes, o no están presentes en las cantidades reguladas.

REGLAMENTO (CE) No 166/2006 relativo al establecimiento de un registro europeo de emisiones y transferencias de contaminantes, ANEXO II: Contaminantes: No están presentes, o no están presentes en las cantidades reguladas.

Directiva 98/24/CE relativa a la protección de los trabajadores contra los riesgos relacionados con los agentes químicos durante el trabajo:

Determinación química	No. CAS	Concentración
Azida de sodio	26628-22-8	0 - <0,1%

**15.2 Evaluación de la
seguridad química:**

No se ha realizado ninguna evaluación de la seguridad química.

Reglamentos internacionales

Protocolo de Montreal
No aplicable

Convención de Estocolmo
No aplicable

Convención de Rotterdam
No aplicable

Protocolo de Kioto
No aplicable

SECCIÓN 16. Otra información

Abreviaturas y acrónimos:
No hay datos disponibles.

**Principales referencias
bibliográficas y las fuentes
de datos:** Agencia Europea de Sustancias y Preparados Químicos (ECHA): información sobre sustancias y preparados químicos.

Enunciado de las frases en los apartados 2 y 3
: ningunos

Información sobre formación: No hay datos disponibles.

No. FDS: UN0000000000000332777-4012-1-01



**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Exención de responsabilidad: Descargo de responsabilidad:
La información aquí contenida ha sido obtenida de diversas fuentes y se cree que es correcta a partir de la fecha de emisión. Sin embargo, ni BD ni ninguna de sus subsidiarias asumen responsabilidad alguna por la exactitud o la exhaustividad de la información contenida en este documento. La determinación final de idoneidad para un uso particular de cualquier material es responsabilidad exclusiva del usuario. Todos los materiales pueden presentar peligros desconocidos y deben usarse con precaución. Si bien se describen ciertos peligros en este documento, no podemos garantizar que éstos sean los únicos peligros que existen. BD proporciona SDS en formato electrónico por lo que la información puede ser más fácil acceso. Debido a la posibilidad de errores durante la transmisión, BD no hace ninguna representación en cuanto a la integridad o exactitud de la información.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SAFETY DATA SHEET

According to Regulation (EC) No. 1907/2006 (REACH) Article 31, Annex II as amended.

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product No.:	Product name:	Common name(s), synonym(s)
332778	CD15 (MMA) FITC	No data available
333169	CD57 (HNK-1) FITC	No data available

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses: Scientific and industrial laboratory use. For In Vitro Diagnostic Use.

Uses advised against: None known.

1.3 Details of the supplier of the safety data sheet

Manufacturer

Becton Dickinson France S.A.S. Belgian
Branch
Erembodegem-Dorp 86
Erembodegem 9320
Belgium

Telephone: 32 2 400 98 95

Fax: 32 2 401 70 94

Contact Person: BD Biosciences - Centralized European Office
Regulatory Compliance Department

E-mail: help.biosciences@europe.bd.com

1.4 Emergency telephone number: 32 2 400 98 95

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

The product has not been classified as hazardous according to the legislation in force.

Classification according to Regulation (EC) No 1272/2008 as amended.

Not classified



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

2.2 Label Elements Not applicable

2.3 Other hazards No data available.

SECTION 3: Composition/information on ingredients

3.2 Mixtures No hazardous ingredients.

General information:

Regulation No. 1272/2008.

SECTION 4: First aid measures

General: Get medical attention if symptoms occur.

4.1 Description of first aid measures

Inhalation: Provide fresh air, warmth and rest, preferably in comfortable upright sitting position.

Eye contact: Immediately flush with plenty of water for at least 15 minutes. If easy to do, remove contact lenses.

Skin Contact: Wash contact areas with soap and water. Remove contaminated clothing. Launder contaminated clothing before reuse.

Ingestion: Call a physician or poison control center immediately. Only induce vomiting at the instruction of medical personnel. Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed: No data available.

4.3 Indication of any immediate medical attention and special treatment needed

Hazards: No data available.

Treatment: No data available.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SECTION 5: Firefighting measures

General Fire Hazards: Extinguish all ignition sources. Avoid sparks, flames, heat and smoking. Ventilate. Use water spray to keep fire-exposed containers cool.

5.1 Extinguishing media
Suitable extinguishing media:

Use fire-extinguishing media appropriate for surrounding materials.

Unsuitable extinguishing media:

Not applicable

5.2 Special hazards arising from the substance or mixture:

Fire or excessive heat may produce hazardous decomposition products.

5.3 Advice for firefighters
Special fire fighting procedures:

No unusual fire or explosion hazards noted.

Special protective equipment for fire-fighters:

Firefighters must use standard protective equipment including flame retardant coat, helmet with face shield, gloves, rubber boots, and in enclosed spaces, SCBA.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures:

Contact local authorities in case of spillage to drain/aquatic environment. Ensure suitable personal protection (including respiratory protection) during removal of spillages in a confined area.

6.2 Environmental Precautions:

Avoid release to the environment.

6.3 Methods and material for containment and cleaning up:

Absorb spillage with suitable absorbent material. Prevent runoff from entering drains, sewers, or streams. See Section 8 of the SDS for Personal Protective Equipment. For waste disposal, see section 13 of the SDS.

6.4 Reference to other sections:

No data available.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SECTION 7: Handling and storage:

- 7.1 Precautions for safe handling:** When using do not eat, drink or smoke. Read and follow manufacturer's recommendations. Use personal protective equipment as required.
- 7.2 Conditions for safe storage, including any incompatibilities:** Store in a cool, dry place. Keep container tightly closed.
- 7.3 Specific end use(s):** Reserved for industrial and professional use. Read label before use.

SECTION 8: Exposure controls/personal protection

8.1 Control Parameters Occupational Exposure Limits

None of the components have assigned exposure limits.

Biological Limit Values

None.

8.2 Exposure controls

Appropriate Engineering Controls: No special requirements under ordinary conditions of use and with adequate ventilation.

Individual protection measures, such as personal protective equipment

General information: Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing to remove contaminants. Discard contaminated footwear that cannot be cleaned.

Eye/face protection: Wear safety glasses with side shields (or goggles).

Skin protection

Hand Protection: Chemical resistant gloves Suitable gloves can be recommended by the glove supplier. Wash hands after contact.

Other: Wear a lab coat or similar protective clothing.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

**Respiratory
Protection:**

If engineering controls do not maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (in countries where exposure limits have not been established), an approved respirator must be worn.

Hygiene measures:

Observe good industrial hygiene practices.

**Environmental
Controls:**

No data available.

SECTION 9: Physical and chemical properties**9.1 Information on basic physical and chemical properties****Appearance**

Physical state:	liquid
Form:	No data available.
Color:	Colorless to slightly yellow
Odor:	Odorless
Odor Threshold:	No data available.
pH:	7.95 - 8.05
Freezing point:	No data available.
Boiling Point:	No data available.
Flash Point:	No data available.
Evaporation Rate:	No data available.
Flammability (solid, gas):	No data available.
Flammability Limit - Upper (%):	No data available.
Flammability Limit - Lower (%):	No data available.
Vapor pressure:	No data available.
Vapor density (air=1):	No data available.
Relative density:	No data available.
Solubility(ies)	
Solubility in Water:	Soluble
Solubility (other):	No data available.
Partition coefficient (n-octanol/water):	No data available.
Autoignition Temperature:	No data available.
Decomposition Temperature:	No data available.
SADT:	No data available.
Viscosity:	No data available.
Explosive properties:	No data available.
Oxidizing properties:	No data available.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

9.2 Other information

Molecular weight:	No data available.
VOC Content:	No data available.
Bulk density:	No data available.
Dust Explosion Limit, Upper:	No data available.
Dust Explosion Limit, Lower:	No data available.
Dust Explosion Description	No data available.
Number Kst:	
Minimum ignition energy:	No data available.
Minimum ignition temperature:	No data available.
Metal Corrosion:	No data available.

SECTION 10: Stability and reactivity

10.1 Reactivity:	Material is stable under normal conditions.
10.2 Chemical Stability:	Material is stable under normal conditions.
10.3 Possibility of hazardous reactions:	Not determined.
10.4 Conditions to avoid:	Avoid exposure to high temperatures or direct sunlight.
10.5 Incompatible Materials:	Metals. Water reactive material.
10.6 Hazardous Decomposition Products:	Stable; however, may decompose if heated.

SECTION 11: Toxicological information

General information: No data on possible toxicity effects have been found.

Information on likely routes of exposure

Inhalation:	Limited inhalation hazard at normal work temperatures.
Ingestion:	No harmful effects expected in amounts likely to be ingested by accident.
Skin Contact:	Negligible irritation to skin at ambient temperatures.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Eye contact: Elevated temperatures or mechanical action may form vapors, mist, or fumes which may be irritating to the eyes, nose, throat, or lungs.

11.1 Information on toxicological effects

Acute toxicity

Oral

Product: Not classified for acute toxicity based on available data.

Dermal

Product: Not classified for acute toxicity based on available data.

Inhalation

Product: Not classified for acute toxicity based on available data.

Repeated dose toxicity

Product: No data available.

Skin

Corrosion/Irritation:

Product: No data available.

Serious Eye Damage/Eye Irritation:

Product: No data available.

Respiratory or Skin Sensitization:

Product: No data available.

Germ Cell Mutagenicity

In vitro

Product: No data available.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

In vivo

Product: No data available.

Carcinogenicity

Product: No data available.

Reproductive toxicity

Product: No data available.

Specific Target Organ Toxicity - Single Exposure

Product: No data available.

Specific Target Organ Toxicity - Repeated Exposure

Product: No data available.

Aspiration Hazard

Product: No data available.

SECTION 12: Ecological information

12.1 Toxicity

Acute toxicity

Fish

Product: No negative effects on the aquatic environment are known.

Aquatic Invertebrates

Product: No negative effects on the aquatic environment are known.

Chronic Toxicity

Fish

Product: No negative effects on the aquatic environment are known.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Aquatic Invertebrates

Product: No negative effects on the aquatic environment are known.

Toxicity to Aquatic Plants

Product: No negative effects on the aquatic environment are known.

12.2 Persistence and Degradability

Biodegradation

Product: Expected to be readily biodegradable.

BOD/COD Ratio

Product No data available.

12.3 Bioaccumulative potential

Product: No data available.

12.4 Mobility in soil:

Product: No data available.

12.5 Results of PBT and vPvB assessment:

Product: No data available.

12.6 Other adverse effects:

The product is not expected to be hazardous to the environment.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

General information: Dispose of waste and residues in accordance with local authority requirements.

Disposal methods: Dispose of waste at an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

SECTION 14: Transport information



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

ADR

14.1 UN Number:	Not regulated.
14.2 UN Proper Shipping Name:	Not regulated.
14.3 Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
Hazard No. (ADR):	Not regulated.
Tunnel restriction code:	Not regulated.
14.4 Packing Group:	Not regulated.
14.5 Environmental Hazards:	Not regulated.
Marine Pollutant:	Not regulated.
14.6 Special precautions for user:	Not regulated.

ADN

14.1 UN Number:	Not regulated.
14.2 UN Proper Shipping Name:	Not regulated.
14.3 Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
Hazard No. (ADR):	Not regulated.
Tunnel restriction code:	Not regulated.
14.4 Packing Group:	Not regulated.
14.5 Environmental Hazards:	Not regulated.
Marine Pollutant:	Not regulated.
14.6 Special precautions for user:	Not regulated.

RID

14.1 UN Number:	Not regulated.
14.2 UN Proper Shipping Name	Not regulated.
14.3 Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
14.4 Packing Group:	Not regulated.
14.5 Environmental Hazards:	Not regulated.
Marine Pollutant:	Not regulated.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

14.6 Special precautions for user: Not regulated.

IMDG

14.1 UN Number: Not regulated.
14.2 UN Proper Shipping Name: Not regulated.
14.3 Transport Hazard Class(es)
Class: Not regulated.
Label(s): Not regulated.
EmS No.: Not regulated.
14.4 Packing Group: Not regulated.
14.5 Environmental Hazards: Not regulated.
Marine Pollutant: Not regulated.

14.6 Special precautions for user: Not regulated.

IATA

14.1 UN Number: Not regulated.
14.2 Proper Shipping Name: Not regulated.
14.3 Transport Hazard Class(es):
Class: Not regulated.
Label(s): Not regulated.
14.4 Packing Group: Not regulated.
14.5 Environmental Hazards: Not regulated.
Marine Pollutant: Not regulated.

14.6 Special precautions for user: Not regulated.

14.7 Transport in bulk according to Annex II of MARPOL and the IBC Code: Not applicable

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture:

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

EU Regulations

Regulation (EC) No. 2037/2000 Substances that deplete the ozone layer: none

Regulation (EC) No. 850/2004 on persistent organic pollutants: none

Regulation (EC) No. 649/2012 Import and export of dangerous chemicals: none

EU. REACH Candidate List of Substances of Very High Concern for Authorization (SVHC): none

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorisation, as amended: none

Regulation (EC) No. 1907/2006 Annex XVII Substances subject to restriction on marketing and use: none

Directive 2004/37/EC on the protection of workers from the risks related to exposure to carcinogens and mutagens at work.: none

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breast feeding.: none

Directive 96/82/EC (Seveso III): on the control of major accident hazards involving dangerous substances:

Chemical name	CAS-No.	Concentration
sodium azide	26628-22-8	0 - <0.1%

EU. Regulation No. 166/2006 PRTR (Pollutant Release and Transfer Registry), Annex II: Pollutants: none

Directive 98/24/EC on the protection of workers from the risks related to chemical agents at work:

Chemical name	CAS-No.	Concentration
sodium azide	26628-22-8	0 - <0.1%

15.2 Chemical safety assessment:

No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

Revision Information: Not relevant.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

References

PBT	PBT: persistent, bioaccumulative and toxic substance.
vPvB	vPvB: very persistent and very bioaccumulative substance.

Key literature references and sources for data: European Chemicals Agency (ECHA): Information on Chemicals.

Wording of the H-statements in section 2 and 3: none

Training information: No data available.

Issue Date: 04.05.2020

SDS No.: UN0000000000000332778-1157-1-01

Disclaimer: Disclaimer:

The information contained herein has been obtained from various sources and is believed to be correct as of the date issued. However, neither BD nor any of its subsidiaries assumes any liabilities whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability for a particular use of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist. BD provides SDS in electronic form so the information may be more easily accessed. Due to the possibility of errors during transmission, BD makes no representations as to the completeness or accuracy of the information.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SIKKERHEDSDATABLAD

Ifølge Forordning (EF) nr. 1907/2006 (REACH) artikel 31, bilag II med ændringer

PUNKT 1: Identifikation af stoffet/blandingen og af selskabet/virksomheden

Produktidentifikator

Produkt nr.:	Produktnavn:	Trivialnavn(e), synonym(er)
332774	BD® CD7 (M-T701) PE	Ingen data tilgængelige
332776	BD® CD10 (HI10a) PE	Ingen data tilgængelige
332779	BD® CD16 (B73.1) PE	Ingen data tilgængelige
332782	BD® CD23 (EBVCS-5) PE	Ingen data tilgængelige
332785	BD® CD117 (104D2) PE	Ingen data tilgængelige
332790	BD® Anti-TdT (E17-1519) PE	Ingen data tilgængelige
333139	BD® Anti-MPO (5B8) PE	Ingen data tilgængelige
333141	BD® Anti-TCR-γ/δ (11F2) PE	Ingen data tilgængelige
333142	BD® CD11b (D12) PE	Ingen data tilgængelige
333149	BD® CD11c (S-HCL-3) PE	Ingen data tilgængelige
333152	BD® CD79a (HM47) PE	Ingen data tilgængelige
333156	BD® CD103 (Ber-ACT8) PE	Ingen data tilgængelige
333167	BD® CD1a (SK9) PE	Ingen data tilgængelige
335833	BD® CD79b (SN8) PE	Ingen data tilgængelige
337899	BD® CD22 (S-HCL-1) PE	Ingen data tilgængelige
341011	BD® CD25 (2A3) PE	Ingen data tilgængelige
345765	BD® CD3 (SK7) PE	Ingen data tilgængelige
345769	BD® CD4 (SK3) PE	Ingen data tilgængelige
345773	BD® CD8 (SK1) PE	Ingen data tilgængelige
345777	BD® CD19 (4G7) PE	Ingen data tilgængelige
345782	BD® CD5 (L17F12) PE	Ingen data tilgængelige



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

345785	BD® CD14 (MφP9) PE	Ingen data tilgængelige
345789	BD® CD19 (SJ25C1) PE	Ingen data tilgængelige
345793	BD® CD20 (L27) PE	Ingen data tilgængelige
345799	BD® CD33 (P67.6) PE	Ingen data tilgængelige
345802	BD® CD34 (8G12) PE	Ingen data tilgængelige
345806	BD® CD38 (HB-7) PE	Ingen data tilgængelige
345810	BD® CD56 (MY31) PE	Ingen data tilgængelige
345812	BD® CD56 (NCAM16.2) PE	Ingen data tilgængelige
347215	BD® CD138 (MI15) PE	Ingen data tilgængelige
347246	BD® Anti-Kappa (TB 28-2) PE	Ingen data tilgængelige
347401	BD® Anti-HLA-DR (L243) PE	Ingen data tilgængelige
347405	BD® CD2 (S5.2) PE	Ingen data tilgængelige
347406	BD® CD13 (L138) PE	Ingen data tilgængelige

1.2 Relevante identificerede anvendelser for stoffet eller blandingen samt anvendelser, der frarådes

Identificerede anvendelser:

Til videnskabelig og industriel laboratoriebrug. Til diagnostisk in vitro-brug.

Anvendelser som frarådes:

Ingen kendte.

1.3 Nærmere oplysninger om leverandøren af sikkerhedsdatabladet

Producent

Becton Dickinson France S.A.S. Belgian Branch
Erembodegem-Dorp 86
9320 Erembodegem
Belgium

Telefon: 32 2 400 98 95

Fax: 32 2 401 70 94

Kontaktperson: BD Biosciences - Centralized European Office
Regulatory Compliance Department
E-mail: help.biosciences@europe.bd.com

1.4 Nødtelefon: 32 2 400 98 95

PUNKT 2: Fareidentifikation

2.1 Klassificering af stoffet eller blandingen

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Produktet er ikke klassificeret som farligt i henhold til gældende lovgivning.

Klassificering i henhold til forordning (EF) nr. 1272/2008 med senere ændringer.

Ikke klassificeret

2.2 Mærkningselementer Ikke relevant

2.3 Andre farer

Hormonforstyrrende egenskaber-Toksicitet

Substansen/blandingen indeholder ikke komponenter, der anses at have egenskaber med hormonforstyrrende virkning i henhold til REACH Artikel 57(f) eller Kommissionens delegerede forordning (EU) 2017/2100 eller Kommissionens forordning (EU) 2018/605 på niveauer på 0.1 % eller derover.

Hormonforstyrrende egenskaber-Økotoxicitet

Substansen/blandingen indeholder ikke komponenter, der anses at have egenskaber med hormonforstyrrende virkning i henhold til REACH Artikel 57(f) eller Kommissionens delegerede forordning (EU) 2017/2100 eller Kommissionens forordning (EU) 2018/605 på niveauer på 0.1 % eller derover.

PUNKT 3: Sammensætning af/oplysning om indholdsstoffer

3.2 Blandinger

Generelle oplysninger: Ingen skadelige ingredienser

PUNKT 4: Førstehjælpsforanstaltninger

4.1 Beskrivelse af førstehjælpsforanstaltninger

Generelle oplysninger:	Søg læge ved tegn på symptomer.
Indånding:	Frisk luft, varme og ro, helst i behagelig halvsiddende stilling.
Hudkontakt:	Vask med vand og sæbe. Tag forurenede beklædninger af. Vask forurenede tøj, før det bruges igen.
Øjenkontakt:	Skyl straks med rigeligt vand i mindst 15 minutter. Hvis det er nemt, fjernes kontaktlinser.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Indtagelse: Kontakt øjeblikkeligt en læge eller en forgiftningsklinik. Opkastning må kun fremkaldes efter vejledning fra sundhedspersonale. Indgiv aldrig noget til en bevidstløs person gennem munden.

Personlige værnemidler for førstehjælpere: Ingen oplysninger.

4.2 Vigtigste symptomer og virkninger, både akutte og forsinkede Symptomer: Ingen oplysninger.

Farer: Ingen oplysninger.

4.3 Angivelse af om øjeblikkelig lægehjælp og særlig behandling er nødvendig

Behandling: Ingen oplysninger.

PUNKT 5: Brandbekæmpelse

Almindelige Brandfarer: Fjern alle antændelseskilder. Undgå gnister, flammer, varme og rygning. Sørg for god udluftning. Brug vandtåge til at holde beholdere, der er udsat for brand, afkølet.

5.1 Slukningsmidler

Egnede slukningsmidler: Brandslukningsmiddel vælges under hensyntagen til evt. andre kemikalier.

Uegnede slukningsmidler: Ikke relevant

5.2 Særlige farer i forbindelse med stoffet eller blandingen: Ild eller kraftig varme kan danne farlige nedbrydningsprodukter.

5.3 Anvisninger for brandmandskab

Særlige forholdsregler ved brandbekæmpelse: Ingen usædvanlig brand- eller eksplosionsfare angivet.

Særlige beskyttelsesmidler for brandmandskab: Brandslukningspersonalet skal benytte almindeligt beskyttelsesudstyr, herunder brandhæmmende frakke, hjelm med ansigtsskærm, handsker, gummistøvler og, på tillukkede steder, SCBA-udstyr.

PUNKT 6: Forholdsregler over for udslip ved uheld

6.1 Personlige sikkerhedsforanstaltninger, personlige værnemidler og nødprocedurer: Ved større udslip til afløb/vandmiljø underrettes lokale myndigheder. Sørg for passende personlig beskyttelse (inklusive åndedrætsværn) ved fjernelse af spild i et lukket område.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

- 6.1.1 For ikke-indsatspersonel:** Ingen oplysninger.
- 6.1.2 For indsatspersonel:** Ingen oplysninger.
- 6.2 Miljøbeskyttelsesforanstaltninger:** Undgå udledning til miljøet.
- 6.3 Metoder og udstyr til inddæmning og oprensning:** Spild opsuges med egnet absorberende materiale. Undgå, at afløbsvand kommer i kloak afløb, kloakker eller vandløb. Se punkt 8 vedr. personlige værnemidler. Se punkt 13 vedr. bortskaffelse.
- 6.4 Henvisning til andre punkter:** Ingen oplysninger.

PUNKT 7: Håndtering og opbevaring

7.1 Forholdsregler for sikker håndtering

- Tekniske foranstaltninger (f.eks. lokal og generel ventilation):** Ingen særlige krav under almindelige anvendelsesbetingelser og ved tilstrækkelig ventilation.
- Håndtering:** Der må ikke spises, drikkes eller ryges under brugen. Læs og følg producentens anvisninger. Anvend de påkrævede personlige værnemidler.
- Forholdsregler til undgåelse af kontakt:** Ingen oplysninger.

7.2 Betingelser for sikker opbevaring, herunder eventuel uforenelighed

- Sikre opbevaringsbetingelser:** Opbevares tørt og køligt. Emballagen skal holdes tæt lukket.
- Sikre emballagematerialer:** Ingen oplysninger.

- 7.3 Særlige anvendelser:** Forbeholdt industriel og erhvervmæssig brug. Læs etiketten før brug.

PUNKT 8: Eksponeringskontrol/personlige værnemidler

8.1 Kontrolparametre

Grænseværdier for Erhvervmæssig Eksponering

Ingen af komponenterne har tildelte eksponeringsgrænser.

Biologiske Grænseværdier

Der er ikke angivet biologiske eksponeringsgrænser for indholdsstoffet/indholdsstofferne.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

DNEL-værdier

Bemærkninger: DNEL-værdier

Kritisk komponent	Type	Eksponeringsvej	Sundhedsfarer	Bemærkninger
Sodium Chloride (NaCl)	Den almindelige befolkning	Inhalation	Systemiske, længerevarende; 443,28 mg/m ³	Toksicitet ved gentagen dosering
	Arbejdstagere	Inhalation	Systemiske, længerevarende; 2068,62 mg/m ³	Toksicitet ved gentagen dosering
	Arbejdstagere	Inhalation	Systemiske, kortvarig; 2068,62 mg/m ³	Toksicitet ved gentagen dosering
	Den almindelige befolkning	Inhalation	Systemiske, kortvarig; 443,28 mg/m ³	Toksicitet ved gentagen dosering
	Den almindelige befolkning	mundtlig	Systemiske, længerevarende; 126,65 mg/kg	Toksicitet ved gentagen dosering
	Arbejdstagere	Hudkontakt	Systemiske, længerevarende; 295,52 mg/kg	Toksicitet ved gentagen dosering
	Arbejdstagere	Hudkontakt	Systemiske, kortvarig; 295,52 mg/kg	Toksicitet ved gentagen dosering
	Den almindelige befolkning	mundtlig	Systemiske, kortvarig; 126,65 mg/kg	Toksicitet ved gentagen dosering
	Den almindelige befolkning	Hudkontakt	Systemiske, kortvarig; 126,65 mg/kg	Toksicitet ved gentagen dosering
	Den almindelige befolkning	Hudkontakt	Systemiske, længerevarende; 126,65 mg/kg	Toksicitet ved gentagen dosering

Phosphoric acid, sodium salt (1:2)	Arbejdstagere	Øjne	Lokal effekt;	Ingen fare identificeret
	Arbejdstagere	Inhalation	Systemiske, længerevarende; 4,07 mg/m ³	Toksicitet ved gentagen dosering
	Den almindelige befolkning	Inhalation	Systemiske, længerevarende; 3,04 mg/m ³	Toksicitet ved gentagen dosering
	Den almindelige befolkning	Inhalation	Systemiske, længerevarende; 6,63 mg/m ³	Toksicitet ved gentagen dosering
	Arbejdstagere	Inhalation	Systemiske, længerevarende; 15,47 mg/m ³	Toksicitet ved gentagen dosering

Sodium azide (Na(N ₃))	Arbejdstagere	Inhalation	Systemiske, længerevarende; 0,164 mg/m ³	Toksicitet ved gentagen dosering
	Den almindelige befolkning	Øjne	Lokal effekt;	Ingen fare identificeret
	Den almindelige befolkning	Inhalation	Systemiske, længerevarende; 29 µg/m ³	Toksicitet ved gentagen dosering
	Arbejdstagere	Øjne	Lokal effekt;	Ingen fare identificeret
	Arbejdstagere	Hudkontakt	Systemiske, længerevarende; 0,0467 mg/kg	Toksicitet ved gentagen dosering
	Den almindelige befolkning	mundtlig	Systemiske, længerevarende; 0,0167 mg/kg	Toksicitet ved gentagen dosering

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Den almindelige befolkning	Hudkontakt	Systemiske, længerevarende; 0,0167 mg/kg	Toksicitet ved gentagen dosering
Potassium chloride (KCl)	Arbejdstagere	Inhalation	Systemiske, længerevarende; 1064 mg/m3	Toksicitet ved gentagen dosering
	Den almindelige befolkning	Inhalation	Systemiske, længerevarende; 273 mg/m3	Toksicitet ved gentagen dosering
	Den almindelige befolkning	Inhalation	Systemiske, kortvarig; 1365 mg/m3	Toksicitet ved gentagen dosering
	Arbejdstagere	Inhalation	Systemiske, kortvarig; 5320 mg/m3	Toksicitet ved gentagen dosering
	Den almindelige befolkning	mundtlig	Systemiske, kortvarig; 455 mg/kg	Toksicitet ved gentagen dosering
	Den almindelige befolkning	Hudkontakt	Systemiske, længerevarende; 182 mg/kg	Toksicitet ved gentagen dosering
	Den almindelige befolkning	mundtlig	Systemiske, længerevarende; 91 mg/kg	Toksicitet ved gentagen dosering
	Arbejdstagere	Hudkontakt	Systemiske, længerevarende; 303 mg/kg	Toksicitet ved gentagen dosering
	Arbejdstagere	Hudkontakt	Systemiske, kortvarig; 910 mg/kg	Toksicitet ved gentagen dosering
	Den almindelige befolkning	Hudkontakt	Systemiske, kortvarig; 910 mg/kg	Toksicitet ved gentagen dosering
Phosphoric acid, potassium salt (1:1)	Arbejdstagere	Øjne	Lokal effekt;	Ingen fare identificeret
	Den almindelige befolkning	Øjne	Lokal effekt;	Ingen fare identificeret
	Arbejdstagere	Inhalation	Systemiske, længerevarende; 14,82 mg/m3	Toksicitet ved gentagen dosering
	Den almindelige befolkning	Inhalation	Systemiske, længerevarende; 6,35 mg/m3	Toksicitet ved gentagen dosering

PNEC-værdier

Bemærkninger: PNEC-værdier

Kritisk komponent	Delmiljø	PNEC-værdier	Bemærkninger
Sodium Chloride (NaCl)	Jord	4,86 mg/kg	
	Vandmiljø (ferskvand)	5 mg/l	
	Rensningsanlæg	500 mg/l	
Phosphoric acid, sodium salt (1:2)	Rensningsanlæg	50 mg/l	
	Vandmiljø (ferskvand)	0,05 mg/l	
	Vandmiljø (havvand)	0,005 mg/l	
Sodium azide (Na(N3))	Vandmiljø (havvand)	15 ng/l	
	Rensningsanlæg	30 µg/l	

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Bundfald (ferskvand)	0,0167 mg/kg	
	Vandmiljø (ferskvand)	0,35 µg/l	
	Bundfald (havvand)	0,00072 mg/kg	
Potassium chloride (KCl)	Vandmiljø (havvand)	0,1 mg/l	
	Rensningsanlæg	10 mg/l	
	Vandmiljø (ferskvand)	0,1 mg/l	

8.2 Eksponeringskontrol

Passende Tekniske

Sikkerhedsforanstaltninger:

Ingen særlige krav under almindelige anvendelsesbetingelser og ved tilstrækkelig ventilation.

Individuelle beskyttelsesforanstaltninger som f.eks. personlige værnemidler

Beskyttelse af øjne/ansigt:

Brug sikkerhedsbriller med sideskærme (eller tætsluttende sikkerhedsbriller).

Beskyttelse af Hænder:

Materiale: Kemikalieresistente handsker
Supplerende oplysninger: Vask hænder efter kontakt.
Materiale: Egnede handsker kan anvises af handskeleverandøren.

Beskyttelse af hud og krop:

Brug laboratoriekittel eller tilsvarende beskyttelsesbeklædning.

Beskyttelse af åndedrætsorganer:

Hvis teknisk styring ikke kan sikre, at luftbårne koncentrationer holdes under de anbefalede eksponeringsgrænser eller på et acceptabelt niveau (i lande hvor der ikke er fastsat eksponeringsgrænser), skal der bæres godkendt åndedrætsværn.

Hygiejniske foranstaltninger:

Følg anvisningerne for god kemikaliehygiejne.

Foranstaltninger til begrænsning af eksponering af miljøet:

Ingen oplysninger.

PUNKT 9: Fysiske og kemiske egenskaber

9.1 Oplysninger om grundlæggende fysiske og kemiske egenskaber

Udseende

Form: flydende

Form: flydende

Farve: Farveløs til lyserød

Lugt: Lugtfri

Lugtgrænse, lugttærskel: Ingen oplysninger.

Frysepunkt: Ingen oplysninger.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Kogepunkt:	Ingen oplysninger.
Brandfarlighed:	Ingen oplysninger.
Øvre/nedre antændelsesgrænse eller eksplosionsgrænser	
Eksplosionsgrænse - øvre (%):	Ingen oplysninger.
Eksplosionsgrænse - nedre (%):	Ingen oplysninger.
Flammepunkt:	Ingen oplysninger.
Selvantændelsestemperatur:	Ingen oplysninger.
Nedbrydningstemperatur:	Ingen oplysninger.
pH-værdi:	7,20 - 7,60
Viskositet	
Dynamisk viskositet:	Ingen oplysninger.
Kinematisk viskositet:	Ingen oplysninger.
Gennemstrømningstid:	Ingen oplysninger.
Opløselighed	
Opløselighed i vand:	Opløselig
Opløselighed (anden):	Ingen oplysninger.
Opløsningshastighed:	Ingen oplysninger.
Fordelingskoefficient (n-octanol/vand):	
Dispersionsstabilitet:	Ingen oplysninger.
Damptryk:	Ingen oplysninger.
Relativ massefylde:	Ingen oplysninger.
Massefylde:	Ingen oplysninger.
Vægtfylde:	Ingen oplysninger.
Relativ dampvægtfylde:	Ingen oplysninger.

9.2 Andre oplysninger

Ingen data tilgængelige

PUNKT 10: Stabilitet og reaktivitet

10.1 Reaktivitet:	Materialet er stabilt under normale betingelser.
10.2 Kemisk stabilitet:	Materialet er stabilt under normale betingelser.
10.3 Risiko for farlige reaktioner:	Stabil

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

- | | | |
|------|---------------------------------------|--|
| 10.4 | Forhold, der skal undgås: | Må ikke udsættes for høje temperaturer eller direkte sollys. |
| 10.5 | Materialer, der skal undgås: | Metaller. Vandreaktivt materiale. |
| 10.6 | Farlige nedbrydningsprodukter: | Stabilt; kan dog nedbrydes ved opvarmning. |

PUNKT 11: Toksikologiske oplysninger

11.1 Oplysninger om fareklasser som defineret i forordning (EF) nr. 1272/2008

- | | |
|---------------------|--------------------|
| Indånding: | Ingen oplysninger. |
| Hudkontakt: | Ingen oplysninger. |
| Øjenkontakt: | Ingen oplysninger. |
| Indtagelse: | Ingen oplysninger. |

Oplysninger om sandsynlige eksponeringsveje

Akut toksicitet (angiv alle eksponeringsveje, som anses for at være mulige)

- | | |
|-------------------|--|
| Indtagelse | |
| Produkt: | Ikke klassificeret for akut toksicitet ud fra tilgængelige data. |
| Hudkontakt | |
| Produkt: | Ikke klassificeret for akut toksicitet ud fra tilgængelige data. |
| Indånding | |
| Produkt: | Ikke klassificeret for akut toksicitet ud fra tilgængelige data. |

Toksicitet ved gentagen dosering

- | | |
|-----------------|--------------------|
| Produkt: | Ingen oplysninger. |
|-----------------|--------------------|

Ætsning og Irritation for Huden

- | | |
|-----------------|--------------------|
| Produkt: | Ingen oplysninger. |
|-----------------|--------------------|

Alvorlig Skade/Irritation for Øjne

- | | |
|-----------------|--------------------|
| Produkt: | Ingen oplysninger. |
|-----------------|--------------------|

Luftvejs Eller Hud Sensibilisering

- | | |
|-----------------|--------------------|
| Produkt: | Ingen oplysninger. |
|-----------------|--------------------|

Kræftfremkaldende egenskaber

- | | |
|-----------------|--------------------|
| Produkt: | Ingen oplysninger. |
|-----------------|--------------------|

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Kimcellemutagenicitet

In vitro

Produkt: Ingen oplysninger.

In vivo

Produkt: Ingen oplysninger.

Reproduktionstoksicitet

Produkt: Ingen oplysninger.

Specifik Organtoksicitet - Enkelt Eksponering

Produkt: Ingen oplysninger.

Specifik Organtoksicitet - Gentagne Eksponeringer

Produkt: Ingen oplysninger.

Inhaleringsfare

Produkt: Ingen oplysninger.

11.2 Oplysninger om andre farer

Hormonforstyrrende egenskaber

Produkt: Substansen/blandingen indeholder ikke komponenter, der anses at have egenskaber med hormonforstyrrende virkning i henhold til REACH Artikel 57(f) eller Kommissionens delegerede forordning (EU) 2017/2100 eller Kommissionens forordning (EU) 2018/605 på niveauer på 0.1 % eller derover.;

Andre oplysninger

Produkt: Ingen oplysninger.

PUNKT 12: Miljøoplysninger

12.1 Toksicitet:

Akutte farer for vandmiljøet:

Fisk

Produkt: Ingen oplysninger.

Hvirvelløse Vandorganismer

Produkt: Ingen oplysninger.

Giftighed for vandplanter

Produkt: Ingen oplysninger.

Giftighed overfor mikroorganismer

Produkt: Ingen oplysninger.

Kroniske farer for vandmiljøet:

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Fisk

Produkt: Ingen oplysninger.

Hvirvelløse Vandorganismer

Produkt: Ingen oplysninger.

Giftighed for vandplanter

Produkt: Ingen oplysninger.

Giftighed overfor mikroorganismer

Produkt: Ingen oplysninger.

12.2 Persistens og nedbrydelighed

Biologisk nedbrydning

Produkt: Ingen oplysninger.

BOD/COD-forhold

Produkt: Ingen oplysninger.

12.3 Bioakkumuleringspotentiale

Biokoncentrationsfaktor (BKF)

Produkt: Ingen oplysninger.

Fordelingskoefficient n-oktanol/vand (log Kow)

Produkt: Ingen oplysninger.

12.4 Mobilitet i jord:

Produkt Ingen oplysninger.

12.5 Resultater af PBT- og vPvB-vurdering:

Produkt Ingen oplysninger.

12.6 Hormonforstyrrende egenskaber:

Produkt: Substansen/blandingen indeholder ikke komponenter, der anses at have egenskaber med hormonforstyrrende virkning i henhold til REACH Artikel 57(f) eller Kommissionens delegerede forordning (EU) 2017/2100 eller Kommissionens forordning (EU) 2018/605 på niveauer på 0.1 % eller derover.

12.7 Andre negative virkninger:

Andre farer

Produkt: Ingen oplysninger.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

PUNKT 13: Bortskaffelse

13.1 Metoder til affaldsbehandling

Generelle oplysninger:	Spild og rester bortskaffes i overensstemmelse med de lokale myndigheders anvisninger.
Bortskaffelsesmetoder:	Aflever affaldsmaterialet på en miljøgodkendt losseplads ihht. gældende forskrifter samt under hensyntagen til produktets egenskaber på det aktuelle tidspunkt.
Forurennet Emballage:	Indhold/beholder bortskaffes i et passende behandlings- og bortskafningsanlæg i henhold til gældende love og forskrifter og produktets tilstand på bortskafningstidspunktet.

PUNKT 14: Transportoplysninger

ADR

14.1 UN-nummer eller ID-nummer:	Ikke reguleret.
14.2 UN-forsendelsesbetegnelse (UN proper shipping name):	Ikke reguleret.
14.3 Transportfareklasse(r)	
Klasse:	Ikke reguleret.
Etiket(ter):	Ikke reguleret.
ADR farenr.:	Ikke reguleret.
Tunnelrestriktionskode:	Ikke reguleret.
14.4 Emballagegruppe:	Ikke reguleret.
Begrænset mængde	Ikke reguleret.
Undtaget mængde	Ikke reguleret.
14.5 Miljøfarer	Ikke reguleret.
14.6 Særlige forsigtighedsregler for brugeren:	Ikke reguleret.

ADN

14.1 UN-nummer eller ID-nummer:	Ikke reguleret.
14.2 UN-forsendelsesbetegnelse (UN proper shipping name):	Ikke reguleret.
14.3 Transportfareklasse(r)	
Klasse:	Ikke reguleret.
Etiket(ter):	Ikke reguleret.
ADR farenr.:	Ikke reguleret.
Tunnelrestriktionskode:	Ikke reguleret.
14.4 Emballagegruppe:	Ikke reguleret.
Begrænset mængde	Ikke reguleret.
Undtaget mængde	Ikke reguleret.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

14.5 Særlige forsigtighedsregler for brugeren: Ikke reguleret.

RID

14.1 UN-nummer eller ID-nummer: Ikke reguleret.
14.2 UN-forsendelsesbetegnelse (UN proper shipping name): Ikke reguleret.
14.3 Transportfareklasse(r)
 Klasse: Ikke reguleret.
 Etiket(ter): Ikke reguleret.
14.4 Emballagegruppe:
 Begrænset mængde Ikke reguleret.
 Undtaget mængde Ikke reguleret.
14.5 Miljøfarer Ikke reguleret.
14.6 Særlige forsigtighedsregler for brugeren: Ikke reguleret.

IMDG

14.1 UN-nummer eller ID-nummer: Ikke reguleret.
14.2 UN-forsendelsesbetegnelse (UN proper shipping name): Ikke reguleret.
14.3 Transportfareklasse(r)
 Klasse: Ikke reguleret.
 Etiket(ter): Ikke reguleret.
 EmS No.: Ikke reguleret.
14.4 Emballagegruppe:
 Begrænset mængde Ikke reguleret.
 Undtaget mængde Ikke reguleret.
14.5 Miljøfarer Ikke reguleret.
14.6 Særlige forsigtighedsregler for brugeren: Ikke reguleret.

IATA

14.1 UN-nummer eller ID-nummer: Ikke reguleret.
14.2 UN-forsendelsesbetegnelse (UN proper shipping name): Ikke reguleret.
14.3 Transportfareklasse(r)
 Klasse: Ikke reguleret.
 Etiket(ter): Ikke reguleret.
14.4 Emballagegruppe:
 Passager- og fragtfly : Ikke reguleret.
 Begrænset mængde Ikke reguleret.
 Undtaget mængde Ikke reguleret.
14.5 Miljøfarer Ikke reguleret.
14.6 Særlige forsigtighedsregler for brugeren: Ikke reguleret.

14.7 Bulktransport til søs i henhold til IMO-instrumenter

Ikke relevant for produktet, som det leveres.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

PUNKT 15: Oplysninger om regulering

15.1 Særlige bestemmelser/særlig lovgivning for stoffet eller blandingen med hensyn til sikkerhed, sundhed og miljø:

EU-forordninger

Forordning 1005/2009/EF om stoffer, der nedbryder ozonlaget, bilag I, Kontrollerede stoffer: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

FORORDNING (EF) Nr. 1907/2006 (REACH), BILAG XIV FORTEGNELSE OVER STOFFER, DER KRÆVER GODKENDELSE: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

Forordning (EU) 2019/1021 om persistente organiske miljøgifte (omarbejdning), med ændringer: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

EUROPA-PARLAMENTETS OG RÅDETS DIREKTIV 2010/75/EU af 24. november 2010 om industrielle emissioner (integreret forebyggelse og bekæmpelse af forurening), BILAG II Liste over forurenende stoffer: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

Forordning (EU) nr. 649/2012 om eksport og import af farlige kemikalier, bilag I, del 1 med ændringer: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

Forordning (EU) nr. 649/2012 om eksport og import af farlige kemikalier, bilag I, del 2 med ændringer: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

Forordning (EU) nr. 649/2012 om eksport og import af farlige kemikalier, bilag I, del 3 med ændringer: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

Forordning (EU) nr. 649/2012 om eksport og import af farlige kemikalier, bilag V med ændringer: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

EU. REACH Kandidatlisten over særligt problematiske stoffer til godkendelse (SVHC): Ikke til stede eller ikke til stede i de i loven regulerede mængder.

Forordning (EF) nr. 1907/2006, bilag XVII om begrænsning vedrørende fremstilling, markedsføring og anvendelse af visse farlige stoffer, kemiske produkter og artikler:

Direktiv 2004/37/EF om beskyttelse af arbejdstagerne mod risici for under arbejdet at være udsat for kræftfremkaldende stoffer eller mutagener.: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

Direktiv 92/85/EØF om iværksættelse af foranstaltninger til forbedring af sikkerheden og sundheden under arbejdet for arbejdstagere som er gravide, som lige har født, eller som ammer.: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

DIREKTIV 2012/18/EU (SEVESO III) om kontrol med risikoen for større uheld med farlige stoffer, BILAG I: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

FORORDNING (EF) Nr. 166/2006 om oprettelse af et europæisk register over udledning og overførsel af forurenende stoffer, BILAG II: Forurenende stoffe: Ikke til stede eller ikke til stede i de i loven

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

regulerede mængder.

Direktiv 98/24/EF om beskyttelse af arbejdstagernes sikkerhed og sundhed under arbejdet mod risici i forbindelse med kemiske agenser:

Kemisk betegnelse	CAS-nr.	Koncentration
natriumazid	26628-22-8	0 - <0,1%

15.2 Der er ikke foretaget nogen kemikaliesikkerhedsvurdering.
Kemikaliesikkerhedsvurdering:

Internationale forordninger

Montrealprotokollen
Ikke relevant

Stockholm-konventionen
Ikke relevant

Rotterdamkonventionen
Ikke relevant

Kyotoprotokollen
Ikke relevant

PUNKT 16: Andre oplysninger

Forkortelser og akronymer:
Ingen oplysninger.

Referencer til den vigtigste faglitteratur og de vigtigste datakilder: ECHA (European Chemicals Agency): Oplysninger om kemikalier.

Ordlyden af sætningerne i afsnit 2 og 3
: intet

Oplysninger om uddannelse: Ingen oplysninger.

SDB nr.: UN000000000000332774-4012-1-01

**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Ansvarsfraskrivelse:

Ansvarsfraskrivelse: Oplysningerne heri er indhentet fra forskellige kilder og anses for korrekte på udgivelsestidspunktet. Imidlertid påtager hverken BD eller BD's datterselskaber sig noget ansvar for, at oplysningerne heri er nøjagtige eller fyldestgørende. Den endelige beslutning om et materiales egnethed til et bestemt formål påhviler alene brugeren. Alle materialer udgør ukendte risici og bør anvendes med forsigtighed. Selvom visse farer er beskrevet heri, kan vi ikke garantere, at disse er de eneste eksisterende farer. BD leverer sikkerhedsdatablad (SDS) i elektronisk form, hvilket giver nemmere adgang til oplysningerne. På grund af risikoen for fejl under overførsel udsteder BD ingen garantier for, at oplysningerne er komplette eller præcise.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

FICHA DE DATOS DE SEGURIDAD

Conforme al Reglamento (CE) nº 1907/2006 (REACH) Artículo 31, Anexo II con las enmiendas correspondientes

SECCIÓN 1. Identificación de la sustancia o la mezcla y de la sociedad o la empresa

Identificador de producto

Núm. de producto:	Nombre del producto:	Nombre(s) común(es) y sinónimo(s)
332777	BD® CD10 (HI10a) APC	No hay datos disponibles.
332791	BD® Anti-TdT (E17-1519) APC	No hay datos disponibles.
333143	BD® CD11b (D12) APC	No hay datos disponibles.
333144	BD® CD11c (S-HCL-3) APC	No hay datos disponibles.
333145	BD® CD22 (S-HCL-1) APC	No hay datos disponibles.
333154	BD® CD79a (HM47) APC	No hay datos disponibles.
333233	BD® CD117 (104D2) APC	No hay datos disponibles.
333951	BD® CD14 (MφP9) APC-Cy7	No hay datos disponibles.
335036	BD® CD23 (EBVCS-5) APC	No hay datos disponibles.
335829	BD® CD20 (L27) APC-Cy7	No hay datos disponibles.
335831	BD® Anti-HLA-DR (L243) APC-Cy7	No hay datos disponibles.
335834	BD® CD79b (SN8) APC	No hay datos disponibles.
337447	BD® CD71 (L01.1) APC	No hay datos disponibles.
340907	BD® CD25 (2A3) APC	No hay datos disponibles.
340908	BD® CD20 (L27) APC	No hay datos disponibles.
341024	BD® CD2 (L303.1) APC	No hay datos disponibles.
341027	BD® CD56 (NCAM16.2) APC	No hay datos disponibles.
341108	BD® Anti-Kappa (TB 28-2) APC	No hay datos disponibles.
341110	BD® CD3 (SK7) APC-Cy7	No hay datos disponibles.
341115	BD® CD4 (SK3) APC-Cy7	No hay datos disponibles.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

345767	BD® CD3 (SK7) APC	No hay datos disponibles.
345771	BD® CD4 (SK3) APC	No hay datos disponibles.
345775	BD® CD8 (SK1) APC	No hay datos disponibles.
345783	BD® CD5 (L17F12) APC	No hay datos disponibles.
345787	BD® CD14 APC	No hay datos disponibles.
345791	BD® CD19 (SJ25C1) APC	No hay datos disponibles.
345800	BD® CD33 (P67.6) APC	No hay datos disponibles.
345804	BD® CD34 (8G12) APC	No hay datos disponibles.
345807	BD® CD38 (HB7) APC	No hay datos disponibles.
345818	BD® Mouse IgG1 (X40) APC	No hay datos disponibles.
347216	BD® CD138 (MI15) APC	No hay datos disponibles.
347403	BD® Anti-HLA-DR (L243) APC-H7	No hay datos disponibles.
348812	BD® Mouse IgG1 (X40) APC-Cy7	No hay datos disponibles.
348813	BD® CD8 (SK1) APC-Cy7	No hay datos disponibles.
348814	BD® CD19 (SJ25C1) APC-Cy7	No hay datos disponibles.
641411	BD® Anti-HLA-DR (L243) APC-H7	No hay datos disponibles.
641414	BD® CD20 (L27) APC-H7	No hay datos disponibles.

1.2 Usos pertinentes identificados de la sustancia o de la mezcla y usos desaconsejados

Uso identificado: Para uso científico y en laboratorios industriales. Para uso en diagnósticos in vitro.

Usos no recomendados: Ningunos conocidos/Ninguna conocida.

1.3 Datos del proveedor de la ficha de datos de seguridad

Fabricante

Becton Dickinson France S.A.S. Belgian Branch
Erembodegem-Dorp 86
9320 Erembodegem
Belgium

teléfono: 32 2 400 98 95
fax: 32 2 401 70 94

Persona de contacto: BD Biosciences - Centralized European Office
Regulatory Compliance Department

Correo electrónico: help.biosciences@europe.bd.com

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

1.4 Teléfono de emergencia: 32 2 400 98 95

SECCIÓN 2. Identificación de los peligros

2.1 Clasificación de la sustancia o de la mezcla

El producto no ha sido clasificado como peligroso de acuerdo con la legislación vigentes.

Clasificación de acuerdo con el reglamento (CE) No. 1272/2008 con sus modificaciones posteriores.

No clasificado

2.2 Elementos de la etiqueta No aplicable

2.3 Otros peligros

Propiedades de alteración endocrina-Toxicidad

La sustancia/la mezcla no contienen componentes que tengan propiedades alteradoras endocrinas de acuerdo con el artículo 57(f) de REACH o el Reglamento delegado de la Comisión (UE) 2017/2100 o el Reglamento de la Comisión (UE) 2018/605 en niveles del 0,1 % o superiores.

Propiedades de alteración endocrina-Ecotoxicidad

La sustancia/la mezcla no contienen componentes que tengan propiedades alteradoras endocrinas de acuerdo con el artículo 57(f) de REACH o el Reglamento delegado de la Comisión (UE) 2017/2100 o el Reglamento de la Comisión (UE) 2018/605 en niveles del 0,1 % o superiores.

SECCIÓN 3. Composición/información sobre los componentes

3.2 Mezclas

Información general: No contiene ingredientes peligrosos.

SECCIÓN 4. Primeros auxilios

4.1 Descripción de los primeros auxilios

Información general: Obtenga atención médica en caso de síntomas.

Inhalación: Proporcionar aire fresco, calor moderado y reposo. Poner la persona en posición vertical, cómoda, y sentada.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Contacto con la Piel:	Lave las áreas de contacto con agua y jabón. Quítese la ropa contaminada. Lave la ropa contaminada antes de volver a usarla.
Contacto con los ojos:	Enjuagar inmediatamente los ojos con agua abundante durante por los menos 15 minutos. Si resulta fácil, quitar las lentes de contacto.
Ingestión:	Llamar inmediatamente al médico o al centro toxicológico. Solamente debe provocar el vómito siguiendo las instrucciones del personal médico. No darle nunca nada por la boca a una persona inconsciente.
Equipo de protección personal para el personal de primeros auxilios:	No hay datos disponibles.
4.2 Principales síntomas y efectos, agudos y retardados	
Síntomas:	No hay datos disponibles.
Riesgos:	No hay datos disponibles.
4.3 Indicación de asistencia médica inmediata y tratamiento especial necesario	
Tratamiento:	No hay datos disponibles.

SECCIÓN 5. Medidas de lucha contra incendios

Riesgos Generales de Incendio:	Extinguir todas las fuentes de ignición. Evitar chispas, llamas, calor y humo. Ventilar. Use agua nebulizada para mantener refrigerados los contenedores expuestos al fuego.
---------------------------------------	--

5.1 Medios de extinción

Medios de extinción apropiados:	Seleccione el medio de extinción más apropiado, teniendo en cuenta la posible presencia de otros productos químicos.
Medios de extinción no apropiados:	No aplicable

5.2 Peligros específicos derivados de la sustancia o la mezcla:	En caso de incendio o calor excesivo se pueden generar productos de descomposición peligrosos.
--	--

5.3 Recomendaciones para el personal de lucha contra incendios

Medidas especiales de lucha contra incendios:	Ningún riesgo excepcional de incendio o explosión señalado.
Equipos de protección especial que debe llevar el personal de lucha contra incendios:	Los bomberos deben utilizar un equipo de protección estándar incluyendo chaqueta ignífuga, casco con careta, guantes, botas de goma, y, en espacios cerrados, equipo de respiración autónomo (SCBA, según sus siglas en inglés).



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SECCIÓN 6. Medidas en caso de vertido accidental

- | | |
|--|--|
| 6.1 Precauciones personales, equipo de protección y procedimientos de emergencia: | Contacte las autoridades locales en caso de escape al desagüe o el ambiente acuático. Asegúrese una protección personal adecuada (protección respiratoria inclusive) durante la eliminación de derrames en cámaras pequeñas. |
| 6.1.1 Para el personal que no forma parte de los servicios de emergencia: | No hay datos disponibles. |
| 6.1.2 Para el personal de emergencia: | No hay datos disponibles. |
| 6.2 Precauciones relativas al medio ambiente: | Evitar su liberación al medio ambiente. |
| 6.3 Métodos y material de contención y de limpieza: | Absorber el producto derramado con material absorbente. Evite que las aguas residuales entren en las cunetas, alcantarillados o vías fluviales. Consulte la sección 8 de la FDS sobre equipo de protección personal. Para información sobre la eliminación, véase la sección 13. |
| 6.4 Referencia a otras secciones: | No hay datos disponibles. |

SECCIÓN 7. Manipulación y almacenamiento

7.1 Precauciones para una manipulación segura

- | | |
|---|--|
| Medidas de carácter técnico (p.ej. Ventilación local y general): | Ningún requisito especial en condiciones normales de uso y con ventilación adecuada. |
| Manipulación: | No comer, ni beber, ni fumar durante su utilización. Leer y seguir las recomendaciones del proveedor. Utilizar los equipos de protección individual según las necesidades. |
| Medidas para evitar el contacto: | No hay datos disponibles. |

7.2 Condiciones de almacenamiento seguro, incluidas posibles incompatibilidades

- | | |
|--|--|
| Condiciones de almacenamiento seguro: | Almacene en un lugar fresco y seco. Manténgase el recipiente bien cerrado. |
| Materiales de embalaje seguros: | No hay datos disponibles. |

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

7.3 Usos específicos finales: Reservado a usos industriales y profesionales. Leer la etiqueta antes del uso.

SECCIÓN 8. Controles de exposición/protección individual

8.1 Parámetros de control

Valores Límite de Exposición Profesional

No se asignaron límites de exposición a ninguno de los componentes.

Valor Límite Biológico

No se han indicado límites de exposición biológica para el/los componente(s).

Valores DNEL

Observaciones: Valores DNEL

Componente crítico	Tipo	Ruta de exposición	Advertencias para la salud	Observaciones
Sodium Chloride (NaCl)	Población general	Inhalation	Sistémicos, largo plazo; 443,28 mg/m3	Toxicidad por dosis repetidas
	Trabajadores	Inhalation	Sistémicos, largo plazo; 2068,62 mg/m3	Toxicidad por dosis repetidas
	Trabajadores	Inhalation	Sistémicos, corto plazo; 2068,62 mg/m3	Toxicidad por dosis repetidas
	Población general	Inhalation	Sistémicos, corto plazo; 443,28 mg/m3	Toxicidad por dosis repetidas
	Población general	Oral	Sistémicos, largo plazo; 126,65 mg/kg	Toxicidad por dosis repetidas
	Trabajadores	Dérmico	Sistémicos, largo plazo; 295,52 mg/kg	Toxicidad por dosis repetidas
	Trabajadores	Dérmico	Sistémicos, corto plazo; 295,52 mg/kg	Toxicidad por dosis repetidas
	Población general	Oral	Sistémicos, corto plazo; 126,65 mg/kg	Toxicidad por dosis repetidas
	Población general	Dérmico	Sistémicos, corto plazo; 126,65 mg/kg	Toxicidad por dosis repetidas
	Población general	Dérmico	Sistémicos, largo plazo; 126,65 mg/kg	Toxicidad por dosis repetidas
Phosphoric acid, sodium salt (1:2)	Trabajadores	Ojos	Efecto local;	Sin peligro identificado
	Trabajadores	Inhalation	Sistémicos, largo plazo; 4,07 mg/m3	Toxicidad por dosis repetidas
	Población general	Inhalation	Sistémicos, largo plazo; 3,04 mg/m3	Toxicidad por dosis repetidas
	Población general	Inhalation	Sistémicos, largo plazo; 6,63 mg/m3	Toxicidad por dosis repetidas
	Trabajadores	Inhalation	Sistémicos, largo plazo; 15,47 mg/m3	Toxicidad por dosis repetidas
Sodium azide (Na(N3))	Trabajadores	Inhalation	Sistémicos, largo plazo; 0,164 mg/m3	Toxicidad por dosis repetidas
	Población general	Ojos	Efecto local;	Sin peligro identificado
	Población general	Inhalation	Sistémicos, largo plazo; 29 µg/m3	Toxicidad por dosis repetidas
	Trabajadores	Ojos	Efecto local;	Sin peligro identificado

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Trabajadores	Dérmico	Sistémicos, largo plazo; 0,0467 mg/kg	Toxicidad por dosis repetidas
	Población general	Oral	Sistémicos, largo plazo; 0,0167 mg/kg	Toxicidad por dosis repetidas
	Población general	Dérmico	Sistémicos, largo plazo; 0,0167 mg/kg	Toxicidad por dosis repetidas

Potassium chloride (KCl)	Trabajadores	Inhalation	Sistémicos, largo plazo; 1064 mg/m3	Toxicidad por dosis repetidas
	Población general	Inhalation	Sistémicos, largo plazo; 273 mg/m3	Toxicidad por dosis repetidas
	Población general	Inhalation	Sistémicos, corto plazo; 1365 mg/m3	Toxicidad por dosis repetidas
	Trabajadores	Inhalation	Sistémicos, corto plazo; 5320 mg/m3	Toxicidad por dosis repetidas
	Población general	Oral	Sistémicos, corto plazo; 455 mg/kg	Toxicidad por dosis repetidas
	Población general	Dérmico	Sistémicos, largo plazo; 182 mg/kg	Toxicidad por dosis repetidas
	Población general	Oral	Sistémicos, largo plazo; 91 mg/kg	Toxicidad por dosis repetidas
	Trabajadores	Dérmico	Sistémicos, largo plazo; 303 mg/kg	Toxicidad por dosis repetidas
	Trabajadores	Dérmico	Sistémicos, corto plazo; 910 mg/kg	Toxicidad por dosis repetidas
	Población general	Dérmico	Sistémicos, corto plazo; 910 mg/kg	Toxicidad por dosis repetidas

Phosphoric acid, potassium salt (1:1)	Trabajadores	Ojos	Efecto local;	Sin peligro identificado
	Población general	Ojos	Efecto local;	Sin peligro identificado
	Trabajadores	Inhalation	Sistémicos, largo plazo; 14,82 mg/m3	Toxicidad por dosis repetidas
	Población general	Inhalation	Sistémicos, largo plazo; 6,35 mg/m3	Toxicidad por dosis repetidas

Valores PNEC

Observaciones: Valores PNEC

Componente crítico	Compartimento medioambiental	Valores PNEC	Observaciones
Sodium Chloride (NaCl)	Tierra	4,86 mg/kg	
	Acuático (agua dulce)	5 mg/l	
	Planta de tratamiento de aguas residuales	500 mg/l	

Phosphoric acid, sodium salt (1:2)	Planta de tratamiento de aguas residuales	50 mg/l	
	Acuático (agua dulce)	0,05 mg/l	
	Acuático (agua marina)	0,005 mg/l	

Sodium azide (Na(N3))	Acuático (agua marina)	15 ng/l	
	Planta de tratamiento de aguas residuales	30 µg/l	
	Sedimento (agua dulce)	0,0167 mg/kg	
	Acuático (agua dulce)	0,35 µg/l	



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Sedimentos (agua marina)	0,00072 mg/kg	
Potassium chloride (KCl)	Acuático (agua marina)	0,1 mg/l	
	Planta de tratamiento de aguas residuales	10 mg/l	
	Acuático (agua dulce)	0,1 mg/l	

8.2 Controles de la exposición

Controles Técnicos Apropriados:

Ningún requisito especial en condiciones normales de uso y con ventilación adecuada.

Medidas de protección individual, tales como equipos de protección personal

Protección de los ojos/la cara:

Use gafas de seguridad con protectores laterales (o gafas estancas).

Protección de las Manos:

Material: Guantes resistente a productos químicos
Información adicional: Lávese las manos después de la exposición.
Material: El proveedor puede recomendar los guantes adecuados.

Protección de la Piel y del Cuerpo:

Utilice una bata de laboratorio o ropa protectora similar.

Protección respiratoria:

Si los controles de ingeniería no mantienen las concentraciones en el aire por debajo de los límites de exposición recomendados (cuando proceda) o a un nivel aceptable (en países donde no se hayan establecido límites de exposición), ha de utilizarse un respirador aprobado.

Medidas de higiene:

Respete las normas para una manipulación correcta de productos químicos.

Controles medioambientales:

No hay datos disponibles.

SECCIÓN 9. Propiedades físicas y químicas

9.1 Información sobre propiedades físicas y químicas básicas

Aspecto

Forma/estado: líquido

Forma/Figura: líquido

Color: De incoloro a azul

Olor: Inodoro

Olor, umbral: No hay datos disponibles.

Punto de congelamiento: No hay datos disponibles.

Punto ebullición: No hay datos disponibles.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Inflamabilidad:	No hay datos disponibles.
Límites superior/inferior de inflamabilidad o de explosividad	
Límite superior de explosividad (%) :	No hay datos disponibles.
Límite inferior de explosividad (%) :	No hay datos disponibles.
Punto de inflamación:	No hay datos disponibles.
Temperatura de autoignición:	No hay datos disponibles.
descomposición, temperatura de:	No hay datos disponibles.
pH:	7,20 - 7,60
Viscosidad	
Viscosidad dinámica:	No hay datos disponibles.
Viscosidad cinemática:	No hay datos disponibles.
flujo, tiempo de:	No hay datos disponibles.
Solubilidad(es)	
Solubilidad en agua:	Soluble
Solubilidad (otra):	No hay datos disponibles.
Velocidad de disolución:	No hay datos disponibles.
Coefficiente de reparto (n-octanol/agua):	No hay datos disponibles.
Estabilidad de la dispersión:	No hay datos disponibles.
Presión de vapor:	No hay datos disponibles.
Densidad relativa:	No hay datos disponibles.
Densidad:	No hay datos disponibles.
Densidad aparente:	No hay datos disponibles.
Densidad relativa del vapor:	No hay datos disponibles.

9.2 Otros datos

Sin datos disponibles

SECCIÓN 10. Estabilidad y reactividad

10.1 Reactividad:	El material es estable bajo condiciones normales.
10.2 Estabilidad química:	El material es estable bajo condiciones normales.
10.3 Posibilidad de reacciones peligrosas:	estable

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

- | | | |
|------|--|---|
| 10.4 | Condiciones que deben evitarse: | Evítese la exposición a altas temperaturas o a los rayos del sol. |
| 10.5 | Materiales incompatibles: | metales Reacciona con el agua. |
| 10.6 | Productos de descomposición peligrosos: | Estable; sin embargo, puede descomponerse en caso de calentamiento. |

SECCIÓN 11. Información toxicológica

11.1 Información sobre las clases de peligro definidas en el Reglamento (CE) n.o 1272/2008

- | | |
|-------------------------------|---------------------------|
| Inhalación: | No hay datos disponibles. |
| Contacto con la Piel: | No hay datos disponibles. |
| Contacto con los ojos: | No hay datos disponibles. |
| Ingestión: | No hay datos disponibles. |

Información sobre posibles vías de exposición

Toxicidad aguda (listar todas las vías de exposición posibles)

Ingestión
Producto: No clasificado en cuanto a toxicidad aguda con los datos disponibles.

Contacto dermal
Producto: No clasificado en cuanto a toxicidad aguda con los datos disponibles.

Inhalación
Producto: No clasificado en cuanto a toxicidad aguda con los datos disponibles.

Toxicidad por dosis repetidas
Producto: No hay datos disponibles.

Corrosión/Irritación Cutáneas
Producto: No hay datos disponibles.

Lesiones Oculares Graves/Irritación Ocular
Producto: No hay datos disponibles.

Sensibilización de la Piel o Respiratoria
Producto: No hay datos disponibles.

Carcinogenicidad
Producto: No hay datos disponibles.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Mutagenicidad en Células Germinales

En vitro

Producto: No hay datos disponibles.

En vivo

Producto: No hay datos disponibles.

Toxicidad para la reproducción

Producto: No hay datos disponibles.

Toxicidad Sistémica Específica de Órganos Diana- Exposición Única

Producto: No hay datos disponibles.

Toxicidad Sistémica Específica de Órganos Diana- Exposiciones Repetidas

Producto: No hay datos disponibles.

Peligro por Aspiración

Producto: No hay datos disponibles.

11.2 Información relativa a otros peligros

Propiedades de alteración endocrina

Producto: La sustancia/la mezcla no contienen componentes que tengan propiedades alteradoras endocrinas de acuerdo con el artículo 57(f) de REACH o el Reglamento delegado de la Comisión (UE) 2017/2100 o el Reglamento de la Comisión (UE) 2018/605 en niveles del 0,1 % o superiores.;

Otros datos

Producto: No hay datos disponibles.

SECCIÓN 12. Información ecológica

12.1 Toxicidad:

Peligros agudos para el medio ambiente acuático:

Pez

Producto: No hay datos disponibles.

Invertebrados Acuáticos

Producto: No hay datos disponibles.

Toxicidad para plantas acuáticas

Producto: No hay datos disponibles.

Toxicidad para los microorganismos

Producto: No hay datos disponibles.

Peligros crónicos para el medio ambiente acuático:



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Pez

Producto: No hay datos disponibles.

Invertebrados Acuáticos

Producto: No hay datos disponibles.

Toxicidad para plantas acuáticas

Producto: No hay datos disponibles.

Toxicidad para los microorganismos

Producto: No hay datos disponibles.

12.2 Persistencia y degradabilidad

Biodegradable

Producto: No hay datos disponibles.

Relación DBO/DQO

Producto: No hay datos disponibles.

12.3 Potencial de bioacumulación

Factor de Bioconcentración (BCF)

Producto: No hay datos disponibles.

Coefficiente de Partición n-octanol/agua (log Kow)

Producto: No hay datos disponibles.

12.4 Movilidad en el suelo:

Producto No hay datos disponibles.

12.5 Resultados de la valoración PBT y mPmB:

Producto No hay datos disponibles.

12.6 Propiedades de alteración endocrina:

Producto: La sustancia/la mezcla no contienen componentes que tengan propiedades alteradoras endocrinas de acuerdo con el artículo 57(f) de REACH o el Reglamento delegado de la Comisión (UE) 2017/2100 o el Reglamento de la Comisión (UE) 2018/605 en niveles del 0,1 % o superiores.

12.7 Otros efectos adversos:

Otros peligros

Producto: No hay datos disponibles.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SECCIÓN 13. Consideraciones relativas a la eliminación

13.1 Métodos para el tratamiento de residuos

Información general:	Eliminar los desperdicios y residuos de conformidad con la normativa promulgada por las autoridades locales.
Métodos de eliminación:	Elimine el residuo en una instalación adecuada de tratamiento y eliminación de acuerdo con las leyes y reglamentos correspondientes y características del producto en el momento de la eliminación.
Envases Contaminados:	Eliminar el contenido/el recipiente en una instalación de tratamiento y eliminación de desechos apropiada de conformidad con las leyes y reglamentos aplicables y con las características del producto en el momento de la eliminación.

SECCIÓN 14. Información relativa al transporte

ADR

14.1 Número ONU o número ID:	No reglamentado.
14.2 Designación oficial de transporte de las Naciones Unidas:	No reglamentado.
14.3 Clase(s) de peligro para el transporte	
Clase:	No reglamentado.
Etiqueta(s):	No reglamentado.
No. de riesgo (ADR):	No reglamentado.
Código de restricciones en túneles:	No reglamentado.
14.4 Grupo de embalaje:	No reglamentado.
Cantidad limitada	No reglamentado.
Cantidad exceptuada	No reglamentado.
14.5 Peligros para el medio ambiente	No reglamentado.
14.6 Precauciones particulares para los usuarios:	No reglamentado.

ADN

14.1 Número ONU o número ID:	No reglamentado.
14.2 Designación oficial de transporte de las Naciones Unidas:	No reglamentado.
14.3 Clase(s) de peligro para el transporte	
Clase:	No reglamentado.
Etiqueta(s):	No reglamentado.
No. de riesgo (ADR):	No reglamentado.
Código de restricciones en túneles:	No reglamentado.
14.4 Grupo de embalaje:	No reglamentado.

SDS_ES



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Cantidad limitada	No reglamentado.
Cantidad exceptuada	No reglamentado.
14.5 Precauciones particulares para los usuarios:	No reglamentado.

RID

14.1 Número ONU o número ID:	No reglamentado.
14.2 Designación oficial de transporte de las Naciones Unidas:	No reglamentado.
14.3 Clase(s) de peligro para el transporte	
Clase:	No reglamentado.
Etiqueta(s):	No reglamentado.
14.4 Grupo de embalaje:	No reglamentado.
Cantidad limitada	No reglamentado.
Cantidad exceptuada	No reglamentado.
14.5 Peligros para el medio ambiente	No reglamentado.
14.6 Precauciones particulares para los usuarios:	No reglamentado.

IMDG

14.1 Número ONU o número ID:	No reglamentado.
14.2 Designación oficial de transporte de las Naciones Unidas:	No reglamentado.
14.3 Clase(s) de peligro para el transporte	
Clase:	No reglamentado.
Etiqueta(s):	No reglamentado.
EmS No.:	No reglamentado.
14.4 Grupo de embalaje:	No reglamentado.
Cantidad limitada	No reglamentado.
Cantidad exceptuada	No reglamentado.
14.5 Peligros para el medio ambiente	No reglamentado.
14.6 Precauciones particulares para los usuarios:	No reglamentado.

IATA

14.1 Número ONU o número ID:	No reglamentado.
14.2 Designación oficial de transporte de las Naciones Unidas:	No reglamentado.
14.3 Clase(s) de peligro para el transporte	
Clase:	No reglamentado.
Etiqueta(s):	No reglamentado.
14.4 Grupo de embalaje:	No reglamentado.
Transporte aéreo de pasajeros y mercancías :	No reglamentado.
Cantidad limitada	No reglamentado.
Cantidad exceptuada	No reglamentado.
14.5 Peligros para el medio ambiente	No reglamentado.
14.6 Precauciones particulares para los usuarios:	No reglamentado.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

14.7 Transporte marítimo a granel con arreglo a los instrumentos de la OMI

No aplicable al producto suministrado.

SECCIÓN 15. Información reglamentaria

15.1 Reglamentación y legislación en materia de seguridad, salud y medio ambiente específicas para la sustancia o la mezcla:

Legislación de la UE

Reglamento 1005/2009/EC sobre las sustancias que agotan la capa de ozono. Anexo I, Sustancias controladas: No están presentes, o no están presentes en las cantidades reguladas.

REGLAMENTO (CE) No 1907/2006 (REACH), ANEXO XIV LISTA DE SUSTANCIAS SUJETAS A AUTORIZACIÓN: No están presentes, o no están presentes en las cantidades reguladas.

Reglamento nº. 2019/1021/UE de la UE que prohíbe y restringe contaminantes orgánicos persistentes (COP), con sus modificaciones ulteriores: No están presentes, o no están presentes en las cantidades reguladas.

UE. Directiva 2010/75/UE sobre las emisiones industriales (prevención y control integrados de la contaminación), Anexo II, L 334/17: No están presentes, o no están presentes en las cantidades reguladas.

Reglamento (UE) nº 649/2012 relativo a la exportación e importación de productos químicos peligrosos, Anexo I, parte 1, con las enmiendas correspondientes: No están presentes, o no están presentes en las cantidades reguladas.

Reglamento (UE) nº 649/2012 relativo a la exportación e importación de productos químicos peligrosos, Anexo I, parte 2, con las enmiendas correspondientes: No están presentes, o no están presentes en las cantidades reguladas.

Reglamento (UE) nº 649/2012 relativo a la exportación e importación de productos químicos peligrosos, Anexo I, parte 3, con las enmiendas correspondientes: No están presentes, o no están presentes en las cantidades reguladas.

Reglamento (UE) nº 649/2012 relativo a la exportación e importación de productos químicos peligrosos, Anexo V, con las enmiendas correspondientes: No están presentes, o no están presentes en las cantidades reguladas.

UE. Lista provisional (lista de candidatas) de sustancias extremadamente preocupantes (SEP) que pueden estar sujetas a autorización en el marco de REACH: No están presentes, o no están presentes en las cantidades reguladas.

Reglamento (CE) No. 1907/2006, Anexo XVII, Sustancias sujetas a restricciones aplicables a la comercialización y uso:

Directiva 2004/37/CE relativa a la protección de los trabajadores contra los riesgos relacionados con la exposición a agentes carcinógenos o mutágenos durante el trabajo.: No están presentes, o no están presentes en las cantidades reguladas.

Directiva 92/85/CEE relativa a la aplicación de medidas para promover la mejora de la seguridad y de

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

la salud en el trabajo de la trabajadora embarazada, que haya dado a luz o en período de lactancia:
No están presentes, o no están presentes en las cantidades reguladas.

DIRECTIVA 2012/18/UE relativa al control de los riesgos inherentes a los accidentes graves en los que intervengan sustancias peligrosas, ANEXO I: No están presentes, o no están presentes en las cantidades reguladas.

REGLAMENTO (CE) No 166/2006 relativo al establecimiento de un registro europeo de emisiones y transferencias de contaminantes, ANEXO II: Contaminantes: No están presentes, o no están presentes en las cantidades reguladas.

Directiva 98/24/CE relativa a la protección de los trabajadores contra los riesgos relacionados con los agentes químicos durante el trabajo:

Determinación química	No. CAS	Concentración
Azida de sodio	26628-22-8	0 - <0,1%

**15.2 Evaluación de la
seguridad química:**

No se ha realizado ninguna evaluación de la seguridad química.

Reglamentos internacionales

Protocolo de Montreal
No aplicable

Convención de Estocolmo
No aplicable

Convención de Rotterdam
No aplicable

Protocolo de Kioto
No aplicable

SECCIÓN 16. Otra información

Abreviaturas y acrónimos:
No hay datos disponibles.

**Principales referencias
bibliográficas y las fuentes
de datos:** Agencia Europea de Sustancias y Preparados Químicos (ECHA): información sobre sustancias y preparados químicos.

Enunciado de las frases en los apartados 2 y 3
: ningunos

Información sobre formación: No hay datos disponibles.

No. FDS: UN0000000000000332777-4012-1-01



**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Exención de responsabilidad: Descargo de responsabilidad:
La información aquí contenida ha sido obtenida de diversas fuentes y se cree que es correcta a partir de la fecha de emisión. Sin embargo, ni BD ni ninguna de sus subsidiarias asumen responsabilidad alguna por la exactitud o la exhaustividad de la información contenida en este documento. La determinación final de idoneidad para un uso particular de cualquier material es responsabilidad exclusiva del usuario. Todos los materiales pueden presentar peligros desconocidos y deben usarse con precaución. Si bien se describen ciertos peligros en este documento, no podemos garantizar que éstos sean los únicos peligros que existen. BD proporciona SDS en formato electrónico por lo que la información puede ser más fácil acceso. Debido a la posibilidad de errores durante la transmisión, BD no hace ninguna representación en cuanto a la integridad o exactitud de la información.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

KÄYTTÖTURVALLISUUSTIEDOTE

Muutetun asetuksen (EY) N:o 1907/2006 (REACH) 31 artiklan, liitteen II mukaisesti

KOHTA 1: Aineen tai seoksen ja yhtiön tai yrityksen tunnistetiedot

Tuotetunniste

Tuoteno:	Tuotenimi:	Yleisesti käytetty nimi/yleisesti käytetyt nimet, synonyymi(t)
332777	BD® CD10 (HI10a) APC	Tietoja ei ole saatavana.
332791	BD® Anti-TdT (E17-1519) APC	Tietoja ei ole saatavana.
333143	BD® CD11b (D12) APC	Tietoja ei ole saatavana.
333144	BD® CD11c (S-HCL-3) APC	Tietoja ei ole saatavana.
333145	BD® CD22 (S-HCL-1) APC	Tietoja ei ole saatavana.
333154	BD® CD79a (HM47) APC	Tietoja ei ole saatavana.
333233	BD® CD117 (104D2) APC	Tietoja ei ole saatavana.
333951	BD® CD14 (MφP9) APC-Cy7	Tietoja ei ole saatavana.
335036	BD® CD23 (EBVCS-5) APC	Tietoja ei ole saatavana.
335829	BD® CD20 (L27) APC-Cy7	Tietoja ei ole saatavana.
335831	BD® Anti-HLA-DR (L243) APC-Cy7	Tietoja ei ole saatavana.
335834	BD® CD79b (SN8) APC	Tietoja ei ole saatavana.
337447	BD® CD71 (L01.1) APC	Tietoja ei ole saatavana.
340907	BD® CD25 (2A3) APC	Tietoja ei ole saatavana.
340908	BD® CD20 (L27) APC	Tietoja ei ole saatavana.
341024	BD® CD2 (L303.1) APC	Tietoja ei ole saatavana.
341027	BD® CD56 (NCAM16.2) APC	Tietoja ei ole saatavana.
341108	BD® Anti-Kappa (TB 28-2) APC	Tietoja ei ole saatavana.
341110	BD® CD3 (SK7) APC-Cy7	Tietoja ei ole saatavana.
341115	BD® CD4 (SK3) APC-Cy7	Tietoja ei ole saatavana.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

345767	BD® CD3 (SK7) APC	Tietoja ei ole saatavana.
345771	BD® CD4 (SK3) APC	Tietoja ei ole saatavana.
345775	BD® CD8 (SK1) APC	Tietoja ei ole saatavana.
345783	BD® CD5 (L17F12) APC	Tietoja ei ole saatavana.
345787	BD® CD14 APC	Tietoja ei ole saatavana.
345791	BD® CD19 (SJ25C1) APC	Tietoja ei ole saatavana.
345800	BD® CD33 (P67.6) APC	Tietoja ei ole saatavana.
345804	BD® CD34 (8G12) APC	Tietoja ei ole saatavana.
345807	BD® CD38 (HB7) APC	Tietoja ei ole saatavana.
345818	BD® Mouse IgG1 (X40) APC	Tietoja ei ole saatavana.
347216	BD® CD138 (MI15) APC	Tietoja ei ole saatavana.
347403	BD® Anti-HLA-DR (L243) APC-H7	Tietoja ei ole saatavana.
348812	BD® Mouse IgG1 (X40) APC-Cy7	Tietoja ei ole saatavana.
348813	BD® CD8 (SK1) APC-Cy7	Tietoja ei ole saatavana.
348814	BD® CD19 (SJ25C1) APC-Cy7	Tietoja ei ole saatavana.
641411	BD® Anti-HLA-DR (L243) APC-H7	Tietoja ei ole saatavana.
641414	BD® CD20 (L27) APC-H7	Tietoja ei ole saatavana.

1.2 Aineen tai seoksen merkitykselliset tunnistetut käytöt ja käytöt, joita ei suositella

Merkitykselliset tunnistetut käytöt:

Tieteelliseen ja teolliseen laboratoriokäyttöön. In vitro - diagnostiikkakäyttöön.

Käytöt, joita ei suositella:

Ei tunnettuja.

1.3 Käyttöturvallisuustiedotteen toimittajan tiedot

Valmistaja

Becton Dickinson France S.A.S. Belgian Branch
Erembodegem-Dorp 86
9320 Erembodegem
Belgium

Puhelin: 32 2 400 98 95

Faksi: 32 2 401 70 94

Yhteyshenkilö: BD Biosciences - Centralized European Office
Regulatory Compliance Department

Sähköposti: help.biosciences@europe.bd.com

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

1.4 Häät puhelinnumero: 32 2 400 98 95

KOHTA 2: Vaaran yksilöinti

2.1 Aineen tai seoksen luokitus

Tuotetta ei voimassaolevan lainsäädännön mukaan ole luokiteltu vaaralliseksi.

Asetuksen (EY) N:o 1272/2008 ja sen muutosten mukainen luokitus.

Ei luokiteltu

2.2 Merkinnät

Ei soveltuva.

2.3 Muut vaarat

Hormonitoimintaa häiritsevät ominaisuudet-Myrkyllisyys

Aine/seos ei sisällä komponentteja, joilla on endokriineja häiritseviä ominaisuuksia REACH-asetuksen 57(f) tai komission delegoidun säädöksen 2017/2100 tai komission säädöksen 2018/605 mukaan 0,1 %:n tai korkeammilla tasoilla.

Hormonitoimintaa häiritsevät ominaisuudet-Ekotoksisuus

Aine/seos ei sisällä komponentteja, joilla on endokriineja häiritseviä ominaisuuksia REACH-asetuksen 57(f) tai komission delegoidun säädöksen 2017/2100 tai komission säädöksen 2018/605 mukaan 0,1 %:n tai korkeammilla tasoilla.

KOHTA 3: Koostumus ja tiedot aineosista

3.2 Seokset

Yleistiedot:

Ei vaarallisia aineksia.

KOHTA 4: Ensiaputoimenpiteet

4.1 Ensiaputoimenpiteiden kuvaus

Yleistiedot:

Ota yhteys lääkäriin, jos oireita esiintyy.

Hengittäminen:

Raitista ilmaa, lämpöä ja lepoa, mieluiten mukavassa istuvassa asennossa.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Iho:	Kosketusalueet on pestävä saippualla ja vedellä. Poista likaantuneet vaatteet. Likaantuneet vaatteet on pestävä ennen käyttöä.
Roiskeet silmiin:	Huuhtelee välittömästi runsaalla vedellä vähintään 15 minuutin ajan. Jos helppoa, poista piilolinssit.
Nieleminen:	Ota välittömästi yhteys lääkäriin tai myrkytyskeskukseen. Oksennuta ainoastaan jos lääkintähenkilökunta niin neuvoo. Älä koskaan anna mitään suun kautta tajuttomalle henkilölle.
Henkilösuojaimet ensiavunantajille:	Tietoja ei ole saatavana.
4.2 Tärkeimmät oireet ja vaikutukset, sekä välittömät että viivästyneet Oireet:	Tietoja ei ole saatavana.
Vaarat:	Tietoja ei ole saatavana.
4.3 Mahdollisesti tarvittavaa välitöntä lääketieteellistä apua ja erityishoitoa koskevat ohjeet	
Käsittely:	Tietoja ei ole saatavana.

KOHTA 5: Palontorjuntatoimenpiteet

Yleiset tulipalovaarat:	Sammuta sytytyslähteet. Vältä kipinöitä, savua, liekkejä ja kuumuutta. Tuuleta. Suihkuta vedellä tulelle altistuneiden säiliöiden pitämiseksi viileänä.
--------------------------------	---

5.1 Sammutusaineet

Soveltuva sammutusaine:	Mahd. muut kemikaalit on otettava huomioon palonsammutusainetta valittaessa.
--------------------------------	--

Soveltumaton sammutusaine:	Ei soveltuva.
-----------------------------------	---------------

5.2 Aineesta tai seoksesta johtuvat erityiset vaarat:	Tuli tai liiallinen kuumuus voi tuottaa vaarallisia hajoamistuotteita.
--	--

5.3 Palontorjuntaa koskevat ohjeet

Palontorjuntaa koskevat ohjeet:	Epätavallista palo- tai räjähdysvaaraa ei ole havaittu.
---------------------------------	---

Erityiset suojaruuvit palomiehille:	Palomiesten on käytettävä tavallisia suojaruuvit, mm. palonkestävää takkia, kasvonsuojuksella varustettua kypärää, käsineitä, kumisaappaita ja suljetuissa tiloissa happilaitetta.
-------------------------------------	--

KOHTA 6: Toimenpiteet onnettomuuspäästöissä

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

- 6.1 Varotoimenpiteet, henkilönsuojaimet ja menettely hätätilanteessa:** Otaa yhteys paikallisiin viranomaisiin jos vuotoja on päässyt viemäriin/vesistöön. Käytettävä suojavarustusta (myös hengityssuojainta) vuotoja poistettaessa saastuneelta alueelta.
- 6.1.1 Muu kuin pelastushenkilökunta:** Tietoja ei ole saatavana.
- 6.1.2 Pelastushenkilökunta:** Tietoja ei ole saatavana.
- 6.2 Ympäristöön kohdistuvat varotoimet:** Vältettävä päästämistä ympäristöön.
- 6.3 Suojarakenteita ja puhdistusta koskevat menetelmät ja -välineet:** Vuoto on imettävä sopivalla imukykyisellä materiaalilla. Estä valuma viemäriin, putkistoihin tai jokiin. Katso henkilökohtaisia suojaimia koskevat tiedot kohdasta 8. Jätteiden käsittelyn osalta, kts. kohta 13.
- 6.4 Viittaukset muihin kohtiin:** Tietoja ei ole saatavana.

KOHTA 7: Käsittely ja varastointi

7.1 Turvallisen käsittelyn edellyttämät toimenpiteet

- Tekniset toimenpiteet (esim. paikallinen ja yleinen ilmanvaihto):** Ei erikoisvaatimuksia tavallisissa käyttöolosuhteissa ja ilmanvaihdon ollessa riittävä.
- Käsittely:** Syöminen, juominen ja tupakointi kielletty kemikaalia käytettäessä. Lue ja seuraa valmistajan ohjeita. Käytä vaadittuja henkilönsuojaimia.
- Kosketuksen välttäminen:** Tietoja ei ole saatavana.

7.2 Turvallisen varastoinnin edellyttämät olosuhteet, mukaan luettuina yhteensopimattomuudet

- Turvalliset varastointiolosuhteet:** Säilytettävä kuivassa ja viileässä. Säytettävä tiiviisti suljettuna.
- Turvalliset pakkausmateriaalit:** Tietoja ei ole saatavana.

- 7.3 Erityinen loppukäyttö:** Varattu teollisuus- ja ammattikäyttöön. Lue merkinnät ennen käyttöä.

KOHTA 8: Altistumisen ehkäiseminen ja henkilönsuojaimet

8.1 Valvontaa koskevat muuttujat Altistumisen raja-arvot

Millään ainesosalla ei ole määrättyjä altistusrajoja.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Biologiset raja-arvot

Aineosalle/aineosille ei ole ilmoitettu biologisia altistumisen raja-arvoja.

DNEL-arvot

Huomautukset: DNEL-arvot

Kriittinen ainesosa	Tyyppi	Altistumisreitti	Terveysvaarallisuus, yleinen	Huomautukset
Sodium Chloride (NaCl)	Yleinen väestö	Inhalation	Systeeminen, pitkäaikainen; 443,28 mg/m ³	Toistuvasta annostuksesta johtuva myrkyllisyys
	Työntekijät	Inhalation	Systeeminen, pitkäaikainen; 2068,62 mg/m ³	Toistuvasta annostuksesta johtuva myrkyllisyys
	Työntekijät	Inhalation	Systeeminen, lyhytaikainen; 2068,62 mg/m ³	Toistuvasta annostuksesta johtuva myrkyllisyys
	Yleinen väestö	Inhalation	Systeeminen, lyhytaikainen; 443,28 mg/m ³	Toistuvasta annostuksesta johtuva myrkyllisyys
	Yleinen väestö	Suun kautta	Systeeminen, pitkäaikainen; 126,65 mg/kg	Toistuvasta annostuksesta johtuva myrkyllisyys
	Työntekijät	Dermaalinen	Systeeminen, pitkäaikainen; 295,52 mg/kg	Toistuvasta annostuksesta johtuva myrkyllisyys
	Työntekijät	Dermaalinen	Systeeminen, lyhytaikainen; 295,52 mg/kg	Toistuvasta annostuksesta johtuva myrkyllisyys
	Yleinen väestö	Suun kautta	Systeeminen, lyhytaikainen; 126,65 mg/kg	Toistuvasta annostuksesta johtuva myrkyllisyys
	Yleinen väestö	Dermaalinen	Systeeminen, lyhytaikainen; 126,65 mg/kg	Toistuvasta annostuksesta johtuva myrkyllisyys
	Yleinen väestö	Dermaalinen	Systeeminen, pitkäaikainen; 126,65 mg/kg	Toistuvasta annostuksesta johtuva myrkyllisyys
Phosphoric acid, sodium salt (1:2)	Työntekijät	Silmät	Paikallinen vaikutus;	Ei tunnistettu vaara
	Työntekijät	Inhalation	Systeeminen, pitkäaikainen; 4,07 mg/m ³	Toistuvasta annostuksesta johtuva myrkyllisyys
	Yleinen väestö	Inhalation	Systeeminen, pitkäaikainen; 3,04 mg/m ³	Toistuvasta annostuksesta johtuva myrkyllisyys
	Yleinen väestö	Inhalation	Systeeminen, pitkäaikainen; 6,63 mg/m ³	Toistuvasta annostuksesta johtuva myrkyllisyys
	Työntekijät	Inhalation	Systeeminen, pitkäaikainen; 15,47 mg/m ³	Toistuvasta annostuksesta johtuva myrkyllisyys
Sodium azide (Na(N ₃))	Työntekijät	Inhalation	Systeeminen, pitkäaikainen; 0,164 mg/m ³	Toistuvasta annostuksesta johtuva myrkyllisyys
	Yleinen väestö	Silmät	Paikallinen vaikutus;	Ei tunnistettu vaara

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Yleinen väestö	Inhalation	Systeeminen, pitkäaikainen; 29 µg/m ³	Toistuvasta annostuksesta johtuva myrkyllisyys
	Työntekijät	Silmät	Paikallinen vaikutus;	Ei tunnistettu vaara
	Työntekijät	Dermaalinen	Systeeminen, pitkäaikainen; 0,0467 mg/kg	Toistuvasta annostuksesta johtuva myrkyllisyys
	Yleinen väestö	Suun kautta	Systeeminen, pitkäaikainen; 0,0167 mg/kg	Toistuvasta annostuksesta johtuva myrkyllisyys
	Yleinen väestö	Dermaalinen	Systeeminen, pitkäaikainen; 0,0167 mg/kg	Toistuvasta annostuksesta johtuva myrkyllisyys

Potassium chloride (KCl)	Työntekijät	Inhalation	Systeeminen, pitkäaikainen; 1064 mg/m ³	Toistuvasta annostuksesta johtuva myrkyllisyys
	Yleinen väestö	Inhalation	Systeeminen, pitkäaikainen; 273 mg/m ³	Toistuvasta annostuksesta johtuva myrkyllisyys
	Yleinen väestö	Inhalation	Systeeminen, lyhytaikainen; 1365 mg/m ³	Toistuvasta annostuksesta johtuva myrkyllisyys
	Työntekijät	Inhalation	Systeeminen, lyhytaikainen; 5320 mg/m ³	Toistuvasta annostuksesta johtuva myrkyllisyys
	Yleinen väestö	Suun kautta	Systeeminen, lyhytaikainen; 455 mg/kg	Toistuvasta annostuksesta johtuva myrkyllisyys
	Yleinen väestö	Dermaalinen	Systeeminen, pitkäaikainen; 182 mg/kg	Toistuvasta annostuksesta johtuva myrkyllisyys
	Yleinen väestö	Suun kautta	Systeeminen, pitkäaikainen; 91 mg/kg	Toistuvasta annostuksesta johtuva myrkyllisyys
	Työntekijät	Dermaalinen	Systeeminen, pitkäaikainen; 303 mg/kg	Toistuvasta annostuksesta johtuva myrkyllisyys
	Työntekijät	Dermaalinen	Systeeminen, lyhytaikainen; 910 mg/kg	Toistuvasta annostuksesta johtuva myrkyllisyys
	Yleinen väestö	Dermaalinen	Systeeminen, lyhytaikainen; 910 mg/kg	Toistuvasta annostuksesta johtuva myrkyllisyys

Phosphoric acid, potassium salt (1:1)	Työntekijät	Silmät	Paikallinen vaikutus;	Ei tunnistettu vaara
	Yleinen väestö	Silmät	Paikallinen vaikutus;	Ei tunnistettu vaara
	Työntekijät	Inhalation	Systeeminen, pitkäaikainen; 14,82 mg/m ³	Toistuvasta annostuksesta johtuva myrkyllisyys
	Yleinen väestö	Inhalation	Systeeminen, pitkäaikainen; 6,35 mg/m ³	Toistuvasta annostuksesta johtuva myrkyllisyys

PNEC-arvot

Huomautukset: PNEC-arvot

Kriittinen ainesosa	Ympäristönosa	PNEC-arvot	Huomautukset
Sodium Chloride (NaCl)	Maaperä	4,86 mg/kg	
	Vesi (makea vesi)	5 mg/l	

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Jätevedenkäsittelylaitos	500 mg/l	
Phosphoric acid, sodium salt (1:2)	Jätevedenkäsittelylaitos	50 mg/l	
	Vesi (makea vesi)	0,05 mg/l	
	Vesi (merivesi)	0,005 mg/l	
Sodium azide (Na(N ₃))	Vesi (merivesi)	15 ng/l	
	Jätevedenkäsittelylaitos	30 µg/l	
	Sakkauma (makea vesi)	0,0167 mg/kg	
	Vesi (makea vesi)	0,35 µg/l	
	Sedimentti (merivesi)	0,00072 mg/kg	
Potassium chloride (KCl)	Vesi (merivesi)	0,1 mg/l	
	Jätevedenkäsittelylaitos	10 mg/l	
	Vesi (makea vesi)	0,1 mg/l	

8.2 Altistumisen ehkäiseminen

Tekniset torjuntatoimenpiteet:

Ei erikoisvaatimuksia tavallisissa käyttöolosuhteissa ja ilmanvaihdon ollessa riittävä.

Henkilökohtaiset suojaustoimenpiteet, kuten henkilönsuojainten käyttö

Silmien tai kasvojen suojaus:	Käytä sivusuojilla varustettuja suojalaseja.
Käsien suojaus:	Materiaali: Kemikaaleja kestävä käsineet Lisätietoja: Pese kädet kosketuksen jälkeen. Materiaali: Maahantuoja voi suositella muita käsineityyppejä.
Ihon ja ruumiin suojaus:	Käytä laboratoriotakkia tai muuta suojavaatetusta.
Hengityksen suojaus:	Jos tekniset hallintalaitteet eivät pidä ilman pitoisuuksia suositeltujen altistuksen raja-arvojen alapuolella (missä soveltuva) tai hyväksytyllä tasolla (maissa joissa altistuksen raja-arvoja ei ole määritetty), hyväksyttyä hengityslaitetta tulee käyttää.
Hygieniaohteita:	Noudata hyvää kemikaalihygieniaa.
Ohjeet työympäristön altistumisen torjumiseksi:	Tietoja ei ole saatavana.

KOHTA 9: Fysikaaliset ja kemialliset ominaisuudet

9.1 Fysikaalisia ja kemiallisia perusominaisuuksia koskevat tiedot

Olomuoto

Olomuoto: nestemäinen

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Fysikaalinen olomuoto:	nestemäinen
Väri:	Väritön tai sininen
Haju:	Hajuton
Hajukynnys:	Tietoja ei ole saatavana.
Jäätymispiste:	Tietoja ei ole saatavana.
Kiehumispiste ja kiehumisalue:	Tietoja ei ole saatavana.
Syttyvyys:	Tietoja ei ole saatavana.
Ylemmät/alemmat syttymis- tai räjähdysarvot	
Räjähdysraja - ylempi (%):	Tietoja ei ole saatavana.
Räjähdysraja - alempi (%):	Tietoja ei ole saatavana.
Leimahduspiste:	Tietoja ei ole saatavana.
Itsesyttymislämpötila:	Tietoja ei ole saatavana.
Hajoamislämpötila:	Tietoja ei ole saatavana.
pH:	7,20 - 7,60
Viskositeetti	
Viskositeetti, dynaaminen:	Tietoja ei ole saatavana.
Viskositeetti, kinemaattinen:	Tietoja ei ole saatavana.
Virtausaika:	Tietoja ei ole saatavana.
Liukoisuus (liukoisuudet)	
Liukoisuus veteen:	Liukeneva
Liukenevuus (muu):	Tietoja ei ole saatavana.
Liukenemisnopeus:	Tietoja ei ole saatavana.
Jakaantumiskerroin (n-oktanoli/vesi):	Tietoja ei ole saatavana.
Dispersion stabiliteetti:	Tietoja ei ole saatavana.
Höyrynpaine:	Tietoja ei ole saatavana.
Suhteellinen tiheys:	Tietoja ei ole saatavana.
tiheys:	Tietoja ei ole saatavana.
Kiintotiheys:	Tietoja ei ole saatavana.
Suhteellinen höyryntiheys:	Tietoja ei ole saatavana.

9.2 Muut tiedot

Tietoja ei ole käytettävissä

KOHTA 10: Stabiilisuus ja reaktiivisuus

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

- | | | |
|-------------|---|--|
| 10.1 | Reaktiivisuus: | Materiaali on stabiili normaaleissa olosuhteissa. |
| 10.2 | Kemiallinen stabiilisuus: | Materiaali on stabiili normaaleissa olosuhteissa. |
| 10.3 | Vaarallisten reaktioiden mahdollisuus: | Stabiili |
| 10.4 | Vältettävät olosuhteet: | Varottava altistamista korkeisiin lämpötiloihin ja suoraan auringonvaloon. |
| 10.5 | Yhteensopimattomat materiaalit: | Metallit. Veden kanssa reagoiva aine. |
| 10.6 | Vaaralliset hajoamistuotteet: | Vakaa; mutta voi hajota kuumennettaessa. |

KOHTA 11: Myrkyllisyyteen liittyvät tiedot

11.1 Tiedot asetuksessa (EY) N:o 1272/2008 määritellyistä vaaraluokista

- | | |
|--------------------------|---------------------------|
| Hengittäminen: | Tietoja ei ole saatavana. |
| Iho: | Tietoja ei ole saatavana. |
| Roiskeet silmiin: | Tietoja ei ole saatavana. |
| Nieleminen: | Tietoja ei ole saatavana. |

Todennäköisiä altistumisreittejä koskevat tiedot

Välitön myrkyllisyys (luetteloi kaikki mahdolliset altistumisreitit)

Nieleminen

- | | |
|---------------|--|
| Tuote: | Saatavilla olevien tietojen perusteella välittömän myrkyllisyyden luokituskriteerit eivät täyty. |
|---------------|--|

Ihokosketus

- | | |
|---------------|--|
| Tuote: | Saatavilla olevien tietojen perusteella välittömän myrkyllisyyden luokituskriteerit eivät täyty. |
|---------------|--|

Hengittäminen

- | | |
|---------------|--|
| Tuote: | Saatavilla olevien tietojen perusteella välittömän myrkyllisyyden luokituskriteerit eivät täyty. |
|---------------|--|

Toistuvasta annoksesta johtuva myrkyllisyys

- | | |
|---------------|---------------------------|
| Tuote: | Tietoja ei ole saatavana. |
|---------------|---------------------------|

Ihosyövyttävyyksi/ihoärsyttävyyksi

- | | |
|---------------|---------------------------|
| Tuote: | Tietoja ei ole saatavana. |
|---------------|---------------------------|

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Vakava silmävaurio/ silmä-ärsytys

Tuote: Tietoja ei ole saatavana.

Hengitysteiden tai ihon herkistyminen

Tuote: Tietoja ei ole saatavana.

Karsinogeenisuus

Tuote: Tietoja ei ole saatavana.

**Sukusolujen perimää vaurioittava
koeputkessa**

Tuote: Tietoja ei ole saatavana.

Elimistössä

Tuote: Tietoja ei ole saatavana.

Lisääntymiselle vaaralliset vaikutukset

Tuote: Tietoja ei ole saatavana.

Elinkohtainen myrkyllisyys - kerta-altistuminen

Tuote: Tietoja ei ole saatavana.

Elinkohtainen myrkyllisyys - toistuva altistuminen

Tuote: Tietoja ei ole saatavana.

Aspiraatiovaara

Tuote: Tietoja ei ole saatavana.

11.2 Tiedot muista vaaroista**Hormonitoimintaa häiritsevät ominaisuudet**

Tuote: Aine/seos ei sisällä komponentteja, joilla on endokriineja häiritseviä ominaisuuksia REACH-asetuksen 57(f) tai komission delegoidun säädöksen 2017/2100 tai komission säädöksen 2018/605 mukaan 0,1 %:n tai korkeammilla tasoilla.;

Muut tiedot

Tuote: Tietoja ei ole saatavana.

KOHTA 12: Tiedot vaarallisuudesta ympäristölle**12.1 Myrkyllisyys:****Vesiympäristölle aiheutuvat välittömät vaarat:****Kala**

Tuote: Tietoja ei ole saatavana.

Vedessä elävät selkärangattomat

Tuote: Tietoja ei ole saatavana.

Myrkyllisyys vesikasveille

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Tuote: Tietoja ei ole saatavana.

Myrkyllisyys mikro-organismeille

Tuote: Tietoja ei ole saatavana.

Vesiympäristölle aiheutuvat krooniset vaarat:

Kala

Tuote: Tietoja ei ole saatavana.

Vedessä elävät selkärangattomat

Tuote: Tietoja ei ole saatavana.

Myrkyllisyys vesikasveille

Tuote: Tietoja ei ole saatavana.

Myrkyllisyys mikro-organismeille

Tuote: Tietoja ei ole saatavana.

12.2 Pysyvyys ja hajoavuus

Biohajoavuus

Tuote: Tietoja ei ole saatavana.

BOD/COD suhde

Tuote: Tietoja ei ole saatavana.

12.3 Biokertyvyys

Biokertyvyystekijä (BCF)

Tuote: Tietoja ei ole saatavana.

Jakautumiskerroin: n-oktanoliv/vesi (log K_{ow})

Tuote: Tietoja ei ole saatavana.

12.4 Liikkuvuus maaperässä:

Tuote Tietoja ei ole saatavana.

12.5 PBT- ja vPvB-arvioinnin tulokset:

Tuote Tietoja ei ole saatavana.

12.6 Hormonitoimintaa häiritsevät ominaisuudet:

Tuote: Aine/seos ei sisällä komponentteja, joilla on endokriineja häiritseviä ominaisuuksia REACH-asetuksen 57(f) tai komission delegoidun säädöksen 2017/2100 tai komission säädöksen 2018/605 mukaan 0,1 %:n tai korkeammilla tasoilla.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

12.7 Muut haitalliset vaikutukset:

Muut vaarat

Tuote: Tietoja ei ole saatavana.

KOHTA 13: Jätteiden käsittelyyn liittyvät näkökohdat

13.1 Jätteiden käsittelymenetelmät

Yleistiedot:	Vuodot ja jätteet hävitetään paikallisten viranomaisten ohjeiden mukaisesti.
Hävittäminen:	Hävitä jäte asianmukaiseen käsittely- ja jätelaitokseen soveltuvien lakien ja määräysten sekä tuotteen hävitysajankohdan mukaisten ominaisuuksien mukaisesti.
Saastunut Pakkaus:	Hävitä sisältö/pakkaus soveltuvassa jätteenkäsittelylaitoksessa soveltuvien lakien ja määräysten sekä tuotteen hävityksenaikaisten ominaisuuksien mukaisesti.

KOHTA 14: Kuljetustiedot

ADR

14.1 YK-numero tai tunnistenumero:	Ei säädelty.
14.2 Kuljetuksessa käytettävä virallinen nimi:	Ei säädelty.
14.3 Kuljetuksen vaaraluokat	
Luokka:	Ei säädelty.
Merkintä (merkinnät):	Ei säädelty.
Vaaranro (ADR):	Ei säädelty.
Tunnelikuljetuksen rajoituskoodi (tunnel restriction code):	Ei säädelty.
14.4 Pakkausryhmä:	Ei säädelty.
Rajoitettu määrä	Ei säädelty.
Määrä, jota ei tarvitse ilmoittaa	Ei säädelty.
14.5 Ympäristövaarat	Ei säädelty.
14.6 Erityiset varotoimet käyttäjälle:	Ei säädelty.

ADN

14.1 YK-numero tai tunnistenumero:	Ei säädelty.
14.2 Kuljetuksessa käytettävä virallinen nimi:	Ei säädelty.
14.3 Kuljetuksen vaaraluokat	
Luokka:	Ei säädelty.
Merkintä (merkinnät):	Ei säädelty.
Vaaranro (ADR):	Ei säädelty.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Tunnelikuljetuksen rajoituskoodi (tunnel restriction code):	Ei säädelty.
14.4 Pakkausryhmä:	Ei säädelty.
Rajoitettu määrä	Ei säädelty.
Määrä, jota ei tarvitse ilmoittaa	Ei säädelty.
14.5 Erityiset varotoimet käyttäjälle:	Ei säädelty.

RID

14.1 YK-numero tai tunnistenumero:	Ei säädelty.
14.2 Kuljetuksessa käytettävä virallinen nimi:	Ei säädelty.
14.3 Kuljetuksen vaaraluokat	
Luokka:	Ei säädelty.
Merkintä (merkinnät):	Ei säädelty.
14.4 Pakkausryhmä:	Ei säädelty.
Rajoitettu määrä	Ei säädelty.
Määrä, jota ei tarvitse ilmoittaa	Ei säädelty.
14.5 Ympäristövaarat	Ei säädelty.
14.6 Erityiset varotoimet käyttäjälle:	Ei säädelty.

IMDG

14.1 YK-numero tai tunnistenumero:	Ei säädelty.
14.2 Kuljetuksessa käytettävä virallinen nimi:	Ei säädelty.
14.3 Kuljetuksen vaaraluokat	
Luokka:	Ei säädelty.
Merkintä (merkinnät):	Ei säädelty.
EmS No.:	Ei säädelty.
14.4 Pakkausryhmä:	Ei säädelty.
Rajoitettu määrä	Ei säädelty.
Määrä, jota ei tarvitse ilmoittaa	Ei säädelty.
14.5 Ympäristövaarat	Ei säädelty.
14.6 Erityiset varotoimet käyttäjälle:	Ei säädelty.

IATA

14.1 YK-numero tai tunnistenumero:	Ei säädelty.
14.2 Kuljetuksessa käytettävä virallinen nimi:	Ei säädelty.
14.3 Kuljetuksen vaaraluokat	
Luokka:	Ei säädelty.
Merkintä (merkinnät):	Ei säädelty.
14.4 Pakkausryhmä:	Ei säädelty.
Matkustaja- ja rahtilentokone :	Ei säädelty.
Rajoitettu määrä	Ei säädelty.
Määrä, jota ei tarvitse ilmoittaa	Ei säädelty.
14.5 Ympäristövaarat	Ei säädelty.
14.6 Erityiset varotoimet käyttäjälle:	Ei säädelty.

14.7 Merikuljetus irtolastina IMO:n asiakirjojen mukaisesti Ei koske toimitettavaa tuotetta.

KOHTA 15: Lainsäädäntöä koskevat tiedot
--

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

15.1 Nimenomaisesti ainetta tai seosta koskevat turvallisuus-, terveys- ja ympäristösäännökset tai -lainsäädäntö:

EY:n asetukset

Asetus 1005/2009/EC otsonikerrosta heikentävistä aineista, Liite I, Valvottavat aineet: Ei mitään läsnä tai ei mitään läsnä säädellyissä pitoisuuksissa.

ASETUS (EY) N:o 1907/2006 (REACH), LIITE XIV LUVANVARAISTEN AINEIDEN LUETTELO: Ei mitään läsnä tai ei mitään läsnä säädellyissä pitoisuuksissa.

Asetus (EU) 2019/1021 pysyvistä orgaanisista yhdisteistä (uudelleen laadittu toisinto), sellaisena kuin se on muutettuna: Ei mitään läsnä tai ei mitään läsnä säädellyissä pitoisuuksissa.

EUROOPAN PARLAMENTIN JA NEUVOSTON DIREKTIIVI 2010/75/EU, annettu 24 päivänä marraskuuta 2010, teollisuuden päästöistä (yhtenäistetty ympäristön pilaantumisen ehkäiseminen ja vähentäminen), LIITE II Pilaavien aineiden luettelo: Ei mitään läsnä tai ei mitään läsnä säädellyissä pitoisuuksissa.

Muutettu asetus (EU) N:o 649/2012 vaarallisten kemikaalien viennistä ja tuonnista, liite I, osa 1: Ei mitään läsnä tai ei mitään läsnä säädellyissä pitoisuuksissa.

Muutettu asetus (EU) N:o 649/2012 vaarallisten kemikaalien viennistä ja tuonnista, liite I, osa 2: Ei mitään läsnä tai ei mitään läsnä säädellyissä pitoisuuksissa.

Muutettu asetus (EU) N:o 649/2012 vaarallisten kemikaalien viennistä ja tuonnista, liite I, osa 3: Ei mitään läsnä tai ei mitään läsnä säädellyissä pitoisuuksissa.

Muutettu asetus (EU) N:o 649/2012 vaarallisten kemikaalien viennistä ja tuonnista, liite V: Ei mitään läsnä tai ei mitään läsnä säädellyissä pitoisuuksissa.

EU REACH ehdokasluettelo erityistä huolta aiheuttavista aineista lupamenettelyä varten (SVHC): Ei mitään läsnä tai ei mitään läsnä säädellyissä pitoisuuksissa.

Asetus (EY) N:o 1907/2006 Liite XVII Tiettyjen vaarallisten aineiden, valmisteiden ja tuotteiden valmistuksen, markkinoille saattamisen ja käytön rajoitukset:

Direktiivi 2004/37/EY työntekijöiden suojelemisesta syöpäsairauden vaaraa aiheuttaville tekijöille tai perimän muutoksia aiheuttaville aineille altistumiseen työssä liittyviltä vaaroilta.: Ei mitään läsnä tai ei mitään läsnä säädellyissä pitoisuuksissa.

Direktiivi 92/85/ETY toimenpiteistä raskaana olevien ja äskettäin synnyttäneiden tai imettävien työntekijöiden turvallisuuden ja terveyden parantamisen kannustamiseksi työssä: Ei mitään läsnä tai ei mitään läsnä säädellyissä pitoisuuksissa.

EU. Direktiivi 2012/18/EU (SEVESO III) vaarallisista aineista aiheutuvien suuronnettomuusvaarojen torjunnasta, muutoksineen.: Ei mitään läsnä tai ei mitään läsnä säädellyissä pitoisuuksissa.

ASETUS (EY) N:o 166/2006 epäpuhtauksien päästöjä ja siirtoja koskevan eurooppalaisen rekisterin, LIITE II: Epäpuhtaudet: Ei mitään läsnä tai ei mitään läsnä säädellyissä pitoisuuksissa.

Direktiivi 98/24/EY työntekijöiden terveyden ja turvallisuuden suojelemisesta työpaikalla esiintyviin

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

kemiallisiin tekijöihin liittyviltä riskeiltä:

Kemiallinen nimi	CAS-nro	Pitoisuus
natriumatsidi	26628-22-8	0 - <0,1%

15.2**Kemikaaliturvallisuusarviointi:**

Kemikaaliturvallisuusarviointia ei tarvitse tehdä tälle tuotteelle.

Kansainväliset määräykset**Montrealin pöytäkirja**

Ei soveltuva.

Tukholman sopimus

Ei soveltuva.

Rotterdamin sopimus

Ei soveltuva.

Kioton pöytäkirja

Ei soveltuva.

KOHTA 16: Muut tiedot**Lyhenteet ja akronyymit:**

Tietoja ei ole saatavana.

Tärkeimmät kirjallisuusviitteet ja tietolähteet:

Euroopan kemikaalivirasto (ECHA): Tietoa kemikaaleista.

Lausekkeiden teksti kohdissa 2 ja 3

: ei

Tiedot koulutuksesta:

Tietoja ei ole saatavana.

KTT-nro:

UN0000000000000332777-4012-1-01

Vastuuvapauslauseke:

Disclaimer:

Tässä olevat tiedot on saatu eri lähteistä, ja niiden uskotaan olevan oikeita. Antamispäivämäärä. Kuitenkaan BD eikä yksikään sen tytäryhtiöistä ota minkäänlaista vastuuta niiden oikeellisuudesta tai täydellisyydestä sisältämiä tietoja. Lopullinen ratkaisu soveltuvuudesta tiettyyn käyttöön kaikki aineisto on yksin käyttäjän vastuulla. Kaikkiin aineisiin saattaa liittyä tuntemattomia vaaroja ja niitä tulee käyttää varoen. Vaikka tietyt vaarat on kuvattu, emme voi taata, että nämä ovat ainoat olemassa olevat vaaratekijät. BD tarjoaa SDS sähköisessä muodossa, joten tiedot saattavat olla helpommin saatavilla. Koska virhemahdollisuuksia lähetyksen aikana, BD ei väitä olevan täydellisiä tai oikeellisuutta.



Versio: 1.4
Päivitetty: 02.01.2023

**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

KARTA CHARAKTERYSTYKI

Zgodnie z rozporządzeniem (WE) nr 1907/2006 (REACH) artykuł 31, załącznik II ze zmianami

SEKCJA 1: Identyfikacja substancji/mieszaniny i identyfikacja przedsiębiorstwa

Identyfikator produktu

Numer produktu:	Nazwa produktu:	Nazwa(-y) zwyczajowa(-e) i synonimy
332773	BD® CD7 (M-T701) FITC	Brak danych.
332775	BD® CD10 (HI10a) FITC	Brak danych.
332786	BD® FMC7 FITC	Brak danych.
332788	BD® Anti-Lambda F(ab') ₂ FITC	Brak danych.
332789	BD® Anti-TdT (E17-1519) FITC	Brak danych.
333138	BD® Anti-MPO (5B8) FITC	Brak danych.
333140	BD® Anti-TCR-α/β (WT31) FITC	Brak danych.
333147	BD® CD41a (HIP8) FITC	Brak danych.
333151	BD® CD71 (L01.1) FITC	Brak danych.
333155	BD® CD103 (Ber-ACT8) FITC	Brak danych.
335035	BD® CD16 (NKP15) FITC	Brak danych.
335039	BD® CD45RA (L48) FITC	Brak danych.
335832	BD® CD79b (SN8) FITC	Brak danych.
337898	BD® CD22 (S-HCL-1) FITC	Brak danych.
340909	BD® CD38 (HB-7) FITC	Brak danych.
345763	BD® CD3 (SK7) FITC	Brak danych.
345764	BD® CD3 (SK7) FITC	Brak danych.
345768	BD® CD4 (SK3) FITC	Brak danych.
345772	BD® CD8 (SK1) FITC	Brak danych.
345776	BD® CD19 (4G7) FITC	Brak danych.
345781	BD® CD5 (L17F12) FITC	Brak danych.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

345784	BD® CD14 (MφP9) FITC	Brak danych.
345788	BD® CD19 (SJ25C1) FITC	Brak danych.
345792	BD® CD20 (L27) FITC	Brak danych.
345796	BD® CD25 (2A3) FITC	Brak danych.
345798	BD® CD33 (P67.6) FITC	Brak danych.
345801	BD® CD34 (8G12) FITC	Brak danych.
345811	BD® CD56 (NCAM16.2) FITC	Brak danych.
347214	BD® CD138 (MI15) FITC	Brak danych.
347247	BD® Anti-Lambda (1-155-2) FITC	Brak danych.
347400	BD® Anti-HLA-DR (243) FITC	Brak danych.
347404	BD® CD2 (S5.2) FITC	Brak danych.
347407	BD® CD61 (RUU-PL7F12) FITC	Brak danych.
644059	BD® Anti-Kappa (TB 28-2) FITC	Brak danych.

1.2 Istotne zidentyfikowane zastosowania substancji lub mieszaniny oraz zastosowania odradzane

Zidentyfikowane zastosowania:

Do użytku laboratoryjnego do celów naukowych i przemysłowych. Do stosowania w diagnostyce in vitro.

Zastosowania odradzane:

Żadnych znanych.

1.3 Dane dotyczące dostawcy karty charakterystyki

Producent

Becton Dickinson France S.A.S. Belgian Branch
Erembodegem-Dorp 86
9320 Erembodegem
Belgium

Telefon: 32 2 400 98 95

Telefaks: 32 2 401 70 94

Osoba kontaktowa: BD Biosciences - Centralized European Office
Regulatory Compliance Department
E-mail: help.biosciences@europe.bd.com

1.4 Numer telefonu alarmowego: 32 2 400 98 95

SEKCJA 2: Identyfikacja zagrożeń

2.1 Klasyfikacja substancji lub mieszaniny

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Produkt nie został sklasyfikowany jako niebezpieczny, zgodnie z obowiązującymi przepisami prawnymi.

Klasyfikacja zgodnie z Rozporządzeniem (WE) Nr 1272/2008, z późniejszymi zmianami.

Nie sklasyfikowano

2.2 Elementy oznakowania Nie dotyczy

2.3 Inne zagrożenia

Właściwości zaburzające funkcjonowanie układu hormonalnego-Toksyczność

Ta substancja/mieszanina nie zawiera składników uważanych za posiadające właściwości endokrynnie czynne wobec środowiska, według Artykułu REACH 57(f), Regulacji Komisji (UE) 2018/605 lub Regulacji Delegowanej Komisji (UE) 2017/2100.

Właściwości zaburzające funkcjonowanie układu hormonalnego-Ekotoksyczność

Ta substancja/mieszanina nie zawiera składników uważanych za posiadające właściwości endokrynnie czynne wobec środowiska, według Artykułu REACH 57(f), Regulacji Komisji (UE) 2018/605 lub Regulacji Delegowanej Komisji (UE) 2017/2100.

SEKCJA 3: Skład/informacja o składnikach

3.2 Mieszaniny

Informacje ogólne: Brak składników niebezpiecznych.

SEKCJA 4: Środki pierwszej pomocy

4.1 Opis środków pierwszej pomocy

Informacje ogólne:	Jeśli wystąpią objawy, zapewnić pomoc medyczną.
Wdychanie:	Zapewnić dopływ świeżego powietrza, ciepło i odpoczynek, najlepiej w wygodnej pozycji siedzącej.
Kontakt ze skórą:	Miejsca kontaktu umyć wodą z mydłem. Zdjąć skażone ubranie. Uprać skażone ubranie przed ponownym założeniem.
Kontakt z oczami:	Natychmiast przemywać dużą ilością wody przez co najmniej 15 minut. Wyjąć soczewki kontaktowe - jeśli jest to łatwe do zrobienia.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Spżycie: Natychmiast wezwać lekarza albo powiadomić centrum zatruc. Wymioty powodować tylko na polecenie personelu medycznego. Nigdy nie podawać niczego doustnie osobie nieprzytomnej.

Środki ochrony osobistej dla udzielających pierwszej pomocy: Brak danych.

4.2 Najważniejsze ostre i opóźnione objawy oraz skutki narażenia
Objawy: Brak danych.

Zagrożenia: Brak danych.

4.3 Wskazania dotyczące natychmiastowej pomocy lekarskiej i szczególnego postępowania z poszkodowanym

Leczenie: Brak danych.

SEKCJA 5: Postępowanie w przypadku pożaru

Ogólne zagrożenia pożarowe: Wygasić wszystkie źródła zapłonu. Unikać iskier, płomieni, wysokiej temperatury i dymienia. Wietrzyć. Rozpylać wodę aby chłodzić pojemniki narażone na działanie ognia.

5.1 Środki gaśnicze

Stosowne środki gaśnicze: Przy doborze środków gaszenia pożaru uwzględnić ewentualną obecność innych środków chemicznych.

Niewłaściwe środki gaśnicze: Nie dotyczy

5.2 Szczególne zagrożenia związane z substancją lub mieszaniną: Pożar lub zbyt wysoka temperatura może uwalniać niebezpieczne produkty rozkładu.

5.3 Informacje dla straży pożarnej

Szczególne procedury gaśnicze: Nie stwierdzono nadzwyczajnych zagrożeń pożarem ani wybuchem.

Specjalny sprzęt ochronny dla strażaków: W pomieszczeniach zamkniętych strażacy muszą stosować normalne środki ochrony, w tym ubrania ognioodporne, hełmy z osłoną twarzy, rękawice, buty gumowe oraz autonomiczne aparaty oddechowe (SCBA).

SEKCJA 6: Postępowanie w przypadku niezamierzonego uwolnienia do środowiska

6.1 Indywidualne środki ostrożności, wyposażenie ochronne i procedury w sytuacjach awaryjnych: Skontaktować się z odpowiednimi władzami w przypadku przedostania się do kanalizacji albo środowiska wodnego. Podczas usuwania wycieków w dusznych miejscach zapewnić odpowiedni sprzęt ochrony osobistej (łącznie ze sprzętem ochrony dróg oddechowych).

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

6.1.1 Dla osób nienależących do personelu udzielającego pomocy:	Brak danych.
6.1.2 Dla osób udzielających pomocy:	Brak danych.
6.2 Środki ostrożności w zakresie ochrony środowiska:	Unikać uwolnienia do środowiska.
6.3 Metody i materiały zapobiegające rozprzestrzenianiu się skażenia i służące do usuwania skażenia:	Rozsypany lub rozlany materiał zebrać chłonnym materiałem. Zapobiegać przedostawaniu się odpływów do studzienek ściekowych, kanalizacji lub strumieni. Informacje na temat środków ochrony indywidualnej patrz SEKCJA 8. Usuwanie odpadów - patrz pkt 13.
6.4 Odniesienia do innych sekcji:	Brak danych.

SEKCJA 7: Postępowanie z substancjami i mieszaninami oraz ich magazynowanie

7.1 Środki ostrożności dotyczące bezpiecznego postępowania

Środki techniczne (np. wentylacja miejscowa i ogólna):	Brak szczególnych wymagań w normalnych warunkach stosowania i przy wystarczającej wentylacji.
Postępowanie:	Nie jeść i nie pić oraz nie palić tytoniu podczas stosowania preparatu. Stosować się do zaleceń producenta. Stosować wymagane środki ochrony indywidualnej.
Działania mające na celu unikanie kontaktu:	Brak danych.

7.2 Warunki bezpiecznego magazynowania, w tym informacje dotyczące wszelkich wzajemnych niezgodności

Bezpieczne warunki przechowywania:	Przechowywać w chłodnym, suchym miejscu. Przechowywać pojemnik szczelnie zamknięty.
Bezpieczne materiały na opakowania:	Brak danych.

7.3 Szczególne zastosowanie(-a) końcowe:	Produkt przeznaczony wyłącznie do użytku przemysłowego i zawodowego. Przed użyciem przeczytać etykietę.
---	---

SEKCJA 8: Kontrola narażenia/środki ochrony indywidualnej

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

8.1 Parametry dotyczące kontroli

Dopuszczalne Wartości Narażenia Zawodowego

Żadnemu ze składników nie przypisano limitów ekspozycji.

Wartości Graniczne dla Działania Biologicznego.

Nie ma biologicznych granic narażenia dla składnika(-ów).

Pochodna ilość nieszkodliwa dla środowiska - wartości

Spostrzeżenia: Pochodna ilość nieszkodliwa dla środowiska - wartości

Krytyczny składnik	Rodzaj	Droga napromieniowania	Ostrzeżenia zagrożenia zdrowia	Spostrzeżenia
Chlorek Sodu	Ogólna populacja	Inhalation	Układowe, długotrwałe; 443,28 mg/m ³	Toksyczność dawki powtarzalnej
	Pracownicy	Inhalation	Układowe, długotrwałe; 2068,62 mg/m ³	Toksyczność dawki powtarzalnej
	Pracownicy	Inhalation	Układowe, krótkotrwałe; 2068,62 mg/m ³	Toksyczność dawki powtarzalnej
	Ogólna populacja	Inhalation	Układowe, krótkotrwałe; 443,28 mg/m ³	Toksyczność dawki powtarzalnej
	Ogólna populacja	Doustnie	Układowe, długotrwałe; 126,65 mg/kg	Toksyczność dawki powtarzalnej
	Pracownicy	Skórny	Układowe, długotrwałe; 295,52 mg/kg	Toksyczność dawki powtarzalnej
	Pracownicy	Skórny	Układowe, krótkotrwałe; 295,52 mg/kg	Toksyczność dawki powtarzalnej
	Ogólna populacja	Doustnie	Układowe, krótkotrwałe; 126,65 mg/kg	Toksyczność dawki powtarzalnej
	Ogólna populacja	Skórny	Układowe, krótkotrwałe; 126,65 mg/kg	Toksyczność dawki powtarzalnej
	Ogólna populacja	Skórny	Układowe, długotrwałe; 126,65 mg/kg	Toksyczność dawki powtarzalnej

Phosphoric acid, sodium salt (1:2)	Pracownicy	Oczy	Lokalne;	Nie zidentyfikowano zagrożenia
	Pracownicy	Inhalation	Układowe, długotrwałe; 4,07 mg/m ³	Toksyczność dawki powtarzalnej
	Ogólna populacja	Inhalation	Układowe, długotrwałe; 3,04 mg/m ³	Toksyczność dawki powtarzalnej
	Ogólna populacja	Inhalation	Układowe, długotrwałe; 6,63 mg/m ³	Toksyczność dawki powtarzalnej
	Pracownicy	Inhalation	Układowe, długotrwałe; 15,47 mg/m ³	Toksyczność dawki powtarzalnej

Sodium azide (Na(N ₃))	Pracownicy	Inhalation	Układowe, długotrwałe; 0,164 mg/m ³	Toksyczność dawki powtarzalnej
	Ogólna populacja	Oczy	Lokalne;	Nie zidentyfikowano zagrożenia
	Ogólna populacja	Inhalation	Układowe, długotrwałe; 29 lg/m ³	Toksyczność dawki powtarzalnej
	Pracownicy	Oczy	Lokalne;	Nie zidentyfikowano zagrożenia
	Pracownicy	Skórny	Układowe, długotrwałe; 0,0467 mg/kg	Toksyczność dawki powtarzalnej
	Ogólna populacja	Doustnie	Układowe, długotrwałe; 0,0167 mg/kg	Toksyczność dawki powtarzalnej

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Ogólna populacja	Skórny	Układowe, długotrwałe; 0,0167 mg/kg	Toksyczność dawki powtarzalnej
dwuwodorofofosforan potasu	Pracownicy	Oczy	Lokalne;	Nie zidentyfikowano zagrożenia
	Ogólna populacja	Oczy	Lokalne;	Nie zidentyfikowano zagrożenia
	Pracownicy	Inhalation	Układowe, długotrwałe; 14,82 mg/m ³	Toksyczność dawki powtarzalnej
	Ogólna populacja	Inhalation	Układowe, długotrwałe; 6,35 mg/m ³	Toksyczność dawki powtarzalnej
Potassium chloride (KCl)	Pracownicy	Inhalation	Układowe, długotrwałe; 1064 mg/m ³	Toksyczność dawki powtarzalnej
	Ogólna populacja	Inhalation	Układowe, długotrwałe; 273 mg/m ³	Toksyczność dawki powtarzalnej
	Ogólna populacja	Inhalation	Układowe, krótkotrwałe; 1365 mg/m ³	Toksyczność dawki powtarzalnej
	Pracownicy	Inhalation	Układowe, krótkotrwałe; 5320 mg/m ³	Toksyczność dawki powtarzalnej
	Ogólna populacja	Doustnie	Układowe, krótkotrwałe; 455 mg/kg	Toksyczność dawki powtarzalnej
	Ogólna populacja	Skórny	Układowe, długotrwałe; 182 mg/kg	Toksyczność dawki powtarzalnej
	Ogólna populacja	Doustnie	Układowe, długotrwałe; 91 mg/kg	Toksyczność dawki powtarzalnej
	Pracownicy	Skórny	Układowe, długotrwałe; 303 mg/kg	Toksyczność dawki powtarzalnej
	Pracownicy	Skórny	Układowe, krótkotrwałe; 910 mg/kg	Toksyczność dawki powtarzalnej
	Ogólna populacja	Skórny	Układowe, krótkotrwałe; 910 mg/kg	Toksyczność dawki powtarzalnej

Przewidywane stężenie nieszkodliwe dla środowiska - wartości

Spostrzeżenia: Przewidywane stężenie nieszkodliwe dla środowiska - wartości

Krytyczny składnik	Dziedzina środowiska	Przewidywane stężenie nieszkodliwe dla środowiska - wartości	Spostrzeżenia
Chlorek Sodu	Ziemia	4,86 mg/kg	
	Środowisko wodne (woda słodka)	5 mg/l	
	Zakład oczyszczania ścieków	500 mg/l	
Phosphoric acid, sodium salt (1:2)	Zakład oczyszczania ścieków	50 mg/l	
	Środowisko wodne (woda słodka)	0,05 mg/l	
	Środowisko wodne (woda morska)	0,005 mg/l	
Sodium azide (Na(N ₃))	Środowisko wodne (woda morska)	15 ng/l	
	Zakład oczyszczania ścieków	30 l/g/l	
	Osad (słodka woda)	0,0167 mg/kg	

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Środowisko wodne (woda słodka)	0,35 lg/l	
	Osad (woda morska)	0,00072 mg/kg	

Potassium chloride (KCl)	Środowisko wodne (woda morska)	0,1 mg/l	
	Zakład oczyszczania ścieków	10 mg/l	
	Środowisko wodne (woda słodka)	0,1 mg/l	

8.2 Kontrola narażenia

Stosowne Techniczne Środki Kontroli:

Brak szczególnych wymagań w normalnych warunkach stosowania i przy wystarczającej wentylacji.

Indywidualne środki ochrony takie jak osobiste wyposażenie ochronne

Ochrona oczu lub twarzy:

Zakładać okulary ochronne z osłonami bocznymi (lub gogle).

Środki ochrony rąk:

Materiał: Rękawice odporne na chemikalia
Dodatkowe informacje: Po kontakcie z substancją umyć ręce.
Materiał: Przy wyborze odpowiednich rękawic należy kierować się zaleceniami dostawcy.

Ochrona skóry oraz ciała:

Nosić fartuch laboratoryjny lub podobną odzież ochronną.

Ochrona dróg oddechowych:

Jeśli środki techniczne nie utrzymują stężeń w powietrzu poniżej zalecanych granic (tam gdzie to dotyczy), albo na akceptowalnym poziomie (w krajach gdzie nie ustalono dopuszczalnych granic narażenia), należy używać respiratora zgodnego ze stosownymi przepisami.

Higieniczne środki ostrożności:

Przestrzegać podstawowych zasad BHP.

Nadzór w zakresie ochrony środowiska:

Brak danych.

SEKCJA 9: Właściwości fizyczne i chemiczne

9.1 Informacje na temat podstawowych właściwości fizycznych i chemicznych

Postać fizyczna

Stan skupienia:

ciekły

Forma:

ciekły

Kolor:

Bezbarwny do żółtego

Zapach:

Bezwonny

Próg zapachu:

Brak danych.

Temperatura krzepnięcia:

Brak danych.

Temperatura wrzenia:

Brak danych.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Zapalność:	Brak danych.
Górny/dolny próg palności lub progi wybuchowości	
Granica wybuchowości - górna:	Brak danych.
Granica wybuchowości - dolna:	Brak danych.
Temperatura zapłonu:	Brak danych.
Temperatura samozapłonu:	Brak danych.
Temperatura rozkładu:	Brak danych.
pH:	7,20 - 7,60
Lepkość	
Lepkość, dynamiczna:	Brak danych.
Lepkość, kinematyczna:	Brak danych.
Upływ czasu:	Brak danych.
Rozpuszczalność	
Rozpuszczalność w wodzie:	Rozpuszczalny
Rozpuszczalność (w innych rozpuszczalnikach):	Brak danych.
Szybkość rozpuszczania:	Brak danych.
Współczynnik podziału (n-oktanol/woda):	Brak danych.
Stabilność dyspersyjna:	Brak danych.
Prężność par:	Brak danych.
Gęstość względna:	Brak danych.
Gęstość:	Brak danych.
Gęstość usypowa:	Brak danych.
Gęstość względna par:	Brak danych.

9.2 Inne informacje

Brak dostępnych danych

SEKCJA 10: Stabilność i reaktywność

10.1 Reaktywność:	Substancja jest stabilna w normalnych warunkach.
10.2 Stabilność chemiczna:	Substancja jest stabilna w normalnych warunkach.
10.3 Możliwość występowania niebezpiecznych reakcji:	Stabilny

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

- 10.4 **Warunki, których należy unikać:** Nie narażać na działanie wysokich temperatur oraz bezpośrednie działanie światła słonecznego.
- 10.5 **Materiały niezgodne:** Metale Materiał reagujący z wodą.
- 10.6 **Niebezpieczne produkty rozkładu:** Substancja jest trwała; jednak przy podgrzewaniu może się rozkładać.

SEKCJA 11: Informacje toksykologiczne

11.1 Informacje na temat klas zagrożenia zdefiniowanych w rozporządzeniu (WE) nr 1272/2008

Wdychanie: Brak danych.

Kontakt ze skórą: Brak danych.

Kontakt z oczami: Brak danych.

Spożycie: Brak danych.

Informacje dotyczące prawdopodobnych dróg narażenia

Toksyczność ostra (wymienić wszystkie możliwe drogi narażenia)

Połknięcie

Produkt: Nie sklasyfikowano na toksyczność ostrą w oparciu o dostępne dane.

Kontakt ze skórą

Produkt: Nie sklasyfikowano na toksyczność ostrą w oparciu o dostępne dane.

Wdychanie

Produkt: Nie sklasyfikowano na toksyczność ostrą w oparciu o dostępne dane.

Toksyczność dla dawki powtarzalnej

Produkt: Brak danych.

Działanie żrące/drażniące na skórę

Produkt: Brak danych.

Poważne uszkodzenie oczu/działanie drażniące na oczy

Produkt: Brak danych.

Działanie uczulające na drogi oddechowe lub skórę

Produkt: Brak danych.

Rakotwórczość

Produkt: Brak danych.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Działanie mutagenne na komórki rozrodcze

In vitro

Produkt: Brak danych.

In vivo

Produkt: Brak danych.

Szkodliwe działanie na rozrodczość

Produkt: Brak danych.

Działanie toksyczne na narządy docelowe - narażenie jednorazowe

Produkt: Brak danych.

Działanie toksyczne na narządy docelowe - narażenie powtarzalne

Produkt: Brak danych.

Zagrożenie spowodowane aspiracją

Produkt: Brak danych.

11.2 Informacje o innych zagrożeniach

Właściwości zaburzające funkcjonowanie układu hormonalnego

Produkt: Ta substancja/mieszanina nie zawiera składników uważanych za posiadające właściwości endokrynnie czynne wobec środowiska, według Artykułu REACH 57(f), Regulacji Komisji (UE) 2018/605 lub Regulacji Delegowanej Komisji (UE) 2017/2100.;

Inne informacje

Produkt: Brak danych.

SEKCJA 12: Informacje ekologiczne

12.1 Toksyczność:

Ostre zagrożenie dla środowiska wodnego:

Ryby

Produkt: Brak danych.

Bezkęgowce Wodne

Produkt: Brak danych.

Toksyczność dla roślin wodnych

Produkt: Brak danych.

Toksyczność dla mikroorganizmów

Produkt: Brak danych.

Chroniczne zagrożenie dla środowiska wodnego:

Ryby

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Produkt: Brak danych.

Bezkęgowce Wodne

Produkt: Brak danych.

Toksyczność dla roślin wodnych

Produkt: Brak danych.

Toksyczność dla mikroorganizmów

Produkt: Brak danych.

12.2 Trwałość i zdolność do rozkładu

Biodegradacja

Produkt: Brak danych.

Stosunek BZT/ChZT

Produkt: Brak danych.

12.3 Zdolność do bioakumulacji

Współczynnik Biokoncentracji (BCF)

Produkt: Brak danych.

Współczynnik Podziału n-oktanol / woda (log Kow)

Produkt: Brak danych.

12.4 Mobilność w glebie:

Produkt Brak danych.

12.5 Wyniki oceny właściwości PBT i vPvB:

Produkt Brak danych.

12.6 Właściwości zaburzające funkcjonowanie układu hormonalnego:

Produkt: Ta substancja/mieszanina nie zawiera składników uważanych za posiadające właściwości endokrynnie czynne wobec środowiska, według Artykułu REACH 57(f), Regulacji Komisji (UE) 2018/605 lub Regulacji Delegowanej Komisji (UE) 2017/2100.

12.7 Inne szkodliwe skutki działania:

Inne zagrożenia

Produkt: Brak danych.

SEKCJA 13: Postępowanie z odpadami

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

13.1 Metody unieszkodliwiania odpadów

Informacje ogólne:	Odpady i pozostałości utylizować zgodnie z lokalnie obowiązującymi przepisami.
Sposób usuwania:	Utylizować odpady we właściwym zakładzie i zgodnie z obowiązującymi ustawami i przepisami oraz charakterystyką substancji w chwili utylizacji.
Zanieczyszczone Opakowanie:	Zawartość/pojemnik usuwać do odpowiedniego zakładu utylizacyjnego zgodnie z obowiązującym prawem i przepisami oraz charakterystyką produktu w chwili usuwania.

SEKCJA 14: Informacje dotyczące transportu

ADR

14.1 Numer UN lub numer identyfikacyjny ID:	Nie objęto przepisami
14.2 Prawidłowa nazwa przewozowa UN:	Nie objęto przepisami
14.3 Klasa(-y) zagrożenia w transporcie	
Klasa:	Nie objęto przepisami
Etykieta(y):	Nie objęto przepisami
Nr zagrożenia (ADR):	Nie objęto przepisami
Kod ograniczeń przejazdu przez tunele:	Nie objęto przepisami
14.4 Grupa pakowania:	Nie objęto przepisami
Ograniczona ilość	Nie objęto przepisami
Wyłączona ilość	Nie objęto przepisami
14.5 Zagrożenia dla środowiska	Nie objęto przepisami
14.6 Szczególne środki ostrożności dla użytkowników:	Nie objęto przepisami

ADN

14.1 Numer UN lub numer identyfikacyjny ID:	Nie objęto przepisami
14.2 Prawidłowa nazwa przewozowa UN:	Nie objęto przepisami
14.3 Klasa(-y) zagrożenia w transporcie	
Klasa:	Nie objęto przepisami
Etykieta(y):	Nie objęto przepisami
Nr zagrożenia (ADR):	Nie objęto przepisami
Kod ograniczeń przejazdu przez tunele:	Nie objęto przepisami
14.4 Grupa pakowania:	Nie objęto przepisami
Ograniczona ilość	Nie objęto przepisami
Wyłączona ilość	Nie objęto przepisami
14.5 Szczególne środki ostrożności dla użytkowników:	Nie objęto przepisami

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

RID

- 14.1 Numer UN lub numer identyfikacyjny ID: Nie objęto przepisami
14.2 Prawidłowa nazwa przewozowa UN: Nie objęto przepisami
14.3 Klasa(-y) zagrożenia w transporcie
 Klasa: Nie objęto przepisami
 Etykieta(y): Nie objęto przepisami
14.4 Grupa pakowania: Nie objęto przepisami
 Ograniczona ilość: Nie objęto przepisami
 Wyłączona ilość: Nie objęto przepisami
14.5 Zagrożenia dla środowiska: Nie objęto przepisami
14.6 Szczególne środki ostrożności dla użytkowników: Nie objęto przepisami

IMDG

- 14.1 Numer UN lub numer identyfikacyjny ID: Nie objęto przepisami
14.2 Prawidłowa nazwa przewozowa UN: Nie objęto przepisami
14.3 Klasa(-y) zagrożenia w transporcie
 Klasa: Nie objęto przepisami
 Etykieta(y): Nie objęto przepisami
 EmS No.: Nie objęto przepisami
14.4 Grupa pakowania: Nie objęto przepisami
 Ograniczona ilość: Nie objęto przepisami
 Wyłączona ilość: Nie objęto przepisami
14.5 Zagrożenia dla środowiska: Nie objęto przepisami
14.6 Szczególne środki ostrożności dla użytkowników: Nie objęto przepisami

IATA

- 14.1 Numer UN lub numer identyfikacyjny ID: Nie objęto przepisami
14.2 Prawidłowa nazwa przewozowa UN: Nie objęto przepisami
14.3 Klasa(-y) zagrożenia w transporcie
 Klasa: Nie objęto przepisami
 Etykieta(y): Nie objęto przepisami
14.4 Grupa pakowania: Nie objęto przepisami
 Samoloty pasażerskie i towarowe : Nie objęto przepisami
 Ograniczona ilość: Nie objęto przepisami
 Wyłączona ilość: Nie objęto przepisami
14.5 Zagrożenia dla środowiska: Nie objęto przepisami
14.6 Szczególne środki ostrożności dla użytkowników: Nie objęto przepisami

14.7 Transport morski luzem zgodnie z instrumentami IMO

Nie ma zastosowania do produktu w stanie takim, w jakim dostarczono.

SEKCJA 15: Informacje dotyczące przepisów prawnych

15.1 Przepisy prawne dotyczące bezpieczeństwa, zdrowia i ochrony środowiska specyficzne dla substancji lub mieszaniny:

Przepisy UE

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Rozporządzenie 1005/2009/WE w sprawie substancji zubożających warstwę ozonową, Załącznik I, substancje kontrolowane: Brak albo brak w ilościach objętych przepisami prawa.

ROZPORZĄDZENIE (WE) NR 1907/2006 (REACH), ZAŁĄCZNIK XIV WYKAZ SUBSTANCJI PODLEGAJĄCYCH PROCEDURZE UDZIELANIA ZEZWOLEŃ: Brak albo brak w ilościach objętych przepisami prawa.

Rozporządzenie (WE) Nr 2019/1021/WE dotyczące trwałych zanieczyszczeń organicznych, z późniejszymi zmianami: Brak albo brak w ilościach objętych przepisami prawa.

UE. DYREKTYWA PARLAMENTU EUROPEJSKIEGO I RADY 2010/75/UE w sprawie emisji przemysłowych (zintegrowane zapobieganie zanieczyszczeniom i ich kontrola), ZAŁĄCZNIK I, L 334/17: Brak albo brak w ilościach objętych przepisami prawa.

Rozporządzenie (UE) nr 649/2012, dotyczące wywozu i przywozu niebezpiecznych chemikaliów, Załącznik I, Część 1 z późniejszymi zmianami: Brak albo brak w ilościach objętych przepisami prawa.

Rozporządzenie (UE) nr 649/2012, dotyczące wywozu i przywozu niebezpiecznych chemikaliów, Załącznik I, Część 2 z późniejszymi zmianami: Brak albo brak w ilościach objętych przepisami prawa.

Rozporządzenie (UE) nr 649/2012, dotyczące wywozu i przywozu niebezpiecznych chemikaliów, Załącznik I, Część 3 z późniejszymi zmianami: Brak albo brak w ilościach objętych przepisami prawa.

Rozporządzenie (UE) nr 649/2012, dotyczące wywozu i przywozu niebezpiecznych chemikaliów, Załącznik V, z późniejszymi zmianami: Brak albo brak w ilościach objętych przepisami prawa.

Lista kandydacka do autoryzacji substancji wzbudzających szczególnie duże obawy (SVHC) EU REACH: Brak albo brak w ilościach objętych przepisami prawa.

Rozporządzenie (WE) Nr 1907/2006, Załącznik XVII: Ograniczenia dotyczące produkcji, wprowadzania do obrotu i stosowania niektórych niebezpiecznych substancji, preparatów i wyrobów: Dyrektywa Nr 2004/37/WE w sprawie ochrony pracowników przed zagrożeniem dotyczącym narażenia na działanie czynników rakotwórczych lub mutagenów podczas pracy.: Brak albo brak w ilościach objętych przepisami prawa.

Dyrektywa Rady 92/85/EWG z dnia 19 października 1992 r. w sprawie wprowadzenia środków służących wspieraniu poprawy w miejscu pracy bezpieczeństwa i zdrowia pracownic w ciąży, pracownic, które niedawno rodziły, i pracownic karmiących piersią: Brak albo brak w ilościach objętych przepisami prawa.

UE. Dyrektywa 2012/18/EU (SEVESO III) w sprawie kontroli zagrożeń poważnymi awariami związanymi z substancjami niebezpiecznymi, Załącznik I: Brak albo brak w ilościach objętych przepisami prawa.

ROZPORZĄDZENIE (WE) NR 166/2006 w sprawie ustanowienia Europejskiego Rejestru Uwalniania i Transferu Zanieczyszczeń, ZAŁĄCZNIK II: Zanieczyszczenia: Brak albo brak w ilościach objętych przepisami prawa.

Dyrektywa 98/24/WE dotycząca ochrony pracowników przed zagrożeniami odnoszącymi się do środków chemicznych w miejscu pracy:

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Nazwa chemiczna	Nr CAS	Stężenie
azydek sodu	26628-22-8	0 - <0,1%

15.2 Ocena bezpieczeństwa chemicznego: Nie dokonano oceny bezpieczeństwa chemicznego.

Przepisy międzynarodowe

Protokół montreal

Nie dotyczy

Konwencji Sztokholmskiej

Nie dotyczy

Konwencja rotterdamska

Nie dotyczy

Protokół z Kioto

Nie dotyczy

SEKCJA 16: Inne informacje

Skróty i skrótownice:

Brak danych.

Odniesienia do kluczowej literatury i źródeł danych:

Europejska Agencja Chemikaliów (ECHA): informacje o substancjach chemicznych.

Brzmienie zwrotów w sekcji 2 i 3

: żadne

Informacje o szkoleniu:

Brak danych.

Nr karty charakterystyki (SDS):

UN0000000000000332773-4012-1-01

**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

**Ograniczenie
odpowiedzialności:**

Zastrzeżenia prawne: Informacje zawarte w niniejszym dokumencie zostały uzyskane z różnych źródeł i są uznawane za poprawne w dacie ich publikacji. BD ani podmioty zależne BD nie ponoszą jednak żadnej odpowiedzialności za dokładność lub kompletność tych informacji. Ostateczna decyzja co do przydatności materiałów do określonego celu leży w wyłącznej gestii użytkownika. Wszystkie materiały mogą stanowić nieznane zagrożenie i powinny być używane z ostrożnością. O ile niektóre zagrożenia zostały opisane w niniejszym dokumencie, BD nie może zagwarantować, że są to jedyne istniejące zagrożenia. BD przekazuje kartę charakterystyki w formie elektronicznej, aby zawarte w niej informacje były łatwiej dostępne. Ze względu na możliwość wystąpienia błędów podczas transmisji BD nie gwarantuje kompletności ani dokładności wspomnianych informacji.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SAFETY DATA SHEET

According to Regulation (EC) No. 1907/2006 (REACH) Article 31, Annex II as amended

SECTION 1: Identification of the substance/mixture and of the company/undertaking

Product identifier

Product No.:	Product name:	Common name(s), synonym(s)
332771	BD® CD3 (SK7) PerCP-Cy5.5	No data available
332772	BD® CD4 (SK3) PerCP-Cy5.5	No data available
332780	BD® CD19 (SJ25C1) PerCP-Cy5.5	No data available
332781	BD® CD20 (L27) PerCP-Cy5.5	No data available
333146	BD® CD33 (P67.6) PerCP-Cy5.5	No data available
333148	BD® CD41a (HIP8) PerCP-Cy5.5	No data available
333153	BD® CD79a (HM47) PerCP-Cy5.5	No data available
333950	BD® CD117 (104D2) PerCP-Cy5.5	No data available
338440	BD® CD16 (3G8) PerCP-Cy5.5	No data available
339216	BD® Anti-HLA-DR (L243) PerCP-Cy5.5	No data available
341050	BD® CD8 (SK1) PerCP-Cy5.5	No data available
341107	BD® CD138 (MI15) PerCP-Cy5.5	No data available
341109	BD® CD5 (L17F12) PerCP-Cy5.5	No data available
345766	BD® CD3 (SK7) PerCP-Cy5.5	No data available
345770	BD® CD4 (SK3) PerCP	No data available
345774	BD® CD8 (SK1) PerCP	No data available
345778	BD® CD19 (4G7) PerCP	No data available
345786	BD® CD14 (MφP9) PerCP	No data available
345790	BD® CD19 (SJ25C1) PerCP	No data available
345794	BD® CD20 (L27) PerCP	No data available
345803	BD® CD34 (8G12) PerCP	No data available



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

347222	BD® CD34 (8G12) PerCP-Cy5.5	No data available
347402	BD® Anti-HLA-DR (L243) PerCP	No data available
347408	BD® CD61 (RUU-PL7F12) PerCP	No data available

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses: Scientific and industrial laboratory use. For In Vitro Diagnostic Use.

Uses advised against: None known.

1.3 Details of the supplier of the safety data sheet

Manufacturer

Becton Dickinson France S.A.S. Belgian Branch
Erembodegem-Dorp 86
9320 Erembodegem
Belgium

Telephone: 32 2 400 98 95

Fax: 32 2 401 70 94

Contact Person: BD Biosciences - Centralized European Office

Regulatory Compliance Department

E-mail: help.biosciences@europe.bd.com

1.4 Emergency telephone number: 32 2 400 98 95

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

The product has not been classified as hazardous according to the legislation in force.

Classification according to Regulation (EC) No 1272/2008 as amended.

Not classified

2.2 Label Elements Not applicable



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

2.3 Other hazards

Endocrine disrupting properties-Toxicity

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Endocrine disrupting properties-Ecotoxicity

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

General information: No hazardous ingredients.

SECTION 4: First aid measures

4.1 Description of first aid measures

General information:	Get medical attention if symptoms occur.
Inhalation:	Provide fresh air, warmth and rest, preferably in comfortable upright sitting position.
Skin Contact:	Wash contact areas with soap and water. Remove contaminated clothing. Launder contaminated clothing before reuse.
Eye contact:	Immediately flush with plenty of water for at least 15 minutes. If easy to do, remove contact lenses.
Ingestion:	Call a physician or poison control center immediately. Only induce vomiting at the instruction of medical personnel. Never give anything by mouth to an unconscious person.
Personal Protection for First-aid Responders:	No data available.

4.2 Most important symptoms and effects, both acute and delayed

Symptoms:	No data available.
Hazards:	No data available.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

4.3 Indication of immediate medical attention and special treatment needed

Treatment: No data available.

SECTION 5: Firefighting measures

General Fire Hazards: Extinguish all ignition sources. Avoid sparks, flames, heat and smoking. Ventilate. Use water spray to keep fire-exposed containers cool.

5.1 Extinguishing media

Suitable extinguishing media: Use fire-extinguishing media appropriate for surrounding materials.

Unsuitable extinguishing media: Not applicable

5.2 Special hazards arising from the substance or mixture: Fire or excessive heat may produce hazardous decomposition products.

5.3 Advice for firefighters

Special fire-fighting procedures: No unusual fire or explosion hazards noted.

Special protective equipment for fire-fighters: Firefighters must use standard protective equipment including flame retardant coat, helmet with face shield, gloves, rubber boots, and in enclosed spaces, SCBA.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures: Contact local authorities in case of spillage to drain/aquatic environment. Ensure suitable personal protection (including respiratory protection) during removal of spillages in a confined area.

6.1.1 For non-emergency personnel: No data available.

6.1.2 For emergency responders: No data available.

6.2 Environmental Precautions: Avoid release to the environment.

6.3 Methods and material for containment and cleaning up: Absorb spillage with suitable absorbent material. Prevent runoff from entering drains, sewers, or streams. See Section 8 of the SDS for Personal Protective Equipment. For waste disposal, see section 13 of the SDS.

6.4 Reference to other sections: No data available.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SECTION 7: Handling and storage

7.1 Precautions for safe handling

- Technical measures (e.g. Local and general ventilation):** No special requirements under ordinary conditions of use and with adequate ventilation.
- Safe handling advice:** When using do not eat, drink or smoke. Read and follow manufacturer's recommendations. Use personal protective equipment as required.
- Contact avoidance measures:** No data available.

7.2 Conditions for safe storage, including any incompatibilities

- Safe storage conditions:** Store in a cool, dry place. Keep container tightly closed.
- Safe packaging materials:** No data available.

- 7.3 Specific end use(s):** Reserved for industrial and professional use. Read label before use.

SECTION 8: Exposure controls/personal protection

8.1 Control Parameters

Occupational Exposure Limits

None of the components have assigned exposure limits.

Biological Limit Values

No biological exposure limits noted for the ingredient(s).

DNEL-Values

Remarks: DNEL-Values

Critical component	Type	Route of Exposure	Health Warnings	Remarks
Sodium Chloride (NaCl)	General population	Inhalation	Systemic, long-term; 443,28 mg/m3	Repeated dose toxicity
	Workers	Inhalation	Systemic, long-term; 2068,62 mg/m3	Repeated dose toxicity
	Workers	Inhalation	Systemic, short-term; 2068,62 mg/m3	Repeated dose toxicity
	General population	Inhalation	Systemic, short-term; 443,28 mg/m3	Repeated dose toxicity
	General population	Oral	Systemic, long-term; 126,65 mg/kg	Repeated dose toxicity
	Workers	Dermal	Systemic, long-term; 295,52 mg/kg	Repeated dose toxicity
	Workers	Dermal	Systemic, short-term; 295,52 mg/kg	Repeated dose toxicity



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	General population	Oral	Systemic, short-term; 126,65 mg/kg	Repeated dose toxicity
	General population	Dermal	Systemic, short-term; 126,65 mg/kg	Repeated dose toxicity
	General population	Dermal	Systemic, long-term; 126,65 mg/kg	Repeated dose toxicity

Phosphoric acid, sodium salt (1:2)	Workers	Eyes	Local effect;	No hazard identified
	Workers	Inhalation	Systemic, long-term; 4,07 mg/m ³	Repeated dose toxicity
	General population	Inhalation	Systemic, long-term; 3,04 mg/m ³	Repeated dose toxicity
	General population	Inhalation	Systemic, long-term; 6,63 mg/m ³	Repeated dose toxicity
	Workers	Inhalation	Systemic, long-term; 15,47 mg/m ³	Repeated dose toxicity

Sodium azide (Na(N ₃))	Workers	Inhalation	Systemic, long-term; 0,164 mg/m ³	Repeated dose toxicity
	General population	Eyes	Local effect;	No hazard identified
	General population	Inhalation	Systemic, long-term; 29 µg/m ³	Repeated dose toxicity
	Workers	Eyes	Local effect;	No hazard identified
	Workers	Dermal	Systemic, long-term; 0,0467 mg/kg	Repeated dose toxicity
	General population	Oral	Systemic, long-term; 0,0167 mg/kg	Repeated dose toxicity
	General population	Dermal	Systemic, long-term; 0,0167 mg/kg	Repeated dose toxicity

Phosphoric acid, potassium salt (1:1)	Workers	Eyes	Local effect;	No hazard identified
	General population	Eyes	Local effect;	No hazard identified
	Workers	Inhalation	Systemic, long-term; 14,82 mg/m ³	Repeated dose toxicity
	General population	Inhalation	Systemic, long-term; 6,35 mg/m ³	Repeated dose toxicity

Potassium chloride (KCl)	Workers	Inhalation	Systemic, long-term; 1064 mg/m ³	Repeated dose toxicity
	General population	Inhalation	Systemic, long-term; 273 mg/m ³	Repeated dose toxicity
	General population	Inhalation	Systemic, short-term; 1365 mg/m ³	Repeated dose toxicity
	Workers	Inhalation	Systemic, short-term; 5320 mg/m ³	Repeated dose toxicity
	General population	Oral	Systemic, short-term; 455 mg/kg	Repeated dose toxicity
	General population	Dermal	Systemic, long-term; 182 mg/kg	Repeated dose toxicity
	General population	Oral	Systemic, long-term; 91 mg/kg	Repeated dose toxicity
	Workers	Dermal	Systemic, long-term; 303 mg/kg	Repeated dose toxicity
	Workers	Dermal	Systemic, short-term; 910 mg/kg	Repeated dose toxicity
	General population	Dermal	Systemic, short-term; 910 mg/kg	Repeated dose toxicity

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

PNEC-Values

Remarks: PNEC-Values

Critical component	Environmental compartment	PNEC-Values	Remarks
Sodium Chloride (NaCl)	Soil	4,86 mg/kg	
	Aquatic (freshwater)	5 mg/l	
	Sewage treatment plant	500 mg/l	
Phosphoric acid, sodium salt (1:2)	Sewage treatment plant	50 mg/l	
	Aquatic (freshwater)	0,05 mg/l	
	Aquatic (marine water)	0,005 mg/l	
Sodium azide (Na(N ₃))	Aquatic (marine water)	15 ng/l	
	Sewage treatment plant	30 µg/l	
	Sediment (freshwater)	0,0167 mg/kg	
	Aquatic (freshwater)	0,35 µg/l	
	Sediment (marine water)	0,00072 mg/kg	
Potassium chloride (KCl)	Aquatic (marine water)	0,1 mg/l	
	Sewage treatment plant	10 mg/l	
	Aquatic (freshwater)	0,1 mg/l	

8.2 Exposure controls

Appropriate Engineering Controls:

No special requirements under ordinary conditions of use and with adequate ventilation.

Individual protection measures, such as personal protective equipment

Eye/face protection:

Wear safety glasses with side shields (or goggles).

Hand Protection:

Material: Chemical resistant gloves
Additional Information: Wash hands after contact.
Material: Suitable gloves can be recommended by the glove supplier.

Skin and Body Protection:

Wear a lab coat or similar protective clothing.

Respiratory Protection:

If engineering controls do not maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (in countries where exposure limits have not been established), an approved respirator must be worn.

Hygiene measures:

Observe good industrial hygiene practices.

Environmental Controls:

No data available.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance

Physical state:	liquid
Form:	liquid
Color:	Colorless to brown
Odor:	Odorless
Odor Threshold:	No data available.
Freezing point:	No data available.
Boiling Point:	No data available.
Flammability:	No data available.

Upper/lower limit on flammability or explosive limits

Explosive limit - upper:	No data available.
Explosive limit - lower:	No data available.
Flash Point:	No data available.
Auto-ignition temperature:	No data available.
Decomposition Temperature:	No data available.
pH:	7,20 - 7,60

Viscosity

Dynamic viscosity:	No data available.
Kinematic viscosity:	No data available.
Flow Time:	No data available.

Solubility(ies)

Solubility in Water:	Soluble
Solubility (other):	No data available.
Dissolution Rate:	No data available.

Partition coefficient (n-octanol/water):	No data available.
Dispersion Stability:	No data available.

Vapor pressure:	No data available.
Relative density:	No data available.
Density:	No data available.
Bulk density:	No data available.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Relative vapor density: No data available.

9.2 Other information
No data available

SECTION 10: Stability and reactivity

- | | |
|---|---|
| 10.1 Reactivity: | Material is stable under normal conditions. |
| 10.2 Chemical Stability: | Material is stable under normal conditions. |
| 10.3 Possibility of hazardous reactions: | Stable |
| 10.4 Conditions to avoid: | Avoid exposure to high temperatures or direct sunlight. |
| 10.5 Incompatible Materials: | Metals. Water reactive material. |
| 10.6 Hazardous Decomposition Products: | Stable; however, may decompose if heated. |

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Inhalation:	No data available.
Skin Contact:	No data available.
Eye contact:	No data available.
Ingestion:	No data available.

Information on likely routes of exposure

Acute toxicity (list all possible routes of exposure)

Oral Product:	Not classified for acute toxicity based on available data.
Dermal Product:	Not classified for acute toxicity based on available data.
Inhalation Product:	Not classified for acute toxicity based on available data.
Repeated dose toxicity Product:	No data available.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Skin Corrosion/Irritation

Product: No data available.

Serious Eye Damage/Eye Irritation

Product: No data available.

Respiratory or Skin Sensitization

Product: No data available.

Carcinogenicity

Product: No data available.

Germ Cell Mutagenicity

In vitro

Product: No data available.

In vivo

Product: No data available.

Reproductive toxicity

Product: No data available.

Specific Target Organ Toxicity - Single Exposure

Product: No data available.

Specific Target Organ Toxicity - Repeated Exposure

Product: No data available.

Aspiration Hazard

Product: No data available.

11.2 Information on other hazards

Endocrine disrupting properties

Product: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.;

Other information

Product: No data available.

SECTION 12: Ecological information

12.1 Toxicity:

Acute hazards to the aquatic environment:

Fish

Product: No data available.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Aquatic Invertebrates

Product: No data available.

Toxicity to Aquatic Plants

Product: No data available.

Toxicity to microorganisms

Product: No data available.

Chronic hazards to the aquatic environment:

Fish

Product: No data available.

Aquatic Invertebrates

Product: No data available.

Toxicity to Aquatic Plants

Product: No data available.

Toxicity to microorganisms

Product: No data available.

12.2 Persistence and Degradability

Biodegradation

Product: No data available.

BOD/COD Ratio

Product: No data available.

12.3 Bioaccumulative potential

Bioconcentration Factor (BCF)

Product: No data available.

Partition Coefficient n-octanol / water (log Kow)

Product: No data available.

12.4 Mobility in soil:

Product No data available.

12.5 Results of PBT and vPvB assessment:

Product No data available.

12.6 Endocrine disrupting properties:



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Product: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects:

Other hazards

Product: No data available.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

General information: Dispose of waste and residues in accordance with local authority requirements.

Disposal methods: Dispose of waste at an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

Contaminated Packaging: Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

SECTION 14: Transport information

ADR

14.1 UN number or ID number: Not regulated.
14.2 UN Proper Shipping Name: Not regulated.
14.3 Transport Hazard Class(es)
 Class: Not regulated.
 Label(s): Not regulated.
 Hazard No. (ADR): Not regulated.
 Tunnel restriction code: Not regulated.
14.4 Packing Group: Not regulated.
 Limited quantity: Not regulated.
 Excepted quantity: Not regulated.
14.5 Environmental Hazards: Not regulated.
14.6 Special precautions for user: Not regulated.

ADN

14.1 UN number or ID number: Not regulated.
14.2 UN Proper Shipping Name: Not regulated.
14.3 Transport Hazard Class(es)
 Class: Not regulated.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Label(s):	Not regulated.
Hazard No. (ADR):	Not regulated.
Tunnel restriction code:	Not regulated.
14.4 Packing Group:	Not regulated.
Limited quantity	Not regulated.
Excepted quantity	Not regulated.
14.5 Special precautions for user:	Not regulated.

RID

14.1 UN number or ID number:	Not regulated.
14.2 UN Proper Shipping Name:	Not regulated.
14.3 Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
14.4 Packing Group:	Not regulated.
Limited quantity	Not regulated.
Excepted quantity	Not regulated.
14.5 Environmental Hazards	Not regulated.
14.6 Special precautions for user:	Not regulated.

IMDG

14.1 UN number or ID number:	Not regulated.
14.2 UN Proper Shipping Name:	Not regulated.
14.3 Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
EmS No.:	Not regulated.
14.4 Packing Group:	Not regulated.
Limited quantity	Not regulated.
Excepted quantity	Not regulated.
14.5 Environmental Hazards	Not regulated.
14.6 Special precautions for user:	Not regulated.

IATA

14.1 UN number or ID number:	Not regulated.
14.2 UN Proper Shipping Name:	Not regulated.
14.3 Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
14.4 Packing Group:	Not regulated.
Passenger and cargo aircraft :	Not regulated.
Limited quantity	Not regulated.
Excepted quantity	Not regulated.
14.5 Environmental Hazards	Not regulated.
14.6 Special precautions for user:	Not regulated.

14.7 Maritime transport in bulk according to IMO instruments

Not applicable for product as supplied.

SECTION 15: Regulatory information

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture:

EU Regulations

Regulation 1005/2009/EC on substances that deplete the ozone layer, Annex I, Controlled Substances: None present or none present in regulated quantities.

EU. REACH Annex XIV, Substances Subject to Authorization: None present or none present in regulated quantities.

EU. Regulation 2019/1021/EU on persistent organic pollutants (POPs) (recast), as amended: None present or none present in regulated quantities.

EU. Directive 2010/75/EU on Industrial Emissions (IPPC), Annex II, L 334/17: None present or none present in regulated quantities.

Regulation (EU) No. 649/2012 concerning the export and import of dangerous chemicals, Annex I, Part 1 as amended: None present or none present in regulated quantities.

Regulation (EU) No. 649/2012 concerning the export and import of dangerous chemicals, Annex I, Part 2 as amended: None present or none present in regulated quantities.

Regulation (EU) No. 649/2012 concerning the export and import of dangerous chemicals, Annex I, Part 3 as amended: None present or none present in regulated quantities.

Regulation (EU) No. 649/2012 concerning the export and import of dangerous chemicals, Annex V as amended: None present or none present in regulated quantities.

EU. REACH Candidate List of Substances of Very High Concern for Authorization (SVHC): None present or none present in regulated quantities.

Regulation (EC) No. 1907/2006 Annex XVII Substances subject to restriction on marketing and use: Directive 2004/37/EC on the protection of workers from the risks related to exposure to carcinogens and mutagens at work.: None present or none present in regulated quantities.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breast feeding.: None present or none present in regulated quantities.

EU. Directive 2012/18/EU (SEVESO III) on major accident hazards involving dangerous substances, Annex I: None present or none present in regulated quantities.

EU. Regulation No. 166/2006 PRTR (Pollutant Release and Transfer Registry), Annex II: Pollutants: None present or none present in regulated quantities.

Directive 98/24/EC on the protection of workers from the risks related to chemical agents at work:

Chemical name	CAS-No.	Concentration
sodium azide	26628-22-8	0 - <0,1%

15.2 Chemical safety

No Chemical Safety Assessment has been carried out.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

assessment:

International regulations

Montreal protocol

Not applicable

Stockholm convention

Not applicable

Rotterdam convention

Not applicable

Kyoto protocol

Not applicable

SECTION 16: Other information

Abbreviations and acronyms:

No data available.

Key literature references and sources for data: European Chemicals Agency (ECHA): Information on Chemicals.

Wording of the statements in section 2 and 3

: none

Training information: No data available.

SDS No.: UN000000000000332771-4012-1-01

Disclaimer: Disclaimer:
The information contained herein has been obtained from various sources and is believed to be correct as of the date issued. However, neither BD nor any of its subsidiaries assumes any liabilities whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability for a particular use of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist. BD provides SDS in electronic form so the information may be more easily accessed. Due to the possibility of errors during transmission, BD makes no representations as to the completeness or accuracy of the information.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

FICHE DE DONNÉES DE SÉCURITÉ

Conformément au règlement (CE) n° 1907/2006 (REACH) Article 31, Annexe II et ses modifications

RUBRIQUE 1 — Identification de la substance/du mélange et de la société/de l'entreprise

Identificateur de produit

N° de produit:	Nom du produit:	Nom(s) commun(s) et synonyme(s)
333952	BD® CD33 (P67.6) PE-Cy7	Aucune donnée disponible
335821	BD® CD2 (L303.1) PE-Cy7	Aucune donnée disponible
335822	BD® CD8 (SK1) PE-Cy7	Aucune donnée disponible
335823	BD® CD16 (B73.1) PE-Cy7	Aucune donnée disponible
335824	BD® CD25 (2A3) PE-Cy7	Aucune donnée disponible
335825	BD® CD38 (HB7) PE-Cy7	Aucune donnée disponible
335826	BD® CD56 (NCAM16.2) PE-Cy7	Aucune donnée disponible
335828	BD® CD20 (L27) PE-Cy7	Aucune donnée disponible
335830	BD® Anti-HLA-DR (L243) PE-Cy7	Aucune donnée disponible
338439	BD® CD13 (L138) PE-Cy7	Aucune donnée disponible
339217	BD® CD117 (104D2) PE-Cy7	Aucune donnée disponible
341111	BD® CD3 (SK7) PE-Cy7	Aucune donnée disponible
341112	BD® CD10 (HI10a) PE-Cy7	Aucune donnée disponible
341113	BD® CD19 (SJ25C1) PE-Cy7	Aucune donnée disponible
348808	BD® Mouse IgG1 (X40) PE-Cy7	Aucune donnée disponible
348809	BD® CD4 (SK3) PE-Cy7	Aucune donnée disponible
348810	BD® CD5 (L17F12) PE-Cy7	Aucune donnée disponible
348811	BD® CD34 (8G12) PE-Cy7	Aucune donnée disponible
337186	088100015566	Aucune donnée disponible

1.2 Utilisations identifiées pertinentes de la substance ou du mélange et utilisations déconseillées

Utilisations identifiées:

Utilisation en laboratoire scientifique et industriel. À usage diagnostique



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

in vitro.

Usages déconseillés: Aucuns connus.

1.3 Renseignements concernant le fournisseur de la fiche de données de sécurité

Fabricant

Becton Dickinson France S.A.S. Belgian Branch
Erembodegem-Dorp 86
9320 Erembodegem
Belgium

Téléphone: 32 2 400 98 95
Télécopie :: 32 2 401 70 94

Personne à contacter: BD Biosciences - Centralized European Office
Regulatory Compliance Department
E-mail: help.biosciences@europe.bd.com

1.4 Numéro d'appel d'urgence: 32 2 400 98 95

RUBRIQUE 2 — Identification des dangers

2.1 Classification de la substance ou du mélange

Le produit n'a pas été classé comme dangereux selon la législation en vigueur.

Classification selon le règlement (CE) n° 1272/2008 et ses amendements.

Non classé

2.2 Éléments d'étiquetage Non applicable

2.3 Autres dangers

Propriétés perturbant le système endocrinien-Toxicité

La substance/Le mélange ne contient pas de composants considérés comme ayant des propriétés perturbatrices du système endocrinien selon l'article 57(f) de REACH ou le règlement délégué de la Commission (UE) 2017/2100 ou le règlement de la Commission (EU) 2018/605 à des niveaux de 0,1 % ou plus.

Propriétés perturbant le système endocrinien-Écotoxicité

La substance/Le mélange ne contient pas de composants considérés comme ayant des propriétés perturbatrices du système endocrinien selon l'article 57(f) de REACH ou le règlement délégué de la Commission (UE) 2017/2100 ou le règlement de la Commission (EU) 2018/605 à des niveaux de 0,1 % ou plus.

RUBRIQUE 3 — Composition/informations sur les composants



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

3.2 Mélanges

Informations générales: Pas d'ingrédient dangereux.

RUBRIQUE 4 — Premiers secours

4.1 Description des mesures de premiers secours

Informations générales: Consulter un médecin en cas de symptômes.

Inhalation: Garder à l'air frais, au chaud et au repos, de préférence en position assise, confortable, le dos droit.

Contact avec la Peau: Laver les zones de contact à l'eau et au savon. Enlever les vêtements contaminés. Laver les vêtements contaminés avant réutilisation.

Contact oculaire: Rincer immédiatement à grande eau pendant au moins 15 minutes. Enlever les lentilles de contact si cela est facile à faire.

Ingestion: Contacter immédiatement un médecin ou un centre antipoison. Faire vomir uniquement à la demande du personnel médical. Ne jamais faire ingérer quoi que ce soit à une personne inconsciente.

Protection individuelle des secouristes: Aucune information disponible.

4.2 Principaux symptômes et effets, aigus et différés

Symptômes: Aucune information disponible.

Dangers: Aucune information disponible.

4.3 Indication d'un besoin médical immédiat et traitement spécial requis

Traitement: Aucune information disponible.

RUBRIQUE 5 — Mesures de lutte contre l'incendie

Dangers d'Incendie Généraux: Éteindre toutes les sources d'ignition. Éviter les étincelles, les flammes et la chaleur. Ne pas fumer. Aérer. Garder au frais les récipients exposés à l'incendie à l'aide d'un jet d'eau.

5.1 Moyens d'extinction

Moyens d'extinction appropriés: Choisir le moyen d'extinction de l'incendie en tenant compte d'autres produits chimiques éventuels.

Moyens d'extinction inappropriés: Non applicable



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

5.2 Dangers particuliers résultant de la substance ou du mélange:

En cas d'incendie ou de chaleur excessive, des produits de décomposition dangereux peuvent se former.

5.3 Conseils aux pompiers

Procédures spéciales de lutte contre l'incendie:

Aucun risque exceptionnel d'incendie et d'explosion.

Équipement de protection spécial pour le personnel préposé à la lutte contre le feu:

Les pompiers doivent porter un équipement de protection standard, notamment vêtement ignifuge, casque à masque facial, gants, bottes en caoutchouc et, dans les espaces clos, un appareil respiratoire autonome.

RUBRIQUE 6 — Mesures à prendre en cas de dispersion accidentelle

6.1 Précautions individuelles, équipement de protection et procédures d'urgence:

Contactez les autorités locales en cas de déversement dans les égouts/le milieu aquatique. Assurer une protection individuelle appropriée (y compris une protection respiratoire) durant l'enlèvement du produit répandu dans une atmosphère confinée.

6.1.1 Pour les non-secouristes:

Aucune information disponible.

6.1.2 Pour les secouristes:

Aucune information disponible.

6.2 Précautions pour la protection de l'environnement:

Éviter le rejet dans l'environnement.

6.3 Méthodes et matériel de confinement et de nettoyage:

Absorber les déversements avec une matière absorbante adéquate. Éviter que les écoulements ne pénètrent les canalisations, les égouts ou les rivières. Voir l'équipement de protection individuelle à la Section 8. Pour l'élimination des déchets, voir la section 13 de la FDS.

6.4 Référence à d'autres rubriques:

Aucune information disponible.

RUBRIQUE 7 — Manipulation et stockage

7.1 Précautions à prendre pour une manipulation sans danger

Mesures techniques (par exemple ventilation localisée et générale):

Aucune exigence particulière dans les conditions normales d'utilisation avec une ventilation suffisante.

Conseil de manipulation en toute sécurité:

Ne pas manger, ne pas boire et ne pas fumer pendant l'utilisation. Lire et suivre les recommandations du fabricant. Utiliser l'équipement de protection individuel requis.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Mesures à prendre pour éviter le contact: Aucune information disponible.

7.2 Conditions d'un stockage sûr, y compris les éventuelles incompatibilités

Conditions d'un stockage sûr: Conserver dans un endroit frais et sec. Conserver le récipient bien fermé.
Matériaux d'emballage sûrs: Aucune information disponible.

7.3 Utilisation(s) finale(s) particulière(s): Réservé aux utilisateurs industriels et professionnels. Lire l'étiquette avant utilisation.

RUBRIQUE 8 — Contrôles de l'exposition/protection individuelle

8.1 Paramètres de contrôle

Valeurs Limites d'Exposition Professionnelle

Aucun des composants ne fait l'objet d'une limite d'exposition.

Valeurs Limites Biologiques

Aucune limite d'exposition biologique n'est indiquée pour ce ou ces composants.

Valeurs de DNEL

Remarques: Valeurs de DNEL

Composant critique	Type	Voie d'exposition	Avertissements sanitaires	Remarques
Sodium Chloride (NaCl)	Population en général	Inhalation	Systémique, long terme; 443,28 mg/m3	Toxicité à des doses répétées
	Travailleurs	Inhalation	Systémique, long terme; 2068,62 mg/m3	Toxicité à des doses répétées
	Travailleurs	Inhalation	Systémique, court terme; 2068,62 mg/m3	Toxicité à des doses répétées
	Population en général	Inhalation	Systémique, court terme; 443,28 mg/m3	Toxicité à des doses répétées
	Population en général	Oral	Systémique, long terme; 126,65 mg/kg	Toxicité à des doses répétées
	Travailleurs	Cutané	Systémique, long terme; 295,52 mg/kg	Toxicité à des doses répétées
	Travailleurs	Cutané	Systémique, court terme; 295,52 mg/kg	Toxicité à des doses répétées
	Population en général	Oral	Systémique, court terme; 126,65 mg/kg	Toxicité à des doses répétées
	Population en général	Cutané	Systémique, court terme; 126,65 mg/kg	Toxicité à des doses répétées
	Population en général	Cutané	Systémique, long terme; 126,65 mg/kg	Toxicité à des doses répétées
Phosphoric acid, sodium salt (1:2)	Travailleurs	Yeux	Effet local;	Aucun danger identifié
	Travailleurs	Inhalation	Systémique, long terme; 4,07 mg/m3	Toxicité à des doses répétées

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Population en général	Inhalation	Systémique, long terme; 3,04 mg/m ³	Toxicité à des doses répétées
	Population en général	Inhalation	Systémique, long terme; 6,63 mg/m ³	Toxicité à des doses répétées
	Travailleurs	Inhalation	Systémique, long terme; 15,47 mg/m ³	Toxicité à des doses répétées

Sodium azide (Na(N ₃))	Travailleurs	Inhalation	Systémique, long terme; 0,164 mg/m ³	Toxicité à des doses répétées
	Population en général	Yeux	Effet local;	Aucun danger identifié
	Population en général	Inhalation	Systémique, long terme; 29 µg/m ³	Toxicité à des doses répétées
	Travailleurs	Yeux	Effet local;	Aucun danger identifié
	Travailleurs	Cutané	Systémique, long terme; 0,0467 mg/kg	Toxicité à des doses répétées
	Population en général	Oral	Systémique, long terme; 0,0167 mg/kg	Toxicité à des doses répétées
	Population en général	Cutané	Systémique, long terme; 0,0167 mg/kg	Toxicité à des doses répétées

Potassium chloride (KCl)	Travailleurs	Inhalation	Systémique, long terme; 1064 mg/m ³	Toxicité à des doses répétées
	Population en général	Inhalation	Systémique, long terme; 273 mg/m ³	Toxicité à des doses répétées
	Population en général	Inhalation	Systémique, court terme; 1365 mg/m ³	Toxicité à des doses répétées
	Travailleurs	Inhalation	Systémique, court terme; 5320 mg/m ³	Toxicité à des doses répétées
	Population en général	Oral	Systémique, court terme; 455 mg/kg	Toxicité à des doses répétées
	Population en général	Cutané	Systémique, long terme; 182 mg/kg	Toxicité à des doses répétées
	Population en général	Oral	Systémique, long terme; 91 mg/kg	Toxicité à des doses répétées
	Travailleurs	Cutané	Systémique, long terme; 303 mg/kg	Toxicité à des doses répétées
	Travailleurs	Cutané	Systémique, court terme; 910 mg/kg	Toxicité à des doses répétées
	Population en général	Cutané	Systémique, court terme; 910 mg/kg	Toxicité à des doses répétées

Phosphoric acid, potassium salt (1:1)	Travailleurs	Yeux	Effet local;	Aucun danger identifié
	Population en général	Yeux	Effet local;	Aucun danger identifié
	Travailleurs	Inhalation	Systémique, long terme; 14,82 mg/m ³	Toxicité à des doses répétées
	Population en général	Inhalation	Systémique, long terme; 6,35 mg/m ³	Toxicité à des doses répétées

Valeurs de PNEC

Remarques: Valeurs de PNEC

Composant critique	Milieu environnemental	Valeurs de PNEC	Remarques
Sodium Chloride (NaCl)	Terre	4,86 mg/kg	
	Aquatique (eau douce)	5 mg/l	
	Station d'épuration des eaux usées	500 mg/l	

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Phosphoric acid, sodium salt (1:2)	Station d'épuration des eaux usées	50 mg/l	
	Aquatique (eau douce)	0,05 mg/l	
	Aquatique (eau de mer)	0,005 mg/l	
Sodium azide (Na(N ₃))	Aquatique (eau de mer)	15 ng/l	
	Station d'épuration des eaux usées	30 µg/l	
	Sédiment (eau douce)	0,0167 mg/kg	
	Aquatique (eau douce)	0,35 µg/l	
	Sédiments (eau de mer)	0,00072 mg/kg	
Potassium chloride (KCl)	Aquatique (eau de mer)	0,1 mg/l	
	Station d'épuration des eaux usées	10 mg/l	
	Aquatique (eau douce)	0,1 mg/l	

8.2 Contrôles de l'exposition

Contrôles Techniques Appropriés:

Aucune exigence particulière dans les conditions normales d'utilisation avec une ventilation suffisante.

Mesures de protection individuelle, telles que les équipements de protection individuelle

Protection des yeux/du visage:

Porter des lunettes de sécurité à écrans latéraux ou des lunettes étanches.

Protection des Mains:

Matière: Gants de protection chimique
Informations supplémentaires: Se laver les mains après tout contact.
Matière: Suivre les recommandations du fournisseur pour le choix des gants adéquats.

Protection de la peau et du corps:

Porter une blouse de laboratoire ou un vêtement de protection semblable.

Protection respiratoire:

Si les mesures techniques de contrôle de l'exposition ne permettent pas de maintenir les concentrations émises dans l'air en-dessous des limites d'exposition recommandées ou à un niveau acceptable (dans les pays où des limites d'exposition n'ont pas été établies), un appareil respiratoire homologué doit être porté.

Mesures d'hygiène:

Se conformer aux bonnes pratiques d'hygiène industrielle.

Contrôles environnementaux:

Aucune information disponible.

RUBRIQUE 9 — Propriétés physiques et chimiques

9.1 Informations sur les propriétés physiques et chimiques essentielles

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Aspect

État: liquide
Forme: liquide
Couleur: Violet pâle

Odeur: Inodore

Seuil olfactif: Aucune information disponible.

Point de congélation: Aucune information disponible.

Point d'ébullition: Aucune information disponible.

Inflammabilité: Aucune information disponible.

Limites supérieures/inférieures d'inflammabilité ou d'explosivité

Limites d'explosivité - supérieure (%) : Aucune information disponible.

Limites d'explosivité - inférieure (%): Aucune information disponible.

Point d'éclair: Aucune information disponible.

Température d'auto-inflammation: Aucune information disponible.

Température de décomposition: Aucune information disponible.

pH: 7,20 - 7,60

Viscosité

Viscosité, dynamique: Aucune information disponible.

Viscosité, cinématique: Aucune information disponible.

Durée d'écoulement: Aucune information disponible.

Solubilités

Solubilité dans l'eau: Soluble

Solubilité (autre): Aucune information disponible.

Taux de dissolution: Aucune information disponible.

Coefficient de partition (n-octanol/eau): Aucune information disponible.

Stabilité de la dispersion: Aucune information disponible.

Pression de vapeur: Aucune information disponible.

Densité relative: Aucune information disponible.

Densité: Aucune information disponible.

Densité apparente: Aucune information disponible.

Densité de vapeur relative: Aucune information disponible.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

9.2 Autres informations

Donnée non disponible

RUBRIQUE 10 — Stabilité et réactivité

10.1	Réactivité:	Ce produit est stable dans des conditions normales.
10.2	Stabilité chimique:	Ce produit est stable dans des conditions normales.
10.3	Possibilité de réactions dangereuses:	Stable
10.4	Conditions à éviter:	Éviter l'exposition aux températures élevées ou à la lumière du jour.
10.5	Matières incompatibles:	Métaux. Matières réactives avec l'eau.
10.6	Produits de décomposition dangereux:	Stable ; cependant, peut se décomposer en cas d'élévation de température.

RUBRIQUE 11 — Informations toxicologiques

11.1 Informations sur les classes de danger telles que définies dans le règlement (CE) no 1272/2008

Inhalation:	Aucune information disponible.
Contact avec la Peau:	Aucune information disponible.
Contact oculaire:	Aucune information disponible.
Ingestion:	Aucune information disponible.

Informations sur les voies d'exposition probables

Toxicité aiguë (répertorier toutes les voies d'exposition possibles)

Ingestion	
Produit:	Non classé comme présentant une toxicité aiguë d'après les données disponibles.
Contact avec la peau	
Produit:	Non classé comme présentant une toxicité aiguë d'après les données disponibles.
Inhalation	
Produit:	Non classé comme présentant une toxicité aiguë d'après les données

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

disponibles.

Toxicité à dose répétée

Produit: Aucune information disponible.

Corrosion ou Irritation de la Peau

Produit: Aucune information disponible.

Blessure ou Irritation Grave des Yeux

Produit: Aucune information disponible.

Sensibilisation Respiratoire ou Cutanée

Produit: Aucune information disponible.

Cancérogénicité

Produit: Aucune information disponible.

Mutagénicité des Cellules Germinales

In vitro

Produit: Aucune information disponible.

In vivo

Produit: Aucune information disponible.

Toxicité pour la reproduction

Produit: Aucune information disponible.

Toxicité Spécifique au Niveau de l'Organe Cible- Exposition Unique

Produit: Aucune information disponible.

Toxicité Spécifique au Niveau de l'Organe Cible- Expositions répétées

Produit: Aucune information disponible.

Risque d'Aspiration

Produit: Aucune information disponible.

11.2 Informations sur les autres dangers

Propriétés perturbant le système endocrinien

Produit: La substance/Le mélange ne contient pas de composants considérés comme ayant des propriétés perturbatrices du système endocrinien selon l'article 57(f) de REACH ou le règlement délégué de la Commission (UE) 2017/2100 ou le règlement de la Commission (EU) 2018/605 à des niveaux de 0,1 % ou plus.;

Autres informations

Produit: Aucune information disponible.

RUBRIQUE 12 — Informations écologiques

12.1 Toxicité:

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Risques aigus pour l'environnement aquatique:

Poisson

Produit: Aucune information disponible.

Invertébrés Aquatiques

Produit: Aucune information disponible.

Toxicité pour les plantes aquatiques

Produit: Aucune information disponible.

Toxicité pour les microorganismes

Produit: Aucune information disponible.

Risques chroniques pour l'environnement aquatique:

Poisson

Produit: Aucune information disponible.

Invertébrés Aquatiques

Produit: Aucune information disponible.

Toxicité pour les plantes aquatiques

Produit: Aucune information disponible.

Toxicité pour les microorganismes

Produit: Aucune information disponible.

12.2 Persistance et dégradabilité

Biodégradation

Produit: Aucune information disponible.

Rapport DBO/DCO

Produit: Aucune information disponible.

12.3 Potentiel de bioaccumulation

Facteur de Bioconcentration (BCF)

Produit: Aucune information disponible.


Coefficient de Partage n-octanol/eau (log Kow)

Produit: Aucune information disponible.

12.4 Mobilité dans le sol:

Produit Aucune information disponible.

12.5 Résultats des évaluations PBT et vPvB:



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Produit	Aucune information disponible.
---------	--------------------------------

12.6 Propriétés perturbant le système endocrinien:

Produit: La substance/Le mélange ne contient pas de composants considérés comme ayant des propriétés perturbatrices du système endocrinien selon l'article 57(f) de REACH ou le règlement délégué de la Commission (UE) 2017/2100 ou le règlement de la Commission (EU) 2018/605 à des niveaux de 0.1 % ou plus.

12.7 Autres effets néfastes:

Autres dangers	
Produit:	Aucune information disponible.

RUBRIQUE 13 — Considérations relatives à l'élimination

13.1 Méthodes de traitement des déchets

Informations générales: Éliminer les rejets et les déchets conformément aux règlements municipaux.

Méthodes d'élimination: Éliminer les déchets dans une installation de traitement et d'élimination des déchets appropriée conformément aux lois et aux réglementations en vigueur et en fonction des caractéristiques du produit au moment de l'élimination.

Emballages Contaminés: Éliminer le contenu/récipient dans une installation de traitement et d'élimination appropriée, conformément aux lois et aux réglementations en vigueur et en fonction des caractéristiques du produit au moment de l'élimination.

RUBRIQUE 14 — Informations relatives au transport

ADR

14.1 Numéro ONU ou numéro d'identification:	Non réglementé.
14.2 Désignation officielle de transport de l'ONU:	Non réglementé.
14.3 Classe(s) de danger pour le transport	
Classe:	Non réglementé.
Étiquettes:	Non réglementé.
N° de danger (ADR):	Non réglementé.
Code de restriction en tunnel:	Non réglementé.
14.4 Groupe d'emballage:	Non réglementé.
Quantité limitée	Non réglementé.
Quantité exemptée	Non réglementé.

**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

- | | |
|---|-----------------|
| 14.5 Dangers pour l'environnement | Non réglementé. |
| 14.6 Précautions particulières à prendre par l'utilisateur: | Non réglementé. |

ADN

- | | |
|---|-----------------|
| 14.1 Numéro ONU ou numéro d'identification: | Non réglementé. |
| 14.2 Désignation officielle de transport de l'ONU: | Non réglementé. |
| 14.3 Classe(s) de danger pour le transport | |
| Classe: | Non réglementé. |
| Étiquettes: | Non réglementé. |
| N° de danger (ADR): | Non réglementé. |
| Code de restriction en tunnel: | Non réglementé. |
| 14.4 Groupe d'emballage: | Non réglementé. |
| Quantité limitée | Non réglementé. |
| Quantité exemptée | Non réglementé. |
| 14.5 Précautions particulières à prendre par l'utilisateur: | Non réglementé. |

RID

- | | |
|---|-----------------|
| 14.1 Numéro ONU ou numéro d'identification: | Non réglementé. |
| 14.2 Désignation officielle de transport de l'ONU: | Non réglementé. |
| 14.3 Classe(s) de danger pour le transport | |
| Classe: | Non réglementé. |
| Étiquettes: | Non réglementé. |
| 14.4 Groupe d'emballage: | Non réglementé. |
| Quantité limitée | Non réglementé. |
| Quantité exemptée | Non réglementé. |
| 14.5 Dangers pour l'environnement | Non réglementé. |
| 14.6 Précautions particulières à prendre par l'utilisateur: | Non réglementé. |

IMDG

- | | |
|--|-----------------|
| 14.1 Numéro ONU ou numéro d'identification: | Non réglementé. |
| 14.2 Désignation officielle de transport de l'ONU: | Non réglementé. |
| 14.3 Classe(s) de danger pour le transport | |
| Classe: | Non réglementé. |
| Étiquettes: | Non réglementé. |
| N° d'urgence: | Non réglementé. |
| 14.4 Groupe d'emballage: | Non réglementé. |
| Quantité limitée | Non réglementé. |
| Quantité exemptée | Non réglementé. |
| 14.5 Dangers pour l'environnement | Non réglementé. |

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

14.6 Précautions particulières à prendre par l'utilisateur: Non réglementé.

IATA

14.1 Numéro ONU ou numéro d'identification: Non réglementé.

14.2 Désignation officielle de transport de l'ONU: Non réglementé.

14.3 Classe(s) de danger pour le transport
Classe: Non réglementé.
Étiquettes: Non réglementé.

14.4 Groupe d'emballage: Non réglementé.
Aéronefs de transport de passagers et de marchandises : Non réglementé.
Quantité limitée Non réglementé.
Quantité exemptée Non réglementé.

14.5 Dangers pour l'environnement Non réglementé.

14.6 Précautions particulières à prendre par l'utilisateur: Non réglementé.

14.7 Transport maritime en vrac conformément aux instruments de l'OMI

Non applicable pour le produit tel qu'il est fourni.

RUBRIQUE 15 — Informations relatives à la réglementation

15.1 Réglementations/législation particulières à la substance ou au mélange en matière de sécurité, de santé et d'environnement:

Règlements UE

Règlement 1005/2009/CE relatif à des substances qui appauvrissent la couche d'ozone, Annexe I, Substances réglementées: Aucun présent ou aucun présent dans des quantités réglementées.

RÈGLEMENT (CE) No 1907/2006 (REACH), ANNEXE XIV LISTE DES SUBSTANCES SOUMISES À AUTORISATION: Aucun présent ou aucun présent dans des quantités réglementées.

Règlement (CE) 2019/1021 concernant les polluants organiques persistants (refonte), et ses modifications: Aucun présent ou aucun présent dans des quantités réglementées.

UE. Directive 2010/75/UE relative aux émissions industrielles (prévention et réduction intégrées de la pollution), Annexe II, L 334/17: Aucun présent ou aucun présent dans des quantités réglementées.

Règlement (UE) n° 649/2012 concernant les exportations et importations de produits chimiques dangereux, Annexe I, partie 1 et ses modifications: Aucun présent ou aucun présent dans des quantités réglementées.

Règlement (UE) n° 649/2012 concernant les exportations et importations de produits chimiques dangereux, Annexe I, partie 2 et ses modifications: Aucun présent ou aucun présent dans des quantités réglementées.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Règlement (UE) n° 649/2012 concernant les exportations et importations de produits chimiques dangereux, Annexe I, partie 3 et ses modifications: Aucun présent ou aucun présent dans des quantités réglementées.

Règlement (UE) n° 649/2012 concernant les exportations et importations de produits chimiques dangereux, Annexe V et ses modifications: Aucun présent ou aucun présent dans des quantités réglementées.

UE. Liste des substances extrêmement préoccupantes candidates en vue d'une autorisation (SVHC), REACH: Aucun présent ou aucun présent dans des quantités réglementées.

Règlement (CE) n° 1907/2006, Annexe XVII, Substances soumises à restrictions de mise sur le marché et d'utilisation:

Directive 2004/37/CE concernant la protection des travailleurs contre les risques liés à l'exposition à des agents cancérigènes ou mutagènes au travail.: Aucun présent ou aucun présent dans des quantités réglementées.

Directive 92/85/CEE concernant la mise en oeuvre de mesures visant à promouvoir l'amélioration de la sécurité et de la santé des travailleuses enceintes, accouchées ou allaitantes au travail.: Aucun présent ou aucun présent dans des quantités réglementées.

DIRECTIVE 2012/18/UE concernant la maîtrise des dangers liés aux accidents majeurs impliquant des substances dangereuses, ANNEXE I: Aucun présent ou aucun présent dans des quantités réglementées.

RÈGLEMENT (CE) No 166/2006 concernant la création d'un registre européen des rejets et des transferts de polluants, ANNEXE II: Polluants: Aucun présent ou aucun présent dans des quantités réglementées.

Directive 98/24/CEE concernant la protection de la santé et de la sécurité des travailleurs contre les risques liés à des agents chimiques sur le lieu de travail:

Désignation chimique	N° CAS	Concentration
azoture de sodium	26628-22-8	0 - <0,1%

Réglementations nationales

INRS, Maladies professionnelles, Tableau des maladies professionnelles
classé: A

15.2 Évaluation de la sécurité chimique: Aucune évaluation de la sécurité chimique n'a été mise en œuvre.

Règlements internationaux

Protocole de Montréal
Non applicable



**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Convention de Stockholm
Non applicable

Convention de Rotterdam
Non applicable

Protocole de Kyoto
Non applicable

RUBRIQUE 16 — Autres informations

Abréviations et acronymes:

Aucune information disponible.

**Principales références de la
littérature et sources de
données:**

Agence européenne des produits chimiques (ECHA) : Informations sur les
substances chimiques.

Texte des mentions dans les sections 2 et 3

: aucune

Informations de formation: Aucune information disponible.

FDS n°: UN0000000000000333952-4012-1-01

Avis de non-responsabilité:

Disclaimer:

Les renseignements contenus dans le présent document ont été
obtenus de diverses sources et l'on croit être justes à la date
d'émission. Toutefois, ni BD ni aucune de ses succursales ne peut
assumer toute responsabilité quant à l'exactitude ou l'exhaustivité
des informations contenues dans ce document. La décision finale
d'aptitude à une utilisation particulière de tout matériel est la
responsabilité exclusive de l'utilisateur. Tous les matériaux peuvent
présenter des dangers inconnus et doivent être utilisés avec
prudence. Bien que certains dangers soient décrits aux présentes,
nous ne pouvons pas garantir que ce sont les seuls risques qui
existent. BD fournit FS sous forme électronique si l'information peut
être plus facilement accessible. En raison de la possibilité d'erreurs
lors de la transmission, BD ne fait aucune déclaration quant à
l'exhaustivité ou l'exactitude de l'information.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SCHEDA DI DATI DI SICUREZZA

A norma del Regolamento (CE) n. 1907/2006 (REACH) Articolo 31, Allegato II e successive modifiche

SEZIONE 1: identificazione della sostanza/miscela e della società/impresa

Identificatore del prodotto

Num. de prodotto:	Nome del prodotto:	Denominazione(i) comune(i), sinonimo(i)
332777	BD® CD10 (HI10a) APC	Nessun dato disponibile.
332791	BD® Anti-TdT (E17-1519) APC	Nessun dato disponibile.
333143	BD® CD11b (D12) APC	Nessun dato disponibile.
333144	BD® CD11c (S-HCL-3) APC	Nessun dato disponibile.
333145	BD® CD22 (S-HCL-1) APC	Nessun dato disponibile.
333154	BD® CD79a (HM47) APC	Nessun dato disponibile.
333233	BD® CD117 (104D2) APC	Nessun dato disponibile.
333951	BD® CD14 (MφP9) APC-Cy7	Nessun dato disponibile.
335036	BD® CD23 (EBVCS-5) APC	Nessun dato disponibile.
335829	BD® CD20 (L27) APC-Cy7	Nessun dato disponibile.
335831	BD® Anti-HLA-DR (L243) APC-Cy7	Nessun dato disponibile.
335834	BD® CD79b (SN8) APC	Nessun dato disponibile.
337447	BD® CD71 (L01.1) APC	Nessun dato disponibile.
340907	BD® CD25 (2A3) APC	Nessun dato disponibile.
340908	BD® CD20 (L27) APC	Nessun dato disponibile.
341024	BD® CD2 (L303.1) APC	Nessun dato disponibile.
341027	BD® CD56 (NCAM16.2) APC	Nessun dato disponibile.
341108	BD® Anti-Kappa (TB 28-2) APC	Nessun dato disponibile.
341110	BD® CD3 (SK7) APC-Cy7	Nessun dato disponibile.
341115	BD® CD4 (SK3) APC-Cy7	Nessun dato disponibile.
345767	BD® CD3 (SK7) APC	Nessun dato disponibile.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

345771	BD® CD4 (SK3) APC	Nessun dato disponibile.
345775	BD® CD8 (SK1) APC	Nessun dato disponibile.
345783	BD® CD5 (L17F12) APC	Nessun dato disponibile.
345787	BD® CD14 APC	Nessun dato disponibile.
345791	BD® CD19 (SJ25C1) APC	Nessun dato disponibile.
345800	BD® CD33 (P67.6) APC	Nessun dato disponibile.
345804	BD® CD34 (8G12) APC	Nessun dato disponibile.
345807	BD® CD38 (HB7) APC	Nessun dato disponibile.
345818	BD® Mouse IgG1 (X40) APC	Nessun dato disponibile.
347216	BD® CD138 (MI15) APC	Nessun dato disponibile.
347403	BD® Anti-HLA-DR (L243) APC-H7	Nessun dato disponibile.
348812	BD® Mouse IgG1 (X40) APC-Cy7	Nessun dato disponibile.
348813	BD® CD8 (SK1) APC-Cy7	Nessun dato disponibile.
348814	BD® CD19 (SJ25C1) APC-Cy7	Nessun dato disponibile.
641411	BD® Anti-HLA-DR (L243) APC-H7	Nessun dato disponibile.
641414	BD® CD20 (L27) APC-H7	Nessun dato disponibile.

1.2 Usi identificati pertinenti della sostanza o della miscela e usi sconsigliati

Usi identificati: Uso in laboratorio scientifico e industriale. Uso per diagnostica in vitro.

Usi non raccomandati: Non noto.

1.3 Informazioni sul fornitore della scheda di dati di sicurezza

Fabbricante

Becton Dickinson France S.A.S. Belgian Branch
Erembodegem-Dorp 86
9320 Erembodegem
Belgium

Telefono: 32 2 400 98 95

Fax: 32 2 401 70 94

Persona da contattare: BD Biosciences - Centralized European Office

Regulatory Compliance Department

E-mail: help.biosciences@europe.bd.com

1.4 Numero telefonico di emergenza: 32 2 400 98 95

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SEZIONE 2: identificazione dei pericoli

2.1 Classificazione della sostanza o della miscela

Il prodotto non è stato classificato come pericoloso secondo la normativa in vigore.

Classificazione ai sensi del regolamento CE n. 1272/2008 e s.m.i.

Non classificato

2.2 Elementi dell'etichetta Non applicabile

2.3 Altri pericoli

Proprietà di interferenza con il sistema endocrino-Tossicità

La sostanza/miscela non contiene componenti considerati aventi proprietà di interferenza endocrina ai sensi dell'articolo 57(f) del REACH o del regolamento delegato (UE) 2017/2100 della Commissione o del regolamento (UE) 2018/605 della Commissione a livelli dello 0,1% o superiori.

Proprietà di interferenza con il sistema endocrino-Ecotossicità

La sostanza/miscela non contiene componenti considerati aventi proprietà di interferenza endocrina ai sensi dell'articolo 57(f) del REACH o del regolamento delegato (UE) 2017/2100 della Commissione o del regolamento (UE) 2018/605 della Commissione a livelli dello 0,1% o superiori.

SEZIONE 3: composizione/informazioni sugli ingredienti

3.2 Miscele

Informazioni generali: Nessun componente pericoloso.

SEZIONE 4: misure di primo soccorso

4.1 Descrizione delle misure di primo soccorso

Informazioni generali:	Contattare un medico se si verificano dei sintomi.
Inalazione:	Tenere a riposo in luogo caldo e ben ventilato, preferibilmente in posizione seduta eretta.
Contatto con la Pelle:	Lavare le aree di contatto con acqua e sapone. Rimuovere gli indumenti contaminati. Lavare accuratamente gli indumenti contaminati prima di riutilizzarli.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Contatto con gli occhi:	Sciacquare immediatamente con abbondante acqua per almeno 15 minuti. Se è possibile, rimuovere le lenti a contatto.
Ingestione:	Consultare immediatamente un medico o un centro antiveneni Indurre il vomito soltanto dietro istruzioni del personale medico. In nessun caso somministrare alcunché per bocca a una persona senza conoscenza.
Protezioni personali per gli addetti al primo soccorso:	Nessun dato disponibile.
4.2 Principali sintomi ed effetti, sia acuti che ritardati	
Sintomi:	Nessun dato disponibile.
Rischi:	Nessun dato disponibile.
4.3 Indicazione dell'eventuale necessità di consultare immediatamente un medico e trattamenti speciali necessari	
Trattamento:	Nessun dato disponibile.

SEZIONE 5: misure di lotta antincendio

Rischi Generali d'Incendio:	Spegnere tutte le sorgenti d'ignizione. Evitare scintille, fiamme, calore. Evitare di fumare. Ventilare. Utilizzare spruzzi d'acqua per raffreddare i contenitori esposti al fuoco.
------------------------------------	---

5.1 Mezzi di estinzione

Mezzi di estinzione appropriati:	Usare il mezzo di estinzione adeguato a seconda dell'eventuale presenza di altre sostanze chimiche.
---	---

Mezzi di estinzione non appropriati:	Non applicabile
---	-----------------

5.2 Pericoli speciali derivanti dalla sostanza o dalla miscela:	Il fuoco o il calore eccessivo può provocare prodotti di decomposizione pericolosi.
--	---

5.3 Raccomandazioni per gli addetti all'estinzione degli incendi

Speciali procedure antincendio:	Non sono indicati rischi d'incendio o di esplosione particolari.
---------------------------------	--

Dispositivi di protezione speciali per gli addetti all'estinzione degli incendi:	Gli addetti all'estinzione dell'incendio devono usare equipaggiamento di protezione standard, inclusi tuta antifiama, elmetto con visiera protettiva, guanti, stivali di gomma e, in spazi chiusi, autorespiratore SCBA.
--	--

SEZIONE 6: misure in caso di rilascio accidentale

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

6.1 Precauzioni personali, dispositivi di protezione e procedure in caso di emergenza:	Contattare le autorità locali in caso di versamento in fognature/ambiente acquatico. Indossare dispositivi di protezione individuale adatti (compresa una protezione respiratoria) durante la rimozione delle fuoriuscite all'interno di una zona confinata.
6.1.1 Per chi non interviene direttamente:	Nessun dato disponibile.
6.1.2 Per chi interviene direttamente:	Nessun dato disponibile.
6.2 Precauzioni ambientali:	Non disperdere nell'ambiente.
6.3 Metodi e materiali per il contenimento e per la bonifica:	Assorbire il prodotto fuoriuscito con materiale assorbente idoneo. Evitare che l'acqua di scarico venga immessa nelle fognature, negli scarichi o nei fiumi. Per l'equipaggiamento di protezione individuale, vedere la Sezione 8 del SDS. Per informazioni sullo smaltimento, consultare il punto 13 del SDS.
6.4 Riferimento ad altre sezioni:	Nessun dato disponibile.

SEZIONE 7: manipolazione e immagazzinamento

7.1 Precauzioni per la manipolazione sicura

Misure tecniche (ad es. ventilazione locale e generale):	Nessun requisito speciale in normali condizioni d'uso e con ventilazione adeguata.
Manipolazione:	Non mangiare, né bere, né fumare durante l'impiego. Leggere e seguire le raccomandazioni del fabbricante. Utilizzare il dispositivo di protezione individuale richiesto.
Misure per evitare il contatto:	Nessun dato disponibile.

7.2 Condizioni per lo stoccaggio sicuro, comprese eventuali incompatibilità

Condizioni di conservazione sicura:	Conservare in luogo fresco e asciutto. Conservare il recipiente ben chiuso.
Materiali di imballaggio sicuro:	Nessun dato disponibile.

7.3 Usi finali particolari:	Riservato agli utilizzatori industriali e professionali. Leggere l'etichetta prima dell'uso.
------------------------------------	--

SEZIONE 8: controlli dell'esposizione/della protezione individuale

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

8.1 Parametri di controllo

Valori Limite per l'Esposizione Professionale

Per nessun componente è stato definito un limite di esposizione.

Valori Limite Biologici

Nessun valore limite biologico di esposizione annotato per l'ingrediente/gli ingredienti.

Valori DNEL

Osservazioni: Valori DNEL

Componente critico	Tipo	Via di esposizione	Avvertenze per la salute	Osservazioni
Sodium Chloride (NaCl)	Popolazione generale	Inhalation	Sistemico, lungo termine; 443,28 mg/m3	Tossicità a dose ripetuta
	Lavoratori	Inhalation	Sistemico, lungo termine; 2068,62 mg/m3	Tossicità a dose ripetuta
	Lavoratori	Inhalation	Sistemico, breve termine; 2068,62 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Inhalation	Sistemico, breve termine; 443,28 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Orale	Sistemico, lungo termine; 126,65 mg/kg	Tossicità a dose ripetuta
	Lavoratori	Dermico	Sistemico, lungo termine; 295,52 mg/kg	Tossicità a dose ripetuta
	Lavoratori	Dermico	Sistemico, breve termine; 295,52 mg/kg	Tossicità a dose ripetuta
	Popolazione generale	Orale	Sistemico, breve termine; 126,65 mg/kg	Tossicità a dose ripetuta
	Popolazione generale	Dermico	Sistemico, breve termine; 126,65 mg/kg	Tossicità a dose ripetuta
	Popolazione generale	Dermico	Sistemico, lungo termine; 126,65 mg/kg	Tossicità a dose ripetuta

Phosphoric acid, sodium salt (1:2)	Lavoratori	Occhi	Locale;	Nessun pericolo identificato
	Lavoratori	Inhalation	Sistemico, lungo termine; 4,07 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Inhalation	Sistemico, lungo termine; 3,04 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Inhalation	Sistemico, lungo termine; 6,63 mg/m3	Tossicità a dose ripetuta
	Lavoratori	Inhalation	Sistemico, lungo termine; 15,47 mg/m3	Tossicità a dose ripetuta

Sodium azide (Na(N3))	Lavoratori	Inhalation	Sistemico, lungo termine; 0,164 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Occhi	Locale;	Nessun pericolo identificato
	Popolazione generale	Inhalation	Sistemico, lungo termine; 29 µgr/m3	Tossicità a dose ripetuta
	Lavoratori	Occhi	Locale;	Nessun pericolo identificato
	Lavoratori	Dermico	Sistemico, lungo termine; 0,0467 mg/kg	Tossicità a dose ripetuta
	Popolazione generale	Orale	Sistemico, lungo termine; 0,0167 mg/kg	Tossicità a dose ripetuta

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Popolazione generale	Dermico	Sistemico, lungo termine; 0,0167 mg/kg	Tossicità a dose ripetuta
Potassium chloride (KCl)	Lavoratori	Inhalation	Sistemico, lungo termine; 1064 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Inhalation	Sistemico, lungo termine; 273 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Inhalation	Sistemico, breve termine; 1365 mg/m3	Tossicità a dose ripetuta
	Lavoratori	Inhalation	Sistemico, breve termine; 5320 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Orale	Sistemico, breve termine; 455 mg/kg	Tossicità a dose ripetuta
	Popolazione generale	Dermico	Sistemico, lungo termine; 182 mg/kg	Tossicità a dose ripetuta
	Popolazione generale	Orale	Sistemico, lungo termine; 91 mg/kg	Tossicità a dose ripetuta
	Lavoratori	Dermico	Sistemico, lungo termine; 303 mg/kg	Tossicità a dose ripetuta
	Lavoratori	Dermico	Sistemico, breve termine; 910 mg/kg	Tossicità a dose ripetuta
	Popolazione generale	Dermico	Sistemico, breve termine; 910 mg/kg	Tossicità a dose ripetuta
Phosphoric acid, potassium salt (1:1)	Lavoratori	Occhi	Locale;	Nessun pericolo identificato
	Popolazione generale	Occhi	Locale;	Nessun pericolo identificato
	Lavoratori	Inhalation	Sistemico, lungo termine; 14,82 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Inhalation	Sistemico, lungo termine; 6,35 mg/m3	Tossicità a dose ripetuta

Valori PNEC

Osservazioni: Valori PNEC

Componente critico	Compartimento ambientale	Valori PNEC	Osservazioni
Sodium Chloride (NaCl)	Terreno	4,86 mg/kg	
	Aquatico (acqua dolce)	5 mg/l	
	Impianto di trattamento delle acque reflue	500 mg/l	
Phosphoric acid, sodium salt (1:2)	Impianto di trattamento delle acque reflue	50 mg/l	
	Aquatico (acqua dolce)	0,05 mg/l	
	Acquatico (acqua marina)	0,005 mg/l	
Sodium azide (Na(N3))	Acquatico (acqua marina)	15 ng/l	
	Impianto di trattamento delle acque reflue	30 µgr/l	
	Sedimento (acqua dolce)	0,0167 mg/kg	
	Aquatico (acqua dolce)	0,35 µgr/l	
	Sedimento (acqua marina)	0,00072 mg/kg	

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Potassium chloride (KCl)	Acquatico (acqua marina)	0,1 mg/l	
	Impianto di trattamento delle acque reflue	10 mg/l	
	Aquatico (acqua dolce)	0,1 mg/l	

8.2 Controlli dell'esposizione

Controlli Tecnici Idonei:

Nessun requisito speciale in normali condizioni d'uso e con ventilazione adeguata.

Misure di protezione individuale, quali dispositivi di protezione individuale

Protezioni per gli occhi/il volto:

Indossare occhiali di protezione con schermi laterali (o occhiali di copertura).

Protezione delle Mani:

Materiale: Guanti a resistenza chimica
Informazioni supplementari: Lavarsi le mani dopo il contatto.
Materiale: Il fornitore di guanti può raccomandare guanti adatti.

Protezione per la pelle e l'organismo:

Indossare un camice da laboratorio o indumenti di protezione simili.

Protezione respiratoria:

Se i controlli sugli impianti non consentono di mantenere concentrazioni nell'aria inferiori ai valori limite di esposizione consigliati (ove applicabile) o a un livello accettabile (nei Paesi in cui i valori limite di esposizione non sono stati stabiliti), occorrerà utilizzare un respiratore a norma.

Misure di igiene:

Osservare le norme di buona igiene industriale.

Controlli ambientali:

Nessun dato disponibile.

SEZIONE 9: proprietà fisiche e chimiche

9.1 Informazioni sulle proprietà fisiche e chimiche fondamentali

Aspetto

Forma: liquido

Forma: liquido

Colore: Da incolore a blu

Odore: Inodore

Soglia di odore: Nessun dato disponibile.

Punto di congelamento: Nessun dato disponibile.

Punto di ebollizione: Nessun dato disponibile.

Infiammabilità: Nessun dato disponibile.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Limiti superiori/inferiori di infiammabilità o esplosività

Limite esplosivo - superiore (%):	Nessun dato disponibile.
Limite esplosivo - inferiore (%):	Nessun dato disponibile.
Punto di infiammabilità:	Nessun dato disponibile.
Temperatura di autoaccensione:	Nessun dato disponibile.
Temperatura di decomposizione:	Nessun dato disponibile.
pH:	7,20 - 7,60

Viscosità

Viscosità dinamica:	Nessun dato disponibile.
Viscosità cinematica:	Nessun dato disponibile.
Tempo di scorrimento:	Nessun dato disponibile.

Solubilità

Solubilità in acqua:	Solubile
Solubilità (altro):	Nessun dato disponibile.
Tasso di dissoluzione:	Nessun dato disponibile.

Coefficiente di ripartizione (n-ottanolo/acqua):	Nessun dato disponibile.
---	--------------------------

Stabilità alla dispersione:	Nessun dato disponibile.
------------------------------------	--------------------------

Pressione di vapore:	Nessun dato disponibile.
Densità relativa:	Nessun dato disponibile.
Densità:	Nessun dato disponibile.
Densità apparente:	Nessun dato disponibile.
Densità di vapore relativa:	Nessun dato disponibile.

9.2 Altre informazioni

Nessun dato disponibile

SEZIONE 10: stabilità e reattività

10.1 Reattività:	Il materiale è stabile in condizioni normali.
10.2 Stabilità chimica:	Il materiale è stabile in condizioni normali.
10.3 Possibilità di reazioni pericolose:	Stabile
10.4 Condizioni da evitare:	Evitare l'esposizione a temperature elevate o luce solare diretta.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

- 10.5 **Materiali incompatibili:** Metalli Materiale che reagisce con l'acqua.
- 10.6 **Prodotti di decomposizione pericolosi:** Stabile; tuttavia, può decomporsi se riscaldato.

SEZIONE 11: informazioni tossicologiche

11.1 Informazioni sulle classi di pericolo definite nel regolamento (CE) n. 1272/2008

- Inalazione:** Nessun dato disponibile.
- Contatto con la Pelle:** Nessun dato disponibile.
- Contatto con gli occhi:** Nessun dato disponibile.
- Ingestione:** Nessun dato disponibile.

Informazioni sulle vie probabili di esposizione

Tossicità acuta (elencare tutte le possibili vie di esposizione)

Ingestione

- Prodotto:** Non classificato per quanto riguarda la tossicità acuta sulla base dei dati disponibili.

Contatto con la pelle

- Prodotto:** Non classificato per quanto riguarda la tossicità acuta sulla base dei dati disponibili.

Inalazione

- Prodotto:** Non classificato per quanto riguarda la tossicità acuta sulla base dei dati disponibili.

Tossicità a dose ripetuta

- Prodotto:** Nessun dato disponibile.

Corrosione/Irritazione della Pelle

- Prodotto:** Nessun dato disponibile.

Gravi Danni Agli Occhi o Irritazione Degli Occhi

- Prodotto:** Nessun dato disponibile.

Sensibilizzazione Respiratoria o della Pelle

- Prodotto:** Nessun dato disponibile.

Carcinogenicità

- Prodotto:** Nessun dato disponibile.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Mutagenicità delle Cellule Germinali

In vitro

Prodotto: Nessun dato disponibile.

In vivo

Prodotto: Nessun dato disponibile.

Tossicità per la riproduzione

Prodotto: Nessun dato disponibile.

Tossicità Specifica per Organo Bersaglio - Esposizione Singola

Prodotto: Nessun dato disponibile.

Tossicità Specifica per Organo Bersaglio - Esposizione Ripetuta

Prodotto: Nessun dato disponibile.

Pericolo da Aspirazione

Prodotto: Nessun dato disponibile.

11.2 Informazioni su altri pericoli

Proprietà di interferenza con il sistema endocrino

Prodotto: La sostanza/miscela non contiene componenti considerati aventi proprietà di interferenza endocrina ai sensi dell'articolo 57(f) del REACH o del regolamento delegato (UE) 2017/2100 della Commissione o del regolamento (UE) 2018/605 della Commissione a livelli dello 0,1% o superiori.;

Altre informazioni

Prodotto: Nessun dato disponibile.

SEZIONE 12: informazioni ecologiche

12.1 Tossicità:

Pericoli acuti per l'ambiente acquatico:

Pesce

Prodotto: Nessun dato disponibile.

Invertebrati Acquatici

Prodotto: Nessun dato disponibile.

Tossicità per le piante acquatiche

Prodotto: Nessun dato disponibile.

Tossicità per i micro-organismi

Prodotto: Nessun dato disponibile.

Pericoli cronici per l'ambiente acquatico:

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Pesce

Prodotto: Nessun dato disponibile.

Invertebrati Acquatici

Prodotto: Nessun dato disponibile.

Tossicità per le piante acquatiche

Prodotto: Nessun dato disponibile.

Tossicità per i micro-organismi

Prodotto: Nessun dato disponibile.

12.2 Persistenza e degradabilità

Biodegradazione

Prodotto: Nessun dato disponibile.

Rapporto BOD/COD

Prodotto: Nessun dato disponibile.

12.3 Potenziale di bioaccumulo

Fattore di Bioconcentrazione (BCF)

Prodotto: Nessun dato disponibile.

Coefficiente di Ripartizione n-ottanolo / acqua (log Kow)

Prodotto: Nessun dato disponibile.

12.4 Mobilità nel suolo:

Prodotto Nessun dato disponibile.

12.5 Risultati della valutazione PBT e vPvB:

Prodotto Nessun dato disponibile.

12.6 Proprietà di interferenza con il sistema endocrino:

Prodotto: La sostanza/miscela non contiene componenti considerati aventi proprietà di interferenza endocrina ai sensi dell'articolo 57(f) del REACH o del regolamento delegato (UE) 2017/2100 della Commissione o del regolamento (UE) 2018/605 della Commissione a livelli dello 0,1% o superiori.

12.7 Altri effetti avversi:

Altri pericoli

Prodotto: Nessun dato disponibile.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SEZIONE 13: considerazioni sullo smaltimento

13.1 Metodi di trattamento dei rifiuti

Informazioni generali:	Smaltire residui e rifiuti conformemente a quanto disposto dalle autorità locali.
Metodi di smaltimento:	Smaltire i rifiuti in un centro di trattamento e smaltimento appropriato in conformità alle leggi e ai regolamenti vigenti e alle caratteristiche del prodotto al momento dello smaltimento.
Contenitori Contaminati:	Smaltire il prodotto/recipient conferendolo a un opportuno impianto di trattamento e smaltimento in accordo con le leggi e i regolamenti vigenti e le caratteristiche del prodotto al momento dello smaltimento.

SEZIONE 14: informazioni sul trasporto

ADR

14.1 Numero ONU o numero ID:	Non regolamentato.
14.2 Designazione ufficiale ONU di trasporto:	Non regolamentato.
14.3 Classi di pericolo connesso al trasporto	
Classe:	Non regolamentato.
Etichetta(-e):	Non regolamentato.
Nr. pericolo (ADR):	Non regolamentato.
Codice restrizioni su trasporto in galleria:	Non regolamentato.
14.4 Gruppo d'imballaggio:	Non regolamentato.
Quantità limitata	Non regolamentato.
Quantità esente	Non regolamentato.
14.5 Pericoli per l'ambiente	Non regolamentato.
14.6 Precauzioni speciali per gli utilizzatori:	Non regolamentato.

ADN

14.1 Numero ONU o numero ID:	Non regolamentato.
14.2 Designazione ufficiale ONU di trasporto:	Non regolamentato.
14.3 Classi di pericolo connesso al trasporto	
Classe:	Non regolamentato.
Etichetta(-e):	Non regolamentato.
Nr. pericolo (ADR):	Non regolamentato.
Codice restrizioni su trasporto in galleria:	Non regolamentato.
14.4 Gruppo d'imballaggio:	Non regolamentato.
Quantità limitata	Non regolamentato.
Quantità esente	Non regolamentato.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

14.5 Precauzioni speciali per gli utilizzatori: Non regolamentato.

RID

14.1 Numero ONU o numero ID: Non regolamentato.
14.2 Designazione ufficiale ONU di trasporto: Non regolamentato.
14.3 Classi di pericolo connesso al trasporto
Classe: Non regolamentato.
Etichetta(-e): Non regolamentato.
14.4 Gruppo d'imballaggio: Non regolamentato.
Quantità limitata Non regolamentato.
Quantità esente Non regolamentato.
14.5 Pericoli per l'ambiente Non regolamentato.
14.6 Precauzioni speciali per gli utilizzatori: Non regolamentato.

IMDG

14.1 Numero ONU o numero ID: Non regolamentato.
14.2 Designazione ufficiale ONU di trasporto: Non regolamentato.
14.3 Classi di pericolo connesso al trasporto
Classe: Non regolamentato.
Etichetta(-e): Non regolamentato.
EmS No.: Non regolamentato.
14.4 Gruppo d'imballaggio: Non regolamentato.
Quantità limitata Non regolamentato.
Quantità esente Non regolamentato.
14.5 Pericoli per l'ambiente Non regolamentato.
14.6 Precauzioni speciali per gli utilizzatori: Non regolamentato.

IATA

14.1 Numero ONU o numero ID: Non regolamentato.
14.2 Designazione ufficiale ONU di trasporto: Non regolamentato.
14.3 Classi di pericolo connesso al trasporto
Classe: Non regolamentato.
Etichetta(-e): Non regolamentato.
14.4 Gruppo d'imballaggio: Non regolamentato.
Aereo di linea e aereo da trasporto
merci : Non regolamentato.
Quantità limitata Non regolamentato.
Quantità esente Non regolamentato.
14.5 Pericoli per l'ambiente Non regolamentato.
14.6 Precauzioni speciali per gli utilizzatori: Non regolamentato.

14.7 Trasporto marittimo alla rinfusa conformemente agli atti dell'IMO

Non applicabile al prodotto nella sua forma fornita.

SEZIONE 15: informazioni sulla regolamentazione

15.1 Disposizioni legislative e regolamentari su salute, sicurezza e ambiente specifiche per la sostanza o la miscela:

Regolamenti dell'UE

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Regolamento (CE) n. 1005/2009 sulle sostanze che riducono lo strato di ozono, Allegato I, Sostanze controllate: Nessuno presente o nessuno presente in quantitàregolate.

REGOLAMENTO 1907/2006 (CE) (REACH), ALLEGATO XIV ELENCO DELLE SOSTANZE SOGGETTE AD AUTORIZZAZIONE: Nessuno presente o nessuno presente in quantitàregolate.

Regolamento (CE) n. 2019/1021/CE che prevede divieti e restrizioni per gli inquinanti organici persistenti (POP), modificata: Nessuno presente o nessuno presente in quantitàregolate.

UE. Direttiva 2010/75/UE relativa alle emissioni industriali (prevenzione e riduzione integrate dell'inquinamento), Allegato II, L334/17: Nessuno presente o nessuno presente in quantitàregolate.

Regolamento (UE) n. 649/2012 riguardante l'esportazione e l'importazione di sostanze chimiche pericolose, Allegato I, Parte 1 e successive modifiche: Nessuno presente o nessuno presente in quantitàregolate.

Regolamento (UE) n. 649/2012 riguardante l'esportazione e l'importazione di sostanze chimiche pericolose, Allegato I, Parte 2 e successive modifiche: Nessuno presente o nessuno presente in quantitàregolate.

Regolamento (UE) n. 649/2012 riguardante l'esportazione e l'importazione di sostanze chimiche pericolose, Allegato I, Parte 3 e successive modifiche: Nessuno presente o nessuno presente in quantitàregolate.

Regolamento (UE) n. 649/2012 riguardante l'esportazione e l'importazione di sostanze chimiche pericolose, Allegato V e successive modifiche: Nessuno presente o nessuno presente in quantitàregolate.

Elenco dei candidati UE. REACH delle sostanze estremamente problematiche per l'autorizzazione (Substances of Very High Concern, SVHC): Nessuno presente o nessuno presente in quantitàregolate.

Regolamento (CE) n. 1907/2006 Allegato XVII - Sostanze soggette a restrizioni in materia di immissione sul mercato e di uso:

Direttiva 2004/37/CE sulla protezione dei lavoratori contro i rischi derivanti da un'esposizione ad agenti cancerogeni omutageni durante il lavoro.: Nessuno presente o nessuno presente in quantitàregolate.

Direttiva 92/85/CEE concernente l'attuazione di misure volte a promuovere il miglioramento della sicurezza e della salute sul lavoro delle lavoratrici gestanti, puerpere o in periodo di allattamento: Nessuno presente o nessuno presente in quantitàregolate.

DIRETTIVA 2012/18/UE sul controllo del pericolo di incidenti rilevanti connessi con sostanze pericolose, ALLEGATO I: Nessuno presente o nessuno presente in quantitàregolate.

REGOLAMENTO (CE) N. 166/2006 relativo all'istituzione di un registro europeo delle emissioni e dei trasferimenti di sostanze inquinanti, ALLEGATO II: Sostanze inquinanti: Nessuno presente o nessuno presente in quantitàregolate.

Direttiva 98/24/CE sulla protezione dei lavoratori contro i rischi legati agli agenti chimici sul lavoro:



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Denominazione chimica	NUMERO CAS	Concentrazione
azoturo di sodio	26628-22-8	0 - <0,1%

15.2 Valutazione della sicurezza chimica:

Non è stata effettuata alcuna valutazione della sicurezza chimica.

Regolamenti internazionali

Protocollo di Montreal

Non applicabile

Convenzione di Stoccolma

Non applicabile

Convenzione di Rotterdam

Non applicabile

Protocollo di Kyoto

Non applicabile

SEZIONE 16: altre informazioni

Abbreviazioni e acronimi:

Nessun dato disponibile.

Principali riferimenti bibliografici e fonti di dati:

Agenzia europea per le sostanze chimiche (ECHA): informazioni sulle sostanze chimiche.

Formulazione delle istruzioni nelle sezioni 2 e 3

: nessuno/nessuna

Indicazioni per la formazione: Nessun dato disponibile.

SDS N.:

UN0000000000000332777-4012-1-01



**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Limitazione di responsabilità: Disclaimer:
Le informazioni qui contenute sono state ottenute da fonti diverse e sono ritenute corrette alla data di pubblicazione. Tuttavia, né BD né alcuna delle sue affiliate si assumono responsabilità riguardo alla correttezza o la completezza delle informazioni ivi contenute. Determinazione finale di idoneità per un particolare uso dei materiali è di esclusiva responsabilità dell'utente. Tutti i materiali possono presentare rischi sconosciuti e devono essere usati con cautela. Sebbene alcuni rischi siano descritti nel presente documento, non possiamo garantire che questi sono gli unici rischi esistenti. BD fornisce schede di sicurezza in formato elettronico, così l'informazione può essere più facilmente accessibile. A causa della possibilità di errori durante la trasmissione, BD si assume alcuna responsabilità per quanto riguarda la completezza o accuratezza delle informazioni.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SIKKERHETSDATABLAD

I samsvar med forskrift (EU) nr. 1907/2006 (REACH) artikkel 31, tillegg II med endringer

Identifikasjon av stoffet/stoffblandingen og av selskapet/foretaket

Produktidentifikator

Produktnr.:	Produktnavn:	Vanlig(e) navn, synonym(er)
332774	BD® CD7 (M-T701) PE	Data ikke tilgjengelig.
332776	BD® CD10 (HI10a) PE	Data ikke tilgjengelig.
332779	BD® CD16 (B73.1) PE	Data ikke tilgjengelig.
332782	BD® CD23 (EBVCS-5) PE	Data ikke tilgjengelig.
332785	BD® CD117 (104D2) PE	Data ikke tilgjengelig.
332790	BD® Anti-TdT (E17-1519) PE	Data ikke tilgjengelig.
333139	BD® Anti-MPO (5B8) PE	Data ikke tilgjengelig.
333141	BD® Anti-TCR-γ/δ (11F2) PE	Data ikke tilgjengelig.
333142	BD® CD11b (D12) PE	Data ikke tilgjengelig.
333149	BD® CD11c (S-HCL-3) PE	Data ikke tilgjengelig.
333152	BD® CD79a (HM47) PE	Data ikke tilgjengelig.
333156	BD® CD103 (Ber-ACT8) PE	Data ikke tilgjengelig.
333167	BD® CD1a (SK9) PE	Data ikke tilgjengelig.
335833	BD® CD79b (SN8) PE	Data ikke tilgjengelig.
337899	BD® CD22 (S-HCL-1) PE	Data ikke tilgjengelig.
341011	BD® CD25 (2A3) PE	Data ikke tilgjengelig.
345765	BD® CD3 (SK7) PE	Data ikke tilgjengelig.
345769	BD® CD4 (SK3) PE	Data ikke tilgjengelig.
345773	BD® CD8 (SK1) PE	Data ikke tilgjengelig.
345777	BD® CD19 (4G7) PE	Data ikke tilgjengelig.
345782	BD® CD5 (L17F12) PE	Data ikke tilgjengelig.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

345785	BD® CD14 (MφP9) PE	Data ikke tilgjengelig.
345789	BD® CD19 (SJ25C1) PE	Data ikke tilgjengelig.
345793	BD® CD20 (L27) PE	Data ikke tilgjengelig.
345799	BD® CD33 (P67.6) PE	Data ikke tilgjengelig.
345802	BD® CD34 (8G12) PE	Data ikke tilgjengelig.
345806	BD® CD38 (HB-7) PE	Data ikke tilgjengelig.
345810	BD® CD56 (MY31) PE	Data ikke tilgjengelig.
345812	BD® CD56 (NCAM16.2) PE	Data ikke tilgjengelig.
347215	BD® CD138 (MI15) PE	Data ikke tilgjengelig.
347246	BD® Anti-Kappa (TB 28-2) PE	Data ikke tilgjengelig.
347401	BD® Anti-HLA-DR (L243) PE	Data ikke tilgjengelig.
347405	BD® CD2 (S5.2) PE	Data ikke tilgjengelig.
347406	BD® CD13 (L138) PE	Data ikke tilgjengelig.

1.2 Relevante, identifiserte bruksområder for stoffet eller blandingen, og bruksmåter det advares mot

Identifisert bruk:

For bruk i vitenskapelige og industrielle laboratorier. For in vitro-diagnostisk bruk.

Bruk som blir frarådd:

Ingen kjente.

1.3 Opplysninger om leverandøren av sikkerhetsdatabladet

Produsent

Becton Dickinson France S.A.S. Belgian Branch
Erembodegem-Dorp 86
9320 Erembodegem
Belgium

telefon: 32 2 400 98 95

faks: 32 2 401 70 94

Kontaktperson: BD Biosciences - Centralized European Office
Regulatory Compliance Department

E-post: help.biosciences@europe.bd.com

1.4 Nødtelefonnr.: 32 2 400 98 95

Avsnitt 2: Fareidentifikasjon

2.1 Klassifisering av stoffet/blandingen

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Produktet er ikke klassifisert som farlig i følge gjeldende lovgivning.

Klassifisering ifølge EU-forskrift nr. 1272/2008, med endringer.

Ikke klassifisert

2.2 Etikettelementer Ikke anvendelig

2.3 Andre farer

Hormonforstyrrende egenskaper-Toksisitet

Stoffet/blandingen inneholder ikke komponenter som anses å ha hormonforstyrrende egenskaper i henhold til REACH artikkel 57(f) eller Kommisjonsdelegert forordning (EU) 2017/2100 eller Kommisjonsforordning (EU) 2018/605 på nivåer på 0,1% eller høyere.

Hormonforstyrrende egenskaper-Økotoksisitet

Stoffet/blandingen inneholder ikke komponenter som anses å ha hormonforstyrrende egenskaper i henhold til REACH artikkel 57(f) eller Kommisjonsdelegert forordning (EU) 2017/2100 eller Kommisjonsforordning (EU) 2018/605 på nivåer på 0,1% eller høyere.

Avsnitt 3: Sammensetning/opplysninger om bestanddeler

3.2 Blanding

Generelle opplysninger: Ingen farlige ingredienser.

Avsnitt 4: Førstehjelpstiltak

Beskrivelse av førstehjelpstiltak

Generelle opplysninger:	Kontakt lege dersom det opptrer sykdomstegn.
Innånding:	Sørg for frisk luft, varme og ro, helst i behagelig halvsittende stilling.
Hudkontakt:	Vask kontaktstedene med såpe og vann. Ta av kontaminerte klær. Vask de kontaminerte klærne før de brukes igjen.
Øyekontakt:	Spyl øyeblikkelig med rikelig vann i minst 15 minutter. Hvis det er lett å få til, bør ev. kontaktlinser tas ut.
Inntak/svelging:	Ring lege eller Giftinformasjonssentralen umiddelbart. Fremkall bare brekninger etter anvisning fra medisinsk personell. Gi aldri noe å innta gjennom munnen til bevisstløse personer.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

**Personlig verneutstyr for
førstehjelpspersonell:**

Data ikke tilgjengelig.

**Viktigste symptomer og virkninger, både akutte og forsinkede
Symptomer:**

Data ikke tilgjengelig.

Farer:

Data ikke tilgjengelig.

Indikasjon av øyeblikkelig medisinsk hjelp og spesialbehandling som er nødvendig

Behandling:

Data ikke tilgjengelig.

Avsnitt 5: Brannsløkkingstiltak

Generelle Brannfarer:

Slokk alle antenningskilder. Unngå gnister, flammer, varme og røyking. Ventiler godt. Bruk vannspray for å holde beholdere som utsettes for brann nedkjølte.

**Egnet (og uegnet) brannsløkkingsutstyr
Egnete brannsløkkingsmedier:**

Ta hensyn til ev. andre kjemikalier ved valg av brannsløkkingsmidler.

Uegnete brannsløkkingsmedier:

Ikke anvendelig

**Spesielle farer forbundet med stoffet
eller blandingen:**

Brann eller overdreven varme kan danne skadelige nedbrytingsprodukter.

Spesielt verneutstyr og forholdsregler for brannsløkkingspersonell

Særlige brannsløkkingstiltak:

Ingen uvanlig brann- eller eksplosjonsfare angitt.

Spesielt verneutstyr for brannmenn:

Brannmannskapene må bruke standard verneutstyr med flammehemmende jakke, hjelm med ansiktsvern, hansker, gummistøvler og røykdykkerapparat i lukkede rom.

Avsnitt 6: Tiltak ved utilsiktet utslipp

**6.1 Personlige forholdsregler,
verneutstyr og
nødprosedyrer:**

Ved større utslipp i avløp/vannmiljø, må lokale myndigheter informeres. Påse at det brukes egnet verneutstyr (herunder åndedrettsvern) ved fjerning av utslipp i lukkede områder.

6.1.1 For ikke-nødpersonell:

Data ikke tilgjengelig.

6.1.2 For nødpersonell:

Data ikke tilgjengelig.

6.2 Miljøverntiltak:

Unngå utslipp til miljøet.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

6.3 Metoder og materiell for avgrensning og opprensning av utslipp: Utslipp oppsamles med egnet absorberende materiale. Avrenning må ikke komme ut i kloakk eller vannveier. Se avsnitt 8 for personlig verneutstyr. Hvis du ønsker mer informasjon om avhending, kan du se avsnitt 13.

6.4 Referanse til andre avsnitt: Data ikke tilgjengelig.

Avsnitt 7: Håndtering og lagring

Håndtering

Tekniske tiltak (dvs. lokal og generell ventilasjon): Ingen spesielle behov under bruk ved vanlige forhold og tilstrekkelig ventilasjon.

Håndtering: Det må ikke spises, drikkes eller røykes under bruk. Les og følg produsentens anvisninger. Bruk påkrevd personlig verneutstyr.

Tiltak for å unngå kontakt: Data ikke tilgjengelig.

Lagring

Betingelser for sikker lagring: Lagres kaldt og tørt. Emballasjen skal holdes tett lukket.
Sikre emballasjematerialer: Data ikke tilgjengelig.

7.3 Spesifikk sluttbruk: Bare for industriell bruk og yrkesbruk. Les etiketten før bruk.

Eksponeringskontroll/personbeskyttelse

8.1 Kontrollparametre

Yrkesmessige Eksponeringsgrenser

Ingen av komponentene er tildelt eksponeringsgrense.

Biologiske Grenseverdier

Ingen biologiske eksponeringsgrenser er oppført for bestanddelen(e).

DNEL-verdier

Merknader: DNEL-verdier

Kritiske komponenter	Type	Eksponeringsmåte	Helsefareinformasjon	Merknader
Sodium Chloride (NaCl)	Befolkningen generelt	Inhalation	Systemisk, langvarig; 443,28 mg/m3	Toksisitet ved gjentatt dose
	Arbeidere	Inhalation	Systemisk, langvarig; 2068,62 mg/m3	Toksisitet ved gjentatt dose
	Arbeidere	Inhalation	Systemisk, kortvarig; 2068,62 mg/m3	Toksisitet ved gjentatt dose
	Befolkningen generelt	Inhalation	Systemisk, kortvarig; 443,28 mg/m3	Toksisitet ved gjentatt dose



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Befolkningen generelt	Oralt	Systemisk, langvarig; 126,65 mg/kg	Toksisitet ved gjentatt dose
	Arbeidere	Dermal	Systemisk, langvarig; 295,52 mg/kg	Toksisitet ved gjentatt dose
	Arbeidere	Dermal	Systemisk, kortvarig; 295,52 mg/kg	Toksisitet ved gjentatt dose
	Befolkningen generelt	Oralt	Systemisk, kortvarig; 126,65 mg/kg	Toksisitet ved gjentatt dose
	Befolkningen generelt	Dermal	Systemisk, kortvarig; 126,65 mg/kg	Toksisitet ved gjentatt dose
	Befolkningen generelt	Dermal	Systemisk, langvarig; 126,65 mg/kg	Toksisitet ved gjentatt dose

Phosphoric acid, sodium salt (1:2)	Arbeidere	Øyne	Lokal effekt;	Ingen fare identifisert
	Arbeidere	Inhalation	Systemisk, langvarig; 4,07 mg/m ³	Toksisitet ved gjentatt dose
	Befolkningen generelt	Inhalation	Systemisk, langvarig; 3,04 mg/m ³	Toksisitet ved gjentatt dose
	Befolkningen generelt	Inhalation	Systemisk, langvarig; 6,63 mg/m ³	Toksisitet ved gjentatt dose
	Arbeidere	Inhalation	Systemisk, langvarig; 15,47 mg/m ³	Toksisitet ved gjentatt dose

Sodium azide (Na(N ₃))	Arbeidere	Inhalation	Systemisk, langvarig; 0,164 mg/m ³	Toksisitet ved gjentatt dose
	Befolkningen generelt	Øyne	Lokal effekt;	Ingen fare identifisert
	Befolkningen generelt	Inhalation	Systemisk, langvarig; 29 µg/m ³	Toksisitet ved gjentatt dose
	Arbeidere	Øyne	Lokal effekt;	Ingen fare identifisert
	Arbeidere	Dermal	Systemisk, langvarig; 0,0467 mg/kg	Toksisitet ved gjentatt dose
	Befolkningen generelt	Oralt	Systemisk, langvarig; 0,0167 mg/kg	Toksisitet ved gjentatt dose
	Befolkningen generelt	Dermal	Systemisk, langvarig; 0,0167 mg/kg	Toksisitet ved gjentatt dose

Potassium chloride (KCl)	Arbeidere	Inhalation	Systemisk, langvarig; 1064 mg/m ³	Toksisitet ved gjentatt dose
	Befolkningen generelt	Inhalation	Systemisk, langvarig; 273 mg/m ³	Toksisitet ved gjentatt dose
	Befolkningen generelt	Inhalation	Systemisk, kortvarig; 1365 mg/m ³	Toksisitet ved gjentatt dose
	Arbeidere	Inhalation	Systemisk, kortvarig; 5320 mg/m ³	Toksisitet ved gjentatt dose
	Befolkningen generelt	Oralt	Systemisk, kortvarig; 455 mg/kg	Toksisitet ved gjentatt dose
	Befolkningen generelt	Dermal	Systemisk, langvarig; 182 mg/kg	Toksisitet ved gjentatt dose
	Befolkningen generelt	Oralt	Systemisk, langvarig; 91 mg/kg	Toksisitet ved gjentatt dose
	Arbeidere	Dermal	Systemisk, langvarig; 303 mg/kg	Toksisitet ved gjentatt dose
	Arbeidere	Dermal	Systemisk, kortvarig; 910 mg/kg	Toksisitet ved gjentatt dose
	Befolkningen generelt	Dermal	Systemisk, kortvarig; 910 mg/kg	Toksisitet ved gjentatt dose

Phosphoric acid, potassium salt (1:1)	Arbeidere	Øyne	Lokal effekt;	Ingen fare identifisert
	Befolkningen generelt	Øyne	Lokal effekt;	Ingen fare identifisert

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Arbeidere	Inhalation	Systemisk, langvarig; 14,82 mg/m ³	Toksisitet ved gjentatt dose
	Befolkningen generelt	Inhalation	Systemisk, langvarig; 6,35 mg/m ³	Toksisitet ved gjentatt dose

PNEC-verdier

Merknader: PNEC-verdier

Kritiske komponenter	Miljørom	PNEC-verdier	Merknader
Sodium Chloride (NaCl)	Grunn	4,86 mg/kg	
	Vannmiljø (ferskvann)	5 mg/l	
	Kloakkrenseanlegg	500 mg/l	

Phosphoric acid, sodium salt (1:2)	Kloakkrenseanlegg	50 mg/l	
	Vannmiljø (ferskvann)	0,05 mg/l	
	Vannmiljø (havvann)	0,005 mg/l	

Sodium azide (Na(N ₃))	Vannmiljø (havvann)	15 ng/l	
	Kloakkrenseanlegg	30 µg/l	
	Sediment (ferskvann)	0,0167 mg/kg	
	Vannmiljø (ferskvann)	0,35 µg/l	
	Sediment (sjøvann)	0,00072 mg/kg	

Potassium chloride (KCl)	Vannmiljø (havvann)	0,1 mg/l	
	Kloakkrenseanlegg	10 mg/l	
	Vannmiljø (ferskvann)	0,1 mg/l	

8.2 Forebyggende tiltak

Egnede Konstruksjonsmessige Kontrolltiltak:

Ingen spesielle behov under bruk ved vanlige forhold og tilstrekkelig ventilasjon.

Individuelle vernetiltak, som personlig verneutstyr

Øye-/ansiktsvern:

Bruk vernebriller med sidevern (eller heldekkende briller).

Håndvern:

Material: kjemikalieresistente hansker
Ytterligere informasjon: Vask hendene etter kontakt.
Material: Egnede hansketyper kan anbefales av hanskeleverandøren.

Hud- og kroppsvern:

Bruk en labfrakk eller lignende verneklær.

Respirasjonsvern:

Hvis ikke konstruksjonsmessige tiltak er tilstrekkelige til å opprettholde konsentrasjonene under gjeldende grenser (der det kommer til anvendelse), kreves det bruk av et godkjent pusteapparat.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Hygienetiltak: Følg yrkeshygienisk praksis.

Miljøkontroll: Data ikke tilgjengelig.

Avsnitt 9: Fysiske og kjemiske egenskaper

Opplysninger om grunnleggende fysiske og kjemiske egenskaper

Utseende

Fysisk tilstand: flytende
Form: flytende
Farge: Fargeløs til rosa

Lukt: Luktfri

Luktterskel: Data ikke tilgjengelig.

frysepunkt: Data ikke tilgjengelig.

Kokepunkt: Data ikke tilgjengelig.

Brennbarhet: Data ikke tilgjengelig.

Øvre/nedre brennbarhets- eller eksplosjonsgrenser

Eksponeringsgrense – øvre (%): Data ikke tilgjengelig.

Eksponeringsgrense – nedre (%): Data ikke tilgjengelig.

Flammepunkt: Data ikke tilgjengelig.

Selvantennelsestemperatur: Data ikke tilgjengelig.

dekomponeringstemperatur: Data ikke tilgjengelig.

pH-verdi: 7,20 - 7,60

Viskositet

Dynamisk viskositet: Data ikke tilgjengelig.

Kinetisk viskositet: Data ikke tilgjengelig.

strømningstid: Data ikke tilgjengelig.

Løselighet(er)

Vannløselighet: Løselig

Løselighet (annen): Data ikke tilgjengelig.

Fordelingskoeffisient n-oktanol/vann: Data ikke tilgjengelig.

Damptrykk: Data ikke tilgjengelig.

Relativ tetthet: Data ikke tilgjengelig.

Tetthet: Data ikke tilgjengelig.

Bulktetthet: Data ikke tilgjengelig.

Relativ damptetthet: Data ikke tilgjengelig.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

ANDRE OPPLYSNINGER

Ingen data tilgjengelig

Avsnitt 10: Stabilitet og reaktivitet

Reaktivitet:	Materialet er stabilt under normale forhold.
Kjemisk Stabilitet:	Materialet er stabilt under normale forhold.
Mulighet for Farlige Reaksjoner:	stabil
Forhold som må Unngås:	Må ikke utsettes for høye temperaturer eller direkte sollys.
Materialer å Unngå:	Metaller. Vannreaktivt materiale.
Farlige Spaltningsprodukter:	Stabilt, kan imidlertid brytes ned hvis det varmes opp.

Avsnitt 11: Toksikologiske opplysninger**Toksikologiske opplysninger**

Innånding:	Data ikke tilgjengelig.
Hudkontakt:	Data ikke tilgjengelig.
Øyekontakt:	Data ikke tilgjengelig.
Inntak/svelging:	Data ikke tilgjengelig.

Opplysninger om sannsynlige eksponeringsveier**Akutt toksisitet (list opp alle mulige eksponeringsveier)**

Svelging
Produkt: Ikke klassifisert for akutt toksisitet, basert på tilgjengelige data.

Hudkontakt
Produkt: Ikke klassifisert for akutt toksisitet, basert på tilgjengelige data.

Innånding
Produkt: Ikke klassifisert for akutt toksisitet, basert på tilgjengelige data.

Toksisitet ved gjentatt inntak
Produkt: Data ikke tilgjengelig.

Etsing/Irritasjon på Huden

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Produkt: Data ikke tilgjengelig.

Alvorlig Øyeskade/-Irritasjon

Produkt: Data ikke tilgjengelig.

Åndedrett- eller Hudsensibilisering

Produkt: Data ikke tilgjengelig.

Kreftfremkallende evne

Produkt: Data ikke tilgjengelig.

Mutagenisitet på Kimceller

In vitro

Produkt: Data ikke tilgjengelig.

In vivo

Produkt: Data ikke tilgjengelig.

Reproduksjonstoksisitet

Produkt: Data ikke tilgjengelig.

Toksisitet for Bestemte Målorganer - Enkelt Eksponering

Produkt: Data ikke tilgjengelig.

Toksisitet for Bestemte Målorganer - Gjentatt Eksponering

Produkt: Data ikke tilgjengelig.

Aspirasjonsfare

Produkt: Data ikke tilgjengelig.

Informasjon om helsefare

Andre farer

Produkt: Data ikke tilgjengelig.

Avsnitt 12: Økologiske opplysninger

Økotoksisitet:

Åkutt fare for vannmiljøet:

Fisk

Produkt: Data ikke tilgjengelig.

Vannlevende, Virvelløse Dyr

Produkt: Data ikke tilgjengelig.

Toksisitet for vannlevende planter

Produkt: Data ikke tilgjengelig.

Toksisitet til mikroorganismer

Produkt: Data ikke tilgjengelig.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Kronisk fare for vannmiljøet:

Fisk

Produkt: Data ikke tilgjengelig.

Vannlevende, Virvelløse Dyr

Produkt: Data ikke tilgjengelig.

Toksisitet for vannlevende planter

Produkt: Data ikke tilgjengelig.

Toksisitet til mikroorganismer

Produkt: Data ikke tilgjengelig.

Stabilitet og Nedbrytbarhet

Biologisk nedbryting

Produkt: Data ikke tilgjengelig.

BOD/COD-forhold

Produkt: Data ikke tilgjengelig.

Potensial for Bioakkumulering

Biokonsentrasjonsfaktor (BCF)

Produkt: Data ikke tilgjengelig.

Fordelingskoeffisient n-oktanol/vann (log Kow)

Produkt: Data ikke tilgjengelig.

Mobilitet i Jord:

Produkt Data ikke tilgjengelig.

Resultater av PBT- og vPvB-vurderinger:

Produkt Data ikke tilgjengelig.

Andre Skadelige Virkninger:

Andre farer

Produkt: Data ikke tilgjengelig.

Avsnitt 13: Instrukser om deponering

13.1 Avfallsbehandlingsmetoder

Generelle opplysninger:

Avfall og rester fjernes/avhendes i overensstemmelse med lokale forskrifter.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Metoder til fjerning:

Avhend avfallet ved et egnet behandlings- og avhendingsanlegg i samsvar med gjeldende lover og regler, og egenskapene til produktet ved avhendingstidspunktet.

Forurenset Emballasje:

Innhold/holder leveres til et passende behandlings- og deponeringsanlegg i samsvar med gjeldende lover og forskrifter og med produktets karakter ved leveringen.

Avsnitt 14: Transportopplysninger**ADR**

Ikke regulert.

ADN

- | | |
|---|----------------|
| 14.1 UN-nummer eller ID-nummer: | Ikke regulert. |
| 14.2 Korrekt Transportnavn, UN: | Ikke regulert. |
| 14.3 Transportfareklasse(r) | |
| Klasse: | Ikke regulert. |
| Etikett(er): | Ikke regulert. |
| ADR-farenr.: | Ikke regulert. |
| Tunnelrestriksjonskode: | Ikke regulert. |
| 14.4 Emballasjegruppe: | Ikke regulert. |
| Begrenset mengde | Ikke regulert. |
| Forventet mengde | Ikke regulert. |
| 14.5 Spesielle forholdsregler for brukeren: | Ikke regulert. |

RID

Ikke regulert.

IMDG

Ikke regulert.

IATA

Ikke regulert.

Transport i bulk, i samsvar med vedlegg II i MARPOL 73/78 og IBC-koden

Ugyldig for produktet i den leverte utgave.

Opplysninger om bestemmelser**15.1 Sikkerhets-, helse- og miljøforskrifter/-lovverk som er spesifikke for stoffet eller blandingen:****EU-forskrifter**

Forskrift 1005/2009/EU om stoffer som skader ozonlaget, vedlegg I, Kontrollerte stoffer: Finnes ikke,

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

eller finnes ikke i regulerte mengder.

EU. REACH Vedlegg XIV, Stoffer som er underlagt autorisasjon: Finnes ikke, eller finnes ikke i regulerte mengder.

Forskrift (EU) 2019/1021 om persistente, organiske forurensende stoffer (omstøpt), med endringer: Finnes ikke, eller finnes ikke i regulerte mengder.

Europaparlaments- og rådsdirektiv 2010/75/EU av 24. november 2010 om industriutslipp (integreert forebygging og begrensning av forurensning), VEDLEGG II Liste over forurensende stoffer: Finnes ikke, eller finnes ikke i regulerte mengder.

Forskrift (EU) nr. 649/2012, vedr. eksport og import av farlige kjemikalier, vedlegg I, del 1 med endringer: Finnes ikke, eller finnes ikke i regulerte mengder.

Forskrift (EU) nr. 649/2012, vedr. eksport og import av farlige kjemikalier, vedlegg I, del 2 med endringer: Finnes ikke, eller finnes ikke i regulerte mengder.

Forskrift (EU) nr. 649/2012, vedr. eksport og import av farlige kjemikalier, vedlegg I, del 3 med endringer: Finnes ikke, eller finnes ikke i regulerte mengder.

Forskrift (EU) nr. 649/2012, vedr. eksport og import av farlige kjemikalier, vedlegg V med endringer: Finnes ikke, eller finnes ikke i regulerte mengder.

EU. REACH Kandidatliste over stoffer med svært høy bekymring for autorisering (SVHC): Finnes ikke, eller finnes ikke i regulerte mengder.

Forskrift (EU) nr. 1907/2006 annekse XVII, Stoffer med restriksjoner på markedsføring og bruk: Direktiv 2004/37/EØF, Vern av arbeidstakerne mot fare ved å være utsatt for kreftfremkallende eller mutagene stoffer på arbeidsplassen.: Finnes ikke, eller finnes ikke i regulerte mengder.

Direktiv 92/85/EØF: Iverksetting av tiltak som forbedrer helse og sikkerhet på arbeidsplassen for gravide arbeidstakere og arbeidstakere som nylig har født eller som ammer: Finnes ikke, eller finnes ikke i regulerte mengder.

EU. Direktiv 2012/18/EU (SEVESO III) om større ulykkesfare som omfatter farlige stoffer, Vedlegg I: Finnes ikke, eller finnes ikke i regulerte mengder.

EUs forskrift nr. 166/2006 PRTR (Register over utslipp og transport av forurensende stoffer), vedlegg II: Forurensende stoffer: Finnes ikke, eller finnes ikke i regulerte mengder.

Direktiv 98/24/EF, Vern av arbeidstakernes helse og sikkerhet mot risiko i forbindelse med kjemisk agens på arbeidsplassen:

Kjemisk navn	CAS-nr.	Konsentrasjon
natriumazid	26628-22-8	0 - <0,1%

15.2 Vurdering av kjemisk sikkerhet:

Det er ikke utført kjemisk sikkerhetsvurdering.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Internasjonal lovgivning

Montrealprotokollen
Ikke anvendelig

Stockholmkonvensjonen
Ikke anvendelig

Rotterdam-konvensjonen
Ikke anvendelig

Kyotoprotokollen
Ikke anvendelig

Avsnitt 16: Andre opplysninger

Forkortelser og akronymer:
Data ikke tilgjengelig.

Referanser til litteratur og datakilder: European Chemicals Agency (ECHA): Informasjon om kjemikalier.

Innholdet i setningene i avsnitt 2 og 3
: ingen

Opplæringsinformasjon: Data ikke tilgjengelig.

HMS-databladnr.: UN000000000000332774-4012-1-01

Ansvarsfraskrivelse: Ansvarsbegrensning: Denne informasjonen er blitt innhentet fra ulike kilder og antas å være korrekt på utgivelsesdatoen. Verken BD eller noen av deres datterselskaper påtar seg imidlertid noe ansvar for nøyaktighet og fullstendighet med hensyn til denne informasjonen. Endelig vurdering av egnethet for en bestemt bruk av et materiale er utelukkende brukerens ansvar. Alle materialer kan representere ukjente farer og skal brukes med varsomhet. Selv om visse farer er beskrevet her, kan vi ikke garantere at disse er de eneste farene som finnes. BD leverer SDS i elektronisk form for å forenkle tilgang til informasjonen. På grunn av mulighet for feil under overføring gir BD ingen erklæringer om informasjonens fullstendighet og nøyaktighet.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SAFETY DATA SHEET

Classified in accordance 29 CFR 1910.1200

1. Identification

Product identifier

Product No.:	Product name:	Common name(s), synonym(s)
349202	BD FACS™ Lysing Solution	No data available

Recommended restrictions

Recommended use: Scientific and industrial laboratory use. For In Vitro Diagnostic Use.

Restrictions on use: None known.

Manufacturer/Importer/Distributor Information

Manufacturer

Company Name: Becton, Dickinson and Company - BD Biosciences

Address: 2350 Qume Drive
San Jose, CA 95131
USA

Telephone: 1 877 232 8995 or 1 800 424 9300

Fax: not available

Contact Person: Technical Services

E-mail: ResearchApplications@bd.com or ClinicalApplications@bd.com

Emergency telephone number: CHEMTREC 1 800 424 9300

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

2. Hazard(s) identification

Hazard Classification

Health Hazards

Acute toxicity (Oral)	Category 4
Acute toxicity (Dermal)	Category 4
Acute toxicity (Inhalation - vapor)	Category 4
Skin Corrosion/Irritation	Category 1B
Serious Eye Damage/Eye Irritation	Category 1
Skin sensitizer	Category 1
Germ Cell Mutagenicity	Category 2
Carcinogenicity	Category 1A
Specific Target Organ Toxicity - Single Exposure	Category 1
Specific Target Organ Toxicity - Repeated Exposure	Category 2
Specific Target Organ Toxicity - Single Exposure	Category 3

Environmental Hazards

Acute hazards to the aquatic environment	Category 3
--	------------

Label Elements

Hazard Symbol:



Signal Word: Danger



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Hazard Statement:	H302+H312+H332: Harmful if swallowed, in contact with skin or if inhaled. H314: Causes severe skin burns and eye damage. H317: May cause an allergic skin reaction. H335: May cause respiratory irritation. H341: Suspected of causing genetic defects. H350: May cause cancer. H370: Causes damage to organs. H373: May cause damage to organs through prolonged or repeated exposure. H402: Harmful to aquatic life.
Precautionary Statements	
Prevention:	P201: Obtain special instructions before use. P202: Do not handle until all safety precautions have been read and understood. P260: Do not breathe dust/fume/gas/mist/vapors/spray. P264: Wash face, hands and any exposed skin thoroughly after handling. P270: Do not eat, drink or smoke when using this product. P271: Use only outdoors or in a well-ventilated area. P272: Contaminated work clothing should not be allowed out of the workplace. P273: Avoid release to the environment. P280: Wear protective gloves/protective clothing/eye protection/face protection.
Response:	P301+P330+P331: IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. P312: Call a POISON CENTER or doctor/ physician if you feel unwell. P303+P361+P353: IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water [or shower]. P363: Wash contaminated clothing before reuse. P333+P313: If skin irritation or rash occurs: Get medical advice/attention. P304+P340: IF INHALED: Remove person to fresh air and keep comfortable for breathing. P310: Immediately call a POISON CENTER/doctor. P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P307+P311: IF exposed: Call a POISON CENTER or doctor/ physician. P308+P313: IF exposed or concerned: Get medical advice/attention.
Storage:	P405: Store locked up.
Disposal:	P501: Dispose of contents/ container to an approved facility in accordance with local, regional, national and international regulations.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Other hazards which do not result in GHS classification:

None.

3. Composition/information on ingredients

Mixtures

Chemical Identity	Common name and synonyms	CAS number	Content in percent (%) [*]
Ethanol, 2,2'-oxybis-	No data available.	111-46-6	31.3453%
Formaldehyde	No data available.	50-00-0	9.7733%
Methanol	No data available.	67-56-1	3.4338%

^{*} All concentrations are percent by weight unless ingredient is a gas. Gas concentrations are in percent by volume.

4. First-aid measures

Description of first aid measures

General information:

Get immediate medical advice/attention. May cause damage to organs through prolonged or repeated exposure. Harmful if swallowed or in contact with skin. May cause an allergic skin reaction. May cause respiratory irritation. Suspected of causing genetic defects. May cause cancer. Harmful if inhaled. Causes damage to organs. Causes severe skin burns and eye damage. Causes serious eye damage.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Inhalation:	Move the exposed person to fresh air at once. Get medical attention immediately.
Skin Contact:	Wash off promptly and flush contaminated skin with water. Promptly remove clothing if soaked through and flush skin with water. Get medical attention immediately.
Eye contact:	Important! Immediately rinse with water for at least 15 minutes. Get medical attention immediately. Continue to rinse.
Ingestion:	If swallowed, rinse mouth with water (only if the person is conscious). Call a physician or poison control center immediately.
Personal Protection for First-aid Responders:	No data available.

Most important symptoms and effects, both acute and delayed

Symptoms:	Symptoms may be delayed.
------------------	--------------------------

Hazards:	May cause damage to organs through prolonged or repeated exposure. Harmful if swallowed or in contact with skin. May cause respiratory irritation. May cause an allergic skin reaction. May cause cancer. Suspected of causing genetic defects. Causes severe skin burns and eye damage. Causes serious eye damage. Causes damage to organs.
-----------------	--

Indication of immediate medical attention and special treatment needed

Treatment:	Get immediate medical advice/attention.
-------------------	---



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

5. Fire-fighting measures

General Fire Hazards:

Extinguish all ignition sources. Avoid sparks, flames, heat and smoking. Ventilate. Use water to keep fire exposed containers cool and disperse vapors.

Suitable (and unsuitable) extinguishing media

Suitable extinguishing media:

Water spray, fog, CO₂, dry chemical, or alcohol resistant foam.

Unsuitable extinguishing media:

Avoid water in straight hose stream; will scatter and spread fire.

Special hazards arising from the substance or mixture:

Fire or excessive heat may produce hazardous decomposition products.

Special protective equipment and precautions for fire-fighters

Special fire-fighting procedures:

No unusual fire or explosion hazards noted.

Special protective equipment for fire-fighters:

Firefighters must use standard protective equipment including flame retardant coat, helmet with face shield, gloves, rubber boots, and in enclosed spaces, SCBA.

6. Accidental release measures



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Personal precautions, protective equipment and emergency procedures:

Ensure suitable personal protection (including respiratory protection) during removal of spillages in a confined area. Contact local authorities in case of spillage to drain/aquatic environment.

Accidental release measures:

No data available.

Methods and material for containment and cleaning up:

Prevent entry into waterways, sewer, basements or confined areas. Stop leak if possible without any risk. Sweep up and place in a clearly labeled container for chemical waste. See Section 8 of the SDS for Personal Protective Equipment. For waste disposal, see section 13 of the SDS.

Environmental Precautions:

Do not release into the environment. Environmental manager must be informed of all major spillages.

7. Handling and storage

Handling

Technical measures:

No data available.

Local/Total ventilation:

No data available.

Safe handling advice:

Do not breathe dust/fume/gas/mist/vapors/spray. Do not get in eyes, on skin, on clothing. Do not eat, drink or smoke when using the product. Read and follow manufacturer's recommendations. Wash promptly with



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

soap and water if skin becomes contaminated. Use personal protective equipment as required.

Contact avoidance measures: No data available.

Storage

Safe storage conditions: Store in tightly closed original container in a dry, cool and well-ventilated place. Should be stored separately from oxidizers, bases, and food chemical substances. Keep in a cool, ventilated location far from heat source and flame.

Safe packaging materials: No data available.

Storage Temperature: > 2 - 25 °C

8. Exposure controls/personal protection

Control Parameters

Occupational Exposure Limits

Chemical Identity	Type	Exposure Limit Values		Source
Formaldehyde	STEL	2 ppm		OSHA Z1A
	TWA	0.75 ppm		OSHA Z1A
	ST ESL		24 ppb	TX ESL
	AN ESL		2.7 ppb	TX ESL
	ST ESL		12 ppb	TX ESL



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	AN ESL		5.4 ppb	TX ESL
	ST ESL		30 µg/m3	TX ESL
	AN ESL		3.3 µg/m3	TX ESL
	AN ESL		6.6 µg/m3	TX ESL
	ST ESL		15 µg/m3	TX ESL
	STEL	2 ppm		US CA OEL
	TWA PEL	0.75 ppm		US CA OEL
	TWA A LV	0.5 ppm		US CA OEL
	STEL	0.3 ppm		ACGIH
	TWA	0.1 ppm		ACGIH
	Ceil_Time	0.1 ppm		NIOSH
Formaldehyde - as formaldehyde	Ceil_Time	0.1 ppm		NIOSH
Formaldehyde	REL	0.016 ppm		NIOSH
Formaldehyde - as formaldehyde	REL	0.016 ppm		NIOSH
Formaldehyde	IDLH	20 ppm		NIOSH IDLH
	STEL	2 ppm		OSHA
	TWA	0.75 ppm		OSHA
	OSHA_ACT	0.5 ppm		OSHA
	LEL		7.0 %	NIOSH IDLH
Methanol	STEL	250 ppm	325 mg/m3	OSHA Z1A
	TWA	200 ppm	260 mg/m3	OSHA Z1A
	STEL	250 ppm	325 mg/m3	TN OEL
	TWA	200 ppm	260 mg/m3	TN OEL
	ST ESL		2,620 µg/m3	TX ESL
	AN ESL		200 ppb	TX ESL
	AN ESL		262 µg/m3	TX ESL
	ST ESL		2,000 ppb	TX ESL



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	STEL	250 ppm	325 mg/m3	US CA OEL
	TWA PEL	200 ppm	260 mg/m3	US CA OEL
	Ceiling	1,000 ppm		US CA OEL
	STEL	250 ppm		ACGIH
	TWA	200 ppm		ACGIH
	REL	200 ppm	260 mg/m3	NIOSH
	STEL	250 ppm	325 mg/m3	NIOSH
	PEL	200 ppm	260 mg/m3	OSHA Z1
	IDLH	6,000 ppm		NIOSH IDLH
	LEL		6.0 %	NIOSH IDLH

Please refer to the latest edition of the appropriate source text and consult an industrial hygienist or similar professional, or local agencies, for further information.

Biological Limit Values

Chemical name	Parameters / Sampling Time	Exposure Limit Values	Source
Methanol	methanol Sampling time: End of shift.	15 mg/l (Urine)	ACGIH BEI

Appropriate Engineering Controls

Adequate ventilation should be provided so that exposure limits are not exceeded.

Individual protection measures, such as personal protective equipment



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Eye/face protection:

Wear safety glasses with side shields (or goggles). A - Safety Glasses

Skin Protection

Hand Protection:

Material: Use suitable protective gloves if risk of skin contact.

Skin and Body Protection:

Wear appropriate clothing to prevent reasonably probable skin contact. Wear chemical-resistant gloves and protective clothing appropriate for the risk of exposure. Recommended gloves:

Respiratory Protection:

If engineering controls do not maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (in countries where exposure limits have not been established), an approved respirator must be worn.

Hygiene measures:

Do not eat, drink or smoke when using the product. Do not get this material in contact with skin. Wash promptly if skin becomes contaminated. Wash at the end of each work shift and before eating, smoking and using the toilet. Do not handle until all safety precautions have been read and understood. Avoid breathing dust/fume/gas/mist/vapors/spray.

9. Physical and chemical properties
--

Information on basic physical and chemical properties

Appearance



**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Physical state:	liquid
Form:	liquid
Color:	Colorless to yellow
Odor:	Slight odor
Odor Threshold:	No data available.
Freezing point:	No data available.
Boiling Point:	No data available.
Flammability:	No data available.
Upper/lower limit on flammability or explosive limits	
Explosive limit - upper:	No data available.
Explosive limit - lower:	No data available.
Flash Point:	295 °F/146 °C
Autoignition Temperature:	No data available.
Decomposition Temperature:	No data available.
pH:	7.10 - 7.80
Viscosity	
Dynamic viscosity:	No data available.
Kinematic viscosity:	No data available.
Flow Time:	No data available.
Solubility(ies)	
Solubility in Water:	Soluble



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Solubility (other): No data available.

Partition coefficient (n-octanol/water): No data available.

Vapor pressure: 23 hPa
68 °F/20 °C

Relative density: No data available.

Density: 1 g/cm³

Bulk density: No data available.

Relative vapor density: No data available.

Other information

No data available

10. Stability and reactivity

Reactivity: No data available.

Chemical Stability: No data available.

Possibility of hazardous reactions: Do not subject to grinding/shock/friction/. Contact with acids and metals can lead to violent decomposition.

Conditions to avoid: Heat, sparks, flames. Shocks and physical damage. Avoid conditions which create dust.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Incompatible Materials: Strong acids. Strong oxidizing agents. Peroxides. Other metals or alloys.

Hazardous Decomposition Products: By fire, toxic gases may be formed (COx, NOx).

11. Toxicological information

General information: Formaldehyde: Formaldehyde has carcinogenic potential and is a known skin and respiratory sensitizer. Symptoms may be delayed.

Information on likely routes of exposure

Inhalation: May cause irritation to the respiratory system. Harmful if inhaled.

Skin Contact: Harmful in contact with skin. Causes severe skin burns.

Eye contact: Causes serious eye damage.

Ingestion: Harmful if swallowed. Ingestion may cause severe irritation of the mouth, the esophagus and the gastrointestinal tract.

Acute toxicity (list all possible routes of exposure)

Oral

Product: ATEmix, 513.45 mg/kg

Components:

Ethanol, 2,2'-oxybis- No data available.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Formaldehyde	LD 50, Rat, 460 mg/kg, 2 = reliable with restrictions, Weight of evidence
--------------	---

Methanol	LD 50, Pig, 5,000 mg/kg
----------	-------------------------

Dermal

Product: ATEmix, 1,441.01 mg/kg

Components:

Ethanol, 2,2'-oxybis-	No data available.
-----------------------	--------------------

Formaldehyde	LD 50, Rabbit, 270 mg/kg
--------------	--------------------------

Methanol	LD 50, Rabbit, 17,100 mg/kg, 4 = not assignable
----------	---

Inhalation

Product: ATEmix, 15.59 mg/l, Vapour

Components:

Ethanol, 2,2'-oxybis-	LC 50, Rat, 6 h, >, 5.08 mg/l
-----------------------	-------------------------------

Formaldehyde	No data available.
--------------	--------------------

Methanol	No data available.
----------	--------------------

Repeated dose toxicity

Product: No data available.

Components:

Ethanol, 2,2'-oxybis-	No data available.
-----------------------	--------------------

Formaldehyde	No data available.
--------------	--------------------

Methanol	NOAEL Mouse, Female, Male, Inhalation, 7,202 - 7,373 h, 0.13 mg/l, Experimental result, Weight of Evidence study Inhalation
----------	---

	NOAEL Rat, Male, Inhalation, 1 - 6 Weeks, 2.65 mg/l, Experimental result, Supporting study Inhalation
--	---

	NOAEL Rat, Male, Inhalation, 1.06 mg/l, Experimental result,
--	--



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Supporting study Inhalation

NOAEL Rat, Female, Male, Inhalation, 7,318 - 7,496 h, 0.13 mg/l,
Experimental result, Weight of Evidence study Inhalation

LOAEL Rat, Female, Male, Inhalation, 7,318 - 7,496 h, 1.3 mg/l,
Experimental result, Weight of Evidence study Inhalation

Skin Corrosion/Irritation

Product: No data available.

Components:

Ethanol, 2,2'-oxybis-	Non-Irritating
Formaldehyde	No data available.
Methanol	No data available.

Serious Eye Damage/Eye Irritation

Product: No data available.

Components:

Ethanol, 2,2'-oxybis-	No data available.
Formaldehyde	No data available.
Methanol	No data available.

Respiratory or Skin Sensitization

Product: No data available.

Components:

Ethanol, 2,2'-oxybis-	Skin sensitizer
	Skin sensitization:, in vivo, Guinea pig, Non sensitising
Formaldehyde	Skin sensitization:, in vivo, Guinea pig, Sensitising
Methanol	Skin sensitization:, in vivo, Guinea pig, Non sensitising



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Carcinogenicity

Product: No data available.

Components:

Ethanol, 2,2'-oxybis- No data available.

Formaldehyde No data available.

Methanol No data available.

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans:

Formaldehyde Overall evaluation: 1. Carcinogenic to humans.

ACGIH: US.ACGIH Threshold Limit Values:

Formaldehyde Hazard Designation: Group A1. Confirmed human carcinogen.
Hazard Designation: Dermal sensitization Hazard Designation:
Respiratory sensitization

US. National Toxicology Program (NTP) Report on Carcinogens:

Formaldehyde Known To Be Human Carcinogen.

US. OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050), as amended:

Formaldehyde Cancer



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Germ Cell Mutagenicity

In vitro

Product: No data available.

Components:

Ethanol, 2,2'-oxybis- No data available.

Formaldehyde No data available.

Methanol No data available.

In vivo

Product: No data available.

Components:

Ethanol, 2,2'-oxybis- No data available.

Formaldehyde No data available.

Methanol No data available.

Reproductive toxicity

Product: No data available.

Components:

Ethanol, 2,2'-oxybis- No data available.

Formaldehyde No data available.

Methanol No data available.

Specific Target Organ Toxicity - Single Exposure

Product: No data available.

Components:

Ethanol, 2,2'-oxybis- Based on available data, the classification criteria are not met.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Formaldehyde	Inhalation - vapor, Respiratory system, Causes damage to organs.
--------------	--

Methanol	Oral, Nervous System, Causes damage to organs.
----------	--

Specific Target Organ Toxicity - Repeated Exposure

Product: No data available.

Components:

Ethanol, 2,2'-oxybis-	No data available.
-----------------------	--------------------

Formaldehyde	No data available.
--------------	--------------------

Methanol	No data available.
----------	--------------------

Aspiration Hazard

Product: No data available.

Components:

Ethanol, 2,2'-oxybis-	No data available.
-----------------------	--------------------

Formaldehyde	No data available.
--------------	--------------------

Methanol	No data available.
----------	--------------------

Information on health hazards

Other hazards

Product: No data available.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

12. Ecological information

General information: Contains a substance which causes risk of hazardous effects to the environment. Harmful to aquatic life with long lasting effects.

Ecotoxicity:

Acute hazards to the aquatic environment:

Fish

Product: No data available.

Components:

Ethanol, 2,2'-oxybis-	LC 50, Pimephales promelas, 96 h, 75,200 mg/lAcute toxicity
	LC 50, Pimephales promelas, 96 h, 75,200 mg/lflow-through, Experimental result, Key study
	LC 50, Western mosquitofish (Gambusia affinis), 48 h, > 32,000 mg/lStatic, Mortality
	LC 50, Carp (Leuciscus idus melanotus), 48 h, > 10,000 mg/l, Mortality
	LC 50, Western mosquitofish (Gambusia affinis), 24 h, > 32,000 mg/lStatic, Mortality
Formaldehyde	LC 50, Morone saxatilis, 96 h, 6.7 mg/lStatic, Experimental result, Key study
Methanol	LC 50, Pimephales promelas, 96 h, 29,400 mg/lAcute toxicity
	EC 50, Pimephales promelas, 96 h, 28,900 mg/lflow-through, Experimental result, Supporting study
	LC 50, Pimephales promelas, 48 h, 28,400 mg/lflow-through, Experimental result, Supporting study
	LC 50, Pimephales promelas, 96 h, 28,100 mg/lflow-through,



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Experimental result, Supporting study

LC 50, *Trachinotus carolinus*, 24 h, 10,112 mg/lStatic,
Experimental result, Supporting study

Aquatic Invertebrates

Product: The product contains a substance which is toxic to aquatic organisms.

Components:

Ethanol, 2,2'-oxybis-	LC 50, Brine shrimp (<i>Artemia salina</i>), 24 h, > 10,000 mg/lStatic, Mortality
Formaldehyde	EC 50, <i>Daphnia pulex</i> , 48 h, 5.8 mg/lStatic, Experimental result, Key study experimental result
Methanol	No data available.

Toxicity to Aquatic Plants

Product: No data available.

Components:

Ethanol, 2,2'-oxybis-	No data available.
Formaldehyde	EC 50, Green algae (<i>Scenedesmus subspicatus</i>), 72 h, 4.89 mg/l
Methanol	No data available.

Toxicity to microorganisms

Product: No data available.

Components:

Ethanol, 2,2'-oxybis-	No data available.
Formaldehyde	No data available.
Methanol	LC 50, Turbellarian, flatworm (<i>Dugesia tigrina</i>), 96 h, > 100 mg/l, Mortality



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Chronic hazards to the aquatic environment:

Fish

Product:	No data available.
Components:	
Ethanol, 2,2'-oxybis-	Not expected to be harmful to aquatic organisms.
Formaldehyde	LC 50, Danio rerio, 144 h, 6.9 mg/l, semi-static, Experimental result, Supporting study experimental result
Methanol	No data available.

Aquatic Invertebrates

Product:	Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment.
Components:	
Ethanol, 2,2'-oxybis-	No data available.
Formaldehyde	LOAEL, Ceriodaphnia dubia, 7 d, 6 mg/l, Experimental result, Not specified experimental result
Methanol	No data available.

Toxicity to microorganisms

Product:	No data available.
Components:	
Ethanol, 2,2'-oxybis-	No data available.
Formaldehyde	No data available.
Methanol	LC 50, Turbellarian, flatworm (Dugesia tigrina), 96 h, > 100 mg/l, Mortality



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Persistence and Degradability

Biodegradation

Product:	No data available.
Components:	
Ethanol, 2,2'-oxybis-	90 - 100 %, 28 d, Experimental result, Weight of Evidence study Detected in water. 25 - 92 %, 28 d, Read-across based on grouping of substances (category approach), Weight of Evidence study Detected in water. 70 - 80 %, 28 d, Experimental result, Weight of Evidence study Detected in water. 90 - 100 %, 20 d, Read-across based on grouping of substances (category approach), Weight of Evidence study Detected in water. 90 - 100 %, 10 d, Read-across based on grouping of substances (category approach), Weight of Evidence study Detected in water.
Formaldehyde	Readily biodegradable 97 %, 2 Weeks, Experimental result, Key study Detected in water.
Methanol	84 %, Experimental result, Key study Detected in water. 46.3 %, 5 d, Experimental result, Supporting study Soil 69 %, Experimental result, Key study Detected in water. 71.5 %, 5 d, Experimental result, Key study Detected in water. 82.7 %, 5 d, Experimental result, Key study Detected in water.

BOD/COD Ratio

Product:	No data available.
Components:	



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Ethanol, 2,2'-oxybis-	No data available.
Formaldehyde	No data available.
Methanol	No data available.

Bioaccumulative potential

Bioconcentration Factor (BCF)

Product:	No data available.
Components:	
Ethanol, 2,2'-oxybis-	No data available.
Formaldehyde	Will not bio-accumulate.
Methanol	Green algae (<i>Chlorella fusca vacuolata</i>), 28,400, Static

Partition Coefficient n-octanol / water (log Kow)

Product:	No data available.
Components:	
Ethanol, 2,2'-oxybis-	No data available.
Formaldehyde	0.35
Methanol	-0.77

Mobility in soil:

Product	No data available.
Components:	
Ethanol, 2,2'-oxybis-	No data available.
Formaldehyde	No data available.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Methanol No data available.

Results of PBT and vPvB assessment:

Product	No data available.
Components:	
Ethanol, 2,2'-oxybis-	No data available.
Formaldehyde	Not fulfilling PBT (persistent/bioaccumulative/toxic) criteria, Not fulfilling vPvB (very persistent/very bioaccumulative) criteria
Methanol	No data available.

Other adverse effects:

Other hazards

Product: No data available.

13. Disposal considerations

General information: This material and its container must be disposed of as hazardous waste.

Disposal methods: Dispose of waste at a facility with special permission to dispose industrial wastes subject to special control. Waste should be accompanied by a manifest for the industrial wastes.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Contaminated Packaging:

Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

14. Transport information

Environmental Hazards

Environmentally Hazardous: No

Marine Pollutant: No

IATA

Not regulated.

IMDG

Not regulated.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

15. Regulatory information

US Federal Regulations

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

None present or none present in regulated quantities.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

US. Toxic Substances Control Act (TSCA) Section 5(a)(2) Final Significant New Use Rules (SNURs) (40 CFR 721, Subpt E)

None present or none present in regulated quantities.

US. OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050), as amended

<u>Chemical Identity</u>	<u>OSHA hazard(s)</u>
FORMALDEHYDE	Respiratory sensitization
	Acute toxicity
	Eye irritation
	Skin sensitization
	Skin irritation
	Flammability
	Cancer
	respiratory tract irritation

CERCLA Hazardous Substance List (40 CFR 302.4):

<u>Chemical Identity</u>
FORMALDEHYDE
METHANOL

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories



**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Acute toxicity (any route of exposure), Skin Corrosion or Irritation, Serious eye damage or eye irritation, Respiratory or Skin Sensitization, Germ Cell Mutagenicity, Carcinogenicity, Specific target organ toxicity (single or repeated exposure)

US. EPCRA (SARA Title III) Section 304 Extremely Hazardous Substances Reporting Quantities and the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) Hazardous Substances

Chemical Identity

Formaldehyde;
Formaldehyde
(solution)

US. EPCRA (SARA Title III Section 313 Toxic Chemical Release Inventory (TRI) Reporting

<u>Chemical Identity</u>	<u>% by weight</u>
FORMALDEHYDE	0.1%
METHANOL	1.0%

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130):

none

Chemical Identity

FORMALDEHYDE (SOLUTION)

Clean Water Act Section 311 Hazardous Substances (40 CFR 117.3)

Chemical Identity

FORMALDEHYDE

US State Regulations



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

US. California Proposition 65



WARNING: This product can expose you to chemicals including, Formaldehyde which is [are] known to the State of California to cause cancer.

This product can expose you to chemicals including, Methanol which is [are] known to the State of California to cause birth defects or other reproductive harm.

For more information go to www.P65Warnings.ca.gov.

International regulations

Montreal protocol

Not applicable

Stockholm convention

Not applicable

Rotterdam convention

Not applicable

Kyoto protocol

Not applicable

16. Other information, including date of preparation or last revision

Issue Date: 04/06/2012



**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Version #: 2.5

Abbreviations and acronyms:

ACGIH:	US. ACGIH Threshold Limit Values, as amended
ACGIH BEI:	US. ACGIH. BEIs. Biological Exposure Indices, as amended
NIOSH IDLH:	US. NIOSH. Immediately Dangerous to Life or Health (IDLH) Values, as amended
NIOSH/GUIDE:	US. NIOSH: Pocket Guide to Chemical Hazards, as amended
OSHA_TRANS:	US. OSHA Table Z-1 Limits for Air Contaminants (29 CFR 1910.1000), as amended
OSHASP:	US. OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053), as amended
TN OEL:	US. Tennessee. OELs. Occupational Exposure Limits, Table Z1A, as amended
TX ESL:	US. Texas. Effects Screening Levels (Texas Commission on Environmental Quality), as amended
US CA OEL:	US. California Code of Regulations, Title 8, Section 5155. Airborne Contaminants, as amended
Z1A:	US. OSHA Table Z-1-A (29 CFR 1910.1000), as amended
ACGIH / STEL:	Short Term Exposure Limit (STEL):
ACGIH / TWA:	Time Weighted Average (TWA):
NIOSH IDLH / LEL:	Lower Explosive Limit (LEL):
NIOSH IDLH / IDLH:	Immediately dangerous to life or health (IDLH) concentration:
NIOSH/GUIDE / Ceil_Time:	Ceiling Limit Value and Time Period (if specified):
NIOSH/GUIDE / REL:	Recommended exposure limit (REL):
NIOSH/GUIDE / STEL:	Short Term Exposure Limit (STEL):
OSHA_TRANS / PEL:	Permissible exposure limit:
OSHASP / OSHA_ACT:	OSHA Action level:



**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

OSHASP / STEL:	Short Term Exposure Limit (STEL):
OSHASP / TWA:	Time Weighted Average (TWA):
TN OEL / STEL:	Short Term Exposure Limit (STEL):
TN OEL / TWA:	Time Weighted Average (TWA):
TX ESL / ST ESL:	Short-Term ESL:
TX ESL / AN ESL:	Annual ESL:
US CA OEL / Ceiling:	Ceiling Limit Value:
US CA OEL / STEL:	Short Term Exposure Limit (STEL):
US CA OEL / TWA A LV:	TWA Action Level:
US CA OEL / TWA PEL:	Time Weighted Average (TWA) Permissible Exposure Limit (PEL):
Z1A / STEL:	Short Term Exposure Limit (STEL):
Z1A / TWA:	Time Weighted Average (TWA):

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse)



**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further Information: No data available.

Disclaimer: Disclaimer:

The information contained herein has been obtained from various sources and is believed to be correct as of the date issued. However, neither BD nor any of its subsidiaries assumes any liabilities whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability for a particular use of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist. BD provides SDS in electronic form so the information may be more easily accessed. Due to the possibility of errors during transmission, BD makes no representations as to the completeness or accuracy of the information.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SIKKERHEDSDATABLAD

Ifølge Forordning (EF) nr. 1907/2006 (REACH) artikel 31, bilag II med ændringer

PUNKT 1: Identifikation af stoffet/blandingen og af selskabet/virksomheden

Produktidentifikator

Produkt nr.:	Produktnavn:	Trivialnavn(e), synonym(er)
349524	BD® CellWASH	Ingen data tilgængelige

1.2 Relevante identificerede anvendelser for stoffet eller blandingen samt anvendelser, der frarådes

Identificerede anvendelser: Til videnskabelig og industriel laboratoriebrug.

Anvendelser som frarådes: Ingen kendte.

1.3 Nærmere oplysninger om leverandøren af sikkerhedsdatabladet

Producent

Becton Dickinson France S.A.S. Belgian Branch
Erembodegem-Dorp 86
9320 Erembodegem
Belgium

Telefon: 32 2 400 98 95

Fax: 32 2 401 70 94

Kontaktperson: BD Biosciences - Centralized European Office
Regulatory Compliance Department
E-mail: help.biosciences@europe.bd.com

1.4 Nødtelefon: 32 2 400 98 95

PUNKT 2: Fareidentifikation

2.1 Klassificering af stoffet eller blandingen

Produktet er ikke klassificeret som farligt i henhold til gældende lovgivning.

Klassificering i henhold til forordning (EF) nr. 1272/2008 med senere ændringer.

Ikke klassificeret

2.2 Mærkningselementer

Ikke relevant

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

2.3 Andre farer

Hormonforstyrrende egenskaber-Toksicitet

Substansen/blandingen indeholder ikke komponenter, der anses at have egenskaber med hormonforstyrrende virkning i henhold til REACH Artikel 57(f) eller Kommissionens delegerede forordning (EU) 2017/2100 eller Kommissionens forordning (EU) 2018/605 på niveauer på 0.1 % eller derover.

Hormonforstyrrende egenskaber-Økotoksicitet

Substansen/blandingen indeholder ikke komponenter, der anses at have egenskaber med hormonforstyrrende virkning i henhold til REACH Artikel 57(f) eller Kommissionens delegerede forordning (EU) 2017/2100 eller Kommissionens forordning (EU) 2018/605 på niveauer på 0.1 % eller derover.

PUNKT 3: Sammensætning af/oplysning om indholdsstoffer

3.2 Blandinger

Generelle oplysninger: Ingen skadelige ingredienser

PUNKT 4: Førstehjælpsforanstaltninger

4.1 Beskrivelse af førstehjælpsforanstaltninger

Generelle oplysninger:	Søg læge ved tegn på symptomer.
Indånding:	Frisk luft, varme og ro, helst i behagelig halvsiddende stilling.
Hudkontakt:	Vask med vand og sæbe. Tag forurenede beklædninger af. Vask forurenede tøj, før det bruges igen.
Øjenkontakt:	Skyl straks med rigeligt vand i mindst 15 minutter. Hvis det er nemt, fjernes kontaktlinser.
Indtagelse:	Kontakt øjeblikkeligt en læge eller en forgiftningsklinik. Opkastning må kun fremkaldes efter vejledning fra sundhedspersonale. Indgiv aldrig noget til en bevidstløs person gennem munden.
Personlige værnemidler for førstehjælper:	Ingen oplysninger.

4.2 Vigtigste symptomer og virkninger, både akutte og forsinkede Symptomer:

Ingen oplysninger.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Farer: Ingen oplysninger.

4.3 Angivelse af om øjeblikkelig lægehjælp og særlig behandling er nødvendig

Behandling: Ingen oplysninger.

PUNKT 5: Brandbekæmpelse

Almindelige Brandfarer: Fjern alle antændelseskilder. Undgå gnister, flammer, varme og rygning. Sørg for god udluftning. Brug vandtåge til at holde beholdere, der er udsat for brand, afkølet.

5.1 Slukningsmidler

Egnede slukningsmidler: Brandslukningsmiddel vælges under hensyntagen til evt. andre kemikalier.

Uegnede slukningsmidler: Ikke relevant

5.2 Særlige farer i forbindelse med stoffet eller blandingen: Ild eller kraftig varme kan danne farlige nedbrydningsprodukter.

5.3 Anvisninger for brandmandskab

Særlige forholdsregler ved brandbekæmpelse: Ingen usædvanlig brand- eller eksplosionsfare angivet.

Særlige beskyttelsesmidler for brandmandskab: Brandslukningspersonalet skal benytte almindeligt beskyttelsesudstyr, herunder brandhæmmende frakke, hjelm med ansigtsskærm, handsker, gummistøvler og, på tillukkede steder, SCBA-udstyr.

PUNKT 6: Forholdsregler over for udslip ved uheld

6.1 Personlige sikkerhedsforanstaltninger, personlige værnemidler og nødprocedurer: Ved større udslip til afløb/vandmiljø underrettes lokale myndigheder. Sørg for passende personlig beskyttelse (inklusive åndedrætsværn) ved fjernelse af spild i et lukket område.

6.1.1 For ikke-indsatspersonel: Ingen oplysninger.

6.1.2 For indsatspersonel: Ingen oplysninger.

6.2 Miljøbeskyttelsesforanstaltninger: Undgå udledning til miljøet.

6.3 Metoder og udstyr til inddæmning og oprensning: Spild opsuges med egnet absorberende materiale. Undgå, at afløbsvand kommer i kloak afløb, kloakker eller vandløb. Se punkt 8 vedr. personlige værnemidler. Se punkt 13 vedr. bortskaffelse.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

- 6.4 Henvisning til andre punkter: Ingen oplysninger.

PUNKT 7: Håndtering og opbevaring

7.1 Forholdsregler for sikker håndtering

- Tekniske forholdsregler:** Ingen oplysninger.
- Punkt/Rum ventilation:** Ingen oplysninger.
- Håndtering:** Der må ikke spises, drikkes eller ryges under brugen. Læs og følg producentens anvisninger. Anvend de påkrævede personlige værnemidler.
- Forholdsregler til undgåelse af kontakt:** Ingen oplysninger.

7.2 Betingelser for sikker opbevaring, herunder eventuel uforenelighed

- Sikre opbevaringsbetingelser:** Opbevares tørt og køligt. Emballagen skal holdes tæt lukket.
- Sikre emballagematerialer:** Ingen oplysninger.

- 7.3 Særlige anvendelser: Forbeholdt industriel og erhvervsmæssig brug. Læs etiketten før brug.

PUNKT 8: Eksponeringskontrol/personlige værnemidler

8.1 Kontrolparametre

Grænseværdier for Erhvervsmæssig Eksponering

Ingen af komponenterne har tildelte eksponeringsgrænser.

Biologiske Grænseværdier

Der er ikke angivet biologiske eksponeringsgrænser for indholdsstoffet/indholdsstofferne.

DNEL-værdier

Bemærkninger: DNEL-værdier

Kritisk komponent	Type	Eksponeringsvej	Sundhedsfarer	Bemærkninger
Sodium azide (Na(N3))	Arbejdstagere	Inhalation	Systemiske, længerevarende; 0,164 mg/m ³	Toksicitet ved gentagen dosering
	Den almindelige befolkning	Øjne	Lokal effekt;	Ingen fare identificeret
	Den almindelige befolkning	Inhalation	Systemiske, længerevarende; 29 µg/m ³	Toksicitet ved gentagen dosering
	Arbejdstagere	Øjne	Lokal effekt;	Ingen fare identificeret

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Arbejdstagere	Hudkontakt	Systemiske, længerevarende; 0,0467 mg/kg	Toksicitet ved gentagen dosering
	Den almindelige befolkning	mundtlig	Systemiske, længerevarende; 0,0167 mg/kg	Toksicitet ved gentagen dosering
	Den almindelige befolkning	Hudkontakt	Systemiske, længerevarende; 0,0167 mg/kg	Toksicitet ved gentagen dosering

Sodium Chloride (NaCl)	Den almindelige befolkning	Inhalation	Systemiske, længerevarende; 443,28 mg/m3	Toksicitet ved gentagen dosering
	Arbejdstagere	Inhalation	Systemiske, længerevarende; 2068,62 mg/m3	Toksicitet ved gentagen dosering
	Arbejdstagere	Inhalation	Systemiske, kortvarig; 2068,62 mg/m3	Toksicitet ved gentagen dosering
	Den almindelige befolkning	Inhalation	Systemiske, kortvarig; 443,28 mg/m3	Toksicitet ved gentagen dosering
	Den almindelige befolkning	mundtlig	Systemiske, længerevarende; 126,65 mg/kg	Toksicitet ved gentagen dosering
	Arbejdstagere	Hudkontakt	Systemiske, længerevarende; 295,52 mg/kg	Toksicitet ved gentagen dosering
	Arbejdstagere	Hudkontakt	Systemiske, kortvarig; 295,52 mg/kg	Toksicitet ved gentagen dosering
	Den almindelige befolkning	mundtlig	Systemiske, kortvarig; 126,65 mg/kg	Toksicitet ved gentagen dosering
	Den almindelige befolkning	Hudkontakt	Systemiske, kortvarig; 126,65 mg/kg	Toksicitet ved gentagen dosering
	Den almindelige befolkning	Hudkontakt	Systemiske, længerevarende; 126,65 mg/kg	Toksicitet ved gentagen dosering

PNEC-værdier

Bemærkninger: PNEC-værdier

Kritisk komponent	Delmiljø	PNEC-værdier	Bemærkninger
Sodium azide (Na(N3))	Vandmiljø (havvand)	15 ng/l	
	Rensningsanlæg	30 µg/l	
	Bundfald (ferskvand)	0,0167 mg/kg	
	Vandmiljø (ferskvand)	0,35 µg/l	
	Bundfald (havvand)	0,00072 mg/kg	

Sodium Chloride (NaCl)	Jord	4,86 mg/kg	
	Vandmiljø (ferskvand)	5 mg/l	
	Rensningsanlæg	500 mg/l	

8.2 Eksponeringskontrol

Passende Tekniske

Sikkerhedsforanstaltninger:

Ingen særlige krav under almindelige anvendelsesbetingelser og ved tilstrækkelig ventilation.

Individuelle beskyttelsesforanstaltninger som f.eks. personlige værnemidler

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Beskyttelse af øjne/ansigt:	Brug sikkerhedsbriller med sideskærme (eller tætsluttende sikkerhedsbriller).
Beskyttelse af Hænder:	Materiale: Kemikalieresistente handsker Supplerende oplysninger: Vask hænder efter kontakt. Materiale: Egnede handsker kan anvises af handskeleverandøren.
Beskyttelse af hud og krop:	Brug laboratoriekittel eller tilsvarende beskyttelsesbeklædning.
Beskyttelse af åndedrætsorganer:	Hvis teknisk styring ikke kan sikre, at luftbårne koncentrationer holdes under de anbefalede eksponeringsgrænser eller på et acceptabelt niveau (i lande hvor der ikke er fastsat eksponeringsgrænser), skal der bæres godkendt åndedrætsværn.
Hygiejniske foranstaltninger:	Følg anvisningerne for god kemikaliehygiejne.
Foranstaltninger til begrænsning af eksponering af miljøet:	Ingen oplysninger.

PUNKT 9: Fysiske og kemiske egenskaber

9.1 Oplysninger om grundlæggende fysiske og kemiske egenskaber

Udseende

Form:	flydende
Form:	Ingen oplysninger.
Farve:	Ingen oplysninger.
Lugt:	Ingen oplysninger.
Lugtgrænse, lugttærskel:	Ingen oplysninger.
Frysepunkt:	Ingen oplysninger.
Kogepunkt:	Ingen oplysninger.
Brandfarlighed:	Ingen oplysninger.
Øvre/nedre antændelsesgrænse eller eksplosionsgrænser	
Eksplosionsgrænse - øvre (%):	Ingen oplysninger.
Eksplosionsgrænse - nedre (%):	Ingen oplysninger.
Flammepunkt:	Ingen oplysninger.
Selvantændelsestemperatur:	Ingen oplysninger.
Nedbrydningstemperatur:	Ingen oplysninger.
pH-værdi:	Ingen oplysninger.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Viskositet

Dynamisk viskositet: Ingen oplysninger.

Kinematisk viskositet: Ingen oplysninger.

Gennemstrømningstid: Ingen oplysninger.

Opløselighed

Opløselighed i vand: Ingen oplysninger.

Opløselighed (anden): Ingen oplysninger.

Opløsningshastighed: Ingen oplysninger.

Fordelingskoefficient (n-octanol/vand):

Ingen oplysninger.

Dispersionsstabilitet: Ingen oplysninger.

Damptryk:

Ingen oplysninger.

Relativ massefylde:

Ingen oplysninger.

Massefylde:

Ingen oplysninger.

Vægtfylde:

Ingen oplysninger.

Relativ dampvægtfylde:

Ingen oplysninger.

9.2 Andre oplysninger

Ingen data tilgængelige

PUNKT 10: Stabilitet og reaktivitet

- | | | |
|-------------|---------------------------------------|--|
| 10.1 | Reaktivitet: | Materialet er stabilt under normale betingelser. |
| 10.2 | Kemisk stabilitet: | Materialet er stabilt under normale betingelser. |
| 10.3 | Risiko for farlige reaktioner: | Stabil |
| 10.4 | Forhold, der skal undgås: | Må ikke udsættes for høje temperaturer eller direkte sollys. |
| 10.5 | Materialer, der skal undgås: | Metaller. Vandreaktivt materiale. |
| 10.6 | Farlige nedbrydningsprodukter: | Stabilt; kan dog nedbrydes ved opvarmning. |

PUNKT 11: Toksikologiske oplysninger

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

11.1 Oplysninger om fareklasser som defineret i forordning (EF) nr. 1272/2008

Indånding: Ingen oplysninger.

Hudkontakt: Ingen oplysninger.

Øjenkontakt: Ingen oplysninger.

Indtagelse: Ingen oplysninger.

Oplysninger om sandsynlige eksponeringsveje

Akut toksicitet (angiv alle eksponeringsveje, som anses for at være mulige)

Indtagelse

Produkt: Ikke klassificeret for akut toksicitet ud fra tilgængelige data.

Hudkontakt

Produkt: Ikke klassificeret for akut toksicitet ud fra tilgængelige data.

Indånding

Produkt: Ikke klassificeret for akut toksicitet ud fra tilgængelige data.

Toksicitet ved gentagen dosering

Produkt: Ingen oplysninger.

Ætsning og Irritation for Huden

Produkt: Ingen oplysninger.

Alvorlig Skade/Irritation for Øjne

Produkt: Ingen oplysninger.

Luftvejs Eller Hud Sensibilisering

Produkt: Ingen oplysninger.

Kræftfremkaldende egenskaber

Produkt: Ingen oplysninger.

Kimcellemutagenicitet

In vitro

Produkt: Ingen oplysninger.

In vivo

Produkt: Ingen oplysninger.

Reproduktionstoksicitet

Produkt: Ingen oplysninger.

Specifik Organtoksicitet - Enkelt Eksponering

Produkt: Ingen oplysninger.

Specifik Organtoksicitet - Gentagne Eksponeringer

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Produkt: Ingen oplysninger.

Inhaleringsfare

Produkt: Ingen oplysninger.

11.2 Oplysninger om andre farer

Hormonforstyrrende egenskaber

Produkt: Substansen/blandingen indeholder ikke komponenter, der anses at have egenskaber med hormonforstyrrende virkning i henhold til REACH Artikel 57(f) eller Kommissionens delegerede forordning (EU) 2017/2100 eller Kommissionens forordning (EU) 2018/605 på niveauer på 0.1 % eller derover.;

Andre oplysninger

Produkt: Ingen oplysninger.

PUNKT 12: Miljøoplysninger

12.1 Toksicitet:

Akutte farer for vandmiljøet:

Fisk

Produkt: Ingen oplysninger.

Hvirvelløse Vandorganismer

Produkt: Ingen oplysninger.

Giftighed for vandplanter

Produkt: Ingen oplysninger.

Giftighed overfor mikroorganismer

Produkt: Ingen oplysninger.

Kroniske farer for vandmiljøet:

Fisk

Produkt: Ingen oplysninger.

Hvirvelløse Vandorganismer

Produkt: Ingen oplysninger.

Giftighed for vandplanter

Produkt: Ingen oplysninger.

Giftighed overfor mikroorganismer

Produkt: Ingen oplysninger.

12.2 Persistens og nedbrydelighed

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Biologisk nedbrydning

Produkt: Ingen oplysninger.

BOD/COD-forhold

Produkt: Ingen oplysninger.

12.3 Bioakkumuleringspotentiale

Biokoncentrationsfaktor (BKF)

Produkt: Ingen oplysninger.

Fordelingskoefficient n-oktanol/vand (log Kow)

Produkt: Ingen oplysninger.

12.4 Mobilitet i jord:

Produkt Ingen oplysninger.

12.5 Resultater af PBT- og vPvB-vurdering:

Produkt Ingen oplysninger.

12.6 Hormonforstyrrende egenskaber:

Produkt: Substansen/blandingen indeholder ikke komponenter, der anses at have egenskaber med hormonforstyrrende virkning i henhold til REACH Artikel 57(f) eller Kommissionens delegerede forordning (EU) 2017/2100 eller Kommissionens forordning (EU) 2018/605 på niveauer på 0.1 % eller derover.

12.7 Andre negative virkninger:

Andre farer

Produkt: Ingen oplysninger.

PUNKT 13: Bortskaffelse

13.1 Metoder til affaldsbehandling

Generelle oplysninger:

Spild og rester bortskaffes i overensstemmelse med de lokale myndigheders anvisninger.

Bortskaffelsesmetoder:

Aflever affaldsmaterialet på en miljøgodkendt losseplads ihht. gældende forskrifter samt under hensyntagen til produktets egenskaber på det aktuelle tidspunkt.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Forurennet Emballage:

Indhold/beholder bortskaffes i et passende behandlings- og bortskafningsanlæg i henhold til gældende love og forskrifter og produktets tilstand på bortskafningstidspunktet.

PUNKT 14: Transportoplysninger**ADR**

- | | |
|---|-----------------|
| 14.1 UN-nummer eller ID-nummer: | Ikke reguleret. |
| 14.2 UN-forsendelsesbetegnelse (UN proper shipping name): | Ikke reguleret. |
| 14.3 Transportfareklasse(r) | |
| Klasse: | Ikke reguleret. |
| Etiket(ter): | Ikke reguleret. |
| ADR farenr.: | Ikke reguleret. |
| Tunnelrestriktionskode: | Ikke reguleret. |
| 14.4 Emballagegruppe: | Ikke reguleret. |
| Begrænset mængde | Ikke reguleret. |
| Undtaget mængde | Ikke reguleret. |
| 14.5 Miljøfarer | Ikke reguleret. |
| 14.6 Særlige forsigtighedsregler for brugeren: | Ikke reguleret. |

ADN

- | | |
|---|-----------------|
| 14.1 UN-nummer eller ID-nummer: | Ikke reguleret. |
| 14.2 UN-forsendelsesbetegnelse (UN proper shipping name): | Ikke reguleret. |
| 14.3 Transportfareklasse(r) | |
| Klasse: | Ikke reguleret. |
| Etiket(ter): | Ikke reguleret. |
| ADR farenr.: | Ikke reguleret. |
| Tunnelrestriktionskode: | Ikke reguleret. |
| 14.4 Emballagegruppe: | Ikke reguleret. |
| Begrænset mængde | Ikke reguleret. |
| Undtaget mængde | Ikke reguleret. |
| 14.5 Særlige forsigtighedsregler for brugeren: | Ikke reguleret. |

RID

- | | |
|---|-----------------|
| 14.1 UN-nummer eller ID-nummer: | Ikke reguleret. |
| 14.2 UN-forsendelsesbetegnelse (UN proper shipping name): | Ikke reguleret. |
| 14.3 Transportfareklasse(r) | |
| Klasse: | Ikke reguleret. |
| Etiket(ter): | Ikke reguleret. |
| 14.4 Emballagegruppe: | Ikke reguleret. |
| Begrænset mængde | Ikke reguleret. |
| Undtaget mængde | Ikke reguleret. |
| 14.5 Miljøfarer | Ikke reguleret. |

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

14.6 Særlige forsigtighedsregler for brugeren: Ikke reguleret.

IMDG

14.1 UN-nummer eller ID-nummer: Ikke reguleret.

14.2 UN-forsendelsesbetegnelse (UN proper shipping name): Ikke reguleret.

14.3 Transportfareklasse(r)

Klasse: Ikke reguleret.

Etiket(ter): Ikke reguleret.

EmS No.: Ikke reguleret.

14.4 Emballagegruppe: Ikke reguleret.

Begrænset mængde Ikke reguleret.

Undtaget mængde Ikke reguleret.

14.5 Miljøfarer Ikke reguleret.

14.6 Særlige forsigtighedsregler for brugeren: Ikke reguleret.

IATA

14.1 UN-nummer eller ID-nummer: Ikke reguleret.

14.2 UN-forsendelsesbetegnelse (UN proper shipping name): Ikke reguleret.

14.3 Transportfareklasse(r)

Klasse: Ikke reguleret.

Etiket(ter): Ikke reguleret.

14.4 Emballagegruppe: Ikke reguleret.

Passager- og fragtfly : Ikke reguleret.

Begrænset mængde Ikke reguleret.

Undtaget mængde Ikke reguleret.

14.5 Miljøfarer Ikke reguleret.

14.6 Særlige forsigtighedsregler for brugeren: Ikke reguleret.

14.7 Bulktransport til søs i henhold til IMO-instrumenter

Ikke relevant for produktet, som det leveres.

PUNKT 15: Oplysninger om regulering

15.1 Særlige bestemmelser/særlig lovgivning for stoffet eller blandingen med hensyn til sikkerhed, sundhed og miljø:

EU-forordninger

Forordning 1005/2009/EF om stoffer, der nedbryder ozonlaget, bilag I, Kontrollerede stoffer: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

FORORDNING (EF) Nr. 1907/2006 (REACH), BILAG XIV FORTEGNELSE OVER STOFFER, DER KRÆVER GODKENDELSE: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

Forordning (EU) 2019/1021 om persistente organiske miljøgifte (omarbejdning), med ændringer: Ikke

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

til stede eller ikke til stede i de i loven regulerede mængder.

EUROPA-PARLAMENTETS OG RÅDETS DIREKTIV 2010/75/EU af 24. november 2010 om industrielle emissioner (integreret forebyggelse og bekæmpelse af forurening), BILAG II Liste over forurenende stoffer: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

Forordning (EU) nr. 649/2012 om eksport og import af farlige kemikalier, bilag I, del 1 med ændringer: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

Forordning (EU) nr. 649/2012 om eksport og import af farlige kemikalier, bilag I, del 2 med ændringer: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

Forordning (EU) nr. 649/2012 om eksport og import af farlige kemikalier, bilag I, del 3 med ændringer: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

Forordning (EU) nr. 649/2012 om eksport og import af farlige kemikalier, bilag V med ændringer: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

EU. REACH Kandidatlisten over særligt problematiske stoffer til godkendelse (SVHC): Ikke til stede eller ikke til stede i de i loven regulerede mængder.

Forordning (EF) nr. 1907/2006, bilag XVII om begrænsning vedrørende fremstilling, markedsføring og anvendelse af visse farlige stoffer, kemiske produkter og artikler:
Direktiv 2004/37/EF om beskyttelse af arbejdstagerne mod risici for under arbejdet at være udsat for kræftfremkaldende stoffer eller mutagener.: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

Direktiv 92/85/EØF om iværksættelse af foranstaltninger til forbedring af sikkerheden og sundheden under arbejdet for arbejdstagere som er gravide, som lige har født, eller som ammer.: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

DIREKTIV 2012/18/EU (SEVESO III) om kontrol med risikoen for større uheld med farlige stoffer, BILAG I: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

FORORDNING (EF) Nr. 166/2006 om oprettelse af et europæisk register over udledning og overførsel af forurenende stoffer, BILAG II: Forurenende stoffe: Ikke til stede eller ikke til stede i de i loven regulerede mængder.

Direktiv 98/24/EF om beskyttelse af arbejdstagernes sikkerhed og sundhed under arbejdet mod risici i forbindelse med kemiske agenser:

Kemisk betegnelse	CAS-nr.	Koncentration
natriumazid	26628-22-8	0 - <0,1%

15.2

Der er ikke foretaget nogen kemikaliesikkerhedsvurdering.

Kemikaliesikkerhedsvurdering:

Internationale forordninger

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Montrealprotokollen
Ikke relevant

Stockholm-konventionen
Ikke relevant

Rotterdamkonventionen
Ikke relevant

Kyotoprotokollen
Ikke relevant

PUNKT 16: Andre oplysninger

Forkortelser og akronymer:
Ingen oplysninger.

Referencer til den vigtigste faglitteratur og de vigtigste datakilder: ECHA (European Chemicals Agency): Oplysninger om kemikalier.

Ordlyden af sætningerne i afsnit 2 og 3
: intet

Oplysninger om uddannelse: Ingen oplysninger.

Ansvarsfraskrivelse: Ansvarsfraskrivelse: Oplysningerne heri er indhentet fra forskellige kilder og anses for korrekte på udgivelsestidspunktet. Imidlertid påtager hverken BD eller BD's datterselskaber sig noget ansvar for, at oplysningerne heri er nøjagtige eller fyldestgørende. Den endelige beslutning om et materiales egnethed til et bestemt formål påhviler alene brugeren. Alle materialer udgør ukendte risici og bør anvendes med forsigtighed. Selvom visse farer er beskrevet heri, kan vi ikke garantere, at disse er de eneste eksisterende farer. BD leverer sikkerhedsdatablad (SDS) i elektronisk form, hvilket giver nemmere adgang til oplysningerne. På grund af risikoen for fejl under overførsel udsteder BD ingen garantier for, at oplysningerne er komplette eller præcise.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SAFETY DATA SHEET

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product No.:	Product name:	Common name(s), synonym(s)
641415	BD® CD3 (SK7) APC-H7	No data available

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses: Scientific and industrial laboratory use. For In Vitro Diagnostic Use.

Uses advised against: None known.

1.3 Details of the supplier of the safety data sheet

Manufacturer

Becton Dickinson France S.A.S. Belgian Branch
Erembodegem-Dorp 86
9320 Erembodegem
Belgium

Telephone: 32 2 400 98 95

Fax: 32 2 401 70 94

Contact Person: BD Biosciences - Centralized European Office
Regulatory Compliance Department
E-mail: help.biosciences@europe.bd.com

1.4 Emergency telephone number: 32 2 400 98 95

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

The product has been classified according to the legislation in force.

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Health Hazards

Skin sensitizer

Category 1

H317: May cause an allergic skin reaction.

2.2 Label Elements

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com



Signal Word: Warning

Hazard Statement(s): H317: May cause an allergic skin reaction.

Precautionary Statements
Prevention:

P261: Avoid breathing dust/fume/gas/mist/vapors/spray.
P272: Contaminated work clothing should not be allowed out of the workplace.
P280: Wear protective gloves/protective clothing/eye protection/face protection.

Response:

P302+P352: IF ON SKIN: Wash with plenty of soap and water.
P333+P313: If skin irritation or rash occurs: Get medical advice/attention.
P362+P364: Take off contaminated clothing and wash it before reuse.

Disposal:

P501: Dispose of contents/ container to an approved facility in accordance with local, regional, national and international regulations.

Hazardous ingredients which must be listed on the label:

CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1)

2.3 Other hazards

No data available.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Chemical name	Concentration	CAS-No.	EC No.	REACH Registration No.	M-Factor:	Notes
1,2,3-Propanetriol	10 - <20%	56-81-5		No data available.	No data available.	#
CMIT/MIT	0.0015 -	55965-84-9		No data	Aquatic	

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

mixture (3:1) - a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1)	<0.06%			available.	Toxicity (Acute): 100; Aquatic Toxicity (Chronic): 100	
--	--------	--	--	------------	--	--

* All concentrations are percent by weight unless ingredient is a gas. Gas concentrations are in percent by volume.

This substance has workplace exposure limit(s).

This substance is listed as SVHC.

Classification

Chemical name	Classification	Notes
1,2,3-Propanetriol	Classification: None known. Supplemental label information: None known.	None.
CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1)	Classification: Acute Tox.: 2: H330; Eye Dam.: 1: H318; Skin Sens.: 1A: H317; Acute Tox.: 3: H301; Skin Corr.: 1C: H314; Acute Tox.: 2: H310; Aquatic Chronic: 1: H410; Aquatic Acute: 1: H400; Supplemental label information: EUH071;	Note B, EUH071

CLP: Regulation No. 1272/2008.

The full text for all H-statements is displayed in section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General information:

Get medical attention if symptoms occur.

Inhalation:

Provide fresh air, warmth and rest, preferably in comfortable upright sitting position. Get medical attention if symptoms persist.

Skin Contact:

Wash off promptly and flush contaminated skin with water. Promptly remove clothing if soaked through and flush skin with water. Get medical attention if symptoms occur. Wash contaminated clothing before reuse.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Eye contact: Immediately flush with plenty of water for at least 15 minutes. If easy to do, remove contact lenses. Get medical attention promptly if symptoms occur after washing.

Ingestion: If swallowed, rinse mouth with water (only if the person is conscious). Do NOT induce vomiting. Get medical attention immediately.

Personal Protection for First-aid Responders: No data available.

4.2 Most important symptoms and effects, both acute and delayed Symptoms: Symptoms may be delayed.

Hazards: May cause an allergic skin reaction.

4.3 Indication of immediate medical attention and special treatment needed

Treatment: Wash off promptly and flush contaminated skin with water. Promptly remove clothing if soaked through and flush skin with water.

SECTION 5: Firefighting measures

General Fire Hazards: Extinguish all ignition sources. Avoid sparks, flames, heat and smoking. Ventilate. Use water to keep fire exposed containers cool and disperse vapors.

5.1 Extinguishing media

Suitable extinguishing media: Water spray, fog, CO₂, dry chemical, or alcohol resistant foam.

Unsuitable extinguishing media: Avoid water in straight hose stream; will scatter and spread fire.

5.2 Special hazards arising from the substance or mixture: Fire or excessive heat may produce hazardous decomposition products.

5.3 Advice for firefighters

Special fire-fighting procedures: No unusual fire or explosion hazards noted.

Special protective equipment for fire-fighters: Firefighters must use standard protective equipment including flame retardant coat, helmet with face shield, gloves, rubber boots, and in enclosed spaces, SCBA.

SECTION 6: Accidental release measures



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

6.1 Personal precautions, protective equipment and emergency procedures:	Ensure suitable personal protection (including respiratory protection) during removal of spillages in a confined area. Contact local authorities in case of spillage to drain/aquatic environment.
6.1.1 For non-emergency personnel:	No data available.
6.1.2 For emergency responders:	No data available.
6.2 Environmental Precautions:	Avoid release to the environment.
6.3 Methods and material for containment and cleaning up:	Stop leak if possible without any risk. Absorb or cover with dry earth, sand or other non-combustible material and transfer to containers. Collect for salvage or disposal. Prevent runoff from entering drains, sewers, or streams. Report spills as required to appropriate authorities. See Section 8 of the SDS for Personal Protective Equipment. For waste disposal, see section 13 of the SDS.
6.4 Reference to other sections:	No data available.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures:	No data available.
Local/Total ventilation:	No data available.
Safe handling advice:	Wash promptly with soap and water if skin becomes contaminated. When using do not eat, drink or smoke. Read and follow manufacturer's recommendations. Use personal protective equipment as required.
Contact avoidance measures:	No data available.

7.2 Conditions for safe storage, including any incompatibilities

Safe storage conditions:	Store in tightly closed original container in a dry, cool and well-ventilated place.
Safe packaging materials:	No data available.

7.3 Specific end use(s):	Reserved for industrial and professional use. Read label before use.
---------------------------------	--

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SECTION 8: Exposure controls/personal protection

8.1 Control Parameters

Occupational Exposure Limits

Chemical name	Type	Form of exposure	Exposure Limit Values	Source
1,2,3-Propanetriol	TWA	Mist.	10 mg/m3	UK. EH40 Workplace Exposure Limits (WELs), as amended (2007)

Please refer to the latest edition of the appropriate source text and consult an industrial hygienist or similar professional, or local agencies, for further information.

Biological Limit Values

No biological exposure limits noted for the ingredient(s).

DNEL-Values

Remarks: DNEL-Values

Critical component	Type	Route of Exposure	Health Warnings	Remarks
1,2,3-Propanetriol	General population	Oral	Systemic, long-term; 229 mg/kg	Repeated dose toxicity
	Workers	Inhalation	Local, long-term; 56 mg/m3	irritation respiratory tract
	General population	Inhalation	Local, long-term; 33 mg/m3	irritation respiratory tract

Sodium Chloride (NaCl)	General population	Inhalation	Systemic, long-term; 443.28 mg/m3	Repeated dose toxicity
	Workers	Inhalation	Systemic, long-term; 2068.62 mg/m3	Repeated dose toxicity
	Workers	Inhalation	Systemic, short-term; 2068.62 mg/m3	Repeated dose toxicity
	General population	Inhalation	Systemic, short-term; 443.28 mg/m3	Repeated dose toxicity
	General population	Oral	Systemic, long-term; 126.65 mg/kg	Repeated dose toxicity
	Workers	Dermal	Systemic, long-term; 295.52 mg/kg	Repeated dose toxicity
	Workers	Dermal	Systemic, short-term; 295.52 mg/kg	Repeated dose toxicity
	General population	Oral	Systemic, short-term; 126.65 mg/kg	Repeated dose toxicity
	General population	Dermal	Systemic, short-term; 126.65 mg/kg	Repeated dose toxicity
	General population	Dermal	Systemic, long-term; 126.65 mg/kg	Repeated dose toxicity

Benzoic acid, sodium salt (1:1)	General population	Inhalation	Systemic, long-term; 1.5 mg/m3	
	Workers	Inhalation	Systemic, long-term; 3 mg/m3	



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	General population	Inhalation	Local, long-term; 0.06 mg/m ³	irritation respiratory tract
	Workers	Inhalation	Local, long-term; 0.1 mg/m ³	irritation respiratory tract
	General population	Eyes	Local effect;	Medium hazard (no threshold derived)
	Workers	Eyes	Local effect;	Medium hazard (no threshold derived)
	Workers	Dermal	Systemic, long-term; 62.5 mg/kg	
	General population	Dermal	Systemic, long-term; 31.25 mg/kg	Repeated dose toxicity
	General population	Oral	Systemic, long-term; 16.6 mg/kg	

Phosphoric acid, sodium salt (1:2)	Workers	Eyes	Local effect;	No hazard identified
	Workers	Inhalation	Systemic, long-term; 4.07 mg/m ³	Repeated dose toxicity
	General population	Inhalation	Systemic, long-term; 3.04 mg/m ³	Repeated dose toxicity
	General population	Inhalation	Systemic, long-term; 6.63 mg/m ³	Repeated dose toxicity
	Workers	Inhalation	Systemic, long-term; 15.47 mg/m ³	Repeated dose toxicity

Sodium azide (Na(N ₃))	Workers	Inhalation	Systemic, long-term; 0.164 mg/m ³	Repeated dose toxicity
	General population	Eyes	Local effect;	No hazard identified
	General population	Inhalation	Systemic, long-term; 29 µg/m ³	Repeated dose toxicity
	Workers	Eyes	Local effect;	No hazard identified
	Workers	Dermal	Systemic, long-term; 0.0467 mg/kg	Repeated dose toxicity
	General population	Oral	Systemic, long-term; 0.0167 mg/kg	Repeated dose toxicity
	General population	Dermal	Systemic, long-term; 0.0167 mg/kg	Repeated dose toxicity

Potassium chloride (KCl)	Workers	Inhalation	Systemic, long-term; 1064 mg/m ³	Repeated dose toxicity
	General population	Inhalation	Systemic, long-term; 273 mg/m ³	Repeated dose toxicity
	General population	Inhalation	Systemic, short-term; 1365 mg/m ³	Repeated dose toxicity
	Workers	Inhalation	Systemic, short-term; 5320 mg/m ³	Repeated dose toxicity
	General population	Oral	Systemic, short-term; 455 mg/kg	Repeated dose toxicity
	General population	Dermal	Systemic, long-term; 182 mg/kg	Repeated dose toxicity
	General population	Oral	Systemic, long-term; 91 mg/kg	Repeated dose toxicity
	Workers	Dermal	Systemic, long-term; 303 mg/kg	Repeated dose toxicity
	Workers	Dermal	Systemic, short-term; 910 mg/kg	Repeated dose toxicity



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	General population	Dermal	Systemic, short-term; 910 mg/kg	Repeated dose toxicity
Phosphoric acid, potassium salt (1:1)	Workers	Eyes	Local effect;	No hazard identified
	General population	Eyes	Local effect;	No hazard identified
	Workers	Inhalation	Systemic, long-term; 14.82 mg/m3	Repeated dose toxicity
	General population	Inhalation	Systemic, long-term; 6.35 mg/m3	Repeated dose toxicity
CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1)	Workers	Eyes	Local effect;	High hazard (no threshold derived)
	General population	Oral	Systemic, short-term; 0.11 mg/kg	Repeated dose toxicity
	Workers	Inhalation	Local, long-term; 0.02 mg/m3	Repeated dose toxicity
	General population	Inhalation	Local, long-term; 0.02 mg/m3	Repeated dose toxicity
	General population	Eyes	Local effect;	High hazard (no threshold derived)
	General population	Inhalation	Local, short-term; 0.04 mg/m3	Repeated dose toxicity
	General population	Oral	Systemic, long-term; 0.09 mg/kg	Repeated dose toxicity
	Workers	Inhalation	Local, short-term; 0.04 mg/m3	Repeated dose toxicity

PNEC-Values

Remarks: PNEC-Values

Critical component	Environmental compartment	PNEC-Values	Remarks
1,2,3-Propanetriol	Sewage treatment plant	1000 mg/l	
	Soil	0.141 mg/kg	
	Sediment (marine water)	0.33 mg/kg	
	Aquatic (freshwater)	0.885 mg/l	
	Aquatic (marine water)	0.088 mg/l	
	Sediment (freshwater)	3.3 mg/kg	
Sodium Chloride (NaCl)	Soil	4.86 mg/kg	
	Aquatic (freshwater)	5 mg/l	
	Sewage treatment plant	500 mg/l	
Benzoic acid, sodium salt (1:1)	Soil	0.06 mg/kg	
	Sewage treatment plant	10 mg/l	
	Sediment (marine water)	0.176 mg/kg	

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Sediment (freshwater)	1.76 mg/kg	
	Aquatic (freshwater)	0.13 mg/l	
	Aquatic (marine water)	0.013 mg/l	
Phosphoric acid, sodium salt (1:2)	Sewage treatment plant	50 mg/l	
	Aquatic (freshwater)	0.05 mg/l	
	Aquatic (marine water)	0.005 mg/l	
Sodium azide (Na(N ₃))	Aquatic (marine water)	15 ng/l	
	Sewage treatment plant	30 µg/l	
	Sediment (freshwater)	0.0167 mg/kg	
	Aquatic (freshwater)	0.35 µg/l	
	Sediment (marine water)	0.00072 mg/kg	
Potassium chloride (KCl)	Aquatic (marine water)	0.1 mg/l	
	Sewage treatment plant	10 mg/l	
	Aquatic (freshwater)	0.1 mg/l	
CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1)	Sediment (freshwater)	0.027 mg/kg	
	Sewage treatment plant	0.23 mg/l	
	Soil	0.01 mg/kg	
	Sediment (marine water)	0.027 mg/kg	
	Aquatic (marine water)	3.39 µg/l	
	Aquatic (freshwater)	3.39 µg/l	

8.2 Exposure controls

Appropriate Engineering Controls:

Adequate ventilation should be provided whenever the material is heated or mists are generated.

Individual protection measures, such as personal protective equipment

Eye/face protection:

Wear safety glasses with side shields (or goggles).

Hand Protection:

Material: Use suitable protective gloves if risk of skin contact.

Skin and Body Protection:

Wear appropriate clothing to prevent repeated or prolonged skin contact.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Respiratory Protection:	If engineering controls do not maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (in countries where exposure limits have not been established), an approved respirator must be worn.
Hygiene measures:	Do not eat, drink or smoke when using the product. Wash promptly if skin becomes contaminated. Wash at the end of each work shift and before eating, smoking and using the toilet. Avoid contact with skin.
Environmental Controls:	Data available upon request.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance

Physical state:	liquid
Form:	liquid
Color:	Colorless to blue
Odor:	Odorless
Odor Threshold:	No data available.
Freezing point:	No data available.
Boiling Point:	No data available.
Flammability:	No data available.

Upper/lower limit on flammability or explosive limits

Explosive limit - upper:	No data available.
Explosive limit - lower:	No data available.
Flash Point:	No data available.
Auto-ignition temperature:	No data available.
Decomposition Temperature:	No data available.
pH:	7.20 - 7.60

Viscosity

Dynamic viscosity:	No data available.
Kinematic viscosity:	No data available.
Flow Time:	No data available.

Solubility(ies)

Solubility in Water:	Soluble
-----------------------------	---------



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Solubility (other):	No data available.
Dissolution Rate:	No data available.
Partition coefficient (n-octanol/water):	No data available.
Dispersion Stability:	No data available.
Vapor pressure:	No data available.
Relative density:	No data available.
Density:	No data available.
Bulk density:	No data available.
Relative vapor density:	No data available.

9.2 Other information

No data available

SECTION 10: Stability and reactivity

10.1 Reactivity:	Stable
10.2 Chemical Stability:	No data available.
10.3 Possibility of hazardous reactions:	None under normal conditions.
10.4 Conditions to avoid:	Avoid exposure to high temperatures or direct sunlight.
10.5 Incompatible Materials:	Strong oxidizing agents.
10.6 Hazardous Decomposition Products:	By heating and fire, harmful vapors/gases may be formed.

SECTION 11: Toxicological information

General information: May cause allergic skin reaction based on human experience.

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Inhalation:	Under normal conditions of intended use, this material is not expected to be an inhalation hazard.
Skin Contact:	Prolonged or repeated contact may cause skin sensitization in susceptible individuals.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Eye contact: Avoid contact with eyes.

Ingestion: Ingestion may cause irritation and malaise.

Information on likely routes of exposure

Acute toxicity (list all possible routes of exposure)

Oral

Product: Not classified for acute toxicity based on available data.

Components:

1,2,3-Propanetriol	No data available.
CMIT/MIT mixture (3:1) -	LD 50 (Rat): 66 mg/kg
a mixture of: 5-chloro-2-	Key study LD 50 (Rat): 200 mg/kg
methyl-4-isothiazolin-3-	Key study
one [EC No 247-500-7]	
and 2-methyl-4-	
isothiazolin-3-one [EC No	
220-239-6] (3:1)	

Dermal

Product: Not classified for acute toxicity based on available data.

Components:

1,2,3-Propanetriol	No data available.
CMIT/MIT mixture (3:1) -	No data available.
a mixture of: 5-chloro-2-	
methyl-4-isothiazolin-3-	
one [EC No 247-500-7]	
and 2-methyl-4-	
isothiazolin-3-one [EC No	
220-239-6] (3:1)	

Inhalation

Product: Not classified for acute toxicity based on available data.

Components:

1,2,3-Propanetriol	No data available.
CMIT/MIT mixture (3:1) -	LC 50 (Rat, 4 h): 0.171 mg/l Aerosol; 1 = reliable without restrictions;
a mixture of: 5-chloro-2-	Aerosol LC 50 (Rat, 4 h): 0.33 mg/l Aerosol; 1 = reliable without
methyl-4-isothiazolin-3-	restrictions; Aerosol LC 50 (Rat, 4 h): 1.23 mg/l Aerosol; 1 = reliable
one [EC No 247-500-7]	without restrictions; Aerosol LC 50 (Rat, 4 h): 0.81 mg/l Aerosol; 1 =
and 2-methyl-4-	reliable without restrictions; Aerosol LC 50 (Rat, 4 h): 2.36 mg/l Aerosol;
isothiazolin-3-one [EC No	1 = reliable without restrictions; Aerosol LC 50 (Rat, 4 h): 810 mg/m3
220-239-6] (3:1)	Aerosol; 1 = reliable without restrictions; Aerosol

Repeated dose toxicity

Product: No data available.

Components:

1,2,3-Propanetriol	LOAEL (Rat(Female, Male), Inhalation): 1,000 mg/m3 Experimental
--------------------	---

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	result, Supporting study Inhalation NOAEL (Rat(Female, Male), Inhalation): 167 mg/m ³ Experimental result, Key study Inhalation
CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2- methyl-4-isothiazolin-3- one [EC No 247-500-7] and 2-methyl-4- isothiazolin-3-one [EC No 220-239-6] (3:1)	No data available.

Skin Corrosion/Irritation

Product: No data available.

Components:

1,2,3-Propanetriol	No data available.
CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2- methyl-4-isothiazolin-3- one [EC No 247-500-7] and 2-methyl-4- isothiazolin-3-one [EC No 220-239-6] (3:1)	

Serious Eye Damage/Eye Irritation

Product: No data available.

Components:

1,2,3-Propanetriol	No data available.
CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2- methyl-4-isothiazolin-3- one [EC No 247-500-7] and 2-methyl-4- isothiazolin-3-one [EC No 220-239-6] (3:1)	Causes serious eye damage.

Respiratory or Skin Sensitization

Product: No data available.

Components:

1,2,3-Propanetriol	No data available.
CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2- methyl-4-isothiazolin-3- one [EC No 247-500-7] and 2-methyl-4- isothiazolin-3-one [EC No 220-239-6] (3:1)	May cause an allergic skin reaction.

Carcinogenicity

Product: No data available.

Components:

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

1,2,3-Propanetriol	No data available.
CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2- methyl-4-isothiazolin-3- one [EC No 247-500-7] and 2-methyl-4- isothiazolin-3-one [EC No 220-239-6] (3:1)	No data available.

Germ Cell Mutagenicity

In vitro

Product: No data available.

Components:

1,2,3-Propanetriol	No data available.
CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2- methyl-4-isothiazolin-3- one [EC No 247-500-7] and 2-methyl-4- isothiazolin-3-one [EC No 220-239-6] (3:1)	No data available.

In vivo

Product: No data available.

Components:

1,2,3-Propanetriol	No data available.
CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2- methyl-4-isothiazolin-3- one [EC No 247-500-7] and 2-methyl-4- isothiazolin-3-one [EC No 220-239-6] (3:1)	No data available.

Reproductive toxicity

Product: No data available.

Components:

1,2,3-Propanetriol	No data available.
CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2- methyl-4-isothiazolin-3- one [EC No 247-500-7] and 2-methyl-4- isothiazolin-3-one [EC No 220-239-6] (3:1)	Based on available data, the classification criteria are not met.

Specific Target Organ Toxicity - Single Exposure

Product: No data available.

Components:

1,2,3-Propanetriol	No data available.
--------------------	--------------------

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

CMIT/MIT mixture (3:1) - No data available.
a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1)

Specific Target Organ Toxicity - Repeated Exposure

Product: No data available.

Components:

1,2,3-Propanetriol No data available.
CMIT/MIT mixture (3:1) - No data available.
a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1)

Aspiration Hazard

Product: No data available.

Components:

1,2,3-Propanetriol No data available.
CMIT/MIT mixture (3:1) - No data available.
a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1)

11.2 Information on other hazards

Other information

Product: No data available.

SECTION 12: Ecological information

12.1 Toxicity:

Acute hazards to the aquatic environment:

Fish

Product: No data available.

Components:

1,2,3-Propanetriol LC 50 (Oncorhynchus mykiss, 96 h): 54,000 mg/l Experimental result, Key study

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

LC 50 (Rainbow trout, donaldson trout (*Oncorhynchus mykiss*), 96 h):
51,000 - 57,000 mg/l Mortality
LC 50 (Carp (*Leuciscus idus melanotus*), 48 h): > 10,000 mg/l Mortality
LC 50 (Goldfish (*Carassius auratus*), 24 h): > 5,000 mg/l Mortality

CMIT/MIT mixture (3:1) - No data available.
a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1)

Aquatic Invertebrates

Product: No data available.

Components:

1,2,3-Propanetriol No data available.
CMIT/MIT mixture (3:1) - No data available.
a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1)

Toxicity to Aquatic Plants

Product: No data available.

Components:

1,2,3-Propanetriol No data available.
CMIT/MIT mixture (3:1) - No data available.
a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1)

Toxicity to microorganisms

Product: No data available.

Components:

1,2,3-Propanetriol No data available.
CMIT/MIT mixture (3:1) - No data available.
a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1)

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Chronic hazards to the aquatic environment:

Fish

Product: No data available.

Components:

1,2,3-Propanetriol	No data available.
CMIT/MIT mixture (3:1) -	No data available.
a mixture of: 5-chloro-2-	
methyl-4-isothiazolin-3-	
one [EC No 247-500-7]	
and 2-methyl-4-	
isothiazolin-3-one [EC	
No 220-239-6] (3:1)	

Aquatic Invertebrates

Product: No data available.

Components:

1,2,3-Propanetriol	No data available.
CMIT/MIT mixture (3:1) -	No data available.
a mixture of: 5-chloro-2-	
methyl-4-isothiazolin-3-	
one [EC No 247-500-7]	
and 2-methyl-4-	
isothiazolin-3-one [EC	
No 220-239-6] (3:1)	

Toxicity to Aquatic Plants

Product: No data available.

Components:

1,2,3-Propanetriol	No data available.
CMIT/MIT mixture (3:1) -	No data available.
a mixture of: 5-chloro-2-	
methyl-4-isothiazolin-3-	
one [EC No 247-500-7]	
and 2-methyl-4-	
isothiazolin-3-one [EC No	
220-239-6] (3:1)	

Toxicity to microorganisms

Product: No data available.

Components:

1,2,3-Propanetriol	No data available.
CMIT/MIT mixture (3:1) -	No data available.
a mixture of: 5-chloro-2-	
methyl-4-isothiazolin-3-	
one [EC No 247-500-7]	
and 2-methyl-4-	
isothiazolin-3-one [EC No	
220-239-6] (3:1)	

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

12.2 Persistence and Degradability

Biodegradation

Product: No data available.

Components:

1,2,3-Propanetriol	86 % Experimental result, Key study Detected in water.
	94 % Experimental result, Key study Detected in water.
	60 % Experimental result, Key study Detected in water.
	98.7 % (24 h) Experimental result, Supporting study Detected in water.

CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2- methyl-4-isothiazolin-3- one [EC No 247-500-7] and 2-methyl-4- isothiazolin-3-one [EC No 220-239-6] (3:1)	Readily biodegradable
--	-----------------------

BOD/COD Ratio

Product: No data available.

Components:

1,2,3-Propanetriol	No data available.
CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2- methyl-4-isothiazolin-3- one [EC No 247-500-7] and 2-methyl-4- isothiazolin-3-one [EC No 220-239-6] (3:1)	No data available.

12.3 Bioaccumulative potential

Bioconcentration Factor (BCF)

Product: No data available.

Components:

1,2,3-Propanetriol	No data available.
CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2- methyl-4-isothiazolin-3- one [EC No 247-500-7] and 2-methyl-4- isothiazolin-3-one [EC No 220-239-6] (3:1)	No data available.

Partition Coefficient n-octanol / water (log Kow)

Product: No data available.

Components:

1,2,3-Propanetriol	Log Kow: -1.76
--------------------	----------------



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

CMIT/MIT mixture (3:1) - No data available.
a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1)

12.4 Mobility in soil:

Product	No data available.
Components:	
1,2,3-Propanetriol	No data available.
CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1)	No data available.

12.5 Results of PBT and vPvB assessment:

Product	No data available.
Components:	
1,2,3-Propanetriol	No data available.
CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1)	Not applicable

12.6 Other adverse effects:

Other hazards	
Product:	No data available.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

General information:	Dispose of waste and residues in accordance with local authority requirements.
-----------------------------	--



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Disposal methods:

Discharge, treatment, or disposal may be subject to national, state, or local laws.

Since emptied containers retain product residue, follow label warnings even after container is emptied.

Contaminated Packaging:

Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

SECTION 14: Transport information
--

ADR

14.1 UN number or ID number:	Not regulated.
14.2 UN Proper Shipping Name:	Not regulated.
14.3 Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
Hazard No. (ADR):	Not regulated.
Tunnel restriction code:	Not regulated.
14.4 Packing Group:	Not regulated.
Limited quantity	Not regulated.
Excepted quantity	Not regulated.
14.5 Environmental Hazards	Not regulated.
14.6 Special precautions for user:	Not regulated.

ADN

14.1 UN number or ID number:	Not regulated.
14.2 UN Proper Shipping Name:	Not regulated.
14.3 Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
Hazard No. (ADR):	Not regulated.
Tunnel restriction code:	Not regulated.
14.4 Packing Group:	Not regulated.
Limited quantity	Not regulated.
Excepted quantity	Not regulated.
14.5 Special precautions for user:	Not regulated.

RID

14.1 UN number or ID number:	Not regulated.
14.2 UN Proper Shipping Name:	Not regulated.
14.3 Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
14.4 Packing Group:	Not regulated.
Limited quantity	Not regulated.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Excepted quantity	Not regulated.
14.5 Environmental Hazards	Not regulated.
14.6 Special precautions for user:	Not regulated.

IMDG

14.1 UN number or ID number:	Not regulated.
14.2 UN Proper Shipping Name:	Not regulated.
14.3 Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
EmS No.:	Not regulated.
14.4 Packing Group:	Not regulated.
Limited quantity	Not regulated.
Excepted quantity	Not regulated.
14.5 Environmental Hazards	Not regulated.
14.6 Special precautions for user:	Not regulated.

IATA

14.1 UN number or ID number:	Not regulated.
14.2 UN Proper Shipping Name:	Not regulated.
14.3 Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
14.4 Packing Group:	Not regulated.
Passenger and cargo aircraft :	Not regulated.
Limited quantity	Not regulated.
Excepted quantity	Not regulated.
14.5 Environmental Hazards	Not regulated.
14.6 Special precautions for user:	Not regulated.

14.7 Maritime transport in bulk according to IMO instruments

Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture:

EU Regulations

EU. REACH Annex XIV, Substances Subject to Authorization: None present or none present in regulated quantities.

EU. REACH Candidate List of Substances of Very High Concern for Authorization (SVHC): None present or none present in regulated quantities.

EU. Regulation 2019/1021/EU on persistent organic pollutants (POPs) (recast), as amended: None present or none present in regulated quantities.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Regulation 1005/2009/EC on substances that deplete the ozone layer, Annex I, Controlled Substances: None present or none present in regulated quantities.

Regulation 1005/2009/EC on substances that deplete the ozone layer, Annex II, New Substances: None present or none present in regulated quantities.

Regulation (EU) No. 649/2012 concerning the export and import of dangerous chemicals, Annex I, Part 1 as amended: None present or none present in regulated quantities.

Regulation (EU) No. 649/2012 concerning the export and import of dangerous chemicals, Annex I, Part 2 as amended: None present or none present in regulated quantities.

Regulation (EU) No. 649/2012 concerning the export and import of dangerous chemicals, Annex I, Part 3 as amended: None present or none present in regulated quantities.

Regulation (EU) No. 649/2012 concerning the export and import of dangerous chemicals, Annex V as amended: None present or none present in regulated quantities.

EU. Directive 2012/18/EU (SEVESO III) on major accident hazards involving dangerous substances, Annex I: None present or none present in regulated quantities.

15.2 Chemical safety assessment: No Chemical Safety Assessment has been carried out.
International regulations

Montreal protocol
Not applicable

Stockholm convention
Not applicable

Rotterdam convention
Not applicable

Kyoto protocol
Not applicable

SECTION 16: Other information

Abbreviations and acronyms:

EH40 WEL:	UK. EH40 Workplace Exposure Limits (WELs), as amended
EH40 WEL / TWA:	Time Weighted Average (TWA):

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; EIGA - European Industrial Gases Association; ELx - Loading rate associated with x% response; EmS -

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Notes:

CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1)	Note B	Some substances (acids, bases, etc.) are placed on the market in aqueous solutions at various concentrations and, therefore, these solutions require different classification and labelling since the hazards vary at different concentrations. In Part 3 entries with Note B have a general designation of the following type: 'nitric acid...%'. In this case the supplier must state the percentage concentration of the solution on the label. Unless otherwise stated, it is assumed that the percentage concentration is calculated on a weight/weight basis.
	EUH071	Corrosive to the respiratory tract.

Key literature references and sources for data: No data available.

Classification and procedure used to derive the classification for mixtures according to Regulation (EC) 1272/2008 [CLP]

Classification according to Regulation (EC) No 1272/2008 as amended.	Classification procedure
Skin sensitizer, Category 1	On basis of test data

Wording of the statements in section 2 and 3



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

H301	Toxic if swallowed.
H310	Fatal in contact with skin.
H314	Causes severe skin burns and eye damage.
H317	May cause an allergic skin reaction.
H318	Causes serious eye damage.
H330	Fatal if inhaled.
H400	Very toxic to aquatic life.
H410	Very toxic to aquatic life with long lasting effects.

Training information: No data available.

Classification according to Regulation (EC) No 1272/2008 as amended.

Skin Sens. 1, H317

SDS No.: UN000000000000641415-1149-1-01

Disclaimer:

Disclaimer:

The information contained herein has been obtained from various sources and is believed to be correct as of the date issued. However, neither BD nor any of its subsidiaries assumes any liabilities whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability for a particular use of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist. BD provides SDS in electronic form so the information may be more easily accessed. Due to the possibility of errors during transmission, BD makes no representations as to the completeness or accuracy of the information.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SAFETY DATA SHEET

According to Regulation (EC) No. 1907/2006 (REACH) Article 31, Annex II as amended.

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product No.:	Product name:	Common name(s), synonym(s)
655872	CD20 (L27) V450	No data available
655874	Anti-HLA-DR (L243) V450	No data available

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses: Scientific and industrial laboratory use. For In Vitro Diagnostic Use.

Uses advised against: None known.

1.3 Details of the supplier of the safety data sheet

Manufacturer

Becton Dickinson France S.A.S. Belgian
Branch
Erembodegem-Dorp 86
Erembodegem 9320
Belgium

Telephone: 32 2 400 98 95

Fax: 32 2 401 70 94

Contact Person: BD Biosciences - Centralized European Office

Regulatory Compliance Department

E-mail: help.biosciences@europe.bd.com

1.4 Emergency telephone number: 32 2 400 98 95

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

The product has not been classified as hazardous according to the legislation in force.

Classification according to Regulation (EC) No 1272/2008 as amended.

Not classified



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

2.2 Label Elements Not applicable

2.3 Other hazards No data available.

SECTION 3: Composition/information on ingredients

3.2 Mixtures No hazardous ingredients.

General information:

Regulation No. 1272/2008.

SECTION 4: First aid measures

General: Get medical attention if symptoms occur.

4.1 Description of first aid measures

Inhalation: Provide fresh air, warmth and rest, preferably in comfortable upright sitting position.

Eye contact: Immediately flush with plenty of water for at least 15 minutes. If easy to do, remove contact lenses.

Skin Contact: Wash contact areas with soap and water. Remove contaminated clothing. Launder contaminated clothing before reuse.

Ingestion: Call a physician or poison control center immediately. Only induce vomiting at the instruction of medical personnel. Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed: No data available.

4.3 Indication of any immediate medical attention and special treatment needed

Hazards: No data available.

Treatment: No data available.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SECTION 5: Firefighting measures

General Fire Hazards: Extinguish all ignition sources. Avoid sparks, flames, heat and smoking. Ventilate. Use water spray to keep fire-exposed containers cool.

5.1 Extinguishing media
Suitable extinguishing media:

Use fire-extinguishing media appropriate for surrounding materials.

Unsuitable extinguishing media:

Not applicable

5.2 Special hazards arising from the substance or mixture:

Fire or excessive heat may produce hazardous decomposition products.

5.3 Advice for firefighters
Special fire fighting procedures:

No unusual fire or explosion hazards noted.

Special protective equipment for fire-fighters:

Firefighters must use standard protective equipment including flame retardant coat, helmet with face shield, gloves, rubber boots, and in enclosed spaces, SCBA.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures:

Contact local authorities in case of spillage to drain/aquatic environment. Ensure suitable personal protection (including respiratory protection) during removal of spillages in a confined area.

6.2 Environmental Precautions:

Avoid release to the environment.

6.3 Methods and material for containment and cleaning up:

Absorb spillage with suitable absorbent material. Prevent runoff from entering drains, sewers, or streams. See Section 8 of the SDS for Personal Protective Equipment. For waste disposal, see section 13 of the SDS.

6.4 Reference to other sections:

No data available.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SECTION 7: Handling and storage:

- 7.1 Precautions for safe handling:** When using do not eat, drink or smoke. Read and follow manufacturer's recommendations. Use personal protective equipment as required.
- 7.2 Conditions for safe storage, including any incompatibilities:** Store in a cool, dry place. Keep container tightly closed.
- 7.3 Specific end use(s):** Reserved for industrial and professional use. Read label before use.

SECTION 8: Exposure controls/personal protection

8.1 Control Parameters Occupational Exposure Limits

None of the components have assigned exposure limits.

Biological Limit Values

None.

8.2 Exposure controls

Appropriate Engineering Controls: No special requirements under ordinary conditions of use and with adequate ventilation.

Individual protection measures, such as personal protective equipment

General information: Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing to remove contaminants. Discard contaminated footwear that cannot be cleaned.

Eye/face protection: Wear safety glasses with side shields (or goggles).

Skin protection

Hand Protection: Chemical resistant gloves Suitable gloves can be recommended by the glove supplier. Wash hands after contact.

Other: Wear a lab coat or similar protective clothing.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

**Respiratory
Protection:**

If engineering controls do not maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (in countries where exposure limits have not been established), an approved respirator must be worn.

Hygiene measures:

Observe good industrial hygiene practices.

**Environmental
Controls:**

No data available.

SECTION 9: Physical and chemical properties**9.1 Information on basic physical and chemical properties****Appearance**

Physical state:	liquid
Form:	No data available.
Color:	Colorless to slightly yellow
Odor:	Odorless
Odor Threshold:	No data available.
pH:	7.2 - 7.6
Freezing point:	No data available.
Boiling Point:	No data available.
Flash Point:	No data available.
Evaporation Rate:	No data available.
Flammability (solid, gas):	No data available.
Flammability Limit - Upper (%):	No data available.
Flammability Limit - Lower (%):	No data available.
Vapor pressure:	No data available.
Vapor density (air=1):	No data available.
Relative density:	No data available.
Solubility(ies)	
Solubility in Water:	Soluble
Solubility (other):	No data available.
Partition coefficient (n-octanol/water):	No data available.
Autoignition Temperature:	No data available.
Decomposition Temperature:	No data available.
SADT:	No data available.
Viscosity:	No data available.
Explosive properties:	No data available.
Oxidizing properties:	No data available.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

9.2 Other information

Molecular weight:	No data available.
VOC Content:	No data available.
Bulk density:	No data available.
Dust Explosion Limit, Upper:	No data available.
Dust Explosion Limit, Lower:	No data available.
Dust Explosion Description	No data available.
Number Kst:	
Minimum ignition energy:	No data available.
Minimum ignition temperature:	No data available.
Metal Corrosion:	No data available.

SECTION 10: Stability and reactivity

10.1 Reactivity:	Material is stable under normal conditions.
10.2 Chemical Stability:	Material is stable under normal conditions.
10.3 Possibility of hazardous reactions:	Not determined.
10.4 Conditions to avoid:	Avoid exposure to high temperatures or direct sunlight.
10.5 Incompatible Materials:	Metals. Water reactive material.
10.6 Hazardous Decomposition Products:	Stable; however, may decompose if heated.

SECTION 11: Toxicological information

General information: No data on possible toxicity effects have been found.

Information on likely routes of exposure

Inhalation: Limited inhalation hazard at normal work temperatures.

Ingestion: No harmful effects expected in amounts likely to be ingested by accident.

Skin Contact: Negligible irritation to skin at ambient temperatures.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Eye contact: Elevated temperatures or mechanical action may form vapors, mist, or fumes which may be irritating to the eyes, nose, throat, or lungs.

11.1 Information on toxicological effects

Acute toxicity

Oral

Product: Not classified for acute toxicity based on available data.

Dermal

Product: Not classified for acute toxicity based on available data.

Inhalation

Product: Not classified for acute toxicity based on available data.

Repeated dose toxicity

Product: No data available.

Skin

Corrosion/Irritation:

Product: No data available.

Serious Eye Damage/Eye Irritation:

Product: No data available.

Respiratory or Skin Sensitization:

Product: No data available.

Germ Cell Mutagenicity

In vitro

Product: No data available.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

In vivo

Product: No data available.

Carcinogenicity

Product: No data available.

Reproductive toxicity

Product: No data available.

Specific Target Organ Toxicity - Single Exposure

Product: No data available.

Specific Target Organ Toxicity - Repeated Exposure

Product: No data available.

Aspiration Hazard

Product: No data available.

SECTION 12: Ecological information

12.1 Toxicity

Acute toxicity

Fish

Product: No negative effects on the aquatic environment are known.

Aquatic Invertebrates

Product: No negative effects on the aquatic environment are known.

Chronic Toxicity

Fish

Product: No negative effects on the aquatic environment are known.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Aquatic Invertebrates

Product: No negative effects on the aquatic environment are known.

Toxicity to Aquatic Plants

Product: No negative effects on the aquatic environment are known.

12.2 Persistence and Degradability

Biodegradation

Product: Expected to be readily biodegradable.

BOD/COD Ratio

Product No data available.

12.3 Bioaccumulative potential

Product: No data available.

12.4 Mobility in soil:

Product: No data available.

12.5 Results of PBT and vPvB assessment:

Product: No data available.

12.6 Other adverse effects:

The product is not expected to be hazardous to the environment.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

General information: Dispose of waste and residues in accordance with local authority requirements.

Disposal methods: Dispose of waste at an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

SECTION 14: Transport information



**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

ADR

14.1 UN Number:	Not regulated.
14.2 UN Proper Shipping Name:	Not regulated.
14.3 Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
Hazard No. (ADR):	Not regulated.
Tunnel restriction code:	Not regulated.
14.4 Packing Group:	Not regulated.
14.5 Environmental Hazards:	Not regulated.
Marine Pollutant:	Not regulated.
14.6 Special precautions for user:	Not regulated.

ADN

14.1 UN Number:	Not regulated.
14.2 UN Proper Shipping Name:	Not regulated.
14.3 Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
Hazard No. (ADR):	Not regulated.
Tunnel restriction code:	Not regulated.
14.4 Packing Group:	Not regulated.
14.5 Environmental Hazards:	Not regulated.
Marine Pollutant:	Not regulated.
14.6 Special precautions for user:	Not regulated.

RID

14.1 UN Number:	Not regulated.
14.2 UN Proper Shipping Name	Not regulated.
14.3 Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
14.4 Packing Group:	Not regulated.
14.5 Environmental Hazards:	Not regulated.
Marine Pollutant:	Not regulated.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

14.6 Special precautions for user: Not regulated.

IMDG

14.1 UN Number: Not regulated.
14.2 UN Proper Shipping Name: Not regulated.
14.3 Transport Hazard Class(es)
Class: Not regulated.
Label(s): Not regulated.
EmS No.: Not regulated.
14.4 Packing Group: Not regulated.
14.5 Environmental Hazards: Not regulated.
Marine Pollutant: Not regulated.
14.6 Special precautions for user: Not regulated.

IATA

14.1 UN Number: Not regulated.
14.2 Proper Shipping Name: Not regulated.
14.3 Transport Hazard Class(es):
Class: Not regulated.
Label(s): Not regulated.
14.4 Packing Group: Not regulated.
14.5 Environmental Hazards: Not regulated.
Marine Pollutant: Not regulated.
14.6 Special precautions for user: Not regulated.

14.7 Transport in bulk according to Annex II of MARPOL and the IBC Code: Not applicable

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture:

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

EU Regulations

Regulation (EC) No. 2037/2000 Substances that deplete the ozone layer: none

Regulation (EC) No. 850/2004 on persistent organic pollutants: none

Regulation (EC) No. 649/2012 Import and export of dangerous chemicals: none

EU. REACH Candidate List of Substances of Very High Concern for Authorization (SVHC): none

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorisation, as amended: none

Regulation (EC) No. 1907/2006 Annex XVII Substances subject to restriction on marketing and use: none

Directive 2004/37/EC on the protection of workers from the risks related to exposure to carcinogens and mutagens at work.: none

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breast feeding.: none

Directive 96/82/EC (Seveso III): on the control of major accident hazards involving dangerous substances:

Chemical name	CAS-No.	Concentration
sodium azide	26628-22-8	0 - <0.1%

EU. Regulation No. 166/2006 PRTR (Pollutant Release and Transfer Registry), Annex II: Pollutants: none

Directive 98/24/EC on the protection of workers from the risks related to chemical agents at work:

Chemical name	CAS-No.	Concentration
sodium azide	26628-22-8	0 - <0.1%

15.2 Chemical safety assessment:

No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

Revision Information: Not relevant.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

References

PBT	PBT: persistent, bioaccumulative and toxic substance.
vPvB	vPvB: very persistent and very bioaccumulative substance.

Key literature references and sources for data: European Chemicals Agency (ECHA): Information on Chemicals.

Wording of the H-statements in section 2 and 3: none

Training information: No data available.

Issue Date: 06.05.2020

SDS No.: UN0000000000000655872-1157-1-01

Disclaimer: Disclaimer:

The information contained herein has been obtained from various sources and is believed to be correct as of the date issued. However, neither BD nor any of its subsidiaries assumes any liabilities whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability for a particular use of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist. BD provides SDS in electronic form so the information may be more easily accessed. Due to the possibility of errors during transmission, BD makes no representations as to the completeness or accuracy of the information.



Becton, Dickinson
and Company
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Versión: 1.4
Fecha de revisión: 18.09.2023

FICHA DE DATOS DE SEGURIDAD

Conforme al Reglamento (CE) nº 1907/2006 (REACH) Artículo 31, Anexo II con las enmiendas correspondientes

SECCIÓN 1. Identificación de la sustancia o la mezcla y de la sociedad o la empresa

1.1 Product identifier

Núm. de producto:	Nombre del producto:	Nombre(s) común(es) y sinónimo(s)
655872	BD® CD20 (L27) V450	No hay datos disponibles
655874	BD® Anti-HLA-DR (L243) V450	No hay datos disponibles

1.2 Usos pertinentes identificados de la sustancia o de la mezcla y usos desaconsejados

Uso identificado: Para uso científico y en laboratorios industriales. Para uso en diagnósticos in vitro.

Usos no recomendados: Ningunos conocidos/Ninguna conocida.

1.3 Datos del proveedor de la ficha de datos de seguridad

Fabricante

Becton Dickinson France S.A.S. Belgian Branch
Erembodegem-Dorp 86
9320 Erembodegem
Belgium

Teléfono: 32 2 400 98 95
Fax: 32 2 401 70 94

Persona de contacto: BD Biosciences - Centralized European Office
Regulatory Compliance Department

Correo electrónico: help.biosciences@europe.bd.com

1.4 Teléfono de emergencia: 32 2 400 98 95

SECCIÓN 2. Identificación de los peligros

2.1 Clasificación de la sustancia o de la mezcla

El producto no ha sido clasificado como peligroso de acuerdo con la legislación vigentes.

Clasificación de acuerdo con el reglamento (CE) No. 1272/2008 con sus modificaciones ulteriores.



Becton, Dickinson
and Company
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Versión: 1.4
Fecha de revisión: 18.09.2023

No clasificado

2.2 Elementos de la etiqueta No aplicable

2.3 Otros peligros

Propiedades de alteración endocrina-Toxicidad

La sustancia/la mezcla no contienen componentes que tengan propiedades alteradoras endocrinas de acuerdo con el artículo 57(f) de REACH o el Reglamento delegado de la Comisión (UE) 2017/2100 o el Reglamento de la Comisión (UE) 2018/605 en niveles del 0,1 % o superiores.

Propiedades de alteración endocrina-Ecotoxicidad

La sustancia/la mezcla no contienen componentes que tengan propiedades alteradoras endocrinas de acuerdo con el artículo 57(f) de REACH o el Reglamento delegado de la Comisión (UE) 2017/2100 o el Reglamento de la Comisión (UE) 2018/605 en niveles del 0,1 % o superiores.

SECCIÓN 3. Composición/información sobre los componentes

3.2 Mezclas

Información general: No contiene ingredientes peligrosos.

SECCIÓN 4. Primeros auxilios

4.1 Descripción de los primeros auxilios

Información general:	Obtenga atención médica en caso de síntomas.
Inhalación:	Proporcionar aire fresco, calor moderado y reposo. Poner la persona en posición vertical, cómoda, y sentada.
Contacto con la Piel:	Lave las áreas de contacto con agua y jabón. Quítese la ropa contaminada. Lave la ropa contaminada antes de volver a usarla.
Contacto con los ojos:	Enjuagar inmediatamente los ojos con agua abundante durante por los menos 15 minutos. Si resulta fácil, quitar las lentes de contacto.



Becton, Dickinson
and Company
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Versión: 1.4
Fecha de revisión: 18.09.2023

Ingestión: Llamar inmediatamente al médico o al centro toxicológico. Solamente debe provocar el vómito siguiendo las instrucciones del personal médico. No darle nunca nada por la boca a una persona inconsciente.

Equipo de protección personal para el personal de primeros auxilios: No hay datos disponibles.

4.2 Principales síntomas y efectos, agudos y retardados

Síntomas: No hay datos disponibles.

Riesgos: No hay datos disponibles.

4.3 Indicación de asistencia médica inmediata y tratamiento especial necesario

Tratamiento: No hay datos disponibles.

SECCIÓN 5. Medidas de lucha contra incendios

Riesgos Generales de Incendio: Extinguir todas las fuentes de ignición. Evitar chispas, llamas, calor y humo. Ventilar. Use agua nebulizada para mantener refrigerados los contenedores expuestos al fuego.

5.1 Medios de extinción

Medios de extinción apropiados: Agua pulverizada, espuma, polvo seco o dióxido de carbono. Seleccione el medio de extinción más apropiado, teniendo en cuenta la posible presencia de otros productos químicos.

Medios de extinción no apropiados: Evitar chorros directos de agua de la manguera, porque puede esparcir y extender el incendio.

5.2 Peligros específicos derivados de la sustancia o la mezcla: En caso de incendio o calor excesivo se pueden generar productos de descomposición peligrosos.

5.3 Recomendaciones para el personal de lucha contra incendios

Medidas especiales de lucha contra incendios: Ningún riesgo excepcional de incendio o explosión señalado.

Equipos de protección especial que debe llevar el personal de lucha contra incendios: Los bomberos deben utilizar un equipo de protección estándar incluyendo chaqueta ignífuga, casco con careta, guantes, botas de goma, y, en espacios cerrados, equipo de respiración autónomo (SCBA, según sus siglas en inglés).



Becton, Dickinson
and Company
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Versión: 1.4
Fecha de revisión: 18.09.2023

SECCIÓN 6. Medidas en caso de vertido accidental

- | | |
|--|--|
| 6.1 Precauciones personales, equipo de protección y procedimientos de emergencia: | Contacte las autoridades locales en caso de escape al desagüe o el ambiente acuático. Asegúrese una protección personal adecuada (protección respiratoria inclusive) durante la eliminación de derrames en cámaras pequeñas. |
| 6.1.1 Para el personal que no forma parte de los servicios de emergencia: | No hay datos disponibles. |
| 6.1.2 Para el personal de emergencia: | No hay datos disponibles. |
| 6.2 Precauciones relativas al medio ambiente: | Evitar su liberación al medio ambiente. |
| 6.3 Métodos y material de contención y de limpieza: | Absorber el producto derramado con material absorbente. Evite que las aguas residuales entren en las cunetas, alcantarillados o vías fluviales. Consulte la sección 8 de la FDS sobre equipo de protección personal. Para información sobre la eliminación, véase la sección 13. |
| 6.4 Referencia a otras secciones: | No hay datos disponibles. |

SECCIÓN 7. Manipulación y almacenamiento

7.1 Precauciones para una manipulación segura

- | | |
|---|--|
| Medidas técnicas: | No hay datos disponibles. |
| Ventilación Local/total: | No hay datos disponibles. |
| Manipulación: | No comer, ni beber, ni fumar durante su utilización. Leer y seguir las recomendaciones del proveedor. Utilizar los equipos de protección individual según las necesidades. |
| Medidas para evitar el contacto: | No hay datos disponibles. |

7.2 Condiciones de almacenamiento seguro, incluidas posibles incompatibilidades

- | | |
|--|--|
| Condiciones de almacenamiento seguro: | Almacene en un lugar fresco y seco. Manténgase el recipiente bien cerrado. |
| Materiales de embalaje seguros: | No hay datos disponibles. |



Becton, Dickinson
and Company
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Versión: 1.4
Fecha de revisión: 18.09.2023

7.3 Usos específicos finales:

Reservado a usos industriales y profesionales. Leer la etiqueta antes del uso.

SECCIÓN 8. Controles de exposición/protección individual

8.1 Parámetros de control

Valores Límite de Exposición Profesional

No se asignaron límites de exposición a ninguno de los componentes.

Valor Límite Biológico

No se han indicado límites de exposición biológica para el/los componente(s).

Valores DNEL

Observaciones: Valores DNEL

Componente crítico	Tipo	Ruta de exposición	Advertencias para la salud	Observaciones
cloruro de sodio	Población general	Inhalación	Sistémicos, largo plazo; 443,28 mg/m3	Toxicidad por dosis repetidas
	Trabajadores	Inhalación	Sistémicos, largo plazo; 2068,62 mg/m3	Toxicidad por dosis repetidas
	Trabajadores	Inhalación	Sistémicos, corto plazo; 2068,62 mg/m3	Toxicidad por dosis repetidas
	Población general	Inhalación	Sistémicos, corto plazo; 443,28 mg/m3	Toxicidad por dosis repetidas
	Población general	Oral	Sistémicos, largo plazo; 126,65 mg/kg	Toxicidad por dosis repetidas
	Trabajadores	Dérmico	Sistémicos, largo plazo; 295,52 mg/kg	Toxicidad por dosis repetidas
	Trabajadores	Dérmico	Sistémicos, corto plazo; 295,52 mg/kg	Toxicidad por dosis repetidas
	Población general	Oral	Sistémicos, corto plazo; 126,65 mg/kg	Toxicidad por dosis repetidas
	Población general	Dérmico	Sistémicos, corto plazo; 126,65 mg/kg	Toxicidad por dosis repetidas
	Población general	Dérmico	Sistémicos, largo plazo; 126,65 mg/kg	Toxicidad por dosis repetidas



**Becton, Dickinson
and Company**
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Versión: 1.4
Fecha de revisión: 18.09.2023

hidrogenoortofosfato de sodio	Trabajadores	Ojos	Efecto local;	Sin peligro identificado
	Trabajadores	Inhalación	Sistémicos, largo plazo; 4,07 mg/m3	Toxicidad por dosis repetidas
	Población general	Inhalación	Sistémicos, largo plazo; 3,04 mg/m3	Toxicidad por dosis repetidas
	Población general	Inhalación	Sistémicos, largo plazo; 6,63 mg/m3	Toxicidad por dosis repetidas
	Trabajadores	Inhalación	Sistémicos, largo plazo; 15,47 mg/m3	Toxicidad por dosis repetidas
Azida de sodio	Trabajadores	Inhalación	Sistémicos, largo plazo; 0,164 mg/m3	Toxicidad por dosis repetidas
	Población general	Ojos	Efecto local;	Sin peligro identificado
	Población general	Inhalación	Sistémicos, largo plazo; 29 µg/m3	Toxicidad por dosis repetidas
	Trabajadores	Ojos	Efecto local;	Sin peligro identificado
	Población general	Oral	Sistémicos, largo plazo; 0,0167 mg/kg	Toxicidad por dosis repetidas
	Trabajadores	Dérmico	Sistémicos, largo plazo; 0,0467 mg/kg	Toxicidad por dosis repetidas
	Población general	Dérmico	Sistémicos, largo plazo; 0,0167 mg/kg	Toxicidad por dosis repetidas
dihidrogenoortofosfato de potasio	Trabajadores	Ojos	Efecto local;	Sin peligro identificado
	Población general	Ojos	Efecto local;	Sin peligro identificado
	Trabajadores	Inhalación	Sistémicos, largo plazo; 14,82 mg/m3	Toxicidad por dosis repetidas
	Población general	Inhalación	Sistémicos, largo plazo; 6,35 mg/m3	Toxicidad por dosis repetidas



**Becton, Dickinson
and Company**
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Versión: 1.4
Fecha de revisión: 18.09.2023

cloruro de potasio	Trabajadores	Inhalación	Sistémicos, largo plazo; 1064 mg/m3	Toxicidad por dosis repetidas
	Población general	Inhalación	Sistémicos, largo plazo; 273 mg/m3	Toxicidad por dosis repetidas
	Población general	Inhalación	Sistémicos, corto plazo; 1365 mg/m3	Toxicidad por dosis repetidas
	Trabajadores	Inhalación	Sistémicos, corto plazo; 5320 mg/m3	Toxicidad por dosis repetidas
	Población general	Oral	Sistémicos, corto plazo; 455 mg/kg	Toxicidad por dosis repetidas
	Población general	Dérmico	Sistémicos, largo plazo; 182 mg/kg	Toxicidad por dosis repetidas
	Población general	Oral	Sistémicos, largo plazo; 91 mg/kg	Toxicidad por dosis repetidas
	Trabajadores	Dérmico	Sistémicos, largo plazo; 303 mg/kg	Toxicidad por dosis repetidas
	Trabajadores	Dérmico	Sistémicos, corto plazo; 910 mg/kg	Toxicidad por dosis repetidas
	Población general	Dérmico	Sistémicos, corto plazo; 910 mg/kg	Toxicidad por dosis repetidas

Valores PNEC

Observaciones: Valores PNEC

Componente crítico	Compartimento medioambiental	Valores PNEC	Observaciones
cloruro de sodio	Tierra	4,86 mg/kg	
	Acuático (agua dulce)	5 mg/l	
	Planta de tratamiento de aguas residuales	500 mg/l	
hidrogenoortofosfato de disodio	Planta de tratamiento de aguas residuales	50 mg/l	



**Becton, Dickinson
and Company**
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Versión: 1.4
Fecha de revisión: 18.09.2023

	Acuático (agua dulce)	0,05 mg/l	
	Acuático (agua marina)	0,005 mg/l	
Azida de sodio	Acuático (agua marina)	15 ng/l	
	Acuático (agua dulce)	0,35 µg/l	
	Sedimento (agua dulce)	0,0167 mg/kg	
	Sedimentos (agua marina)	0,00072 mg/kg	
	Planta de tratamiento de aguas residuales	30 µg/l	
cloruro de potasio	Acuático (agua marina)	0,1 mg/l	
	Planta de tratamiento de aguas residuales	10 mg/l	
	Acuático (agua dulce)	0,1 mg/l	

8.2 Controles de la exposición

Controles Técnicos Apropriados:

Ningún requisito especial en condiciones normales de uso y con ventilación adecuada.

Medidas de protección individual, tales como equipos de protección personal

Protección de los ojos/la cara:

Use gafas de seguridad con protectores laterales (o gafas estancas).

Protección de las Manos:

Material: Guantes resistente a productos químicos
Información adicional: Lávese las manos después de la exposición.
Material: El proveedor puede recomendar los guantes adecuados.

Protección de la Piel y del Cuerpo:

Utilice una bata de laboratorio o ropa protectora similar.



Becton, Dickinson
and Company
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Versión: 1.4
Fecha de revisión: 18.09.2023

Protección respiratoria:	Si los controles de ingeniería no mantienen las concentraciones en el aire por debajo de los límites de exposición recomendados (cuando proceda) o a un nivel aceptable (en países donde no se hayan establecido límites de exposición), ha de utilizarse un respirador aprobado.
Medidas de higiene:	Respete las normas para una manipulación correcta de productos químicos.
Controles medioambientales:	No hay datos disponibles.

SECCIÓN 9. Propiedades físicas y químicas

9.1 Información sobre propiedades físicas y químicas básicas

Aspecto

Forma/estado:	Líquido
Forma/Figura:	Líquido
Color:	De incoloro a amarillo
Olor:	Inodoro
Olor, umbral:	No hay datos disponibles.
Punto de congelamiento:	No hay datos disponibles.
Punto ebullición:	No hay datos disponibles.
Inflamabilidad:	No hay datos disponibles.
Límites superior/inferior de inflamabilidad o de explosividad	
Límite superior de explosividad (%):	No hay datos disponibles.
Límite inferior de explosividad (%):	No hay datos disponibles.
Punto de inflamación:	No hay datos disponibles.
Temperatura de auto-inflamación:	No hay datos disponibles.
Descomposición, temperatura de:	No hay datos disponibles.
pH:	7,20 - 7,60
Viscosidad	
Viscosidad dinámica:	No hay datos disponibles.
Viscosidad cinemática:	No hay datos disponibles.
Solubilidad(es)	
Solubilidad en agua:	Soluble



Becton, Dickinson
and Company
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Versión: 1.4
Fecha de revisión: 18.09.2023

Coefficiente de reparto (n-octanol/agua):	No hay datos disponibles.
Presión de vapor:	No hay datos disponibles.
Densidad relativa:	No hay datos disponibles.
Densidad:	No hay datos disponibles.
Densidad relativa del vapor:	No hay datos disponibles.

9.2 Otros datos

Sin datos disponibles

SECCIÓN 10. Estabilidad y reactividad

10.1 Reactividad:	El material es estable bajo condiciones normales.
10.2 Estabilidad química:	El material es estable bajo condiciones normales.
10.3 Posibilidad de reacciones peligrosas:	estable
10.4 Condiciones que deben evitarse:	Evítese la exposición a altas temperaturas o a los rayos del sol.
10.5 Materiales incompatibles:	metales Reacciona con el agua.
10.6 Productos de descomposición peligrosos:	Estable; sin embargo, puede descomponerse en caso de calentamiento.

SECCIÓN 11. Información toxicológica

11.1 Información sobre las clases de peligro definidas en el Reglamento (CE) n.o 1272/2008

Inhalación: No hay datos disponibles.

Contacto con la Piel: No hay datos disponibles.

Contacto con los ojos: No hay datos disponibles.

Ingestión: No hay datos disponibles.

Toxicidad aguda (listar todas las vías de exposición posibles)

Ingestión

Producto: No clasificado en cuanto a toxicidad aguda con los datos disponibles.



Becton, Dickinson
and Company
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Versión: 1.4
Fecha de revisión: 18.09.2023

Contacto dermal

Producto: No clasificado en cuanto a toxicidad aguda con los datos disponibles.

Inhalación

Producto: No clasificado en cuanto a toxicidad aguda con los datos disponibles.

Toxicidad por dosis repetidas

Producto: No hay datos disponibles.

Corrosión/Irritación Cutáneas

Producto: No hay datos disponibles.

Lesiones Oculares Graves/Irritación Ocular

Producto: No hay datos disponibles.

Sensibilización de la Piel o Respiratoria

Producto: No hay datos disponibles.

Carcinogenicidad

Producto: No hay datos disponibles.

Mutagenicidad en Células Germinales

En vitro

Producto: No hay datos disponibles.

En vivo

Producto: No hay datos disponibles.

Toxicidad para la reproducción

Producto: No hay datos disponibles.

Toxicidad Sistémica Específica de Órganos Diana- Exposición Única

Producto: No hay datos disponibles.

Toxicidad Sistémica Específica de Órganos Diana- Exposiciones Repetidas

Producto: No hay datos disponibles.

Peligro por Aspiración

Producto: No hay datos disponibles.

11.2 Información relativa a otros peligros

Propiedades de alteración endocrina



**Becton, Dickinson
and Company**
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Versión: 1.4
Fecha de revisión: 18.09.2023

Producto: La sustancia/la mezcla no contienen componentes que tengan propiedades alteradoras endocrinas de acuerdo con el artículo 57(f) de REACH o el Reglamento delegado de la Comisión (UE) 2017/2100 o el Reglamento de la Comisión (UE) 2018/605 en niveles del 0,1 % o superiores.;

**Otros datos
Producto:** No hay datos disponibles.

SECCIÓN 12. Información ecológica

12.1 Toxicidad:

Peligros agudos para el medio ambiente acuático:

Pez

Producto: No hay datos disponibles.

Invertebrados Acuáticos

Producto: No hay datos disponibles.

Toxicidad para plantas acuáticas

Producto: No hay datos disponibles.

Toxicidad para los microorganismos

Producto: No hay datos disponibles.

Peligros crónicos para el medio ambiente acuático:

Pez

Producto: No hay datos disponibles.

Invertebrados Acuáticos

Producto: No hay datos disponibles.

Toxicidad para los microorganismos

Producto: No hay datos disponibles.

12.2 Persistencia y degradabilidad

Biodegradable

Producto: No hay datos disponibles.



Becton, Dickinson
and Company
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Versión: 1.4
Fecha de revisión: 18.09.2023

12.3 Potencial de bioacumulación

Factor de Bioconcentración (BCF)

Producto: No hay datos disponibles.

Coeficiente de Partición n-octanol/agua (log Kow)

Producto: No hay datos disponibles.

12.4 Movilidad en el suelo:

Producto: No hay datos disponibles.

12.5 Resultados de la valoración PBT y mPmB:

Producto: No hay datos disponibles.

12.6 Propiedades de alteración endocrina:

Producto: La sustancia/la mezcla no contienen componentes que tengan propiedades alteradoras endocrinas de acuerdo con el artículo 57(f) de REACH o el Reglamento delegado de la Comisión (UE) 2017/2100 o el Reglamento de la Comisión (UE) 2018/605 en niveles del 0,1 % o superiores.

12.7 Otros efectos adversos:

Otros peligros

Producto: No hay datos disponibles.

SECCIÓN 13. Consideraciones relativas a la eliminación

13.1 Métodos para el tratamiento de residuos

Información general:

Eliminar los desperdicios y residuos de conformidad con la normativa promulgada por las autoridades locales.

Métodos de eliminación:

Elimine el residuo en una instalación adecuada de tratamiento y eliminación de acuerdo con las leyes y reglamentos correspondientes y características del producto en el momento de la eliminación.



**Becton, Dickinson
and Company**
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Versión: 1.4
Fecha de revisión: 18.09.2023

Envases Contaminados:

Eliminar el contenido/el recipiente en una instalación de tratamiento y eliminación de desechos apropiada de conformidad con las leyes y reglamentos aplicables y con las características del producto en el momento de la eliminación.

SECCIÓN 14. Información relativa al transporte

ADR

- | | |
|--|------------------|
| 14.1 Número ONU o número ID: | No reglamentado. |
| 14.2 Designación oficial de transporte de las Naciones Unidas: | No reglamentado. |
| 14.3 Clase(s) de peligro para el transporte | |
| Clase: | No reglamentado. |
| Etiqueta(s): | No reglamentado. |
| No. de riesgo (ADR): | No reglamentado. |
| Código de restricciones en túneles: | No reglamentado. |
| 14.4 Grupo de embalaje: | No reglamentado. |
| Cantidad limitada | No reglamentado. |
| Cantidad exceptuada | No reglamentado. |
| 14.5 Peligros para el medio ambiente | No reglamentado. |
| 14.6 Precauciones particulares para los usuarios: | No reglamentado. |

ADN

- | | |
|--|------------------|
| 14.1 Número ONU o número ID: | No reglamentado. |
| 14.2 Designación oficial de transporte de las Naciones Unidas: | No reglamentado. |
| 14.3 Clase(s) de peligro para el transporte | |
| Clase: | No reglamentado. |
| Etiqueta(s): | No reglamentado. |
| No. de riesgo (ADR): | No reglamentado. |
| Código de restricciones en túneles: | No reglamentado. |
| 14.4 Grupo de embalaje: | No reglamentado. |
| Cantidad limitada | No reglamentado. |
| Cantidad exceptuada | No reglamentado. |
| 14.5 Precauciones particulares para los usuarios: | No reglamentado. |

RID

- | | |
|--|------------------|
| 14.1 Número ONU o número ID: | No reglamentado. |
| 14.2 Designación oficial de transporte de las Naciones Unidas: | No reglamentado. |
| 14.3 Clase(s) de peligro para el transporte | |



**Becton, Dickinson
and Company**
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Versión: 1.4
Fecha de revisión: 18.09.2023

Clase:	No reglamentado.
Etiqueta(s):	No reglamentado.
14.4 Grupo de embalaje:	No reglamentado.
Cantidad limitada	No reglamentado.
Cantidad exceptuada	No reglamentado.
14.5 Peligros para el medio ambiente	No reglamentado.
14.6 Precauciones particulares para los usuarios:	No reglamentado.

IMDG

14.1 Número ONU o número ID:	No reglamentado.
14.2 Designación oficial de transporte de las Naciones Unidas:	No reglamentado.
14.3 Clase(s) de peligro para el transporte	
Clase:	No reglamentado.
Etiqueta(s):	No reglamentado.
EmS No.:	No reglamentado.
14.4 Grupo de embalaje:	No reglamentado.
Cantidad limitada	No reglamentado.
Cantidad exceptuada	No reglamentado.
14.5 Peligros para el medio ambiente	No reglamentado.
14.6 Precauciones particulares para los usuarios:	No reglamentado.

IATA

14.1 Número ONU o número ID:	No reglamentado.
14.2 Designación oficial de transporte de las Naciones Unidas:	No reglamentado.
14.3 Clase(s) de peligro para el transporte	
Clase:	No reglamentado.
Etiqueta(s):	No reglamentado.
14.4 Grupo de embalaje:	No reglamentado.
Transporte aéreo de pasajeros y mercancías :	No reglamentado.
Cantidad limitada	No reglamentado.
Cantidad exceptuada	No reglamentado.
14.5 Peligros para el medio ambiente	No reglamentado.
14.6 Precauciones particulares para los usuarios:	No reglamentado.

14.7 Transporte marítimo a granel con arreglo a los instrumentos de la OMI

No aplicable al producto suministrado.

SECCIÓN 15. Información reglamentaria

15.1 Reglamentación y legislación en materia de seguridad, salud y medio ambiente específicas

SDS_ES

15/19



Becton, Dickinson
and Company
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Versión: 1.4
Fecha de revisión: 18.09.2023

para la sustancia o la mezcla:

Legislación de la UE

Reglamento 1005/2009/EC sobre las sustancias que agotan la capa de ozono. Anexo I, Sustancias controladas: No están presentes, o no están presentes en las cantidades reguladas.

REGLAMENTO (CE) No 1907/2006 (REACH), ANEXO XIV LISTA DE SUSTANCIAS SUJETAS A AUTORIZACIÓN: No están presentes, o no están presentes en las cantidades reguladas.

Reglamento nº. 2019/1021/UE de la UE que prohíbe y restringe contaminantes orgánicos persistentes (COP), con sus modificaciones ulteriores: No están presentes, o no están presentes en las cantidades reguladas.

UE. Directiva 2010/75/UE sobre las emisiones industriales (prevención y control integrados de la contaminación), Anexo II, L 334/17: No están presentes, o no están presentes en las cantidades reguladas.

Reglamento (UE) nº 649/2012 relativo a la exportación e importación de productos químicos peligrosos, Anexo I, parte 1, con las enmiendas correspondientes: No están presentes, o no están presentes en las cantidades reguladas.

Reglamento (UE) nº 649/2012 relativo a la exportación e importación de productos químicos peligrosos, Anexo I, parte 2, con las enmiendas correspondientes: No están presentes, o no están presentes en las cantidades reguladas.

Reglamento (UE) nº 649/2012 relativo a la exportación e importación de productos químicos peligrosos, Anexo I, parte 3, con las enmiendas correspondientes: No están presentes, o no están presentes en las cantidades reguladas.

Reglamento (UE) nº 649/2012 relativo a la exportación e importación de productos químicos peligrosos, Anexo V, con las enmiendas correspondientes: No están presentes, o no están presentes en las cantidades reguladas.

UE. Lista provisional (lista de candidatas) de sustancias extremadamente preocupantes (SEP) que pueden estar sujetas a autorización en el marco de REACH: No están presentes, o no están presentes en las cantidades reguladas.

Reglamento (CE) No. 1907/2006, Anexo XVII, Sustancias sujetas a restricciones aplicables a la comercialización y uso:

Determinación química	No. CAS	Número de lista
Sodium azide (Na(N ₃))	26628-22-8	3

Directiva 2004/37/CE relativa a la protección de los trabajadores contra los riesgos relacionados con la exposición a agentes carcinógenos o mutágenos durante el trabajo.: No están presentes, o no están presentes en las cantidades reguladas.



Becton, Dickinson
and Company
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Versión: 1.4
Fecha de revisión: 18.09.2023

Directiva 92/85/CEE relativa a la aplicación de medidas para promover la mejora de la seguridad y de la salud en el trabajo de la trabajadora embarazada, que haya dado a luz o en período de lactancia: No están presentes, o no están presentes en las cantidades reguladas.

DIRECTIVA 2012/18/UE relativa al control de los riesgos inherentes a los accidentes graves en los que intervengan sustancias peligrosas, ANEXO I: No están presentes, o no están presentes en las cantidades reguladas.

REGLAMENTO (CE) No 166/2006 relativo al establecimiento de un registro europeo de emisiones y transferencias de contaminantes, ANEXO II: Contaminantes: No están presentes, o no están presentes en las cantidades reguladas.

Directiva 98/24/CE relativa a la protección de los trabajadores contra los riesgos relacionados con los agentes químicos durante el trabajo:

Determinación química	No. CAS	Concentración
Sodium azide (Na(N ₃))	26628-22-8	0 - <0,1%

UE. Precursores de explosivos restringidos (anexo I) e informables (anexo II), Reglamento 2019/1148 / UE sobre precursores de explosivos (EU EXPLD): No están presentes, o no están presentes en las cantidades reguladas.

UE. Anexos I y II del Reglamento 98/2013/UE sobre la comercialización y utilización de precursores de explosivos (EU EXPRE): No están presentes, o no están presentes en las cantidades reguladas.

UE. Precursores de explosivos restringidos: Anexo I, Reglamento 2019/1148/UE sobre precursores explosivos (EUEXPL1D): No están presentes, o no están presentes en las cantidades reguladas.

UE. Precursores de explosivos notificables (Anexo II), Reglamento 2019/1148/UE sobre precursores de explosivos (EUEXPL2D): No están presentes, o no están presentes en las cantidades reguladas.

UE. Precursores de explosivos notificables (Anexo II), Reglamento 2019/1148/UE sobre precursores de explosivos (EUEXPL2L): No están presentes, o no están presentes en las cantidades reguladas.

15.2 Evaluación de la seguridad química:

No se ha realizado ninguna evaluación de la seguridad química.

SECCIÓN 16. Otra información

**Becton, Dickinson
and Company**
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Abreviaturas y acrónimos:

ADN - Acuerdo europeo relativo al transporte internacional de mercancías peligrosas por vías navegables interiores; ADR - Acuerdo relativo al transporte internacional de mercancías peligrosas por carretera; AIIC - Inventario de productos químicos industriales de Australia; ASTM - Sociedad Estadounidense para la Prueba de Materiales; bw - Peso corporal; CLP - Reglamentación sobre clasificación, etiquetado y envasado; Reglamento (EC) No 1272/2008; CMR - Carcinógeno, mutágeno o tóxico para la reproducción; DIN - Norma del Instituto Alemán para la Normalización; DSL - Lista Nacional de Sustancias (Canadá); ECHA - Agencia Europea de Sustancias Químicas; EC-Number - Número de la Comunidad Europea; ECx - Concentración asociada con respuesta x%; EIGA - Asociación Europea de Gases Industriales; ELx - Tasa de carga asociada con respuesta x%; EmS - Procedimiento de emergencia; ENCS - Sustancias Químicas Existentes y Nuevas (Japón); ErCx - Concentración asociada con respuesta de tasa de crecimiento x%; GHS - Sistema Globalmente Armonizado; GLP - Buena práctica de laboratorio; IARC - Agencia Internacional para la investigación del cáncer; IATA - Asociación Internacional de Transporte Aéreo; IBC - Código internacional para la construcción y equipamiento de Embarcaciones que transportan químicos peligros a granel; IC50 - Concentración inhibitoria máxima media; ICAO - Organización Internacional de Aviación Civil; IECSC - Inventario de Sustancias Químicas en China; IMDG - Código Marítimo Internacional de Mercancías Peligrosas; IMO - Organización Marítima Internacional; ISHL - Ley de Seguridad e Higiene Industrial (Japón); ISO - Organización Internacional para la Normalización; KECI - Inventario de Químicos Existentes de Corea; LC50 - Concentración letal para 50% de una población de prueba; LD50 - Dosis letal para 50% de una población de prueba (Dosis letal mediana); MARPOL - Convenio Internacional para prevenir la Contaminación en el mar por los buques; n.o.s. - N.E.P.: No especificado en otra parte; NO(A)EC - Concentración de efecto (adverso) no observable; NO(A)EL - Nivel de efecto (adverso) no observable; NOELR - Tasa de carga de efecto no observable; NZIoC - Inventario de Químicos de Nueva Zelanda; OECD - Organización para la Cooperación y el Desarrollo Económico; OPPTS - Oficina para la Seguridad Química y Prevención de Contaminación; PBT - Sustancia persistente, bioacumulativa y tóxica; PICCS - Inventario Filipino de Químicos y Sustancias Químicas; (Q)SAR - Relación estructura-actividad (cuantitativa); REACH - Reglamento (EC) No 1907/2006 del Parlamento y Consejo Europeos con respecto al registro, evaluación autorización y restricción de químicos; RID - reglamento relativo al transporte internacional de mercancías peligrosas por ferrocarril; SADT - Temperatura de descomposición autoacelerada; SDS - Ficha de datos de seguridad; SVHC - sustancia altamente preocupante; TCSI - Inventario de Sustancias Químicas de Taiwán; TECI - Inventario de productos químicos existentes de Tailandia; TRGS - Regla técnica para sustancias peligrosas; TSCA - Ley para el Control de Sustancias Tóxicas (Estados Unidos); UN - Naciones Unidas; vPvB - Muy persistente y muy bioacumulativo

Principales referencias bibliográficas y las fuentes de datos:

Agencia Europea de Sustancias y Preparados Químicos (ECHA):
información sobre sustancias y preparados químicos.

Enunciado de las frases en los apartados 2 y 3

: ningunos



**Becton, Dickinson
and Company**
BD, Franklin Lakes,
NJ 07417 USA
www.bd.com

Versión: 1.4
Fecha de revisión: 18.09.2023

**Información sobre
formación:**

No hay datos disponibles.

**Exención de
responsabilidad:**

Descargo de responsabilidad:
La información aquí contenida ha sido obtenida de diversas fuentes y se cree que es correcta a partir de la fecha de emisión. Sin embargo, ni BD ni ninguna de sus subsidiarias asumen responsabilidad alguna por la exactitud o la exhaustividad de la información contenida en este documento. La determinación final de idoneidad para un uso particular de cualquier material es responsabilidad exclusiva del usuario. Todos los materiales pueden presentar peligros desconocidos y deben usarse con precaución. Si bien se describen ciertos peligros en este documento, no podemos garantizar que éstos sean los únicos peligros que existen. BD proporciona SDS en formato electrónico por lo que la información puede ser más fácil acceso. Debido a la posibilidad de errores durante la transmisión, BD no hace ninguna representación en cuanto a la integridad o exactitud de la información.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SAFETY DATA SHEET

1. Identification

Product identifier

Product No.:	Product name:	Common name(s), synonym(s)
656646	CD38 (HB7) APC-H7	No data available

Other means of identification

SDS number: 088100075108

Recommended use and restriction on use

Recommended use: Scientific and industrial laboratory use. For research use only.

Restrictions on use: Not for use in diagnostic or therapeutic procedures.

Manufacturer/Importer/Supplier/Distributor Information

Manufacturer

Company Name: Becton, Dickinson and Company - BD Biosciences
Address: 2350 Qume Drive
San Jose, CA 95131 USA
Telephone: 1 877 232 8995 or 1 800 424 9300
Fax:
Contact Person: Technical Services
E-mail: ResearchApplications@bd.com or ClinicalApplications@bd.com

Emergency telephone number: CHEMTREC 1 800 424 9300

2. Hazard(s) identification

Hazard Classification

Health Hazards

Skin sensitizer Category 1

Environmental Hazards

Acute hazards to the aquatic environment Category 3

Chronic hazards to the aquatic environment Category 3



**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Label Elements

Hazard Symbol:



Signal Word: Warning

Hazard Statement: H317: May cause an allergic skin reaction.
H412: Harmful to aquatic life with long lasting effects.

Precautionary Statements

Prevention: P261: Avoid breathing dust/fume/gas/mist/vapors/spray.
P272: Contaminated work clothing should not be allowed out of the workplace.
P280: Wear protective gloves/protective clothing/eye protection/face protection.
P273: Avoid release to the environment.

Response: P302+P352: IF ON SKIN: Wash with plenty of water/...
P333+P313: If skin irritation or rash occurs: Get medical advice/attention.
P321: Specific treatment (see on this label).
P362+P364: Take off contaminated clothing and wash it before reuse.

Disposal: P501: Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

Other hazards which do not result in GHS classification: None.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

3. Composition/information on ingredients

Mixtures

Chemical Identity	Common name and synonyms	CAS number	Content in percent (%)*
1,2,3-Propanetriol	No data available.	56-81-5	19.003%
CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1)	, Kathon 886	55965-84-9	29.36PPM
Sodium azide (Na(N ₃))	No data available.	26628-22-8	10.357PPM

* All concentrations are percent by weight unless ingredient is a gas. Gas concentrations are in percent by volume.

4. First-aid measures

General information:	Get medical attention if symptoms occur.
Ingestion:	If swallowed, rinse mouth with water (only if the person is conscious). Do NOT induce vomiting. Get medical attention immediately.
Inhalation:	Provide fresh air, warmth and rest, preferably in comfortable upright sitting position. Get medical attention if symptoms persist.
Skin Contact:	Wash off promptly and flush contaminated skin with water. Promptly remove clothing if soaked through and flush skin with water. Get medical attention if symptoms occur. Wash contaminated clothing before reuse.
Eye contact:	Immediately flush with plenty of water for at least 15 minutes. If easy to do, remove contact lenses. Get medical attention promptly if symptoms occur after washing.

Most important symptoms/effects, acute and delayed

Symptoms: Symptoms may be delayed.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Hazards: May cause an allergic skin reaction.

Indication of immediate medical attention and special treatment needed

Treatment: Wash off promptly and flush contaminated skin with water. Promptly remove clothing if soaked through and flush skin with water.

5. Fire-fighting measures

General Fire Hazards: Extinguish all ignition sources. Avoid sparks, flames, heat and smoking. Ventilate. Use water to keep fire exposed containers cool and disperse vapors.

Suitable (and unsuitable) extinguishing media

Suitable extinguishing media: Water spray, fog, CO₂, dry chemical, or alcohol resistant foam.

Unsuitable extinguishing media: Avoid water in straight hose stream; will scatter and spread fire.

Specific hazards arising from the chemical: Fire or excessive heat may produce hazardous decomposition products.

Special protective equipment and precautions for firefighters

Special fire fighting procedures: No unusual fire or explosion hazards noted.

Special protective equipment for fire-fighters: Firefighters must use standard protective equipment including flame retardant coat, helmet with face shield, gloves, rubber boots, and in enclosed spaces, SCBA.

6. Accidental release measures



**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

**Personal precautions,
protective equipment
and emergency
procedures:**

Ensure suitable personal protection (including respiratory protection) during removal of spillages in a confined area. Contact local authorities in case of spillage to drain/aquatic environment.

**Methods and material for
containment and
cleaning up:**

Stop leak if possible without any risk. Absorb or cover with dry earth, sand or other non-combustible material and transfer to containers. Collect for salvage or disposal. Prevent runoff from entering drains, sewers, or streams. Report spills as required to appropriate authorities. See Section 8 of the SDS for Personal Protective Equipment. For waste disposal, see section 13 of the SDS.

**Environmental
Precautions:**

Avoid release to the environment.

7. Handling and storage

Handling

**Technical measures (e.g.
Local and general
ventilation):**

Adequate ventilation should be provided whenever the material is heated or mists are generated.

Safe handling advice:

Wash promptly with soap and water if skin becomes contaminated. When using do not eat, drink or smoke. Read and follow manufacturer's recommendations. Use personal protective equipment as required.

**Contact avoidance
measures:**

No data available.

Hygiene measures:

Do not eat, drink or smoke when using the product. Wash promptly if skin becomes contaminated. Wash at the end of each work shift and before eating, smoking and using the toilet. Avoid contact with skin.

Storage



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Safe storage conditions: Store in tightly closed original container in a dry, cool and well-ventilated place.

Safe packaging materials: No data available.

Storage Temperature: No data available.

8. Exposure controls/personal protection

Control Parameters

Occupational Exposure Limits

Chemical Identity	Type	Exposure Limit Values	Source
1,2,3-Propanetriol - Total dust.	TWA	10 mg/m ³	US. OSHA Table Z-1-A (29 CFR 1910.1000), as amended (1989)
1,2,3-Propanetriol - Respirable fraction.	TWA	5 mg/m ³	US. OSHA Table Z-1-A (29 CFR 1910.1000), as amended (1989)
1,2,3-Propanetriol - Respirable fraction and dust or fume.	TWA	5 mg/m ³	US. Tennessee. OELs. Occupational Exposure Limits, Table Z1A, as amended (06 2008)
1,2,3-Propanetriol - Total dust and mist.	TWA	10 mg/m ³	US. Tennessee. OELs. Occupational Exposure Limits, Table Z1A, as amended (06 2008)
1,2,3-Propanetriol	ST ESL	50 µg/m ³	US. Texas. Effects Screening Levels (Texas Commission on Environmental Quality), as amended (03 2012)
	AN ESL	5 µg/m ³	US. Texas. Effects Screening Levels (Texas Commission on Environmental Quality), as amended (03 2012)
	ST ESL	1,000 µg/m ³	US. Texas. Effects Screening Levels (Texas Commission on Environmental Quality), as amended (03 2012)
	AN ESL	100 µg/m ³	US. Texas. Effects Screening Levels (Texas Commission on Environmental Quality), as amended (03 2012)
1,2,3-Propanetriol - Respirable fraction.	PEL	5 mg/m ³	US. OSHA Table Z-1 Limits for Air Contaminants (29 CFR 1910.1000), as amended (02 2006)
1,2,3-Propanetriol - Total dust.	PEL	15 mg/m ³	US. OSHA Table Z-1 Limits for Air Contaminants (29 CFR 1910.1000), as amended (02 2006)
Sodium azide (Na(N ₃)) - as HN ₃	Ceiling	0.1 ppm	US. OSHA Table Z-1-A (29 CFR 1910.1000), as amended (1989)
Sodium azide (Na(N ₃)) - as NaN ₃	Ceiling	0.3 mg/m ³	US. OSHA Table Z-1-A (29 CFR 1910.1000), as amended (1989)
	Ceiling	0.3 mg/m ³	US. Tennessee. OELs. Occupational Exposure Limits, Table Z1A, as amended



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

			(06 2008)
Sodium azide (Na(N3)) - as HN3	Ceiling	0.1 ppm	US. Tennessee. OELs. Occupational Exposure Limits, Table Z1A, as amended (06 2008)
Sodium azide (Na(N3))	AN ESL	0.07 ppb	US. Texas. Effects Screening Levels (Texas Commission on Environmental Quality), as amended (12 2010)
	ST ESL	0.7 ppb	US. Texas. Effects Screening Levels (Texas Commission on Environmental Quality), as amended (12 2010)
	AN ESL	0.2 µg/m3	US. Texas. Effects Screening Levels (Texas Commission on Environmental Quality), as amended (12 2010)
	ST ESL	2 µg/m3	US. Texas. Effects Screening Levels (Texas Commission on Environmental Quality), as amended (12 2010)
	Ceiling	0.1 ppm 0.3 mg/m3	US. California Code of Regulations, Title 8, Section 5155. Airborne Contaminants, as amended (08 2010)
Sodium azide (Na(N3)) - as hydrazoic acid vapor	Ceiling	0.11 ppm	US. ACGIH Threshold Limit Values, as amended (12 2010)
Sodium azide (Na(N3)) - as NaN3	Ceiling	0.29 mg/m3	US. ACGIH Threshold Limit Values, as amended (12 2010)
	Ceil_Time	0.3 mg/m3	US. NIOSH: Pocket Guide to Chemical Hazards, as amended (2005)
Sodium azide (Na(N3)) - as HN3	Ceil_Time	0.1 ppm	US. NIOSH: Pocket Guide to Chemical Hazards, as amended (2005)

Appropriate Engineering Controls

Adequate ventilation should be provided whenever the material is heated or mists are generated.

Individual protection measures, such as personal protective equipment

General information:

Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing to remove contaminants. Discard contaminated footwear that cannot be cleaned.

Eye/face protection:

Wear safety glasses with side shields (or goggles).

Skin Protection

Hand Protection:

Use suitable protective gloves if risk of skin contact.

Other:

Wear appropriate clothing to prevent repeated or prolonged skin contact.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

**Respiratory
Protection:**

If engineering controls do not maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (in countries where exposure limits have not been established), an approved respirator must be worn.

Hygiene measures:

Do not eat, drink or smoke when using the product. Wash promptly if skin becomes contaminated. Wash at the end of each work shift and before eating, smoking and using the toilet. Avoid contact with skin.

9. Physical and chemical properties

Appearance

Physical state:

liquid

Form:

No data available.

Color:

No data available.

Odor:

No data available.

Odor threshold:

No data available.

pH:

No data available.

Melting point/freezing point:

No data available.

**Initial boiling point and boiling
range:**

No data available.

Flash Point:

No data available.

Evaporation rate:

No data available.

Flammability (solid, gas):

No data available.

Upper/lower limit on flammability or explosive limits

Flammability limit - upper (%):

No data available.

Flammability limit - lower (%):

No data available.

Explosive limit - upper:

No data available.

Explosive limit - lower:

No data available.

Vapor pressure:

No data available.

Vapor density:

No data available.

Relative density:

No data available.

Solubility(ies)

Solubility in water:

No data available.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Solubility (other):	No data available.
Partition coefficient (n-octanol/water):	No data available.
Auto-ignition temperature:	No data available.
Decomposition temperature:	No data available.
Viscosity:	No data available.

10. Stability and reactivity

Reactivity:	Stable
Chemical Stability:	No data available.
Possibility of hazardous reactions:	None under normal conditions.
Conditions to avoid:	Avoid exposure to high temperatures or direct sunlight.
Incompatible Materials:	Strong oxidizing agents.
Hazardous Decomposition Products:	By heating and fire, harmful vapors/gases may be formed.

11. Toxicological information

General information: May cause allergic skin reaction based on human experience.

Information on likely routes of exposure

Ingestion: Ingestion may cause irritation and malaise.

Inhalation: Under normal conditions of intended use, this material is not expected to be an inhalation hazard.

Skin Contact: Prolonged or repeated contact may cause skin sensitization in susceptible individuals.

Eye contact: Avoid contact with eyes.

Symptoms related to the physical, chemical and toxicological characteristics



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Ingestion: No data available.

Inhalation: No data available.

Skin Contact: No data available.

Eye contact: No data available.

Information on toxicological effects

Acute toxicity (list all possible routes of exposure)

Oral

Product: No data available.

Dermal

Product: No data available.

Inhalation

Product: No data available.

Repeated dose toxicity

Product: No data available.

Specified substance(s):

1,2,3-Propanetriol LOAEL (Rat(Female, Male), Oral, 90 d): 200,000 ppm(m) Oral
Experimental result, Key study
NOAEL (Rat(Female, Male), Inhalation): 167 mg/m3 Inhalation
Experimental result, Key study
LOAEL (Rat(Female, Male), Inhalation): 1,000 mg/m3 Inhalation
Experimental result, Supporting study

Sodium azide LOAEL (Rat(Female, Male), Oral, 13 Weeks): 20 mg/kg Oral
(Na(N3)) Experimental result, Supporting study
LOAEL (Rat(Female, Male), Oral, 103 Weeks): 5 mg/kg Oral
Experimental result, Key study

Skin Corrosion/Irritation

Product: No data available.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Specified substance(s):

CMIT/MIT mixture Causes severe skin burns and eye damage.
(3:1) - a mixture of:
5-chloro-2-methyl-
4-isothiazolin-3-one
[EC No 247-500-7]
and 2-methyl-4-
isothiazolin-3-one
[EC No 220-239-6]
(3:1)

Sodium azide Based on available data, the classification criteria are not met.
(Na(N₃))

Serious Eye Damage/Eye Irritation

Product: No data available.

Specified substance(s):

1,2,3-Propanetriol in vivo (Rabbit, 24 hrs): Not irritating Expert judgment

Respiratory or Skin Sensitization

Product: No data available.

Specified substance(s):

CMIT/MIT mixture May cause an allergic skin reaction.
(3:1) - a mixture of:
5-chloro-2-methyl-
4-isothiazolin-3-one
[EC No 247-500-7]
and 2-methyl-4-
isothiazolin-3-one
[EC No 220-239-6]
(3:1)

Sodium azide Not a skin sensitizer.
(Na(N₃))

Carcinogenicity

Product: No data available.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans:

No carcinogenic components identified

US. National Toxicology Program (NTP) Report on Carcinogens:

No carcinogenic components identified

US. OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050), as amended:

No carcinogenic components identified

Germ Cell Mutagenicity

In vitro

Product: No data available.

In vivo

Product: No data available.

Reproductive toxicity

Product: No data available.

Specified substance(s):

CMIT/MIT mixture Based on available data, the classification criteria are not met.
(3:1) - a mixture of:
5-chloro-2-methyl-4-
isothiazolin-3-one [EC
No 247-500-7] and 2-
methyl-4-isothiazolin-
3-one [EC No 220-
239-6] (3:1)

Specific Target Organ Toxicity - Single Exposure

Product: No data available.

Specific Target Organ Toxicity - Repeated Exposure

Product: No data available.

Aspiration Hazard

Product: No data available.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Other effects: No data available.

12. Ecological information

Ecotoxicity:

Acute hazards to the aquatic environment:

Fish

Product: No data available.

Specified substance(s):

1,2,3-Propanetriol LC 50 (Rainbow trout,donaldson trout (*Oncorhynchus mykiss*), 96 h): 51,000 - 57,000 mg/l Mortality
LC 50 (Goldfish (*Carassius auratus*), 24 h): > 5,000 mg/l Mortality
LC 50 (*Pimephales promelas*, 96 h): 885 mg/l Experimental result, Supporting study
LC 50 (*Oncorhynchus mykiss*, 96 h): 54,000 mg/l Experimental result, Key study

Sodium azide (Na(N₃)) LC 50 (Fathead minnow (*Pimephales promelas*), 96 h): 5.46 mg/l Mortality
LC 50 (Rainbow trout,donaldson trout (*Oncorhynchus mykiss*), 96 h): 4.6 mg/l Mortality
LC 50 (Northern squawfish (*Ptychocheilus oregonensis*), 24 h): < 10 mg/l Mortality
LC 50 (Trout family (*Salmonidae*), 24 h): < 10 mg/l Mortality
LC 50 (Fathead minnow (*Pimephales promelas*), 96 h): 5.091 - 5.871 mg/l Mortality

Aquatic Invertebrates

Product: No data available.

Specified substance(s):

1,2,3-Propanetriol EC 50 (*Daphnia magna*, 24 h): > 10,000 mg/l Experimental result, Weight of Evidence study
EC 50 (*Daphnia magna*, 24 h): > 10,000 mg/l Experimental result, Weight of Evidence study



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Sodium azide (Na(N ₃))	LC 50 (Water flea (<i>Simocephalus serrulatus</i>), 48 h): 6.4 mg/l LC 50 (Water flea (<i>Daphnia pulex</i>), 48 h): 4.2 mg/l LC 50 (Crayfish (<i>Orconectes rusticus</i>), 96 h): < < 1 mg/l LC 50 (Red swamp crayfish (<i>Procambarus clarkii</i>), 48 h): 0.4 - 0.6 mg/l LC 50 (<i>Procambarus clarkii</i> , 48 h): > 0.4 - 0.6 mg/l Experimental result, Weight of Evidence study
---------------------------------------	--

Chronic hazards to the aquatic environment:

Fish

Product: No data available.

Aquatic Invertebrates

Product: No data available.

Toxicity to Aquatic Plants

Product: No data available.

Specified substance(s):

Sodium azide (Na(N ₃))	EC 50 (Algae (<i>Pseudokirchneriella subcapitata</i>), 96 h): 0.35 mg/l EC 50 (Green algae (<i>Chlorococcum</i>), 24 h): 176 mg/l
---------------------------------------	--

Persistence and Degradability

Biodegradation

Product: No data available.

Specified substance(s):

1,2,3-Propanetriol	94 % Detected in water. Experimental result, Key study 86 % Detected in water. Experimental result, Key study 98.7 % (24 h) Detected in water. Experimental result, Supporting study 60 % Detected in water. Experimental result, Key study
--------------------	--



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1) Readily biodegradable

BOD/COD Ratio

Product: No data available.

Bioaccumulative potential

Bioconcentration Factor (BCF)

Product: No data available.

Partition Coefficient n-octanol / water (log Kow)

Product: No data available.

Specified substance(s):

1,2,3-Propanetriol Log Kow: -1.76

Mobility in soil: No data available.

Known or predicted distribution to environmental compartments

1,2,3-Propanetriol No data available.

CMIT/MIT mixture (3:1) No data available.

- a mixture of: 5-chloro-

2-methyl-4-isothiazolin-

3-one [EC No 247-500-

7] and 2-methyl-4-

isothiazolin-3-one [EC

No 220-239-6] (3:1)

Sodium azide (Na(N3)) No data available.

Other adverse effects: No data available.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

13. Disposal considerations

General information:	Dispose of waste and residues in accordance with local authority requirements.
Disposal instructions:	Discharge, treatment, or disposal may be subject to national, state, or local laws. Since emptied containers retain product residue, follow label warnings even after container is emptied.
Contaminated Packaging:	No data available.

14. Transport information

DOTUN Number:	Not regulated.
UN Proper Shipping Name:	Not regulated.
Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
Packing Group:	Not regulated.
Marine Pollutant:	Not regulated.
Limited quantity	Not regulated.
Excepted quantity	Not regulated.
Special precautions for user:	Not regulated.

IMDG

UN Number:	Not regulated.
UN Proper Shipping Name:	Not regulated.
Transport Hazard Class(es)	
Class:	Not regulated.
Subsidiary risk:	Not regulated.
EmS No.:	Not regulated.
Packing Group:	Not regulated.
Environmental Hazards	
Marine Pollutant:	Not regulated.
Special precautions for user:	Not regulated.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

IATA

UN Number:	Not regulated.
Proper Shipping Name:	Not regulated.
Transport Hazard Class(es):	
Class:	Not regulated.
Subsidiary risk:	Not regulated.
Packing Group:	Not regulated.
Environmental Hazards	
Marine pollutant:	Not regulated.

Special precautions for user: Not regulated.

15. Regulatory information

US Federal Regulations

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

None present or none present in regulated quantities.

US. Toxic Substances Control Act (TSCA) Section 5(a)(2) Final Significant New Use Rules (SNURs) (40 CFR 721, Subpt E)

None present or none present in regulated quantities.

US. OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050), as amended

None present or none present in regulated quantities.

CERCLA Hazardous Substance List (40 CFR 302.4):

Chemical Identity

SODIUM AZIDE

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories

Respiratory or Skin Sensitization



**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

US. EPCRA (SARA Title III) Section 304 Extremely Hazardous Substances Reporting Quantities and the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) Hazardous Substances

None present or none present in regulated quantities.

US. EPA Emergency Planning and Community Right-To-Know Act (EPCRA) SARA Title III Section 313 Toxic Chemicals (40 CFR 372.65) - Supplier Notification Required

None present or none present in regulated quantities.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130):

None present or none present in regulated quantities.

Clean Water Act Section 311 Hazardous Substances (40 CFR 117.3)

None present or none present in regulated quantities.

US State Regulations

US. California Proposition 65

No ingredient requiring a warning under CA Prop 65.

US. New Jersey Worker and Community Right-to-Know Act

Chemical Identity

1,2,3-Propanetriol

US. Massachusetts RTK - Substance List

Chemical Identity

1,2,3-Propanetriol

Sodium azide (Na(N₃))

US. Pennsylvania RTK - Hazardous Substances

Chemical Identity

1,2,3-Propanetriol

US. Rhode Island RTK

Chemical Identity

1,2,3-Propanetriol



**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

16. Other information, including date of preparation or last revision
--

Issue Date: 01/25/2021

Version #: 2.2

Revision Information:

Further Information: No data available.

Disclaimer:
Disclaimer:
The information contained herein has been obtained from various sources and is believed to be correct as of the date issued. However, neither BD nor any of its subsidiaries assumes any liabilities whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability for a particular use of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist. BD provides SDS in electronic form so the information may be more easily accessed. Due to the possibility of errors during transmission, BD makes no representations as to the completeness or accuracy of the information.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SAFETY DATA SHEET

According to Regulation (EC) No. 1907/2006 (REACH) Article 31, Annex II as amended.

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product No.:	Product name:	Common name(s), synonym(s)
658331	CD24 (ML5) APC-H7	No data available

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses: Scientific and industrial laboratory use. For research use only.

Uses advised against: Not for use in diagnostic or therapeutic procedures.

1.3 Details of the supplier of the safety data sheet

Manufacturer

Becton Dickinson France S.A.S. Belgian
Branch
Erembodegem-Dorp 86
Erembodegem 9320
Belgium

Telephone: 32 2 400 98 95

Fax: 32 2 401 70 94

Contact Person: BD Biosciences - Centralized European Office
Regulatory Compliance Department

E-mail: help.biosciences@europe.bd.com

1.4 Emergency telephone number: 32 2 400 98 95

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

The product has not been classified as hazardous according to the legislation in force.

Classification according to Regulation (EC) No 1272/2008 as amended.

Not classified



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

2.2 Label Elements

Not applicable

Supplemental information

EUH208: Contains (CMIT/MIT mixture (3:1) - a mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1)). May produce an allergic reaction.
EUH210: Safety data sheet available on request.

2.3 Other hazards

No data available.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Chemical name	Concentration	CAS-No.	EC No.	REACH Registration No.	M-Factor:	Notes
reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)	0.001 - <0.0015%	55965-84-9		No data available.	100	

* All concentrations are percent by weight unless ingredient is a gas. Gas concentrations are in percent by volume.

This substance has workplace exposure limit(s).

Classification

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Chemical name	CLP Classification	Notes
reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)	Skin Sens.: 1A: H317Skin Corr.: 1C: H314Acute Tox.: 2: H310Eye Dam.: 1: H318Acute Tox.: 2: H330Acute Tox.: 3: H301Aquatic Chronic: 1: H410Aquatic Acute: 1: H400	Note B, EUH071

Regulation No. 1272/2008.

Note B: Some substances (acids, bases, etc.) are placed on the market in aqueous solutions at various concentrations and, therefore, these solutions require different classification and labelling since the hazards vary at different concentrations. In Part 3 entries with Note B have a general designation of the following type: 'nitric acid...%'. In this case the supplier must state the percentage concentration of the solution on the label. Unless otherwise stated, it is assumed that the percentage concentration is calculated on a weight/weight basis.

EUH071: Corrosive to the respiratory tract.

The full text for all H-statements is displayed in section 16.

SECTION 4: First aid measures

General: Get medical attention if symptoms occur.

4.1 Description of first aid measures

Inhalation: Provide fresh air, warmth and rest, preferably in comfortable upright sitting position.

Eye contact: Immediately flush with plenty of water for at least 15 minutes. If easy to do, remove contact lenses.

Skin Contact: Wash contact areas with soap and water. Remove contaminated clothing. Launder contaminated clothing before reuse.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Ingestion:

Call a physician or poison control center immediately. Only induce vomiting at the instruction of medical personnel. Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed:

No data available.

4.3 Indication of any immediate medical attention and special treatment needed

Hazards:

No data available.

Treatment:

No data available.

SECTION 5: Firefighting measures

General Fire Hazards:

Extinguish all ignition sources. Avoid sparks, flames, heat and smoking. Ventilate. Use water spray to keep fire-exposed containers cool.

**5.1 Extinguishing media
Suitable extinguishing media:**

Use fire-extinguishing media appropriate for surrounding materials.

**Unsuitable
extinguishing media:**

Not applicable

5.2 Special hazards arising from the substance or mixture:

Fire or excessive heat may produce hazardous decomposition products.

**5.3 Advice for firefighters
Special fire fighting procedures:**

No unusual fire or explosion hazards noted.

Special protective equipment for firefighters:

Firefighters must use standard protective equipment including flame retardant coat, helmet with face shield, gloves, rubber boots, and in enclosed spaces, SCBA.

SECTION 6: Accidental release measures



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

- 6.1 Personal precautions, protective equipment and emergency procedures:** Contact local authorities in case of spillage to drain/aquatic environment. Ensure suitable personal protection (including respiratory protection) during removal of spillages in a confined area.
- 6.2 Environmental Precautions:** Avoid release to the environment.
- 6.3 Methods and material for containment and cleaning up:** Absorb spillage with suitable absorbent material. Prevent runoff from entering drains, sewers, or streams. See Section 8 of the SDS for Personal Protective Equipment. For waste disposal, see section 13 of the SDS.
- 6.4 Reference to other sections:** No data available.

SECTION 7: Handling and storage:

- 7.1 Precautions for safe handling:** When using do not eat, drink or smoke. Read and follow manufacturer's recommendations. Use personal protective equipment as required.
- 7.2 Conditions for safe storage, including any incompatibilities:** Store in a cool, dry place. Keep container tightly closed.
- 7.3 Specific end use(s):** Reserved for industrial and professional use. Read label before use.

SECTION 8: Exposure controls/personal protection

8.1 Control Parameters Occupational Exposure Limits

Chemical name	Type	Exposure Limit Values	Source
---------------	------	-----------------------	--------

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Glycerol - Mist.	TWA	10 mg/m ³	UK. EH40 Workplace Exposure Limits (WELs), as amended (2007)
------------------	-----	-------------------------	--

Biological Limit Values

None.

DNEL-Values

Critical component	Type	Route of Exposure	Health Warnings	Remarks
Glycerol	Workers	Inhalation	Local, short-term; 56 mg/m ³	respiratory tract irritation

PNEC-Values

Critical component	Environmental compartment	PNEC-Values	Remarks
Glycerol	Sediment (freshwater)	3.3 mg/kg	
	Sewage treatment plant	1000 mg/l	
	Soil	0.141 mg/kg	
	Sediment (marine water)	0.33 mg/kg	
	Aquatic (freshwater)	0.885 mg/l	
	Aquatic (marine water)	0.088 mg/l	

8.2 Exposure controls

Appropriate

Engineering Controls:

No special requirements under ordinary conditions of use and with adequate ventilation.

Individual protection measures, such as personal protective equipment



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

General information:	Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing to remove contaminants. Discard contaminated footwear that cannot be cleaned.
Eye/face protection:	Wear safety glasses with side shields (or goggles).
Skin protection	
Hand Protection:	Chemical resistant gloves Suitable gloves can be recommended by the glove supplier. Wash hands after contact.
Other:	Wear a lab coat or similar protective clothing.
Respiratory Protection:	If engineering controls do not maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (in countries where exposure limits have not been established), an approved respirator must be worn.
Hygiene measures:	Observe good industrial hygiene practices.
Environmental Controls:	No data available.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance

Physical state:	liquid
Form:	No data available.
Color:	No data available.
Odor:	No data available.
Odor Threshold:	No data available.
pH:	No data available.
Freezing point:	No data available.
Boiling Point:	No data available.
Flash Point:	No data available.
Evaporation Rate:	No data available.
Flammability (solid, gas):	No data available.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Flammability Limit - Upper (%):	No data available.
Flammability Limit - Lower (%):	No data available.
Vapor pressure:	No data available.
Vapor density (air=1):	No data available.
Relative density:	No data available.
Solubility(ies)	
Solubility in Water:	No data available.
Solubility (other):	No data available.
Partition coefficient (n-octanol/water):	No data available.
Autoignition Temperature:	No data available.
Decomposition Temperature:	No data available.
SADT:	No data available.
Viscosity:	No data available.
Explosive properties:	No data available.
Oxidizing properties:	No data available.

9.2 Other information

Molecular weight:	No data available.
VOC Content:	No data available.
Bulk density:	No data available.
Dust Explosion Limit, Upper:	No data available.
Dust Explosion Limit, Lower:	No data available.
Dust Explosion Description	No data available.
Number Kst:	
Minimum ignition energy:	No data available.
Minimum ignition temperature:	No data available.
Metal Corrosion:	No data available.

SECTION 10: Stability and reactivity

10.1 Reactivity:	Material is stable under normal conditions.
10.2 Chemical Stability:	Material is stable under normal conditions.
10.3 Possibility of hazardous reactions:	Not determined.



Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

10.4 Conditions to avoid: Avoid exposure to high temperatures or direct sunlight.

10.5 Incompatible Materials: Metals. Water reactive material.

10.6 Hazardous Decomposition Products: Stable; however, may decompose if heated.

SECTION 11: Toxicological information

General information: No data on possible toxicity effects have been found.

Information on likely routes of exposure

Inhalation: Limited inhalation hazard at normal work temperatures.

Ingestion: No harmful effects expected in amounts likely to be ingested by accident.

Skin Contact: Negligible irritation to skin at ambient temperatures.

Eye contact: Elevated temperatures or mechanical action may form vapors, mist, or fumes which may be irritating to the eyes, nose, throat, or lungs.

11.1 Information on toxicological effects

Acute toxicity

Oral

Product: Not classified for acute toxicity based on available data.

Specified substance(s)

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) Toxic if swallowed.

Dermal

Product: Not classified for acute toxicity based on available data.

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) Toxic in contact with skin.

Inhalation

Product: Not classified for acute toxicity based on available data.

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) Toxic by inhalation.

Repeated dose toxicity

Product: No data available.

Specified substance(s)

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) No data available.

Skin

Corrosion/Irritation:

Product: No data available.

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) Causes severe skin burns and eye damage.

Serious Eye Damage/Eye

Irritation:

Product: No data available.

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) Causes serious eye damage.

Respiratory or Skin Sensitization:

Product: No data available.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) May cause an allergic skin reaction.

Germ Cell Mutagenicity

In vitro

Product: No data available.

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) No data available.

In vivo

Product: No data available.

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) No data available.

Carcinogenicity

Product: No data available.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) No data available.

Reproductive toxicity

Product: No data available.

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) Based on available data, the classification criteria are not met.

Specific Target Organ Toxicity - Single Exposure

Product: No data available.

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) No data available.

Specific Target Organ Toxicity - Repeated Exposure

Product: No data available.

Specified substance(s)

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) No data available.

Aspiration Hazard

Product: No data available.

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) No data available.

SECTION 12: Ecological information

12.1 Toxicity

Acute toxicity

Fish

Product: No negative effects on the aquatic environment are known.

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) No data available.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Aquatic Invertebrates

Product: No negative effects on the aquatic environment are known.

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) No data available.

Chronic Toxicity

Fish

Product: No negative effects on the aquatic environment are known.

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) No data available.

Aquatic Invertebrates

Product: No negative effects on the aquatic environment are known.

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) No data available.

Toxicity to Aquatic Plants

Product: No negative effects on the aquatic environment are known.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) No data available.

12.2 Persistence and Degradability

Biodegradation

Product: Expected to be readily biodegradable.

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) Readily biodegradable

BOD/COD Ratio

Product No data available.

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) No data available.

12.3 Bioaccumulative potential

Product: No data available.

Specified substance(s)

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) No data available.

12.4 Mobility in soil:

Product: No data available.

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) No data available.

12.5 Results of PBT and vPvB assessment:

Product: No data available.

Specified substance(s)

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) Not applicable

12.6 Other adverse effects:

The product is not expected to be hazardous to the environment.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

General information: Dispose of waste and residues in accordance with local authority requirements.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Disposal methods: Dispose of waste at an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

SECTION 14: Transport information

ADR

14.1 UN Number:	Not regulated.
14.2 UN Proper Shipping Name:	Not regulated.
14.3 Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
Hazard No. (ADR):	Not regulated.
Tunnel restriction code:	Not regulated.
14.4 Packing Group:	Not regulated.
14.5 Environmental Hazards:	Not regulated.
Marine Pollutant:	Not regulated.
14.6 Special precautions for user:	Not regulated.

ADN

14.1 UN Number:	Not regulated.
14.2 UN Proper Shipping Name:	Not regulated.
14.3 Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
Hazard No. (ADR):	Not regulated.
Tunnel restriction code:	Not regulated.
14.4 Packing Group:	Not regulated.
14.5 Environmental Hazards:	Not regulated.
Marine Pollutant:	Not regulated.
14.6 Special precautions for user:	Not regulated.

RID

14.1 UN Number:	Not regulated.
-----------------	----------------



**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

14.2 UN Proper Shipping Name	Not regulated.
14.3 Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
14.4 Packing Group:	Not regulated.
14.5 Environmental Hazards:	Not regulated.
Marine Pollutant:	Not regulated.
14.6 Special precautions for user:	Not regulated.

IMDG

14.1 UN Number:	Not regulated.
14.2 UN Proper Shipping Name:	Not regulated.
14.3 Transport Hazard Class(es)	
Class:	Not regulated.
Label(s):	Not regulated.
EmS No.:	Not regulated.
14.4 Packing Group:	Not regulated.
14.5 Environmental Hazards:	Not regulated.
Marine Pollutant:	Not regulated.
14.6 Special precautions for user:	Not regulated.

IATA

14.1 UN Number:	Not regulated.
14.2 Proper Shipping Name:	Not regulated.
14.3 Transport Hazard Class(es):	
Class:	Not regulated.
Label(s):	Not regulated.
14.4 Packing Group:	Not regulated.
14.5 Environmental Hazards:	Not regulated.
Marine Pollutant:	Not regulated.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

14.6 Special precautions for user: Not regulated.

14.7 Transport in bulk according to Annex II of MARPOL and the IBC Code: Not applicable

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture:

EU Regulations

Regulation (EC) No. 2037/2000 Substances that deplete the ozone layer: none

Regulation (EC) No. 2037/2000 Substances that deplete the ozone layer: none

Regulation (EC) No. 850/2004 on persistent organic pollutants: none

Regulation (EC) No. 649/2012 Import and export of dangerous chemicals: none

EU. REACH Candidate List of Substances of Very High Concern for Authorization (SVHC): none

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorisation, as amended: none

Regulation (EC) No. 1907/2006 Annex XVII Substances subject to restriction on marketing and use: none

Directive 2004/37/EC on the protection of workers from the risks related to exposure to carcinogens and mutagens at work.: none

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breast feeding.:

Chemical name	CAS-No.	Concentration
---------------	---------	---------------

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7]and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)	55965-84-9	0 - <0.1%
--	------------	-----------

Directive 96/82/EC (Seveso III): on the control of major accident hazards involving dangerous substances:

Chemical name	CAS-No.	Concentration
sodium azide	26628-22-8	0 - <0.1%
reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7]and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)	55965-84-9	0 - <0.1%

EU. Regulation No. 166/2006 PRTR (Pollutant Release and Transfer Registry), Annex II: Pollutants: none

Directive 98/24/EC on the protection of workers from the risks related to chemical agents at work:

Chemical name	CAS-No.	Concentration
sodium azide	26628-22-8	0 - <0.1%
reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7]and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)	55965-84-9	0 - <0.1%

15.2 Chemical safety assessment:

No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

Revision Information: Not relevant.

References

PBT
vPvB

PBT: persistent, bioaccumulative and toxic substance.
vPvB: very persistent and very bioaccumulative substance.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Key literature references and sources for data: European Chemicals Agency (ECHA): Information on Chemicals.

Wording of the H-statements in section 2 and 3

H301	Toxic if swallowed.
H310	Fatal in contact with skin.
H314	Causes severe skin burns and eye damage.
H317	May cause an allergic skin reaction.
H318	Causes serious eye damage.
H330	Fatal if inhaled.
H400	Very toxic to aquatic life.
H410	Very toxic to aquatic life with long lasting effects.

Training information: No data available.

Issue Date: 08.02.2021

SDS No.: UN0000000000000658331-4012-1-01

Disclaimer: Disclaimer:

The information contained herein has been obtained from various sources and is believed to be correct as of the date issued. However, neither BD nor any of its subsidiaries assumes any liabilities whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability for a particular use of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist. BD provides SDS in electronic form so the information may be more easily accessed. Due to the possibility of errors during transmission, BD makes no representations as to the completeness or accuracy of the information.



Becton, Dickinson and Company

BD, Franklin Lakes, NJ 07417
USA
www.bd.com

Componenti del kit

N. kit prodotto	Descrizione kit prodotto
658619	BD OneFlow™ LST

Componenti del kit	Descrizione componenti del kit
91-0949	BD OneFlow™ LST

IMDG

Numero ONU o numero ID:	Non regolamentato.
Designazione ufficiale ONU di trasporto:	Non regolamentato.
Classi di pericolo connesso al trasporto	
Classe:	Non regolamentato.
Etichetta(-e):	Non regolamentato.
EmS No.:	Non regolamentato.
Gruppo d'imballaggio:	Non regolamentato.
Pericoli per l'ambiente:	Non regolamentato.
Inquinante marino:	Non regolamentato.
Precauzioni speciali per gli utilizzatori:	Non regolamentato.

IATA

Numero ONU o numero ID:	Non regolamentato.
Nome proprio di trasporto:	Non regolamentato.
Classi di pericolo connesso al trasporto:	
Classe:	Non regolamentato.
Etichetta(-e):	Non regolamentato.
Gruppo d'imballaggio:	Non regolamentato.
Pericoli per l'ambiente:	Non regolamentato.
Inquinante marino:	Non regolamentato.



**Becton, Dickinson and
Company**

BD, Franklin Lakes, NJ 07417
USA
www.bd.com

Precauzioni speciali per gli
utilizzatori:

Non regolamentato.

Attenzione: se ad un componente in elenco non è associato alcun documento, vuol dire che il prodotto non è pericoloso e non richiede una scheda di sicurezza.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

SCHEDA DI DATI DI SICUREZZA

A norma del Regolamento (CE) n. 1907/2006 (REACH) Articolo 31, Allegato II e successive modifiche

SEZIONE 1: identificazione della sostanza/miscela e della società/impresa

Identificatore del prodotto

Num. de prodotto:	Nome del prodotto:	Denominazione(i) comune(i), sinonimo(i)
91-0949	BD OneFlow™ LST	Nessun dato disponibile.

1.2 Usi identificati pertinenti della sostanza o della miscela e usi sconsigliati

Usi identificati: Uso in laboratorio scientifico e industriale. Uso per diagnostica in vitro.

Usi non raccomandati: Non noto.

1.3 Informazioni sul fornitore della scheda di dati di sicurezza

Fabbricante

Becton Dickinson France S.A.S. Belgian Branch
Erembodegem-Dorp 86
9320 Erembodegem
Belgium

Telefono: 32 2 400 98 95

Fax: 32 2 401 70 94

Persona da contattare: BD Biosciences - Centralized European Office
Regulatory Compliance Department
E-mail: help.biosciences@europe.bd.com

1.4 Numero telefonico di emergenza: 32 2 400 98 95

SEZIONE 2: identificazione dei pericoli

2.1 Classificazione della sostanza o della miscela

Il prodotto è stato classificato in base alle norme vigenti.

Classificazione ai sensi del regolamento CE n. 1272/2008 e s.m.i.

Pericoli per la Salute

Sensibilizzatore della pelle

Categoria 1

H317: Può provocare una reazione allergica cutanea.

Pericoli per l'ambiente

Pericoli cronici per l'ambiente
acquatico

Categoria 3

H412: Nocivo per gli organismi acquatici con effetti di lunga durata.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

2.2 Elementi dell'etichetta



Avvertenza:

Attenzione

Indicazioni di pericolo:

H317: Può provocare una reazione allergica cutanea.
H412: Nocivo per gli organismi acquatici con effetti di lunga durata.

**Consigli di prudenza
Prevenzione:**

P261: Evitare di respirare la polvere/i fumi/i gas/la nebbia/i vapori/gli aerosol.
P272: Gli indumenti da lavoro contaminati non devono essere portati fuori dal luogo di lavoro.
P273: Non disperdere nell'ambiente.
P280: Indossare guanti/indumenti protettivi/Proteggere gli occhi/il viso.

Risposta:

P302+P352: IN CASO DI CONTATTO CON LA PELLE: lavare abbondantemente con acqua e sapone.
P333+P313: In caso di irritazione o eruzione della pelle: consultare un medico.
P321: Trattamento specifico (vedere le istruzioni supplementari di primo soccorso su questa etichetta).
P362+P364: Togliere tutti gli indumenti contaminati e lavarli prima di indossarli nuovamente.

Smaltimento:

P501: Smaltire il prodotto/ recipiente in un impianto autorizzato in conformità alla regolamentazione locale, regionale, nazionale e internazionale.

Componenti pericolosi da segnalare in etichetta:

2-Methyl-4-isothiazolin-3-one

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

2.3 Altri pericoli

Proprietà di interferenza con il sistema endocrino-Tossicità

La sostanza/miscela non contiene componenti considerati aventi proprietà di interferenza endocrina ai sensi dell'articolo 57(f) del REACH o del regolamento delegato (UE) 2017/2100 della Commissione o del regolamento (UE) 2018/605 della Commissione a livelli dello 0,1% o superiori.

Proprietà di interferenza con il sistema endocrino-ECOTossicità

La sostanza/miscela non contiene componenti considerati aventi proprietà di interferenza endocrina ai sensi dell'articolo 57(f) del REACH o del regolamento delegato (UE) 2017/2100 della Commissione o del regolamento (UE) 2018/605 della Commissione a livelli dello 0,1% o superiori.

SEZIONE 3: composizione/informazioni sugli ingredienti

3.2 Miscele

Denominazione chimica	Concentrazione	NUMERO CAS	CE N.	N. di registrazione REACH	Fattore M:	Note
2-metilisotiazol-3(2H)-one	0,25 - <1%	2682-20-4	220-239-6	Nessun dato disponibile.	Tossicità acquatica (acuta): 10; Tossicità acquatica (cronica): 1	
azoturo di sodio	0,25 - <1%	26628-22-8	247-852-1	Nessun dato disponibile.	Nessun dato disponibile.	#

*Nel caso di componenti gassosi le concentrazioni sono espresse in percentuale volume, negli altri casi in percentuale peso.

Questa sostanza ha limiti di esposizione specificati per il luogo di lavoro.

Questa sostanza è elencata come SVHC.

Classificazione

Denominazione chimica	Classificazione	Note
2-metilisotiazol-3(2H)-one	Classificazione: STOT RE: 3: H335; Skin Corr.: 1B: H314; Skin Sens.: 1A: H317; Eye Dam.: 1: H318; Acute Tox.: 2: H330; Acute Tox.: 3: H301; Acute Tox.: 3: H311; Aquatic Chronic: 1: H410; Aquatic Acute: 1: H400; Informazioni supplementari sulle etichette: EUH071; Limite di concentrazione specifico: Sensibilizzatore della pelle	Nessuno.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Categoria 1A, $\geq 0,0015\%$; Tossicità acuta, per via orale: Non noto. Tossicità acuta, per inalazione: Non noto. Tossicità acuta, per via cutanea: Non noto.	
azoturo di sodio	Classificazione: Acute Tox.: 2: H300; Aquatic Acute: 1: H400; Aquatic Chronic: 1: H410; Informazioni supplementari sulle etichette: EUH032; Limite di concentrazione specifico: Non noto. Tossicità acuta, per via orale: LD 50: 27 mg/kg Tossicità acuta, per inalazione: Non noto. Tossicità acuta, per via cutanea: Non noto.	Nessuno.

CLP: Regolamento n. 1272/2008.

I testi completi per tutte le Frasi H sono visualizzati al punto 16.

SEZIONE 4: misure di primo soccorso

4.1 Descrizione delle misure di primo soccorso

Informazioni generali:	Contattare un medico se si verificano dei sintomi.
Inalazione:	Tenere a riposo in luogo caldo e ben ventilato, preferibilmente in posizione seduta eretta. Contattare un medico se i sintomi persistono.
Contatto con la Pelle:	Lavare prontamente, con un forte getto d'acqua, la pelle contaminata. Togliersi di dosso immediatamente gli indumenti bagnati e lavare la pelle con acqua. Contattare un medico se si verificano dei sintomi. Lavare gli indumenti contaminati prima di indossarli nuovamente.
Contatto con gli occhi:	Sciacquare immediatamente con abbondante acqua per almeno 15 minuti. Se è possibile, rimuovere le lenti a contatto. Se dopo aver lavato la parte si riscontrano dei sintomi, consultare prontamente un medico.
Ingestione:	Dopo aver ingoiato, sciacquare la bocca con acqua (solo se il soggetto è cosciente) NON provocare il vomito. Consultare immediatamente un medico.
Protezioni personali per gli addetti al primo soccorso:	Nessun dato disponibile.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

4.2 Principali sintomi ed effetti, sia acuti che ritardati

Sintomi: I sintomi possono essere ritardati.

Rischi: Può provocare una reazione allergica cutanea.

4.3 Indicazione dell'eventuale necessità di consultare immediatamente un medico e trattamenti speciali necessari

Trattamento: Lavare prontamente, con un forte getto d'acqua, la pelle contaminata. Togliersi di dosso immediatamente gli indumenti bagnati e lavare la pelle con acqua.

SEZIONE 5: misure di lotta antincendio

Rischi Generali d'Incendio: Spegnerne tutte le sorgenti d'ignizione. Evitare scintille, fiamme, calore. Evitare di fumare. Ventilare. Usare l'acqua per raffreddare i contenitori esposti al fuoco e per disperdere i vapori.

5.1 Mezzi di estinzione

Mezzi di estinzione appropriati: Spruzzi d'acqua, nebulizzazioni, CO₂, prodotto chimico secco o schiuma resistente ad alcol

Mezzi di estinzione non appropriati: Evitare getti d'acqua violenti che possano propagare e diffondere l'incendio.

5.2 Pericoli speciali derivanti dalla sostanza o dalla miscela: Il fuoco o il calore eccessivo può provocare prodotti di decomposizione pericolosi.

5.3 Raccomandazioni per gli addetti all'estinzione degli incendi

Speciali procedure antincendio: Non sono indicati rischi d'incendio o di esplosione particolari.

Dispositivi di protezione speciali per gli addetti all'estinzione degli incendi: Gli addetti all'estinzione dell'incendio devono usare equipaggiamento di protezione standard, inclusi tuta antifiama, elmetto con visiera protettiva, guanti, stivali di gomma e, in spazi chiusi, autorespiratore SCBA.

SEZIONE 6: misure in caso di rilascio accidentale

6.1 Precauzioni personali, dispositivi di protezione e procedure in caso di emergenza: Indossare dispositivi di protezione individuale adatti (compresa una protezione respiratoria) durante la rimozione delle fuoriuscite all'interno di una zona confinata. Contattare le autorità locali in caso di versamento in fognature/ambiente acquatico.

6.1.1 Per chi non interviene direttamente: Nessun dato disponibile.

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

6.1.2 Per chi interviene direttamente:	Nessun dato disponibile.
6.2 Precauzioni ambientali:	Non disperdere nell'ambiente.
6.3 Metodi e materiali per il contenimento e per la bonifica:	Se possibile, arrestare la perdita senza correre rischi. Assorbire o coprire con terra asciutta, sabbia o altro materiale non combustibile e riporre in contenitori. Raccogliere per il salvataggio o lo smaltimento. Evitare che l'acqua di scarico venga immessa nelle fognature, negli scarichi o nei fiumi. Riferire eventuali fuoriuscite accidentali di liquidi/prodotti alle autorità competenti. Per l'equipaggiamento di protezione individuale, vedere la Sezione 8 del SDS. Per informazioni sullo smaltimento, consultare il punto 13 del SDS.
6.4 Riferimento ad altre sezioni:	Nessun dato disponibile.

SEZIONE 7: manipolazione e immagazzinamento

7.1 Precauzioni per la manipolazione sicura

Misure tecniche (ad es. ventilazione locale e generale):	Predisporre una ventilazione adeguata ogniqualvolta il materiale si riscalda o si generano nebulizzazioni.
Manipolazione:	Lavarsi prontamente con acqua e sapone in caso di contaminazione della pelle. Non mangiare, né bere, né fumare durante l'impiego. Leggere e seguire le raccomandazioni del fabbricante. Utilizzare il dispositivo di protezione individuale richiesto.
Misure per evitare il contatto:	Nessun dato disponibile.

7.2 Condizioni per lo stoccaggio sicuro, comprese eventuali incompatibilità

Condizioni di conservazione sicura:	Conservare nell'imballaggio originale ben chiuso in luogo asciutto, fresco e ben ventilato.
Materiali di imballaggio sicuro:	Nessun dato disponibile.

7.3 Usi finali particolari:	Riservato agli utilizzatori industriali e professionali. Leggere l'etichetta prima dell'uso.
------------------------------------	--

SEZIONE 8: controlli dell'esposizione/della protezione individuale

8.1 Parametri di controllo Valori Limite per l'Esposizione Professionale

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Denominazione chimica	Tipo	Tipo di esposizione	Valori Limite di Esposizione	Fonte
glicerolo	TWA	particelle inalabile	10 mg/m ³	Italia. Valori limite di esposizione professionale e successive modifiche (05 2020)
	TWA	particelle respirabile	3 mg/m ³	Italia. Valori limite di esposizione professionale e successive modifiche (05 2020)
azoturo di sodio	STEL		0,3 mg/m ³	UE. Valori limite indicativi di esposizione nelle Direttive 91/322/CEE, 2000/39/CE, 2006/15/CE, 2009/161/UE, 2017/164/UE e successive modifiche (12 2009)
	TWA		0,1 mg/m ³	UE. Valori limite indicativi di esposizione nelle Direttive 91/322/CEE, 2000/39/CE, 2006/15/CE, 2009/161/UE, 2017/164/UE e successive modifiche (12 2009)
	TWA 15 minuti		0,1 mg/m ³	Italia. Valori limite di esposizione professionale e successive modifiche (05 2020)
	STEL 15 minuti		0,3 mg/m ³	Italia. Valori limite di esposizione professionale e successive modifiche (05 2020)

Fare riferimento all'ultima edizione del testo originale appropriato e consultare un igienista industriale o un professionista simile, o agenzie locali, per ulteriori informazioni.

Valori Limite Biologici

Nessun valore limite biologico di esposizione annotato per l'ingrediente/gli ingredienti.

Valori DNEL

Osservazioni: Valori DNEL

Componente critico	Tipo	Via di esposizione	Avvertenze per la salute	Osservazioni
--------------------	------	--------------------	--------------------------	--------------

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

1,2,3-Propanetriol	Popolazione generale	Orale	Sistemico, lungo termine; 229 mg/kg	Tossicità a dose ripetuta
	Lavoratori	Inhalation	Locale, lungo termine; 56 mg/m ³	irritazione delle vie respiratorie
	Popolazione generale	Inhalation	Locale, lungo termine; 33 mg/m ³	irritazione delle vie respiratorie

Sodium Chloride (NaCl)	Popolazione generale	Inhalation	Sistemico, lungo termine; 443,28 mg/m ³	Tossicità a dose ripetuta
	Lavoratori	Inhalation	Sistemico, lungo termine; 2068,62 mg/m ³	Tossicità a dose ripetuta
	Lavoratori	Inhalation	Sistemico, breve termine; 2068,62 mg/m ³	Tossicità a dose ripetuta
	Popolazione generale	Inhalation	Sistemico, breve termine; 443,28 mg/m ³	Tossicità a dose ripetuta
	Popolazione generale	Orale	Sistemico, lungo termine; 126,65 mg/kg	Tossicità a dose ripetuta
	Lavoratori	Dermico	Sistemico, lungo termine; 295,52 mg/kg	Tossicità a dose ripetuta
	Lavoratori	Dermico	Sistemico, breve termine; 295,52 mg/kg	Tossicità a dose ripetuta
	Popolazione generale	Orale	Sistemico, breve termine; 126,65 mg/kg	Tossicità a dose ripetuta
	Popolazione generale	Dermico	Sistemico, breve termine; 126,65 mg/kg	Tossicità a dose ripetuta
	Popolazione generale	Dermico	Sistemico, lungo termine; 126,65 mg/kg	Tossicità a dose ripetuta

2-Methyl-4-isothiazolin-3-one	Lavoratori	Inhalation	Locale, lungo termine; 0,021 mg/m ³	irritazione delle vie respiratorie
	Lavoratori	Inhalation	Locale, breve termine; 0,043 mg/m ³	irritazione delle vie respiratorie
	Popolazione generale	Occhi	Locale;	Alto rischio (nessuna soglia derivata)
	Popolazione generale	Inhalation	Locale, lungo termine; 0,021 mg/m ³	irritazione delle vie respiratorie
	Lavoratori	Occhi	Locale;	Alto rischio (nessuna soglia derivata)
	Popolazione generale	Inhalation	Locale, breve termine; 0,043 mg/m ³	irritazione delle vie respiratorie
	Popolazione generale	Orale	Sistemico, lungo termine; 0,027 mg/kg	Tossicità a dose ripetuta
	Popolazione generale	Orale	Sistemico, breve termine; 0,053 mg/kg	Tossicità a dose ripetuta

Sodium azide (Na(N ₃))	Lavoratori	Inhalation	Sistemico, lungo termine; 0,164 mg/m ³	Tossicità a dose ripetuta
	Popolazione generale	Occhi	Locale;	Nessun pericolo identificato
	Popolazione generale	Inhalation	Sistemico, lungo termine; 29 µg/m ³	Tossicità a dose ripetuta
	Lavoratori	Occhi	Locale;	Nessun pericolo identificato
	Lavoratori	Dermico	Sistemico, lungo termine; 0,0467 mg/kg	Tossicità a dose ripetuta
	Popolazione generale	Orale	Sistemico, lungo termine; 0,0167 mg/kg	Tossicità a dose ripetuta
	Popolazione generale	Dermico	Sistemico, lungo termine; 0,0167 mg/kg	Tossicità a dose ripetuta

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Phosphoric acid, sodium salt (1:2)	Lavoratori	Occhi	Locale;	Nessun pericolo identificato
	Lavoratori	Inhalation	Sistemico, lungo termine; 4,07 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Inhalation	Sistemico, lungo termine; 3,04 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Inhalation	Sistemico, lungo termine; 6,63 mg/m3	Tossicità a dose ripetuta
	Lavoratori	Inhalation	Sistemico, lungo termine; 15,47 mg/m3	Tossicità a dose ripetuta

Potassium chloride (KCl)	Lavoratori	Inhalation	Sistemico, lungo termine; 1064 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Inhalation	Sistemico, lungo termine; 273 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Inhalation	Sistemico, breve termine; 1365 mg/m3	Tossicità a dose ripetuta
	Lavoratori	Inhalation	Sistemico, breve termine; 5320 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Orale	Sistemico, breve termine; 455 mg/kg	Tossicità a dose ripetuta
	Popolazione generale	Dermico	Sistemico, lungo termine; 182 mg/kg	Tossicità a dose ripetuta
	Popolazione generale	Orale	Sistemico, lungo termine; 91 mg/kg	Tossicità a dose ripetuta
	Lavoratori	Dermico	Sistemico, lungo termine; 303 mg/kg	Tossicità a dose ripetuta
	Lavoratori	Dermico	Sistemico, breve termine; 910 mg/kg	Tossicità a dose ripetuta
	Popolazione generale	Dermico	Sistemico, breve termine; 910 mg/kg	Tossicità a dose ripetuta

Phosphoric acid, potassium salt (1:1)	Lavoratori	Occhi	Locale;	Nessun pericolo identificato
	Popolazione generale	Occhi	Locale;	Nessun pericolo identificato
	Lavoratori	Inhalation	Sistemico, lungo termine; 14,82 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Inhalation	Sistemico, lungo termine; 6,35 mg/m3	Tossicità a dose ripetuta

Disodium pyrophosphate	Lavoratori	Inhalation	Sistemico, lungo termine; 17,63 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Occhi	Locale;	Basso rischio (nessuna soglia derivata)
	Popolazione generale	Inhalation	Sistemico, lungo termine; 10,87 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Inhalation	Sistemico, lungo termine; 4,35 mg/m3	Tossicità a dose ripetuta
	Lavoratori	Occhi	Locale;	Basso rischio (nessuna soglia derivata)

Trometamol	Lavoratori	Inhalation	Sistemico, lungo termine; 117,5 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Dermico	Sistemico, lungo termine; 83,3 mg/kg	Tossicità a dose ripetuta
	Lavoratori	Dermico	Sistemico, lungo termine; 166,7 mg/kg	Tossicità a dose ripetuta
	Popolazione generale	Orale	Sistemico, lungo termine; 8,3 mg/kg	Tossicità a dose ripetuta

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, hydrochloride (1:1)	Popolazione generale	Occhi	Locale;	Nessun pericolo identificato
	Lavoratori	Inhalation	Sistemico, lungo termine; 152,8 mg/m3	Tossicità a dose ripetuta
	Popolazione generale	Inhalation	Sistemico, lungo termine; 37,7 mg/m3	Tossicità a dose ripetuta
	Lavoratori	Occhi	Locale;	Nessun pericolo identificato
	Popolazione generale	Dermico	Sistemico, lungo termine; 108,3 mg/kg	Tossicità a dose ripetuta
	Popolazione generale	Orale	Sistemico, lungo termine; 10,8 mg/kg	Tossicità a dose ripetuta
	Lavoratori	Dermico	Sistemico, lungo termine; 216,6 mg/kg	Tossicità a dose ripetuta

Valori PNEC

Osservazioni: Valori PNEC

Componente critico	Compartimento ambientale	Valori PNEC	Osservazioni
1,2,3-Propanetriol	Impianto di trattamento delle acque reflue	1000 mg/l	
	Terreno	0,141 mg/kg	
	Sedimento (acqua marina)	0,33 mg/kg	
	Aquatico (acqua dolce)	0,885 mg/l	
	Acquatico (acqua marina)	0,088 mg/l	
	Sedimento (acqua dolce)	3,3 mg/kg	

Sodium Chloride (NaCl)	Terreno	4,86 mg/kg	
	Aquatico (acqua dolce)	5 mg/l	
	Impianto di trattamento delle acque reflue	500 mg/l	

2-Methyl-4-isothiazolin-3-one	Terreno	0,047 mg/kg	
	Aquatico (acqua dolce)	3,39 µgr/l	
	Impianto di trattamento delle acque reflue	0,23 mg/l	
	Acquatico (acqua marina)	3,39 µgr/l	

Sodium azide (Na(N3))	Acquatico (acqua marina)	15 ng/l	
	Impianto di trattamento delle acque reflue	30 µgr/l	
	Sedimento (acqua dolce)	0,0167 mg/kg	
	Aquatico (acqua dolce)	0,35 µgr/l	
	Sedimento (acqua marina)	0,00072 mg/kg	

Phosphoric acid, sodium salt (1:2)	Impianto di trattamento delle acque reflue	50 mg/l	
------------------------------------	--	---------	--

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

	Aquatico (acqua dolce)	0,05 mg/l	
	Acquatico (acqua marina)	0,005 mg/l	
Potassium chloride (KCl)	Acquatico (acqua marina)	0,1 mg/l	
	Impianto di trattamento delle acque reflue	10 mg/l	
	Aquatico (acqua dolce)	0,1 mg/l	
Disodium pyrophosphate	Acquatico (acqua marina)	0,005 mg/l	
	Impianto di trattamento delle acque reflue	50 mg/l	
	Aquatico (acqua dolce)	0,05 mg/l	
Trometamol	Impianto di trattamento delle acque reflue	300 mg/l	

8.2 Controlli dell'esposizione

Controlli Tecnici Idonei:

Predisporre una ventilazione adeguata ogniqualvolta il materiale si riscalda o si generano nebulizzazioni.

Misure di protezione individuale, quali dispositivi di protezione individuale

Protezioni per gli occhi/il volto:

Indossare occhiali di protezione con schermi laterali (o occhiali di copertura).

Protezione delle Mani:

Materiale: Usare guanti protettivi adatti per rischi di contatto sulla pelle.

Protezione per la pelle e l'organismo:

Indossare indumenti protettivi adatti per prevenire il ripetuto e prolungato contatto con la pelle.

Protezione respiratoria:

Se i controlli sugli impianti non consentono di mantenere concentrazioni nell'aria inferiori ai valori limite di esposizione consigliati (ove applicabile) o a un livello accettabile (nei Paesi in cui i valori limite di esposizione non sono stati stabiliti), occorrerà utilizzare un respiratore a norma.

Misure di igiene:

Non mangiare, né bere, né fumare durante l'impiego del prodotto. Lavare prontamente la pelle in caso di contaminazione. Lavarsi alla fine di ogni turno di lavoro e prima di mangiare, fumare o andare alla toilette. Evitare il contatto con la pelle.

Controlli ambientali:

Dati disponibili su richiesta.

SEZIONE 9: proprietà fisiche e chimiche

9.1 Informazioni sulle proprietà fisiche e chimiche fondamentali

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Aspetto

Forma: solido
Forma: Fanghiglia
Colore: Incolore

Odore: Inodore

Soglia di odore: Nessun dato disponibile.

Punto di fusione: Nessun dato disponibile.

Punto di ebollizione: Nessun dato disponibile.

Infiammabilità: Nessun dato disponibile.

Limiti superiori/inferiori di infiammabilità o esplosività

Limite esplosivo - superiore (%): Nessun dato disponibile.

Limite esplosivo - inferiore (%): Nessun dato disponibile.

Punto di infiammabilità: Nessun dato disponibile.

Temperatura di autoaccensione: Nessun dato disponibile.

Temperatura di decomposizione: Nessun dato disponibile.

pH: 6,40 - 6,60

Viscosità

Viscosità dinamica: Nessun dato disponibile.

Viscosità cinematica: Nessun dato disponibile.

Tempo di scorrimento: Nessun dato disponibile.

Solubilità

Solubilità in acqua: Solubile

Solubilità (altro): Nessun dato disponibile.

Tasso di dissoluzione: Nessun dato disponibile.

Coefficiente di ripartizione (n-ottanolo/acqua): Nessun dato disponibile.

Stabilità alla dispersione: Nessun dato disponibile.

Pressione di vapore: Nessun dato disponibile.

Densità relativa: Nessun dato disponibile.

Densità: Nessun dato disponibile.

Densità apparente: Nessun dato disponibile.

Densità di vapore (aria=1): Nessun dato disponibile.

9.2 Altre informazioni

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Nessun dato disponibile

SEZIONE 10: stabilità e reattività

10.1	Reattività:	Stabile
10.2	Stabilità chimica:	Nessun dato disponibile.
10.3	Possibilità di reazioni pericolose:	Nessuno in condizioni normali.
10.4	Condizioni da evitare:	Evitare l'esposizione a temperature elevate o luce solare diretta.
10.5	Materiali incompatibili:	Agenti ossidanti forti.
10.6	Prodotti di decomposizione pericolosi:	In caso di riscaldamento e d'incendio possono crearsi vapori/gas nocivi.

SEZIONE 11: informazioni tossicologiche

Informazioni generali: Può provocare una reazione allergica della pelle in base all'esperienza umana.

11.1 Informazioni sulle classi di pericolo definite nel regolamento (CE) n. 1272/2008

Inalazione:	Nelle normali condizioni d'uso previsto, questo materiale non è pericoloso se inalato.
Contatto con la Pelle:	Un contatto prolungato o ripetuto può provocare sensibilizzazione della pelle negli individui sensibili.
Contatto con gli occhi:	Evitare il contatto con gli occhi.
Ingestione:	L'ingestione può provocare irritazione e stato di malessere.

Informazioni sulle vie probabili di esposizione

Tossicità acuta (elencare tutte le possibili vie di esposizione)

Ingestione

Prodotto: Stima della tossicità acuta per miscele: 3.616,7 mg/kg

Componenti:
2-metilisotiazol-3(2H)-one Nessun dato disponibile.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

azoturo di sodio	LD 50 (Ratto): 27 mg/kg LD 50 (Topo): 27 mg/kg
------------------	---

Contatto con la pelle

Prodotto:

Stima della tossicità acuta per miscela: 42.444,82 mg/kg

Componenti:

2-metilisotiazol-3(2H)-
one

Nessun dato disponibile.

azoturo di sodio

Nessun dato disponibile.

Inalazione

Prodotto:

Non classificato per quanto riguarda la tossicità acuta sulla base dei dati disponibili.

Componenti:

2-metilisotiazol-3(2H)-
one

Nessun dato disponibile.

azoturo di sodio

Nessun dato disponibile.

Tossicità a dose ripetuta

Prodotto:

Nessun dato disponibile.

Componenti:

2-metilisotiazol-3(2H)-

Nessun dato disponibile.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

one

azoturo di sodio Nessun dato disponibile.

Corrosione/Irritazione della Pelle

Prodotto: Nessun dato disponibile.

Componenti:
2-metilisotiazol-3(2H)-one Nessun dato disponibile.

azoturo di sodio Nessun dato disponibile.

Gravi Danni Agli Occhi o Irritazione Degli Occhi

Prodotto: Nessun dato disponibile.

Componenti:
2-metilisotiazol-3(2H)-one Nessun dato disponibile.

azoturo di sodio Nessun dato disponibile.

Sensibilizzazione Respiratoria o della Pelle



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Prodotto: Nessun dato disponibile.
Componenti:
2-metilisotiazol-3(2H)-one Nessun dato disponibile.

azoturo di sodio Non è un sensibilizzatore per la pelle.

Carcinogenicità
Prodotto: Nessun dato disponibile.
Componenti:
2-metilisotiazol-3(2H)-one Nessun dato disponibile.

azoturo di sodio Nessun dato disponibile.

Mutagenicità delle Cellule Germinali

In vitro

Prodotto: Nessun dato disponibile.
Componenti:
2-metilisotiazol-3(2H)-one Nessun dato disponibile.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

azoturo di sodio Nessun dato disponibile.

In vivo

Prodotto: Nessun dato disponibile.

Componenti:
2-metilisotiazol-3(2H)-one Nessun dato disponibile.

azoturo di sodio Nessun dato disponibile.

Tossicità per la riproduzione

Prodotto: Nessun dato disponibile.

Componenti:
2-metilisotiazol-3(2H)-one Nessun dato disponibile.

azoturo di sodio Nessun dato disponibile.

Tossicità Specifica per Organo Bersaglio - Esposizione Singola

Prodotto: Nessun dato disponibile.

Componenti:



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

2-metilisotiazol-3(2H)-one	Nessun dato disponibile.
----------------------------	--------------------------

azoturo di sodio	Nessun dato disponibile.
------------------	--------------------------

Tossicità Specifica per Organo Bersaglio - Esposizione Ripetuta

Prodotto:	Nessun dato disponibile.
------------------	--------------------------

Componenti:	
2-metilisotiazol-3(2H)-one	Nessun dato disponibile.

azoturo di sodio	Nessun dato disponibile.
------------------	--------------------------

Pericolo da Aspirazione

Prodotto:	Nessun dato disponibile.
------------------	--------------------------

Componenti:	
2-metilisotiazol-3(2H)-one	Nessun dato disponibile.

azoturo di sodio	Nessun dato disponibile.
------------------	--------------------------

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

11.2 Informazioni su altri pericoli

Proprietà di interferenza con il sistema endocrino

Prodotto: La sostanza/miscela non contiene componenti considerati aventi proprietà di interferenza endocrina ai sensi dell'articolo 57(f) del REACH o del regolamento delegato (UE) 2017/2100 della Commissione o del regolamento (UE) 2018/605 della Commissione a livelli dello 0,1% o superiori.;

Componenti:
2-metilisotiazol-3(2H)-one Nessun dato disponibile.

azoturo di sodio Nessun dato disponibile.

Altre informazioni

Prodotto: Nessun dato disponibile.

SEZIONE 12: informazioni ecologiche

12.1 Tossicità:

Pericoli acuti per l'ambiente acquatico:

Pesce

Prodotto: Nessun dato disponibile.

Componenti:
2-metilisotiazol-3(2H)-one Nessun dato disponibile.

azoturo di sodio LC 50 (Ciprinidi Fathead (Pimephales promelas), 96 h): 5,46 mg/l
Mortalità
LC 50 (Trota iridea, trota donaldson (Oncorhynchus mykiss), 96 h): 4,6 mg/l Mortalità

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

LC 50 (Ptychocheilus oregonensis, 24 h): < 10 mg/l Mortalità
LC 50 (Salmonidae, 24 h): < 10 mg/l Mortalità
LC 50 (Trota iridea, trota donaldson (Oncorhynchus mykiss), 24 h): 1 mg/l Mortalità

Invertebrati Acquatici

Prodotto: Nessun dato disponibile.

Componenti:
2-metilisotiazol-3(2H)-one Nessun dato disponibile.

azoturo di sodio LC 50 (Pulce d'acqua (Simocephalus serrulatus), 48 h): 6,4 mg/l
LC 50 (Pulce d'acqua (Daphnia pulex), 48 h): 4,2 mg/l
LC 50 (Orconectes rusticus, 96 h): < < 1 mg/l
LC 50 (Gambero rosso della Louisiana (Procambarus clarkii), 48 h): 0,4 - 0,6 mg/l
LC 50 (Gamberetto (Gammarus lacustris), 24 h): 13 - 15 mg/l Mortalità

Tossicità per le piante acquatiche

Prodotto: Nessun dato disponibile.

Componenti:
2-metilisotiazol-3(2H)-one Nessun dato disponibile.

azoturo di sodio EC 50 (Chlorococcum, 24 h): 176 mg/l

Tossicità per i micro-organismi

Prodotto: Nessun dato disponibile.

Componenti:
2-metilisotiazol-3(2H)-one Nessun dato disponibile.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

azoturo di sodio	Nessun dato disponibile.
------------------	--------------------------

Pericoli cronici per l'ambiente acquatico:

Pesce

Prodotto:	Nessun dato disponibile.
Componenti:	
2-metilisotiazol-3(2H)-one	Nessun dato disponibile.

azoturo di sodio	Nessun dato disponibile.
------------------	--------------------------

Invertebrati Acquatici

Prodotto:	Nessun dato disponibile.
Componenti:	
2-metilisotiazol-3(2H)-one	Nessun dato disponibile.

azoturo di sodio	Nessun dato disponibile.
------------------	--------------------------

Tossicità per le piante acquatiche

Prodotto:	Nessun dato disponibile.
Componenti:	
2-metilisotiazol-3(2H)-one	Nessun dato disponibile.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

azoturo di sodio	Nessun dato disponibile.
------------------	--------------------------

Tossicità per i micro-organismi

Prodotto:	Nessun dato disponibile.
------------------	--------------------------

Componenti:	
2-metilisotiazol-3(2H)-one	Nessun dato disponibile.

azoturo di sodio	Nessun dato disponibile.
------------------	--------------------------

12.2 Persistenza e degradabilità

Biodegradazione

Prodotto:	Nessun dato disponibile.
------------------	--------------------------

Componenti:	
2-metilisotiazol-3(2H)-one	Nessun dato disponibile.

azoturo di sodio	Nessun dato disponibile.
------------------	--------------------------



**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Rapporto BOD/COD

Prodotto: Nessun dato disponibile.

Componenti:
2-metilisotiazol-3(2H)-
one Nessun dato disponibile.

azoturo di sodio Nessun dato disponibile.

12.3 Potenziale di bioaccumulo

Fattore di Bioconcentrazione (BCF)

Prodotto: Nessun dato disponibile.

Componenti:
2-metilisotiazol-3(2H)-
one Nessun dato disponibile.

azoturo di sodio Nessun dato disponibile.

Coefficiente di Ripartizione n-ottanolo / acqua (log Kow)

Prodotto: Nessun dato disponibile.

Componenti:
2-metilisotiazol-3(2H)-
one Nessun dato disponibile.



Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

azoturo di sodio	Nessun dato disponibile.
------------------	--------------------------

12.4 Mobilità nel suolo:

Prodotto	Nessun dato disponibile.
Componenti:	
2-metilisotiazol-3(2H)-one	Nessun dato disponibile.

azoturo di sodio	Nessun dato disponibile.
------------------	--------------------------

12.5 Risultati della valutazione PBT e vPvB:

Prodotto	Nessun dato disponibile.
Componenti:	
2-metilisotiazol-3(2H)-one	Nessun dato disponibile.

azoturo di sodio	Nessun dato disponibile.
------------------	--------------------------

12.6 Proprietà di interferenza con il sistema endocrino:

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Prodotto:	La sostanza/miscela non contiene componenti considerati aventi proprietà di interferenza endocrina ai sensi dell'articolo 57(f) del REACH o del regolamento delegato (UE) 2017/2100 della Commissione o del regolamento (UE) 2018/605 della Commissione a livelli dello 0,1% o superiori.
Componenti: 2-metilisotiazol-3(2H)-one	Nessun dato disponibile.
azoturo di sodio	Nessun dato disponibile.

12.7 Altri effetti avversi:

Altri pericoli Prodotto:	Nessun dato disponibile.
-------------------------------------	--------------------------

SEZIONE 13: considerazioni sullo smaltimento

13.1 Metodi di trattamento dei rifiuti

Informazioni generali:	Smaltire residui e rifiuti conformemente a quanto disposto dalle autorità locali.
Metodi di smaltimento:	Lo scarico, il trattamento o lo smaltimento possono essere soggetti a normative nazionali, statali o locali. Seguire tutte le precauzioni riportate sull'etichetta anche dopo avere svuotato il contenitore, poiché potrebbe contenere residui del prodotto.
Contenitori Contaminati:	Smaltire il prodotto/recipiente conferendolo a un opportuno impianto di trattamento e smaltimento in accordo con le leggi e i regolamenti vigenti e le caratteristiche del prodotto al momento dello smaltimento.

SEZIONE 14: informazioni sul trasporto

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

ADR

14.1 Numero ONU o numero ID:	Non regolamentato.
14.2 Designazione ufficiale ONU di trasporto:	Non regolamentato.
14.3 Classi di pericolo connesso al trasporto	
Classe:	Non regolamentato.
Etichetta(-e):	Non regolamentato.
Nr. pericolo (ADR):	Non regolamentato.
Codice restrizioni su trasporto in galleria:	Non regolamentato.
14.4 Gruppo d'imballaggio:	Non regolamentato.
Quantità limitata	Non regolamentato.
Quantità esente	Non regolamentato.
14.5 Pericoli per l'ambiente	Non regolamentato.
14.6 Precauzioni speciali per gli utilizzatori:	Non regolamentato.

ADN

14.1 Numero ONU o numero ID:	Non regolamentato.
14.2 Designazione ufficiale ONU di trasporto:	Non regolamentato.
14.3 Classi di pericolo connesso al trasporto	
Classe:	Non regolamentato.
Etichetta(-e):	Non regolamentato.
Nr. pericolo (ADR):	Non regolamentato.
Codice restrizioni su trasporto in galleria:	Non regolamentato.
14.4 Gruppo d'imballaggio:	Non regolamentato.
Quantità limitata	Non regolamentato.
Quantità esente	Non regolamentato.
14.5 Precauzioni speciali per gli utilizzatori:	Non regolamentato.

RID

14.1 Numero ONU o numero ID:	Non regolamentato.
14.2 Designazione ufficiale ONU di trasporto:	Non regolamentato.
14.3 Classi di pericolo connesso al trasporto	
Classe:	Non regolamentato.
Etichetta(-e):	Non regolamentato.
14.4 Gruppo d'imballaggio:	Non regolamentato.
Quantità limitata	Non regolamentato.
Quantità esente	Non regolamentato.
14.5 Pericoli per l'ambiente	Non regolamentato.
14.6 Precauzioni speciali per gli utilizzatori:	Non regolamentato.

IMDG

14.1 Numero ONU o numero ID:	Non regolamentato.
14.2 Designazione ufficiale ONU di trasporto:	Non regolamentato.
14.3 Classi di pericolo connesso al trasporto	
Classe:	Non regolamentato.
Etichetta(-e):	Non regolamentato.
EmS No.:	Non regolamentato.
14.4 Gruppo d'imballaggio:	Non regolamentato.

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Quantità limitata	Non regolamentato.
Quantità esente	Non regolamentato.
14.5 Pericoli per l'ambiente	Non regolamentato.
14.6 Precauzioni speciali per gli utilizzatori:	Non regolamentato.

IATA

14.1 Numero ONU o numero ID:	Non regolamentato.
14.2 Designazione ufficiale ONU di trasporto:	Non regolamentato.
14.3 Classi di pericolo connesso al trasporto	
Classe:	Non regolamentato.
Etichetta(-e):	Non regolamentato.
14.4 Gruppo d'imballaggio:	Non regolamentato.
Aereo di linea e aereo da trasporto merci :	Non regolamentato.
Quantità limitata	Non regolamentato.
Quantità esente	Non regolamentato.
14.5 Pericoli per l'ambiente	Non regolamentato.
14.6 Precauzioni speciali per gli utilizzatori:	Non regolamentato.

14.7 Trasporto marittimo alla rinfusa conformemente agli atti dell'IMO

Non applicabile al prodotto nella sua forma fornita.

SEZIONE 15: informazioni sulla regolamentazione

15.1 Disposizioni legislative e regolamentari su salute, sicurezza e ambiente specifiche per la sostanza o la miscela:

Regolamenti dell'UE

Regolamento (CE) n. 1005/2009 sulle sostanze che riducono lo strato di ozono, Allegato I, Sostanze controllate: Nessuno presente o nessuno presente in quantità regolata.

REGOLAMENTO 1907/2006 (CE) (REACH), ALLEGATO XIV ELENCO DELLE SOSTANZE SOGGETTE AD AUTORIZZAZIONE: Nessuno presente o nessuno presente in quantità regolata.

Regolamento (CE) n. 2019/1021/CE che prevede divieti e restrizioni per gli inquinanti organici persistenti (POP), modificata: Nessuno presente o nessuno presente in quantità regolata.

UE. Direttiva 2010/75/UE relativa alle emissioni industriali (prevenzione e riduzione integrate dell'inquinamento), Allegato II, L334/17:

Denominazione chimica	NUMERO CAS
1,2,3-Propanetriol	56-81-5

Regolamento (UE) n. 649/2012 riguardante l'esportazione e l'importazione di sostanze chimiche pericolose, Allegato I, Parte 1 e successive modifiche: Nessuno presente o nessuno presente in quantità regolata.

Regolamento (UE) n. 649/2012 riguardante l'esportazione e l'importazione di sostanze chimiche

Becton, Dickinson and
Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

pericolose, Allegato I, Parte 2 e successive modifiche: Nessuno presente o nessuno presente in quantitàregolate.

Regolamento (UE) n. 649/2012 riguardante l'esportazione e l'importazione di sostanze chimiche pericolose, Allegato I, Parte 3 e successive modifiche: Nessuno presente o nessuno presente in quantitàregolate.

Regolamento (UE) n. 649/2012 riguardante l'esportazione e l'importazione di sostanze chimiche pericolose, Allegato V e successive modifiche: Nessuno presente o nessuno presente in quantitàregolate.

Elenco dei candidati UE. REACH delle sostanze estremamente problematiche per l'autorizzazione (Substances of Very High Concern, SVHC): Nessuno presente o nessuno presente in quantitàregolate.

Regolamento (CE) n. 1907/2006 Allegato XVII - Sostanze soggette a restrizioni in materia di immissione sul mercato e di uso:

Denominazione chimica	NUMERO CAS	Concentrazione	La confezione sarà contrassegnata visibilmente,in modo leggibile e indelebile nel modo seguente:
2-metilisotiazol-3(2H)-one	2682-20-4	0,1 - 1,0%	nessuno/nessuna

Direttiva 2004/37/CE sulla protezione dei lavoratori contro i rischi derivanti da un'esposizione ad agenti cancerogeni omutageni durante il lavoro.: Nessuno presente o nessuno presente in quantitàregolate.

Direttiva 92/85/CEE concernente l'attuazione di misure volte a promuovere il miglioramento della sicurezza e della salute sul lavoro delle lavoratrici gestanti, puerpere o in periodo di allattamento: Nessuno presente o nessuno presente in quantitàregolate.

DIRETTIVA 2012/18/UE sul controllo del pericolo di incidenti rilevanti connessi con sostanze pericolose, ALLEGATO I:

Classificazione	Requisiti di soglia inferiore	Requisiti di soglia superior
E1. Pericoloso per l'ambiente acquatico	100 t	200 t

REGOLAMENTO (CE) N. 166/2006 relativo all'istituzione di un registro europeo delle emissioni e dei trasferimenti di sostanze inquinanti, ALLEGATO II: Sostanze inquinanti:

Denominazione chimica	NUMERO CAS	Concentrazione
1,2,3-Propanetriol	56-81-5	1,0 - 10%

Direttiva 98/24/CE sulla protezione dei lavoratori contro i rischi legati agli agenti chimici sul lavoro:

Denominazione chimica	NUMERO CAS	Concentrazione
-----------------------	------------	----------------

Becton, Dickinson and Company
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

2-metilisotiazol-3(2H)-one	2682-20-4	0,1 - 1,0%
azoturo di sodio	26628-22-8	0,1 - 1,0%

15.2 Valutazione della sicurezza chimica:

Non è stata effettuata alcuna valutazione della sicurezza chimica.

Regolamenti internazionali

Protocollo di Montreal

Non applicabile

Convenzione di Stoccolma

Non applicabile

Convenzione di Rotterdam

Non applicabile

Protocollo di Kyoto

Non applicabile

SEZIONE 16: altre informazioni

Abbreviazioni e acronimi:

Nessun dato disponibile.

Principali riferimenti bibliografici e fonti di dati:

Nessun dato disponibile.

Classificazione e procedura utilizzata per derivarla a norma del regolamento (CE) 1272/2008 [CLP] in relazione alle miscele

Classificazione ai sensi del regolamento CE n. 1272/2008 e s.m.i.	Procedura di classificazione
Sensibilizzatore della pelle, Categoria 1	Sulla base di dati di sperimentazione
Pericoli cronici per l'ambiente acquatico, Categoria 3	Sulla base di dati di sperimentazione

Formulazione delle istruzioni nelle sezioni 2 e 3

H300	Letale se ingerito.
H301	Tossico se ingerito.
H311	Tossico per contatto con la pelle.
H314	Provoca gravi ustioni cutanee e gravi lesioni oculari.
H317	Può provocare una reazione allergica cutanea.
H318	Provoca gravi lesioni oculari.
H330	Letale se inalato.
H335	Può irritare le vie respiratorie.
H400	Molto tossico per gli organismi acquatici.
H410	Molto tossico per gli organismi acquatici con effetti di lunga durata.
H412	Nocivo per gli organismi acquatici con effetti di lunga durata.

Indicazioni per la formazione:

Nessun dato disponibile.



**Becton, Dickinson and
Company**
BD, Franklin Lakes, NJ
07417 USA
www.bd.com

Classificazione ai sensi del regolamento CE n. 1272/2008 e s.m.i.

Skin Sens. 1, H317

Aquatic Chronic 3, H412

SDS N.: UN91-0949-1149-1-02

Limitazione di responsabilità: Disclaimer:

Le informazioni qui contenute sono state ottenute da fonti diverse e sono ritenute corrette alla data di pubblicazione. Tuttavia, né BD né alcuna delle sue affiliate si assumono responsabilità riguardo alla correttezza o la completezza delle informazioni ivi contenute. Determinazione finale di idoneità per un particolare uso dei materiali è di esclusiva responsabilità dell'utente. Tutti i materiali possono presentare rischi sconosciuti e devono essere usati con cautela. Sebbene alcuni rischi siano descritti nel presente documento, non possiamo garantire che questi sono gli unici rischi esistenti. BD fornisce schede di sicurezza in formato elettronico, così l'informazione può essere più facilmente accessibile. A causa della possibilità di errori durante la trasmissione, BD si assume alcuna responsabilità per quanto riguarda la completezza o accuratezza delle informazioni.